Method for identifying the quantitative cellular composition in a biological sample

ABSTRACT

The present invention provides an epigenetic haemogram, also referred to as an epigenetic blood cell count that identifies the quantitative, comprehensive picture of cellular composition in a biological sample, wherein advantageously a normalization standard is used. The normalization standard is a nucleic acid molecule comprising at least one marker-region being specific for each of the blood cells to be detected, and at least one control-region being cell-unspecific, wherein said regions are present in the same number of copies on said molecule and/or a natural blood cell sample of known composition. Furthermore, the present invention relates to a kit and the use of a kit for performing the epigenetic assessment of comprehensive, quantitative cellular composition of a biological sample. The biological sample is derived from e.g. a mammalian body fluid, including peripheral, capillary or venous blood samples or subfractions thereof, such as peripheral blood mononuclear cells or peripheral blood monocytes, or a tissue sample, organ sample, or from frozen, dried, embedded, stored or fresh body fluids or tissue samples.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a Divisional Application of co-pending applicationSer. No. 14/771,496, filed Aug. 30, 2015; which is a National StageApplication of International Application Number PCT/EP2014/058087, filedApr. 22, 2014; which claims the benefit of U.S. Provisional ApplicationNo. 61/813,802, filed Apr. 19, 2014 and claims priority to EuropeanApplication No. 13173442.8, filed Jun. 24, 2013; all of which areincorporated herein by reference in their entirety.

The Sequence Listing for this application is labeled“SeqList-15Feb18-ST25.txt”, which was created on Feb. 15, 2018, and is654 KB. The Sequence Listing is incorporated herein by reference in itsentirety.

FIELD OF THE INVENTION

The present invention provides an epigenetic haemogram, also referred toas an epigenetic blood cell count that identifies the quantitative,comprehensive picture of cellular composition in a biological sample,wherein advantageously a normalization standard is used. Thenormalization standard is a nucleic acid molecule comprising at leastone marker-region being specific for each of the blood and/or immunecells to be detected, and at least one control-region beingcell-unspecific, wherein said regions are present in the same number ofcopies on said molecule and/or a natural blood cell sample of knowncomposition. Furthermore, the present invention relates to a kit and theuse of a kit for performing the epigenetic assessment of comprehensive,quantitative cellular composition of a biological sample. The biologicalsample is derived from e.g. a mammalian body fluid, includingperipheral, capillary or venous blood samples or subfractions thereof,such as peripheral blood mononuclear cells or peripheral bloodmonocytes, or a tissue sample, organ sample, or from frozen, dried,embedded, stored or fresh body fluids or tissue samples.

BACKGROUND OF THE INVENTION

A “blood count”, “complete blood count”, or “blood cell profile”commonly designates a set of tests to determine the number, ratio andappearances of blood cells and/or their cellular subgroups (e.g.,neutrophils, eosinophils, basophils, CD19 or CD3 cells, and theirsubgroups, such as CD3⁺/CD4⁺ and/or CD3⁺/CD8⁺ cells). Such a blood countis used in clinical diagnostics as a broad screening test for disordersor a determination of the general health status of an individual. Ingeneral, a “blood count” includes assays directed at hematocrit,quantification of hemoglobin, total blood cells, and red blood cellindex (e.g. mean corpuscular volume, mean corpuscular hemoglobin, meancorpuscular hemoglobin concentration, red blood cell distribution).

White blood cells (also referred to as leukocytes) are part of thecellular immune system (we explicitly define all immune cells, includingB-cells as cellular immune system) and play a key role in defending anmammals from pathological effects caused either by foreign organisms (inparticular for example: viruses, bacteria, parasites, etc.), but alsofrom aberrations of diseased self-cells, such as tumor cells. Inaddition, immune cells are themselves subject to diseases, either asprimary (congenital) immune diseases, such as the IPEX syndrome or assecondary (acquired) immune diseases, such as for example AIDS, HIV. Inthe former, the immune system itself is impaired, whereas in the latterexternal factors (such as virus infections, radiation, chemotherapies orenvironmental factors) lead to a weakening of the immune system. Severaltypes of leukocytes exist and they either derive from the myeloidlineage—e.g. neutrophil, eosinophil and basophil granulocytes, mastcells and macrophages—or derive from the lymphoid lineage including alllymphocyte subpopulations—such as for example T-cells, B-cells, NKcells. Since the composition of the immune system, and its cellularmembers, has been subjected to many analyses, aberrations of this normalimmune cell count (or ratio) can be recognized easily, is useddiagnostically, and may be used for clinical decision-making. Thus, theratio and count of these cells are regularly analyzed in clinicalsettings—both as routine diagnostic or analytical tool as well as inclinical research or trials—in order to detect any abnormalities orapparent changes that may be caused by a disease or a disease treatmentor other internal or external factors. For example, blood counts areused to diagnose the onset/occurence of leuko-or lymphopenias orleuko-or lymphocytosis, such as granulocytosis. Furthermore, bloodcounts are taken to monitor the treatment success of all diseases thatresult from, cause or whose treatment may result in changes of theoverall or specific leuko- or lymphocyte counts. For example, fordiagnosing or monitoring infections, anemia, leukemia or the effects ofchemotherapies, a so-called “differential” whole blood count is used inorder to analyze and identify immune cells and subpopulations thereof.In some primary and secondary immune disorders, this procedure may bethe only available diagnostic tool. The differential blood countincludes assays directed at a quantification of total white blood cells,neutrophil granulocytes, lymphocytes, monocytes, eosinophilgranulocytes, and basophil granulocytes.

Routinely, for soluble cells, i.e., mainly blood but also solubilizedtissues or body fluids such a specific immune cell profile is measuredby flow cytometry, or by immunohistochemistry (IHC) for solid tissues.Both technologies work on the basis of protein epitopes exposed on cellmembranes that are specific for each subtype of cell subpopulation.Recently, research focused on the biological role of leukocytesubpopulations, and this results in a strong demand for clinical as wellas for research applications allowing to identifying such populations.

Technically, in routine diagnostics, hematocrit, hemoglobin as well astotal white blood counts are determined by an automatic cell counterbased on light detection and electrical impedance. A differential whiteblood count, including neutrophil, eosinophil, basophil granulocytes,monocytes and mast cells are determined either via manual microscopiccounting or automatic counting of blood smears.

Additional methods, allowing for the detection of T cell populations areMHC multimetric analyses, the Cytokine-Capture Assay, individual T celldetections (ELISPOT-Assay) or the merely qualitative detection andlocalization of immune cells (immunohistochemical analyses). Like flowcytometry, these assays are based on a detection of proteins; nospecific expression level-independent markers are used. It is noteworthythat all of these assays as well as all assays based on the detection ofmRNA, vary from cell to cell. This is because even cells that areundoubtedly positive for a certain protein present time wise varyingamounts of protein. Hence, a threshold for “positivity” has to bedetermined for each and every protein marker depending on the affinityand unspecific binding properties of the given antibody as well as onthe average amount of surface expression of the target protein.

Even though almost all cells in an individual contain the exact samecomplement/composition of DNA code, higher organisms must impose andmaintain different patterns of gene expression in the various types oftissue. Most gene regulation is transitory, depending on the currentstate of the cell and changes in external stimuli. Persistentregulation, on the other hand, is a primary role ofepigenetics—heritable regulatory patterns that do not alter the basicgenetic coding of the DNA. DNA methylation is the archetypical form ofepigenetic regulation; it serves as the stable memory for cells andperforms a crucial role in maintaining the long-term identity of variouscell types. Recently, other forms of epigenetic regulation werediscovered. In addition to the “fifth base” 5-methylcytosine (mC), asixth (5-hydroxymethylcytosine, hmC), seventh (5-formylcytosine, fC) andeighth (5-carboxycytosine, cC) can be found (Michael J. Booth et al.Quantitative Sequencing of 5-Methylcytosine and 5-Hydroxymethylcytosineat Single-Base Resolution Science 18 May 2012, Vol. 336 no. 6083 pp.934-937). The primary target of mentioned DNA modifications is thetwo-nucleotide sequence Cytosine-Guanine (a ‘CpG site’); within thiscontext cytosine (C) can undergo a simple chemical modification tobecome formylated, methylated, hydroxymethylated, or carboxylated. Inthe human genome, the CG sequence is much rarer than expected, except incertain relatively dense clusters called ‘CpG islands’. CpG islands arefrequently associated with gene promoters, and it has been estimatedthat more than half of the human genes have CpG islands (Antequera andBird, Proc Natl Acad Sci USA 90: 11995-9, 1993).

For one of the recently described modification of cytosine,5-hydroxymethylation, the utility of oxidative bisulfite sequencing tomap and quantify 5hmC at CpG islands was shown (Michael J. Booth et al.Quantitative Sequencing of 5-Methylcytosine and 5-Hydroxymethylcytosineat Single-Base Resolution Science 18 May 2012, Vol. 336 no. 6083 pp.934-937).

In the context of the present invention, the term “bisulfite convertiblechromatin” shall mean a chromatin structure (e.g. a sufficiently openedstructure) that allows bisulfite to chemically modify cytosines.Consequently, the term “DNA bisulfite convertibility” relates to theextent of cytosine ba-bases in said chromatin and/or the respectivenucleic acid that is part of said chromatin, that can be (or have been)converted using a bisulfite treatment. The term also relates to theextent of cytosine bases in a reference nucleic acid (such as a plasmid)that can be (or have been) converted using a bisulfite treatment. Inturn, the term “non-bisulfite convertible chromatin” or “non-bisulfiteconvertible nucleic acid” relates to the extent of cytosine bases thatcannot be (or could not been) converted using a bisulfite treatment.

As mentioned above, recently three new cytosine modifications werediscovered. Therefore, it is expected that future scientific findingswill lead to a more precise interpretation of epigenetic patterns ofbisulfite convertibility described in the past. These past result ofcytosine modification encompass bisulfite convertible (non-methylated,non-modified) and non-convertible (methylated, modified) cytosine. Bothtermini need to be reinterpreted, as described. According to the novelscientific findings (i) non-bisulfite convertible cytosine encompasses5-methylcytosine (mC) and 5-hydroxymethylcytosine (hmC), and (ii)bisulfite convertible cytosine encompasses 5-formylcytosine (fC),5-carboxycytosine (cC) as well as non-modified cytosine.

Additionally, earlier inventions are based on (i) the ratio of bisulfiteconvertible cytosine to whole amount of chromatin (cell-typeindependent, 100% bisulfite convertible DNA locus) or (ii) on the ratioof bisulfite convertible cytosine (fC, cC, non-modified cytosine) tonon-bisulfite convertible cytosine (hmC and mC). These ratios are usedto characterize cell type, cell differentiation, cell stage as well aspathological cell stages. Therefore, new techniques will result innovel, more specific ratios and might supplement current cell specific,cell state specific as well as pathological patterns of epigeneticmodifications and therefore, define potential novel biomarkers. Novelratios to be discovered as biomarkers can be defined as:Biomarker Ratio=a/ba=(C and/or mC and/or hmC and/or fC and/or cC)b=(C and/or mC and/or hmC and/or fC and/or cC),whereby a and b differs from each other by one to four kinds ofmodifications. Discovery of novel DNA modifications will certainlybroaden this enumeration.

For the purpose of the present application, epigenetic modifications inthe DNA sequence is referred to by the terminology of (i) bisulfiteconvertible cytosine (5-formylcytosine, (fC) and/or 5-carboxycytosine(cC)) and (ii) non-bisulfite convertible cytosine ((including5-methylcytosine (mC), 5-hydroxymethylcytosine, (hmC)). As both kinds ofmethylation, mC and hmC are not bisulfite convertible it is not possibleto distinguish between these two. Likewise, fC, cC as well asnon-modified cytosine are bisulfite convertible and can also not bedistinguished from each other as well.

Furthermore, apart from the modifications of DNA also histones undergoposttranslational modifications that alter their interaction with DNAand nuclear proteins. Modifications include methylation, acetylation,phosphorylation, ubiquitination, sumoylation, citrullination, andADP-ribosylation. The core of the histones H2A, H2B, and H3 can also bemodified. Histone modifications act in diverse biological processes suchas gene regulation, DNA repair, chromosome condensation (mitosis) andspermatogenesis (meiosis). Also for these modifications a specificpattern of modification is specific for different cell types, cellstages, differentiation status and such a pattern can be analyzed forbisulfite convertibility or similar methods in order to identify certaincells and cell stages. The present invention also encompasses a use ofthese modifications.

It is expected that further variants of DNA modifications will bediscovered in future. Each type of modification will be eitherbisulfite-convertible or not. These novel modifications can also be usedas biomarker readout. Additionally, it is expected that novel methodsfor bisulfite modification will be established, resulting in a differentset of convertible and non-convertible DNA.

The variety of indications for which reporting of the cellular immunestatus is clinically or analytically helpful is very large. For almostevery disease the cellular immune status is either directly relevantor—such as in cancer—becomes relevant due to the impact of drugs thatmay cause secondary immunological disorders and aberrations. This broadsignificance of the overall immune status in diseases settings resultsin a significant demand for methods to measure these parameters, i.e.,the leukocyte subtypes and subpopulations.

The current way of addressing this demand is by flow cytometric andimmunohistochemical methods, which are well-established and have beendeveloped into high throughput systems for hospital use, are standardprocedures in reference laboratories and are, for more simpleapplications, made available for practitioners. However, certainproblems and requirements limit the applicability of flow cytometry andimmunohistochemistry.

a) For flow cytometry, cells need to be intact. This means that theblood sample has to be measured in a “fresh” state, any delay inmeasurement may lead to deviation of results. As a rule of thumb,samples should be measured within 8 hours, since after that time framegranulocytes (one main cellular fraction in the blood) begin todisintegrate. As an alternative to fresh handling, it is possible tocryopreserve blood samples, but there are significant issues associatedwith respect to performance and reproducibility. As a consequence, flowcytometry in clinical routine is avoided and many potentially meaningfulanalyzes are omitted, whereas in clinical trials, where immune markersare prime biomarker candidates for treatment predictions, are often leftout, or if required by regulations extra facilities need to be set up.

b) Antigen expression is not a digital (on-off), but an analog (low,medium, high) process. Therefore, thresholds defining positive versusnegative signals must be determined. For certain markers, this isunproblematic, for others thresholds are very difficult and imprecise.

c) For flow cytometry, it also poses problems that many cell types arenot simply identified by a surface (cluster of differentiation—CD)molecule, but some cell types are characterized by intra- orextracellular soluble proteins, e.g. transcription factors or cytokines.Current markers for Tfh, Th1, Th2 cells, and Tregs belong to thiscategory of cell types—the application of fully standardized proceduresis even more difficult. This is because the cell-type specific markersneed to be captured in order to be associated to the cell.

d) Furthermore, flow cytometry is dependent on the solubility of theanalyzed substrate (cell suspensions). With respect to this, tissuecells may be solubilized by enzymatic digestion, but this often leads tothe loss of their surface molecules—rendering the CD markers, as primetargets for flow cytometric analysis useless.

e) Often, neither surface-nor intra- or extracellular markers are 100%cell-type specific. “Leaky” expression of certain gene products has beenreported (Wiezcorek et al., Cancer Res. 2009 Jan. 15; 69(2):599-608),rendering the quantification somewhat imprecise.

f) Since immunohistochemistry is based on the same principle as flowcytometry, specificity problems overlap. However, the main problem withthis technology is that it is considered only semiquantitative. Inparticular, a particular problem is that an overall cell counting is notfeasible due to the presence of various different cell layers, which aredifficult to distinguish and count correctly.

As far as aspect e) is concerned, the inventors have previouslypublished a publication proving that flow cytometry detects expressedsurface epitopes, but it cannot distinguish between cell-type specificepitope expression and cell-type independent induction of epitopeexpressions as well as it cannot detect specific-cells that currentlynot express or less express certain surface markers. In vitrostimulation of CD4⁺CD25⁺CD45RA⁺ T cells, for example, leads to a highexpression level of FOXP3 whereby the FOXP3 gene is still methylated andtherefore inactivated (Baron et al., Epigenetics. 2006 January-March;1(1):55-60). Additionally, for in vitro differentiated Th17 cells nodemethylation of IL-17A promotor was observed despite high levels ofIL-17A transcripts (Janson P. C. J. et al. Profiling of CD4+ T cellswith epigenetic immune lineage analysis. The Journal of Immunology.2010, 92-102). On the other side it is disclosed that methylation isconnected with marker expression (Hamerman, Page, Pullen. Distinctmethylation states of the CD8ß gene in peripheral T cells andIntraepithelial Lymphocytes. The Journal of Immunology 1997, P1240-1246;Janson P. C. J. et al. Profiling of CD4+ T cells with epigenetic immunelineage analysis. The Journal of Immunology. 2010. 92-102; Melvin et al.Hypomethylation in IFN-Gamma Gen correlates with expression of IFN-G,including CD8 cells., Eur J Immunol. 1995 February; 25(2):426-30;Landolfi M M et al. CD2⁺CD4⁺CD8⁺ lymph node T lymphocytes in MRL lpr/lprmice are derived from a CD2⁺CD4⁺CD8⁺ thymic precursor J Immunol. 1993Jul. 15; 151(2):1086-96; and Carbone A M et al. Demethylation in CD8suggests that CD4+ derives from CD8⁺ cells. Role of methylation patternduring cell development. Science. 1988 Nov. 25; 242(4882):1174-6).

In view of the above mentioned demands in both clinical diagnostics andpharmaceutical research, a new method to provide a precise andcomprehensive quantification of a variety of cell types in a sample isdesired, in order to establish a more precise and thus markedly improvedhaemogram. Further objects and advantages will become apparent to theperson of skill upon reading the present disclosure, and particularlythe examples below.

In a first aspect thereof, this object is solved by the presentinvention by a method for producing an epigenetic haemogram, comprisingthe steps of epigenetically detecting blood cells in a biologicalsample, and quantifying said blood cells as detected using anormalization standard, wherein said normalization standard is a nucleicacid molecule comprising at least one marker-region being specific foreach of the blood cells to be detected, and at least one control-regionbeing cell-unspecific, wherein said regions are present in the samenumber of copies on said molecule and/or a natural blood cell sample ofknown composition.

Key and basis of the present invention is the use of a variety ofdifferent cell-type specific bisulfite-convertible DNA marker. Thesemarkers are employed for the identification and quantification of asingle blood and immune cell types.

In principle, it was previously shown how a quantification of cell typesand blood cell counting based on known epigenetic procedures isperformed ((Wiezcorek et al., Cancer Res. 2009 Jan. 15; 69(2):599-608,Sehouli et al. Epigenetics. 2011 February; 6(2):236-46.). In brief,either a cell type specifically modified gene region is specifically(amplified and) counted and hence quantitated along with the oppositespecies of the cell type specific gene region. To provide for anindependent quantification, these two measurements are then put intorelation to provide the percentile part of the cell type in the given(blood) sample:Copy number of bisulfite convertible DNA of cell-type specific genomicregion/(copy number of bisulfite convertible DNA of cell-type specificgenomic region)+(Copy number of non-bisulfite convertible DNA ofcell-type specific genomic region)=% cell type.

Alternatively, the number of copies of bisulfite convertible DNA of acell-type specific gene region is measured and divided by the copynumber of bisulfite-convertible DNA of a cell-type non-specific generegion in the given sample. The latter can be determined by measuringall DNA copies using a completely bisulfite-convertible, cell-unspecificgene region or a region that is known to be uniformlybisulfite-unconvertible or bisulfite-convertible in all cell types.Copy number of bisulfite convertible DNA of cell-type specific genomicregion/Copy number of a bisulfite convertible DNA of cell-typeunspecific genomic region=% cell type.

Hence, when a single specific bisulfite-convertible genomic marker isknown, the previously established system allows the relative (percentile(%)) quantification of any one cell type in a given sample. For this,any given standardization of copy numbers or copy equivalents can beused. The resulting percentile share of the cell type in questioncorrelates with the share of cells measured with a different method.Here, “correlating” means that—according to Spearman correlation—thelowest share measured by the epigenetic technology corresponds to thelowest share measured by—for example—flow cytometry. Such system hasbeen shown to be very stable, technically robust and reliable.Therefore, whenever there is a highly cell-specific bisulfiteconvertible DNA marker achieved, in theory it should be possible to makean accurate and precise determination of the amount of those cells thatown the specific bisulfite convertible genomic marker region.

It is known that the efficiency and performance of Real time (RT-)PCRsystems differ depending on the RT-PCR components, including primers,probes, and the purity of DNA. Therefore, standards are employed inorder to account for the problem to know at which Cp (crossing point) orCt (threshold cycle) value a given (known) amount of standard DNA can bedetected. A dilution series of said standard DNA gives a standard curve,and allows for the normalization of differently performing/efficientRT-PCR systems. Since the quantification is performed on an equivalentsystem, differences in performance are normalized. However, the problemaddressed concerns an (RT-)PCR that is performed on DNA aiming at thedetection of biologically and/or chemically altered DNA. The complexityof this biologically and/or chemically altered DNA differs fromnormal/natural genomic DNA (starting by the simple fact that thecomplexity of the DNA molecules differ, since a plasmid consists ofdouble stranded DNA of four bases (CTGA), whereas genomic DNA consistsof double stranded five bases (CTGAC^(m)), and bisulfite converted DNAmerely consists of only three single stranded bases (TGA)). Thus, theefficiency of amplification differs between the target DNA (i.e., humanchromosomal genomic or bisulfite-converted DNA) and the standard DNA, ifthe standard is a plasmid or genomic DNA, but more importantly, the“amplification efficiency difference” between (plasmid) standard and thetarget DNA differs from amplification target to amplification target.(i.e., primer pair, probe etc.). This leads to a number of observations,when qPCR is performed on bisulfite treated and amplified DNA, such as,for example:

When different blood cells in a sample shall be measured, independentlyof method as used, the total cell number should be equivalent. However,in a given sample that is equally distributed for the performance ofdifferent qPCR-assays, despite the use of individual standards for eachreaction the total number of copies as detected is different. This leadsto the following problem (here shown with CD3 as an example) in case of(e.g.) blood samples that are measured using different RT-PCR systems:

TABLE 1 Calculation of overall DNA copy numbers and quantitative cellcontent following epigenetic qPCR using bisulfite- treated, amplifiedDNA of a blood sample. (CP) crossing point, (CN-BC) copy numbersbisulfite converted CD3⁺ marker DNA region, (CN-NBC) copy numbersnon-bisulfite converted CD3⁺ marker DNA region, (CN-GAPDH) copy numbersbisulfite converted GAPDH marker DNA region. PCR for CD3⁺ bisulfiteconverted DNA copy numbers acc. to sample plasmid mean copy numbers IDCP standard (CN-BC) WBL02 31.81 114.00 WBL02 30.31 323.00 WBL02 30.17357.00 264.67 WBL03 29.21 692.00 WBL03 29.3 650.00 WBL03 29.12 737.00693.00 PCR for CD3⁺ non-bisulfite converted DNA copy numbers acc. tosample plasmid mean copy numbers ID CP standard (CN-BC) WBL02 27.011410.00 WBL02 26.99 1430.00 WBL02 27.03 1400.00 1413.33 WBL03 27.461070.00 WBL03 27.53 1020.00 WBL03 27.45 1070.00 1053.33 PCR for GAPDHbisulfite converted DNA copy numbers acc. to sample plasmid mean copynumbers ID CP standard (CN-GAPDH) WBL02 27.3 1520.00 WBL02 27.48 1350.00WBL02 27.44 1390.00 1420.00 WBL03 27.47 1360.00 WBL03 27.43 1390.00WBL03 27.42 1400.00 1383.33 Calculation overall DNA copy numbers sampleCN-BC + CN-NBC CN-GAPDH WBL02 1678 1420 WBL03 1746.33 1383.33Calculation of % CD3+ cell content sample$\frac{{CN}\text{-}{BC} \times 100}{\left( {{{CN}\text{-}{BC}} + {{CN}\text{-}{NBC}}} \right)}$$\frac{{CN}\text{-}{BC} \times 100}{{CN}\text{-}{GAPDH}}$ WBL02 15.8%18% WBL03 36.6% 50.1%

As indicated in Table 1, calculated overall CD3⁺ DNA copy numbers differbetween the two used standardization systems: bisulfite-converted vs.non-converted DNA and bisulfite-converted CD3⁺ marker region tobisulfite-converted GAPDH (overall cell) marker region. For the firstblood sample (WBL02), number of CD3⁺ DNA copies calculated via number ofGAPDH bisulfite converted DNA (1420 copies) is smaller than calculatedvia bisulfite converted added to non-bisulfite converted CD3⁺ DNA copynumbers (1678 copies). For the second sample (WBL03) the situation issimilar. Differences become more obvious when using these calculatedcopy numbers for quantification of CD3⁺ cells within these two bloodsamples. For sample WBL02, quantification via bisulfite converted tonon-converted DNA copy numbers results in 36.6% CD3⁺ cells, whereasquantification via bisulfite converted CD3⁺ DNA copy numbers tobisulfite converted GAPDH DNA copy numbers results in 50.1% CD3⁺ cells.Both results and methods differ strongly.

As mentioned, even if normalization on a bisulfite-converted plasmidstandard is performed, the different performances/efficiencies of thedifferent assays do not lead to the same copy number.

This problem becomes particularly apparent, when purified cell types aremeasured with “their” specific epigenetic cell type markers, andcompared to the total amount of cells in the sample (as measured by ancell-type unspecific marker (GAPDH)) as well as measured bynon-bisulfite convertible DNA of a cell-type specific marker region(here FOXP3).

TABLE 2 Assessment of quantitative amount of regulatory T cell (Treg)within two samples of purified Tregs. DNA was isolated, bisulfitetreated and relative amount of bisulfite converted and non-converted DNAassessed via qPCR. Copy numbers of bisulfite converted DNA incell-specific FOXP3 regions were set in relation to copy numbers ofbisulfite converted DNA in cell- unspecific GAPDH region as well as tobisulfite non-converted DNA in cell-type specific FOXP3 regions toobtain quantitative number of Tregs. (CP) crossing point), (CN-BC) copynumbers bisulfite converted cell-type specific FOXP3 DNA region,(CN-NBC) copy numbers non-bisulfite converted cell-type specific FOXP3DNA region (CN-GAPDH) copy numbers bisulfite converted GAPDH DNA region.PCR for FOXP3 bisulfite converted DNA mean copy numbers acc. to sampleplasmid standard ID CP (CN-BC) 88 27.52 2366.6 95 29.73 513.34 PCR forFOXP3 non-bisulfite converted DNA mean copy numbers acc. to sampleplasmid standard ID CP (CN-NBC) 88 32.82 72.54 95 35.48 10.92 PCR forGAPDH bisulfite converted DNA mean copy numbers acc. to sample plasmidstandard ID CP (CN-GAPDH) 88 26.6 2320.00 95 28.91 483.67 Calculation of% Treg cell content sample ID$\frac{{CN}\text{-}{BC} \times 100}{\left( {{{CN}\text{-}{BC}} + {{CN}\text{-}{NBC}}} \right)}$$\frac{{CN}\text{-}{BC} \times 100}{{CN}\text{-}{GAPDH}}$ 88 97.03% 102%95 97.92% 106%

As can be seen from table 2, again, results for both of thequantification methods differ strongly (97% vs. 102% and 97% vs. 106%).

Finally, when different cell fractions, e.g. blood leukocytes, aremeasured that, when added up, should make up all cells in the sample aspresent, the above problem makes it impossible to provide for a correct“complete blood count”. As an example for this, for two blood samplesthe leukocytes were quantified (Table 3, sample 04 and sample 08). Here,the term leukocytes summarize all the five types of white blood cells:granulocytes, monocytes, B-lympocytes, natural killer cells, and CD3⁺T-lymphocytes. Accordingly, it was expected that the single cell countssum up to 100%, representing a (complete) leukocytogram. However, whenusing epigenetic qPCR analyses, this is often not the case (see Table3). The sum of individual quantities of leukocytes often differs from100%.

TABLE 3 Assessment of the quantitative cell composition of two bloodsamples. DNA was isolated, bisulfite treated and relative amount ofbisulfite converted DNA assessed via qPCR. Copy numbers of bisulfiteconverted DNA in cell-specific regions were set in relation to bisulfiteconverted copy numbers of the cell-unspecific DNA region for GAPDH toobtain quantitative number of leukocytes. (CN-BC) copy numbers bisulfiteconverted cell-type specific marker DNA region, (CN-GAPDH) copy numbersbisulfite converted GAPDH marker DNA region. Calculation ofLeukocytogram (% of cells) sample04 sample08 cell type$\frac{{CN}\text{-}{BC} \times 100}{{CN}\text{-}{GAPDH}}$$\frac{{CN}\text{-}{BC} \times 100}{{CN}\text{-}{GAPDH}}$ granulozytes79.74% 81.29% monozytes 7.94% 11.05% B cells 1.63% 1.68% natural killercells 2.74% 2.04% T cells 23.25% 22.09% Sum: 115.3 118.15

When summarizing the above mentioned problems of epigenetic cellquantification, a precise blood counting tool provides the following:

1. allows for the assessment of a precise, comprehensive blood andimmune cell count,

2. overcomes differences in assay performance and/or efficiency betweenstandards as used and the biological sample to be analyzed,

3. is independent of membrane integrity of cells to be counted (intactor non-intact cells), and

4. is independent of type of cell containing sample (fresh, frozen,embedded, stored, fluids, solid tissues).

The present invention provides such a tool, and respective methods.According to the present invention, assessing the epigenetic haemogramcomprises measurement of the absolute amount of cells by normalizationof qPCR results on a bisulfite-unconverted or-converted normalizationstandard. The normalization standards consist of a nucleic acid moleculecomprising at least one marker-region being specific for each of theblood cells to be detected, and at least one control-region beingcell-unspecific, wherein said regions are present in the same number ofcopies on said molecule and/or a natural blood cell sample of knowncomposition.

In a first step of a preferred embodiment of the method, qPCRassay-specific correction factors are determined to achievenormalization and comparability of all qPCR assays as well as to correctfor differences in assay efficiencies. In a second step, DNA ofbiological sample is isolated, purified and bisulfite treated. This isfollowed by qPCR specific for bisulfite-converted cell-type specificand/or cell-type unspecific genomic marker regions. The qPCRamplification results are then normalized with said normalizationstandard, which represents the relative amount of copies of marker DNA,and therefore the relative amount of specific cells. The normalizationstandard contains bisulfite-converted genomic marker regions or containsnative, bisulfite-unconverted, marker regions. Before starting the qPCR,in the latter case the nucleic acid will be bisulfite treated inparallel to the biological sample as analyzed is treated. In a nextstep, following qPCR, the normalized relative amount of copies of markerDNA is corrected by an assay specific correction factor as describedherein in order to correct for differences in assay efficienciesindicating the absolute amount of cells.

The present method allows for a quantification of non-intact but alsointact blood cells in biological samples, such as, for example, dried,frozen, embedded, stored as well as fresh body fluids, dried bloodspots, blood clots and tissue samples. The sample does not containpurified or enriched cells. Furthermore, the method of the presentinvention provides for a blood count, wherein the identity and quantityof cells is based on a clear yes/no information on the genomic levelthat is independent from protein expression levels.

The present invention thus provides a blood and/or immune cell count tobe used as an analytical and diagnostic tool for medical use and as abasis for decisions in therapy.

Preferred is a method according to the present invention, furthermorecomprising the step of obtaining a comprehensive blood picture, based onsaid detecting and quantifying. The blood cell count thus identifies thecomprehensive picture of the cellular composition based on a number ofepigenetic parameters. The combination of these epigenetic parameters isused to identify the cell composition of a blood or tissue sample, i.e.an epigenetic haemogram, and said epigenetic haemogram is provided basedon the analysis of the bisulfite convertibility of cell-specific genomicregions.

Preferably, said epigenetic haemogram resembles a leukocytogram and/or aT-lymphocytogram and/or a granulocytogram and/or a monocytogram and/or aB-lymphocytogram and/or a NK cytogram.

Preferably, the method according to the present invention furthermorecomprises the use of a bisulfite-unconverted or-converted normalizationstandard for the normalization, e.g. of the qPCR results. The term“bisulfite-unconverted” normalization standard encompasses natural DNAmolecules containing the original/primary biologic modifications, suchas formylation, carboxylation, methylation, or hydroxymethylation andthat is not bisulfite-treated, and therefore bisulfite-unconverted. Theterm “bisulfite-converted” normalization standard encompasses DNAmolecules containing (genomic) marker sequences corresponding to alreadybisulfite-converted cell-type specific and unspecific marker regions.

The bisulfite-unconverted or bisulfite-converted nucleic acid moleculeis preferably selected from a plasmid, a yeast artificial chromosome(YAC), human artificial chromosome (HAC), P1-derived artificialchromosome (PAC), a bacterial artificial chromosome (BAC), and aPCR-product. Bisulfite-converted normalization standard is a plasmid,yeast artificial chromosomes (YAC), human artificial chromosome (HAC),P1-derived artificial chromosome (PAC), bacterial artificial chromosome(BAC) or a PCR-product.

The natural blood cell sample preferably is a blood sample of knowncellular composition, and/or of known composition of blood cell types,and is preferably produced in advance, i.e. the amount and number bloodcell types as combined is pre-determined.

In a preferred embodiment of the method according to the invention, thenormalization standard, i.e. the plasmid, YAC, HAC, PAC, BAC, andPCR-product, contains cell-specific and unspecific genomic markerregions (to be analyzed in accordance with the epigenetic haemogram) inthe same known number of copies on said molecule. In one embodiment,each of these standards is a single molecule containing the same numberof all cell-type specific and unspecific genomic marker regions ofinterest in the epigenetic haemogram to be established. The naturalblood cell sample (preferably mammalian, such as human) used as thebisulfite-unconverted normalization standard contains cells in a knowncomposition and quantity, whereby cells can be pre-purified andpre-mixed to obtain a sample of known composition, that is alsopre-determined.

During analytical processing, the bisulfite-unconverted normalizationstandard is bisulfite-treated in parallel and in the same fashion thanthe bisulfite treatment of the biological sample to be analyzed.

Then, qPCR on the unknown biological sample as well as on the (now)bisulfite-treated bisulfite-unconverted normalization standard isperformed using specific primers that help to detect cell-type specificor unspecific bisulfite-converted genomic regions. In contrast, thebisulfite-converted normalization standard will (obviously) not bebisulfite-treated, as it already contains specific marker sequences thatcorrespond to bisulfite-converted marker sequences recognized by qPCRprimers that are specific for bisulfite-converted genomic regions.

In a preferred embodiment, the normalization standard comprises apredetermined amount of blood cells of the types to be detected andanalyzed according to the haemogram. Preferably, a normalizationstandard is used consisting of a defined copy number and samestoichiometric amount of specific cells and/or of cell-type specificand/or cell-type unspecific marker regions. Preferred is a singleplasmid containing the same copy number and/or stoichiometric amount ofcell-type specific and/or cell-type unspecific marker regions for allcell types of interest for the haemogram.

A preferred embodiment of the method according to the inventionfurthermore comprises the step of correcting said epigenetic haemogramas produced with an assay specific correction factor. Saidassay-specific correction factor (for the cells as detected andanalyzed) is determined by comparing the known quantitative amount ofcells in said mammalian natural cell sample as provided with therelative amount of copy numbers of bisulfite-converted cell-typespecific marker DNA of said mammalian natural cell sample assessed bythe qPCR using the normalization standard. Using this approach, thepresent method allows for an accurate quantification of cells, as anyassay-specific variations that may have occurred are taken into account.Depending from the kind of normalization standard as used, the assayspecific correction factors can differ. The more the normalizationstandard and its analytical processing are adapted to the biologicalsample and its processing, the more the assay specific correctionfactors will approach 1, or even can be neglected. In a preferredembodiment, a bisulfite-unconverted normalization standard is used as itresembles the complexity and impureness of natural cell samples, andtherefore the qPCR efficiency between a biological sample and standardshould be aligned. Most preferred is the use of a mammalian natural cellsample of known cell composition and quantity as described herein.

The method according to the present invention then comprises the step ofdetermining the relative amount (of copies) of cell-type specific andunspecific DNA within the biological sample of unknown composition. Thisis achieved by qPCR on isolated, purified and bisulfite-converted DNA ofsaid biological sample under the use of primers specific forbisulfite-converted cell-type specific and unspecific DNA markersequences. qPCR amplification results for all target cell types are thenormalized on said bisulfite-unconverted or converted standardindicating the relative amount of target cells. According to standardsand assays used, specific assay correction factors are applied onrelative amount of target cells to receive the absolute amount andpercentage of the content of cells according to said haemogram asestablished. Thereby, the absolute, comprehensive cellular compositionin said biological sample is determined. Depending from thenormalization standard used, the assay correction factor differs from 1,or is approximately 1, and then can be neglected. Other methods fordetermining the relative amount (of copies) of cell-type specific andunspecific DNA comprise a method selected from specific enzymaticdigests or dye exclusion technologies, bisulfite sequencing, nextgeneration sequencing, nanopore sequencing, single molecule real-timesequencing, analyses of epigenetic modifications in promoter regions,using primers specific for bisulfite-converted DNA, using blockingoligonucleotides specific for bisulfite-converted DNA, usingfluorescence-labeled, quenched oligonucleotide probes, using primers forsingle nucleotide primer extension specific for bisulfite-converted DNA,digital or quantitative PCR analysis, and specific selective (nucleicacid and/or chromatin) precipitation.

Preferred is a method according to the present invention, wherein thedetermination of the relative amount of target cells is based oncomparing the amounts of copies of said bisulfite-convertedcell-specific regions as determined with the amounts of copies of thebisulfite-converted regions that are unspecific for a cell-type asdetermined, thereby identifying the relative amount of a specific celltype in relation to all cells present in the sample.

In one embodiment according to the present invention, the relativeamount of target cells is determined based on comparing the amounts ofcopies of said bisulfite-converted cell-specific regions as determinedwith the amounts of copies of bisulfite-unconverted cell-specificregions as determined, thereby identifying the relative amount of targetcells in relation all other cells present in the sample.

In a preferred embodiment of the method according to the invention,further a knowledge base comprising information about cell-specificassay-correction factors estimated/calculated during previousassessments of epigenetic assays is generated. These values may beadvantageously used in order to select particularly suitablenormalization standards.

In a particularly preferred embodiment of the method according to thepresent invention, cell-type marker regions are detected thatdiscriminate a specific cell type and/or at least one specificsubpopulation of cells from other cells of a leukocytogram, aT-lymphocytogram, a granulocytogram, a monocytogram, a B-lymphocytogramand/or a NK-cytogram. Preferably, a) the leukocytogram consists ofT-lymphocytes, natural killer cells, B-lymphocytes, monocytes and/orgranulocytes, b) the T-lymphocytogram consists of CD3⁺CD4⁺, CD3⁺CD8⁺,CD8⁻CD4⁻, and/or CD8⁺CD4⁺ c) the granulocytogram consists of basophilic,eosinophilic, neutrophilicgranulocytes, and/or granulocyticmyeloid-derived suppressor cells, d) the monocytogram consists of CD14⁺monocytes, CD14⁻ monocytes, macrophages, monocytic myeloid-derivedsuppressor cells, plasmacytoid dendritic cells, myeloid dendritic cells,and/or overall dendritic cells, e) the B-lymphocytogram consists ofnaïve B cells, pre-B cells, memory B cells, transitional B cells and/orimmature B cells, and 1) the NK cytogam consists of CD56^(dim) and/orCD56^(bright) NK cells.

Preferably, within the haemogram as determined sub-haemograms (orsubpopulations) can be determined. Preferred is a T-helper-cytogramcomprising, e.g., Th1, Th2, Th9, Th17, Th19, Th 21, Th22, Tfh, CD4⁺natural killer cells (NKT), naïve CD4⁺, memory CD4⁺, effector CD4⁺cells, and/or CD4⁺ regulatory T cells, or a T-cytotoxogram comprising,e.g., naïve CD8⁺, effector CD8⁺, memory CD8⁺, CD8⁺ natural killer cells(NKT), and/or CD8⁺ regulatory T cells. Furthermore, sub-populations ofmonocytes can be determined, comprising classical monocytes (CD14⁻),intermediate monocytes (CD14⁺) and/or non-classical monocytes (CD14⁺⁺)or a dendritogram comprising myeloid dendritic cells, and plasmacytoiddendritic cells. Future scientific studies may discover and identify yetunknown blood cells and leukocyte subgroups and may will assign newfunctions to certain blood cells and/or will assign known blood cells todifferent leukocyte subpopulations.

To determine the relative amount of bisulfite-convertible and/ornon-bisulfite convertible DNA or nucleic acid comprises a methodselected from specific enzymatic digests or dye exclusion technologies,bisulfite sequencing, next generation sequencing, nanopore sequencing,single molecule real-time sequencing, analyses of epigeneticmodifications in promoter regions, using primers specific forbisulfite-converted DNA, using blocking oligonucleotides specific forbisulfite-converted DNA, using fluorescence-labeled, quenchedoligonucleotide probes, using primers for single nucleotide primerextension specific for bisulfite-converted DNA, digital or quantitativePCR analysis, and specific selective (nucleic acid and/or chromatin)precipitation.

Further preferred is a method according to the present invention,wherein said normalization standard is bisulfite-unconverted andcontains at least one bisulfite-convertible CpG position.

Further preferred is a method according to the present invention,wherein said quantifying of cell types in said biological sample isbased on the normalization of the relative amount of cell-type specificand unspecific chromatin using the bisulfite-unconverted normalizationstandard or using the bisulfite-converted normalization standard.

Even further preferred is a method according to the present invention,wherein said normalization using the bisulfite-unconverted normalizationstandard is indicative for the absolute amount and/or percentage ofcontent of cells within said biological sample.

Even further preferred is a method according to the present invention,wherein said biological sample is a sample of unknown cellularcomposition.

The biological sample as analyzed in the context of the presentinvention is any sample that contains cells to be analyzed, i.e. cellsof the blood and/or immune system, such as cells of a leukocytogram,selected from T-lymphocytes, natural killer cells, B lymphocytes,monocytes, and/or granulocytes, and combinations thereof; aT-lymphocytogram, selected from CD3⁺CD4⁺, CD4⁺ memory, CD4⁺ effectorcells, CD4⁺ naîve, CD3⁺CD8⁺, CD8⁺ memory, CD8⁺ effector cells, CD8⁺naîve, CD3⁺CD8⁺CD4⁺, CD3⁺CD8⁺CD4⁺, NKT cells, iTreg, Treg, Tfh, Th1,Th2, TH9, Th17, Th19, Th21, Th22, memory and/or effector T helper cells,and combinations thereof, a granulocytogram, selected from basophilic,eosinophilic, neutrophilic, overall neutrophil granulocytes, and/orgranulocytic myeloid-derived suppressor cells, and combinations thereof,a monocytogram, selected from CD14⁺ monocytes, CD14-monocyes,macrophages, plasmacytoid dendritic cells, monocytic myeloid-derivedsuppressor cells, intermediate monocyets, classical monocytes,non-classical monocytes, and/or overall dendritic cells, andcombinations thereof, a B-lymphocytogram, selected from naïve B cells,pre B cells, memory B cells, transitional B cells and/or immature Bcells, and combinations thereof, and a NK cytogram, selected fromCD56^(dim) and/or CD56^(bright) NK cells.

The term “cell-specific region(s)” herein shall mean genetic regions inthe genome of cells and/or nucleic acids that are selected todiscriminate on an epigenetic level one cell type and/or subpopulationsof cells from all other cell types and/or subpopulations of cells. Theseregions include the genes of certain markers (such as, for example,certain protein markers), such as 5′ untranslated regions, promoterregions, introns, exons, intron/exon borders, 3′ regions, CpG islands,and in particular include specific regions as amplified after bisulfitetreatment (amplicons) that are “informative” about the one cell typeand/or subpopulations of cells. Examples for these cell-specific regionsare known from the literature, such as, for example, the gene CD3 γ, δand ε (WO 2010/069499); the granulysine gene (WO 2010/125106); the CCR6gene (WO 2011/135088); the FOXP3 gene (WO 2004/050706 and Wieczorek etal. Quantitative DNA methylation analysis of FOXP3 as a new method forcounting regulatory T cells in peripheral blood and solid tissue. CancerRes. 2009 Jan. 15; 69(2):599-608.)

Cell-specific marker region usually are DNA regions that contain singleCpGs or CpG islands that are bisulfite-convertible only in a specificcell type and therefore indicative for the specific cell type.Additionally, these cell-specific marker regions discriminate one celltype from all other blood cells as well as other tissue cells.

According to the present invention, cells of the epigenetic haemogramare identified and quantified by analyzing the bisulfite convertibilityof at least on CpG position in said cell-specific genomic regions.

Thus, preferred is a method according to the present invention, whereina bisulfite conversion of at least one CpG position within a region aslisted in the following table 4 is indicative for the respective bloodcell type as listed in said table. These are e.g. the following genomicmarker regions for the given cell types:

TABLE 4 cell-specific genomic regions ENSEMBL Pos Marker-ID TargetIDSYMBOL Accession (ENSG #) Granulocytes 1 NK_nm1 cg08766149 GZMBNM_004131 00100453 0.91 2 NK_nm2 cg22917487 CX3CR1 NM_001337 001683290.92 3 NK_nm3 cg12445208 ZNF583 NM_152478 00198440 0.77 4 NK_nm4cg02196805 CSF2 NM_000758 00164400 0.78 5 NK_nm5 cg23617121 OSBPL5NT_009237 00021762 0.95 6 NK_nm6 cg20697204 FLJ40172 NM_173649 002396050.78 7 NK_nm7 cg11801011 SHANK1 NM_016148 00161681 0.68 8 NK_nm8cg07873128 OSBPL5 NT_009237 00021762 0.93 9 NK_nm9 cg03368758 LDB2NM_001290 00169744 0.74 10 NK_nm10 cg00515905 EPS8L3 NM_024526 001987580.92 11 NK_nm11 cg22228134 GZMH NM_033423 00100450 0.83 12 NK_nm12cg26379475 SH2D1B NM_053282 00198574 0.79 13 NK_nm13 cg04384208 FCGR3ANM_000569 00203747 0.84 14 NK_nm14 cg00453258 FAM26C NM_00100141200185933 0.71 15 NK_nm15 cg06827976 FGR NM_005248 00000938 0.78 16NK_nm16 cg12491710 LIM2 NM_030657 00105370 0.95 17 NK_nm17 cg18250832NMUR1 NM_006056 00171596 0.76 18 NK_nm18 cg15544721 PPP1R9A XM_37193300158528 0.64 19 NK_nm19 cg25943702 BRD1 NM_014577 00100425 0.80 20NK_nm20 cg04230060 SUSD1 NM_022486 00106868 0.69 21 NK_nm21 cg06229674ARP10 NM_181773 00100298 0.94 22 NK_nm22 cg14701962 C1orf111 NM_18258100171722 0.81 23 NK_nm23 cg16522484 C14orf49 NM_152592 00176438 0.72 24NK_nm24 cg26738080 TNNC1 NM_003280 00114854 0.84 25 NK_nm25 cg13525683TIAF1 NM_004740 00221995 0.81 26 NK_nm26 cg23352030 PRIC285 NM_03340500130589 0.85 27 NK_nm27 cg23282949 RENBP NM_002910 00102032 0.72 28NK_nm28 cg00491404 EPS8L3 NM_024526 00198758 0.88 29 NK_nm29 cg25903122MGC2747 NM_024104 00214046 0.87 30 NK_nm30 cg22202141 FCGR3A NM_00056900203747 0.90 31 NK_nm31 cg11094938 ATP2A1 NM_173201 00196296 0.91 32NK_nm32 cg23580000 ADCY7 NM_001114 00121281 0.80 33 NK_m1 cg12167564LYST NM_000081 00143669 0.30 34 NK_m2 cg18881723 SLAMF1 NM_00303700117090 0.03 35 NK_m3 cg18096388 PDCD1 NM_005018 00188389 0.41 36 NK_m5cg27016307 HRC NM_002152 00130528 0.46 37 NK_m6 cg18818531 FOSL1NM_005438 00175592 0.40 38 NK_m7 cg27067618 CYP4F3 NM_000896 001865290.15 39 NK_m8 cg04790129 ITGB2 NM_000211 00160255 0.13 40 NK_m9cg25944100 MS4A3 NM_006138 00149516 0.10 41 NK_m10 cg09076123 NCF2NM_000433 00116701 0.03 42 NK_m11 cg05275752 GALM NM_138801 001438910.19 43 NK_m12 cg19030554 NME3 NM_002513 00103024 0.15 44 NKT_n1cg02833725 ISG20L2 NM_030980 00143319 0.81 45 NKT_n2 cg06736444 SRRM2NM_016333 00167978 0.84 46 NKT_n3 cg14862827 SUSD1 NM_022486 001068680.62 47 NKT_n4 cg06154597 MGC4618 NM_032326 00127419 0.82 48 NKT_n5cg17267907 DEFA1 NM_004084 00239839 0.80 49 NKT_n6 cg15210427 CST9LNM_080610 00101435 0.82 50 NKT_n7 cg08603768 WNT8A NM_031933 000614920.81 51 NKT_n8 cg14366490 TXNL6 NM_138454 00171773 0.81 52 NKT_n9cg25827666 NTRK1 NM_001007792 00198400 0.86 53 NKT_n10 cg10624445 CNGB1NM_001297 00070729 0.83 54 NKT_n11 cg01605984 SURF5 NM_181491 001482970.77 55 NKT_n12 cg20661303 LEFTY2 NM_003240 00143768 0.74 56 NKT_n13cg12240237 WBSCR23 NM_025042 00006704 0.84 57 NKT_n14 cg14375111 TMEM43NM_024334 00170876 0.92 58 NKT_n15 cg19464252 FBS1 NM_022452 001568600.86 59 NKT_n16 cg14076161 PRB4 NM_002723 00230657 0.82 60 NKT_n17cg10848367 SCGB1D2 NM_006551 00124935 0.78 61 NKT_n18 cg00626119 NTRK1NM_001007792 00198400 0.79 62 NKT_n19 cg13881341 FUT1 NM_000148 001749510.88 63 NKT_n20 cg10779183 ELA3A NM_005747 00142789 0.84 64 NKT_m13cg00754253 HRASLS5 NM_054108 00168004 0.09 65 NKT_m12 cg13492227 FGF11NM_004112 00161958 0.17 66 NKT_m1 cg07233761 ESM1 NM_007036 001642830.09 67 NKT_m2 cg03973663 LYN NM_002350 00254087 0.12 68 NKT_m6cg09082287 DNAJC6 NM_014787 00116675 0.15 69 NKT_m7 cg14289511 FLJ45256NM_207448 00224310 0.09 70 NKT_m8 cg03682712 LOXL1 NM_005576 001290380.04 71 NKT_m3 cg16907566 COL14A1 NM_021110 00187955 0.14 72 NKT_m5cg22854223 CD82 NM_002231 00085117 0.04 73 NKT_m15 cg01305421 IGF1NM_000618 00017427 0.07 74 NKT_m17 cg05989054 GAMT NM_000156 001300050.08 75 NKT_m4 cg26482939 GNA15 NM_002068 00060558 0.06 76 NKT_m16cg20876010 CACHD1 NM_020925 00158966 0.12 77 NKT_m19 cg15526708 TGFBR1NM_004612 00106799 0.15 78 NKT_m14 cg22799850 FBXL13 NM_145032 001610400.07 79 NKT_m18 cg13105904 KIAA0323 NM_015299 00100441 0.13 80 NKT_m20cg22268231 SPIB NM_003121 00269404 0.13 81 NKT_m10 cg10784030 INPP5BNM_005540 00204084 0.08 82 NKT_m11 cg19766460 C21orf128 NM_15250700184385 0.04 83 B_nm1 cg00226923 FGD2 NM_173558 00146192 0.93 84 B_nm2cg03860768 BLK NM_001715 00136573 0.83 85 B_nm3 cg16280667 BLR1NM_001716 00160683 0.88 86 B_nm4 cg14127336 TCL1A NM_021966 001007210.92 87 B_nm5 cg22679120 SNX8 NM_013321 00106266 0.64 88 B_nm6cg16698623 MGMT NT_008818 00170430 0.95 89 B_nm7 cg10115873 DNAJB7NM_145174 00172404 0.68 90 B_nm8 cg27394566 PLD4 NM_138790 00166428 0.7291 B_nm9 cg14102807 CD19 NM_001770 00177455 0.88 92 B_nm10 cg17399166CD1D NM_001766 00158473 0.89 93 B_nm11 cg22194129 CLEC4C NM_13044100198178 0.85 94 B_nm12 cg15121304 — — 00197549 0.89 95 B_nm13cg18979762 EGLN1 NM_022051 00135766 0.80 96 B_nm14 cg03221619 FCER2NM_002002 00104921 0.80 97 B_nm15 cg07597976 CD19 NM_001770 001774550.72 98 B_nm16 cg00126698 BTK NM_000061 00010671 0.63 99 B_nm17cg16098726 GP9 NM_000174 00169704 0.71 100 B_nm18 cg02630207 FLJ10379NM_018079 00068784 0.73 101 B_nm19 cg07790638 LOC91431 NM_138698 — 0.85102 B_nm20 cg06667406 AASS NM_005763 00008311 0.85 103 B_nm21 cg26574610VPREB3 NM_013378 00128218 0.81 104 B_nm22 cg07426848 S100A3 NM_00296000188015 0.88 105 B_nm23 cg23984130 — 0.80 106 B_nm24 cg00113020 LILRB4NM_006847 00186818 0.78 107 B_nm25 cg25769980 TLR6 NM_006068 001741300.90 108 B_nm26 cg16873863 SLC22A18 NM_183233 00110628 0.59 109 B_nm27cg22295573 AQP4 NM_001650 00171885 0.87 110 B_nm28 cg18075299 C14orf54NM_173526 00172717 0.84 111 B_nm29 cg02399455 SRI NM_198901 000751420.88 112 B_nm30 cg10762615 FBXW10 NM_031456 00171931 0.88 113 B_nm31cg18557145 CD72 NM_001782 00137101 0.80 114 B_nm32 cg00374717 ARSGNM_014960 00141337 0.90 115 B_nm33 cg19437319 KIAA0196 NM_01484600164961 0.90 116 B_nm34 cg14959707 ZC3H7A NM_014153 00122299 0.89 117B_nm35 cg18152830 TNFRSF13B NM_012452 00240505 0.92 118 B_nm36cg16593081 DYX1C1 NM_001033559 00256061 0.91 119 B_nm37 cg26394380 SFTPBNM_000542 00168878 0.66 120 B_nm38 cg01909245 LSP1 NM_002339 001305920.87 121 B_nm39 cg03270204 DDR1 NM_001954 00204580 0.94 122 B_nm40cg11042320 PDGFRB NM_002609 00113721 0.67 123 B_nm41 cg08251036 MGAT5NM_002410 00152127 0.83 124 B_nm42 cg05921699 CD79A NM_001783 001053690.84 125 B_nm43 cg25211252 KCNMB3 NM_014407 00171121 0.86 126 B_nm44cg21960110 HBZ NM_005332 00130656 0.85 127 B_m1 cg27398547 C14orf39NM_174978 00179008 0.27 128 B_m2 cg22226839 ATP2B4 NM_001684 000586680.16 129 B_m3 cg11997899 DLX5 NM_005221 00105880 0.30 130 B_m4cg19350340 ASPM NM_018136 00066279 0.14 131 B_m5 cg00049986 C14orf10NM_017917 00092020 0.17 132 B_m6 cg08360728 GPATC3 NM_022078 001987460.28 133 B_m7 cg01222684 TTC1 NM_003314 00113312 0.06 134 B_m8cg00571634 WDR5B NM_019069 00196981 0.18 135 B_m9 cg18908499 C1orf150NM_145278 00169224 0.13 136 B_m10 cg00678539 MNS1 NM_018365 001385870.12 137 B_m11 cg19756611 DACH1 NM_004392 00165659 0.17 138 B_m12cg23668631 CAMKK1 NM_032294 00004660 0.10 139 B_m13 cg18967846 CLDN12NM_012129 00157224 0.14 140 B_m14 cg25482967 MRPS10 NM_018141 000485440.12 141 B_m15 cg06751597 SNAP23 NM_003825 00092531 0.07 142 B_m16cg22285621 SSH3 NM_018276 00172830 0.01 143 B_m17 cg17378989 ERCC1NM_202001 00012061 0.11 144 B_m18 cg03825921 RAB4A NM_004578 001681180.11 145 B_m19 cg11250058 RAPH1 NM_203365 00173166 0.06 146 B_m20cg03643709 VPS18 NM_020857 00104142 0.18 147 B_m21 cg24641737 DENND2DNM_024901 00162777 0.03 148 B_m22 cg07732037 MPHOSPH9 NM_022782 000518250.27 149 B_m23 cg05091653 SP100 NM_003113 00067066 0.08 150 B_m24cg16007628 ZNF207 NM_001032293 00010244 0.13 151 B_m25 cg26954174 CARD15NM_022162 00167207 0.07 152 B_m26 cg01988129 ADHFE1 NM_144650 001475760.16 153 CD8_nm1 cg18149207 RORC NM_005060 00143365 0.83 154 CD8_nm2cg02519218 CHFR NT_024477 00072609 0.85 155 CD8_nm3 cg21755709 C21orf124NM_032920 00136014 0.66 156 CD8_nm4 cg24019564 RUNX3 NT_004610 000206330.55 157 CD8_nm5 cg19700658 UCP3 NM_003356 00175564 0.83 158 CD8_nm6cg14027234 CD248 NM_020404 00174807 0.83 159 CD8_nm7 cg03024246 JRKLNM_003772 00183340 0.69 160 CD8_nm8 cg21232015 CHFR NT_024477 000726090.87 161 CD8_nm9 cg12108912 MGC10993 NM_030577 00144120 0.82 162CD8_nm10 cg17505463 GGT3 NM_002058 00197421 0.82 163 CD8_nm11 cg07232688LRRC39 NM_144620 00122477 0.71 164 CD8_m1 cg26848126 CYSLTR1 NM_00663900173198 0.12 165 CD8_m3 cg25511807 MMP7 NM_002423 00137673 0.09 166CD8_m4 cg16604516 FBLN2 NM_001004019 00163520 0.19 167 CD8_m5 cg23771929FREQ NM_014286 00107130 0.20 168 CD8_m6 cg20340242 IL1R2 NM_00463300115590 0.03 169 CD8_m7 cg09106999 CDK2 NM_001798 00123374 0.07 170CD8_m8 cg00516481 PDE9A NM_002606 00160191 0.19 171 CD8_m9 cg22054164ECE1 NM_001397 00117298 0.17 172 CD8_m10 cg06415153 PITPNM2 NM_02084500090975 0.19 173 CD8_m11 cg22778947 FSD1NL NM_031919 00106701 0.16 174CD8_m12 cg03627896 LOC283932 NM_175901 — 0.34 175 CD8_m13 cg00833777ITGAM NM_000632 00169896 0.08 176 CD8_m14 cg01356829 IL12RB2 NM_00155900081985 0.08 177 CD8_m15 cg18661868 FES NM_002005 00182511 0.08 178CD8_m16 cg08899626 LDB2 NM_001290 00169744 0.05 179 CD8_m17 cg14700707NOTCH4 NM_004557 00204301 0.05 180 CD4_nm1 cg03602500 FLJ00060 NM_03320600104970 0.86 181 CD4_nm2 cg16470760 CD4 NM_000616 00010610 0.74 182CD4_nm3 cg02989940 ERAF NM_016633 00169877 0.90 183 CD4_nm4 cg22972055UNC84A NM_025154 00164828 0.91 184 CD4_nm5 cg22335340 PTPN6 NM_00283100111679 0.66 185 CD4_nm6 cg08214029 CCL18 NM_002988 00006074 0.74 186CD4_nm7 cg02385474 PCNXL2 NM_024938 00135749 0.78 187 CD4_nm8 cg01782486ZBTB7B NM_015872 00160685 0.75 188 CD4_nm9 cg25598083 ACOT2 NM_00682100119673 0.85 189 CD4_nm10 cg07327347 AQP8 NM_001169 00103375 0.88 190CD4_nm11 cg12703269 PSTPIP1 NM_003978 00140368 0.82 191 CD4_nm12cg23909633 IL24 NM_181339 00162892 0.87 192 CD4_nm13 cg18669588 PTK9LNM_007284 00247596 0.80 193 CD4_m1 cg25655096 GPR92 NM_020400 001845740.44 194 CD4_m2 cg05697976 MLSTD1 NM_018099 00064763 0.09 195 CD4_m3cg10521852 EDG4 NM_004720 00064547 0.07 196 CD4_m4 cg08159444 PNMA5NM_052926 00198883 0.26 197 CD4_m5 cg00443307 KLRG1 NM_005810 001391870.37 198 CD4_m6 cg04541607 CRYBB1 NM_001887 00100122 0.06 199 CD4_m7cg03085312 RARA NM_001024809 00131759 0.16 200 CD4_m8 cg20764656 GPX2NM_002083 00176153 0.04 201 CD4_m9 cg07837085 SLAMF7 NM_021181 000267510.06 202 CD4_m10 cg18440048 ZNF70 NM_021916 00187792 0.12 203 CD4_m11cg18752880 C1QTNF3 NM_181435 00082196 0.06 204 CD4_m12 cg24576425 GALNT5NM_014568 00136542 0.11 205 CD4_m13 cg18055007 DDAH2 NM_013974 002266340.11 206 CD4_m14 cg14913610 KLRG1 NM_005810 00139187 0.06 207 CD4_m15cg00563926 TGFBR3 NM_003243 00069702 0.11 208 CD4_m16 cg05252264 FCARNM_002000 00186431 0.06 209 CD4_m17 cg16465939 KCNQ1 NT_009237 000539180.05 210 CD4_m18 cg19963522 PIP3-E NM_015553 00074706 0.09 211 CD4_m19cg05512099 PLEKHF1 NM_024310 00166289 0.15 212 CD4_m20 cg07376232 AMICA1NM_153206 00160593 0.05 213 CD4_m21 cg18059933 TP53INP1 NM_03328500164938 0.23 214 MOC_nm1 cg02780988 KRTHA6 NM_003771 00126337 0.71 215MOC_nm2 cg18854666 SLC11A1 NM_000578 00018280 0.61 216 MOC_nm3cg18589858 SLCO2B1 NM_007256 00137491 0.73 217 MOC_nm4 cg22456522 LILRB3NM_006864 00204577 0.84 218 MOC_nm5 cg27443224 CCL21 NM_002989 001370770.67 219 MOC_nm6 cg22954818 APOBEC3A NM_145699 00128383 0.55 220 MOC_nm7cg05445326 TM4SF19 NM_138461 00145107 0.91 221 MOC_nm8 cg10045881 CHI3L2NM_001025197 00064886 0.61 222 MOC_nm9 cg11051139 LOC144501 NM_18250700167767 0.58 223 MOC_nm11 cg01193293 SIGLEC7 NM_014385 00168995 0.65224 MOC_nm12 cg04387658 CD86 NM_006889 00114013 0.55 225 MOC_nm13cg22319147 CDH5 NM_001795 00179776 0.56 226 MOC_nm14 cg13253729 RgrNM_153615 00159496 0.85 227 MOC_nm15 cg00412772 C19orf33 NM_03352000167644 0.57 228 MOC_nm16 cg07986773 NUP50 NM_153645 00093000 0.85 229MOC_nm17 cg06407137 CD300LB NM_174892 00178789 0.78 230 MOC_nm18cg12564453 CETP NM_000078 00087237 0.61 231 MOC_nm19 cg02497428 IGSF6NM_005849 00140749 0.92 232 MOC_nm20 cg16501235 C1orf54 NM_02457900118292 0.83 233 MOC_meth1 cg05044994 FLJ42393 NM_207488 00213132 0.47234 MOC_meth2 cg23213217 DEGS1 NM_144780 00143753 0.04 235 MOC_meth3cg24921858 BCL2L14 NM_030766 00121380 0.48 236 MOC_meth4 cg07747299C21orf56 NM_032261 00160284 0.47 237 MOC_meth5 cg20839025 PRSS7NM_002772 00154646 0.43 238 MOC_meth6 cg15551881 TRAF1 NM_00565800056558 0.08 239 MOC_meth7 cg17233935 DSCR10 NM_148676 00233316 0.46240 MOC_meth8 cg07376029 GC NM_000583 00145321 0.47 241 MOC_meth9cg14893161 FLJ32569 NM_152491 00162877 0.36 242 MOC_meth10 cg24884084SPRR1B NM_003125 00169469 0.45 243 MOC_meth11 cg12022621 LAX1 NM_01777300122188 0.48 244 MOC_meth12 cg16399745 CNAP1 NM_014865 00010292 0.45245 MOC_meth13 cg10117369 LAX1 NM_017773 00122188 0.46 246 MOC_meth14cg24988345 SCHIP1 NM_014575 00250588 0.44 247 MOC_meth15 cg03427831MTHFR NM_005957 00177000 0.36 248 MOC_meth16 cg05546044 MAPK1 NM_00274500100030 0.30 249 GRC_nm1 cg22381196 DHODH NM_001361 00102967 0.05 250GRC_nm2 cg06270401 DYRK4 NM_003845 00010219 0.06 251 GRC_nm3 cg22266967S100P NM_005980 00163993 0.08 252 GRC_nm4 cg21283680 SH3BP5 NM_00484400131370 0.12 253 GRC_nm5 cg20720686 POR NM_000941 00127948 0.15 254GRC_nm6 cg12949760 KCNQ1 NT_009237 00053918 0.17 255 GRC_nm7 cg01718139UNQ3033 NM_198481 00189068 0.18 256 GRC_nm8 cg05681757 FGD4 NM_13924100139132 0.19 257 GRC_nm9 cg00145118 GNPDA1 NM_005471 00113552 0.19 258GRC_nm10 cg10758292 DEFA1 NM_004084 00206047 0.20 259 nGRC_nm11cg22438810 LCN2 NM_005564 00148346 0.20 260 GRC_nm12 cg02593766 EPN3NM_017957 00049283 0.20 261 GRC_nm13 cg06625767 F12 NM_000505 001311870.21 262 GRC_nm14 cg18934187 STARD6 NM_139171 00174448 0.22 263 GRC_nm15cg26306976 ITGB1BP1 NM_022334 00119185 0.22 264 GRC_nm16 cg09948350FLJ25084 NM_152792 00244617 0.23 265 GRC_nm17 cg13265003 SLC37A1NM_018964 00160190 0.24 266 GRC_nm18 cg25600606 HIPK3 NM_005734 001104220.25 267 GRC_nm19 cg12788313 MST1 NM_020998 00173531 0.26 268 GRC_nm20cg17051440 CLDN2 NM_020384 00165376 0.27 269 GRC_nm21 cg24422489 FCGR2ANM_021642 00143226 0.27 270 GRC_nm22 cg15361231 GLRX2 NM_016066 000235720.27 271 GRC_nm23 cg10591659 NYX NM_022567 00188937 0.28 272 GRC_nm24cg20098659 CLEC9A NM_207345 00197992 0.29 273 GRC_nm25 cg16504798 MYO1FNM_012335 00142347 0.30 274 GRC_nm26 cg15379858 ChGn NM_018371 001474080.31 275 GRC_nm27 cg07423149 CHI3L1 NM_001276 00133048 0.32 276 GRC_nm28cg17823175 AZU1 NM_001700 00172232 0.35 277 GRC_nm29 cg21685427 SGK2NM_016276 00101049 0.36 278 GRC_nm30 cg11849692 LDB1 NM_003893 001987280.36 279 GRC_nm31 cg22286764 C3orf35 NM_178339 00198590 0.37 280GRC_nm32 cg18530324 KIAA0427 NM_014772 00134030 0.38 281 GRC_nm33cg22630748 INHBE NM_031479 00139269 0.39 282 GRC_nm34 cg03311899 GPR109ANM_177551 00182782 0.43 283 GRC_nm35 cg00840516 HYAL2 NM_003773 002619210.43 284 GRC_nm36 cg02039171 CEBPE NM_001805 00092067 0.43 285 GRC_nm37cg05826823 CIZ1 NM_012127 00148337 0.46 286 GRC_m1 cg02212836 LY86NM_004271 00112799 0.90 287 GRC_m2 cg08136806 KRT6E NM_173086 001704650.65 288 GRC_m3 cg18959422 MYBPH NM_004997 00133055 0.64 289 GRC_m4cg05106502 SCAP1 NM_003726 00141293 0.61 290 GRC_m5 cg10896774 C7orf34NM_178829 00165131 0.55 291 GRC_m6 cg00323915 GIMAP4 NM_018326 001335740.55 292 GRC_m7 cg12605747 RPL4 NM_000968 00174444 0.54 293 GRC_m8cg15625636 GPR65 NM_003608 00140030 0.54 294 GRC_m9 cg12810837 CLEC2DNM_001004419 00069493 0.52 295 GRC_m10 cg26839325 BMP15 NM_00544800130385 0.52 296 eGRC_nm1 NA PRG2 00186652 NA 297 OTL_nm1 cg07728874CD3D NM_000732.3 00167286 0.87 298 OTL_nm2 cg24841244 CD3D NM_000732.300167286 0.83 299 OTL_nm3 cg15880738 CD3G NM_000073.1 00160654 0.87 300OTL_nm4 cg07545925 CD3G NM_000073.1 00160654 0.78 301 OTL_nm05cg24612198 CD3E NM_000733.2 00198851 0.74 302 OTL_nm06 cg04759756 SLA2NM_032214.2 00101082 0.91 303 OTL_nm07 cg08539991 ZBTB32 NM_014383.100011590 0.84 304 OTL_nm08 cg18350391 IL32 NM_001012631.1 00008517 0.82305 OTL_nm09 cg19812619 ITGB7 NM_000889.1 00139626 0.90 306 OTL_nm10cg20366831 APBA3 NM_004886.3 00011132 0.68 307 OTL_nm11 cg22670733CHRNA3 NM_000743.2 00080644 0.78 308 OTL_nm12 cg16173109 FLJ38379XR_001026.1 00204098 0.87 309 OTL_nm13 cg00620024 PPP6C NM_002721.300119414 0.86 310 OTL_nm14 cg15503752 ST6GALNAC1 NM_018414.2 000705260.75 311 OTL_nm15 cg15055101 SH2D3A NM_005490.1 00125731 0.77 312OTL_nm16 cg18149207 RORC NM_005060.3 00143365 0.85 313 OTL_nm17cg16854606 DAND5 NM_152654.2 00179284 0.66 314 OTL_m1 cg24091474 TYROBPNM_003332.2 00011600 0.12 315 OTL_m2 cg25957124 DNAH3 NM_017539.100158486 0.05 316 OTL_m3 cg01526089 P2RX1 NM_002558.2 00108405 0.03 317OTL_m4 cg12971694 CD72 NM_001782.1 00137101 0.11 318 OTL_m5 cg19906550SLC22A18 NM_183233.1 00110628 0.03 319 OTL_m6 cg17468997 NCF1NM_000265.1 00158517 0.12 320 OTL_m7 cg19399532 FLJ35530 NM_207467.100204482 0.07 321 OTL_m8 cg09208010 MMP14 NM_004995.2 00157227 0.09 322OTL_m9 cg15512851 FGD2 NM_173558.2 00146192 0.12 323 OTL_m10 cg20191453AMT NM_000481.2 00145020 0.16 324 OTL_m11 cg24453664 CD59 NM_203331.100085063 0.07 325 OTL_m12 cg10257049 C5orf4 NM_032385.1 00170271 0.07326 OTL_m13 cg16003913 MPG NM_001015052.1 00103152 0.05 327 OTL_m14cg14088811 SPI1 NM_003120.1 00066336 0.10 328 OTL_m15 cg15146752 EPHA2NM_004431.2 00142627 0.26 329 OTL_m16 cg02082571 CLEC4A NM_016184.200111729 0.23 330 OTL_m17 cg16989646 SLC25A15 NM_014252.1 00102743 0.04331 OTL_m18 cg03574571 CD22 NM_001771.1 00012124 0.12 332 OTL_m19cg13703437 FYB NM_199335.2 00082074 0.12 333 OTL_m20 cg21237418 RAB34NM_031934.3 00109113 0.04 334 OTL_m21 cg01129847 C19orf35 NM_198532.100188305 0.08 335 OTL_m22 cg16139316 S100A9 NM_002965.2 00163220 0.06336 OTL_m23 cg00666746 SYDE1 NM_033025.4 00105137 0.08 337 OTL_m24cg20050826 K6IRS2 NM_080747.1 00170486 0.14 338 OTL_m25 cg12876594 NPR2NM_000907.2 00139626 0.23 339 OTL_m26 cg17105014 GYPC NM_002101.300136732 0.13 340 OTL_m27 cg03886110 PECAM1 NM_000442.2 00261371 0.05341 OTL_m28 cg14324675 LST1 NM_205838.1 00204482 0.05 342 OTL_m29cg08519905 CD9 NM_001769.2 00010278 0.10 SEQ ID Discovery fragment/ CD4+cytotoxic SEQ ID Pos Monocytes cells T-cells B-cells NK-cells NK T's ROI 1 0.90 0.87 0.89 0.57 0.13 1/2  2 0.92 0.94 0.92 0.57 0.13 3/4  3 0.830.76 0.64 0.73 0.18 0.54 5/6  4 0.78 0.50 0.60 0.77 0.22 0.52 7/8  50.95 0.92 0.89 0.85 0.22 0.81  9/10  6 0.89 0.91 0.83 0.73 0.23 11/12  70.62 0.64 0.72 0.56 0.26 13/14  8 0.94 0.93 0.93 0.60 0.27 15/16  9 0.780.75 0.71 0.67 0.27 0.68 17/18  10 0.93 0.92 0.94 0.84 0.29 19/20  110.90 0.90 0.89 0.53 0.30 21/22  12 0.79 0.64 0.64 0.59 0.32 0.61 23/24 13 0.87 0.82 0.83 0.71 0.32 25/26  14 0.71 0.85 0.82 0.92 0.33 27/28 15 0.83 0.88 0.80 0.78 0.35 0.60 29/30  16 0.94 0.93 0.93 0.86 0.3631/32  17 0.72 0.78 0.74 0.77 0.38 33/34  18 0.76 0.85 0.88 0.53 0.3835/36  19 0.84 0.80 0.78 0.73 0.38 0.71 37/38  20 0.69 0.91 0.87 0.710.39 0.84 39/40  21 0.95 0.93 0.92 0.50 0.40 41/42  22 0.85 0.79 0.770.74 0.41 0.69 43/44  23 0.80 0.74 0.74 0.53 0.42 45/46  24 0.76 0.870.86 0.66 0.42 47/48  25 0.83 0.78 0.77 0.75 0.42 0.75 49/50  26 0.820.95 0.94 0.90 0.43 51/52  27 0.76 0.91 0.85 0.86 0.44 0.81 53/54  280.83 0.88 0.87 0.79 0.45 55/56  29 0.92 0.92 0.89 0.68 0.48 57/58  300.87 0.88 0.89 0.58 0.48 59/60  31 0.85 0.90 0.90 0.92 0.49 61/62  320.81 0.96 0.94 0.92 0.49 63/64  33 0.13 0.47 0.50 0.36 0.68 0.37 65/66 34 0.03 0.03 0.05 0.08 0.66 67/68  35 0.50 0.11 0.20 0.36 0.65 0.2569/70  36 0.44 0.21 0.33 0.30 0.56 0.11 71/72  37 0.42 0.17 0.17 0.370.56 0.25 73/74  38 0.29 0.38 0.41 0.40 0.55 0.23 75/76  39 0.24 0.350.40 0.13 0.54 0.39 77/78  40 0.20 0.46 0.41 0.40 0.54 0.38 79/80  410.07 0.28 0.31 0.24 0.53 0.13 81/82  42 0.18 0.29 0.44 0.30 0.52 0.3383/84  43 0.36 0.29 0.34 0.49 0.51 85/86  44 0.86 0.52 0.55 0.63 0.880.15 87/88  45 0.87 0.59 0.59 0.53 0.86 0.25 89/90  46 0.62 0.59 0.710.55 0.65 0.17 91/92  47 0.84 0.61 0.58 0.83 0.62 0.27 93/94  48 0.830.71 0.54 0.77 0.56 0.32 95/96  49 0.88 0.56 0.63 0.62 0.79 0.34 97/98 50 0.81 0.54 0.51 0.59 0.66 0.28  99/100  51 0.81 0.51 0.56 0.58 0.740.30 101/102  52 0.86 0.63 0.64 0.82 0.57 0.36 103/104  53 0.86 0.580.58 0.64 0.82 0.35 105/106  54 0.86 0.51 0.55 0.62 0.81 0.32 107/108 55 0.75 0.59 0.65 0.77 0.86 0.39 109/110  56 0.86 0.51 0.53 0.60 0.770.36 111/112  57 0.95 0.62 0.61 0.65 0.89 0.45 113/114  58 0.90 0.620.54 0.55 0.83 0.40 115/116  59 0.78 0.52 0.53 0.64 0.76 0.36 117/118 60 0.78 0.55 0.60 0.56 0.68 0.34 119/120  61 0.82 0.59 0.61 0.80 0.570.38 121/122  62 0.86 0.65 0.67 0.69 0.80 0.45 123/124  63 0.85 0.580.64 0.70 0.72 0.42 125/126  64 0.37 0.33 0.40 0.44 0.50 0.70 127/128 65 0.20 0.50 0.45 0.31 0.38 0.69 129/130  66 0.08 0.37 0.38 0.05 0.160.68 131/132  67 0.11 0.39 0.42 0.24 0.14 0.66 133/134  68 0.15 0.410.35 0.30 0.24 0.66 135/136  69 0.10 0.45 0.40 0.23 0.12 0.62 137/138 70 0.12 0.47 0.46 0.23 0.10 0.62 139/140  71 0.14 0.28 0.35 0.19 0.130.62 141/142  72 0.04 0.42 0.43 0.13 0.19 0.61 143/144  73 0.06 0.420.47 0.24 0.36 0.61 145/146  74 0.08 0.44 0.37 0.11 0.17 0.55 147/148 75 0.04 0.24 0.28 0.09 0.10 0.55 149/150  76 0.12 0.31 0.28 0.20 0.180.54 151/152  77 0.13 0.31 0.36 0.13 0.15 0.54 153/154  78 0.07 0.310.48 0.07 0.18 0.54 155/156  79 0.20 0.13 0.28 0.16 0.30 0.53 157/158 80 0.08 0.36 0.45 0.06 0.14 0.53 159/160  81 0.08 0.23 0.17 0.11 0.130.49 161/162  82 0.04 0.06 0.24 0.04 0.06 0.44 163/164  83 0.96 0.950.96 0.10 0.95 165/166  84 0.88 0.87 0.86 0.11 0.82 167/168  85 0.870.87 0.90 0.14 0.89 169/170  86 0.92 0.92 0.92 0.14 0.93 171/172  870.65 0.59 0.63 0.15 0.72 0.64 173/174  88 0.94 0.96 0.97 0.15 0.93175/176  89 0.80 0.80 0.75 0.16 0.79 177/178  90 0.56 0.88 0.89 0.160.85 179/180  91 0.90 0.92 0.93 0.16 0.89 181/182  92 0.81 0.88 0.880.17 0.87 183/184  93 0.88 0.90 0.92 0.17 0.85 185/186  94 0.85 0.730.80 0.18 0.64 187/188  95 0.84 0.83 0.81 0.19 0.72 189/190  96 0.730.75 0.71 0.19 0.76 0.59 191/192  97 0.63 0.63 0.68 0.20 0.60 0.58193/194  98 0.62 0.86 0.77 0.20 0.76 0.81 195/196  99 0.82 0.92 0.910.20 0.87 197/198 100 0.74 0.71 0.68 0.21 0.65 0.67  199/200/ 101 0.870.83 0.82 0.21 0.79 201/202 102 0.84 0.85 0.83 0.22 0.81 203/204 1030.84 0.87 0.89 0.22 0.83 205/206 104 0.89 0.93 0.92 0.22 0.87 207/208105 0.80 0.69 0.60 0.24 0.59 0.68 209/210 106 0.77 0.77 0.69 0.24 0.560.73 211/212 107 0.90 0.87 0.87 0.25 0.81 213/214 108 0.61 0.75 0.760.25 0.74 0.71 215/216 109 0.90 0.87 0.89 0.25 0.84 217/218 110 0.890.85 0.89 0.26 0.86 219/220 111 0.87 0.90 0.86 0.26 0.78 221/222 1120.89 0.88 0.85 0.26 0.83 223/224 113 0.87 0.89 0.91 0.26 0.83 0.84225/226 114 0.91 0.85 0.85 0.26 0.85 227/228 115 0.89 0.86 0.84 0.260.87 229/230 116 0.89 0.89 0.92 0.27 0.89 231/232 117 0.91 0.86 0.910.27 0.91 0.86 233/234 118 0.92 0.89 0.88 0.28 0.87 235/236 119 0.800.72 0.75 0.29 0.86 0.70 237/238 120 0.84 0.64 0.63 0.30 0.71 0.62239/240 121 0.92 0.84 0.92 0.31 0.94 241/242 122 0.74 0.73 0.79 0.320.63 0.73 243/244 123 0.87 0.83 0.79 0.32 0.68 0.83 245/246 124 0.810.80 0.67 0.32 0.70 0.78 247/248 125 0.83 0.83 0.83 0.34 0.83 0.80249/250 126 0.88 0.80 0.69 0.36 0.81 0.57 251/252 127 0.19 0.22 0.210.73 0.26 253/254 128 0.18 0.25 0.23 0.72 0.34 255/256 129 0.23 0.290.21 0.72 0.28 257/258 130 0.13 0.16 0.20 0.72 0.22 259/260 131 0.110.21 0.17 0.70 0.20 261/262 132 0.31 0.33 0.24 0.69 0.31 263/264 1330.05 0.10 0.05 0.66 0.14 265/266 134 0.18 0.16 0.16 0.65 0.20 267/268135 0.13 0.20 0.16 0.65 0.23 269/270 136 0.13 0.19 0.18 0.60 0.15271/272 137 0.07 0.15 0.14 0.59 0.26 273/274 138 0.22 0.36 0.44 0.580.44 0.35 275/276 139 0.14 0.16 0.10 0.58 0.24 277/278 140 0.09 0.140.11 0.56 0.17 279/280 141 0.07 0.11 0.09 0.56 0.07 281/282 142 0.080.05 0.11 0.55 0.07 283/284 143 0.12 0.12 0.12 0.55 0.17 285/286 1440.11 0.14 0.13 0.55 0.18 287/288 145 0.08 0.07 0.24 0.55 0.09 289/290146 0.13 0.19 0.10 0.54 0.22 291/292 147 0.03 0.04 0.03 0.54 0.05293/294 148 0.47 0.06 0.10 0.53 0.25 0.09 295/296 149 0.06 0.04 0.050.52 0.06 297/298 150 0.15 0.17 0.15 0.52 0.18 0.22 299/300 151 0.070.25 0.38 0.51 0.14 0.26 301/302 152 0.18 0.20 0.22 0.50 0.20 0.19303/304 153 0.87 0.65 0.31 0.65 0.75 305/306 154 0.84 0.52 0.39 0.600.71 0.62 307/308 155 0.71 0.65 0.43 0.63 0.64 0.66 309/310 156 0.750.67 0.44 0.74 0.51 0.62 311/312 157 0.84 0.69 0.44 0.78 0.54 0.54313/314 158 0.83 0.82 0.45 0.71 0.82 315/316 159 0.78 0.77 0.45 0.530.63 0.67 317/318 160 0.88 0.61 0.46 0.63 0.81 0.73 319/320 161 0.850.50 0.47 0.57 0.73 0.77 321/322 162 0.80 0.59 0.47 0.69 0.66 0.60323/324 163 0.75 0.72 0.47 0.59 0.50 0.64 325/326 164 0.04 0.18 0.720.26 0.10 327/328 165 0.09 0.43 0.62 0.27 0.44 329/330 166 0.15 0.400.61 0.16 0.15 331/332 167 0.21 0.46 0.60 0.28 0.34 0.46 333/334 1680.04 0.44 0.60 0.18 0.42 335/336 169 0.08 0.48 0.60 0.29 0.29 337/338170 0.18 0.49 0.57 0.18 0.32 0.46 339/340 171 0.09 0.28 0.57 0.17 0.42341/342 172 0.12 0.39 0.56 0.22 0.40 343/344 173 0.18 0.50 0.55 0.180.33 345/346 174 0.41 0.31 0.53 0.21 0.31 0.12 347/348 175 0.09 0.420.52 0.25 0.16 349/350 176 0.07 0.38 0.52 0.15 0.12 0.16 351/352 1770.11 0.34 0.51 0.29 0.13 353/354 178 0.09 0.18 0.51 0.18 0.12 355/356179 0.05 0.39 0.50 0.14 0.35 0.30 357/358 180 0.85 0.26 0.52 0.66 0.87359/360 181 0.70 0.31 0.61 0.68 0.66 0.67 361/362 182 0.87 0.39 0.640.55 0.79 0.72 363/364 183 0.93 0.42 0.64 0.50 0.89 365/366 184 0.730.42 0.64 0.59 0.78 0.57 367/368 185 0.78 0.42 0.76 0.58 0.80 0.72369/370 186 0.78 0.43 0.52 0.54 0.65 0.62 371/372 187 0.82 0.44 0.880.52 0.81 0.83 373/374 188 0.86 0.44 0.55 0.65 0.72 0.54 375/376 1890.65 0.46 0.70 0.67 0.79 0.54 377/378 190 0.82 0.46 0.61 0.80 0.84 0.59379/380 191 0.87 0.48 0.65 0.74 0.76 0.80 381/382 192 0.83 0.50 0.640.75 0.77 0.62 383/384 193 0.19 0.69 0.49 0.19 0.13 385/386 194 0.140.62 0.50 0.42 0.36 0.48 387/388 195 0.08 0.61 0.41 0.22 0.22 0.35389/390 196 0.06 0.61 0.48 0.48 0.46 391/392 197 0.22 0.60 0.38 0.340.35 0.29 393/394 198 0.10 0.59 0.46 0.14 0.47 395/396 199 0.15 0.590.38 0.18 0.17 0.39 397/398 200 0.06 0.58 0.47 0.17 0.12 0.34 399/400201 0.07 0.57 0.35 0.27 0.07 401/402 202 0.17 0.56 0.21 0.13 0.20 0.34403/404 203 0.29 0.56 0.46 0.46 0.15 0.21 405/406 204 0.08 0.56 0.460.26 0.24 0.46 407/408 205 0.08 0.55 0.21 0.15 0.13 0.14 409/410 2060.07 0.55 0.43 0.18 0.16 0.17 411/412 207 0.10 0.55 0.15 0.18 0.17 0.38413/414 208 0.08 0.55 0.47 0.21 0.38 415/416 209 0.05 0.54 0.22 0.280.11 417/418 210 0.11 0.54 0.38 0.19 0.32 0.46 419/420 211 0.19 0.540.42 0.18 0.11 0.21 421/422 212 0.03 0.52 0.36 0.21 0.20 423/424 2130.16 0.50 0.43 0.10 0.10 0.31 425/426 214 0.08 0.69 0.64 0.54 0.64 0.62427/428 215 0.14 0.94 0.94 0.79 0.92 429/430 216 0.15 0.89 0.86 0.580.81 431/432 217 0.17 0.80 0.83 0.68 0.80 433/434 218 0.17 0.63 0.600.52 0.52 0.64 435/436 219 0.20 0.65 0.61 0.50 0.65 0.64 437/438 2200.21 0.93 0.93 0.58 0.64 439/440 221 0.21 0.66 0.73 0.62 0.69 0.77441/442 222 0.21 0.76 0.77 0.74 0.70 0.71 443/444 223 0.29 0.66 0.660.60 0.50 445/446 224 0.33 0.76 0.72 0.58 0.57 0.80 447/448 225 0.340.95 0.95 0.72 0.90 449/450 226 0.41 0.94 0.93 0.53 0.90 451/452 2270.42 0.74 0.72 0.52 0.62 453/454 228 0.42 0.90 0.89 0.77 0.83 455/456229 0.42 0.84 0.79 0.80 0.74 0.85 457/458 230 0.44 0.95 0.94 0.65 0.66459/460 231 0.48 0.95 0.95 0.77 0.94 461/462 232 0.48 0.86 0.82 0.750.83 0.81 463/464 233 0.74 0.16 0.24 0.32 0.17 465/466 234 0.73 0.040.03 0.24 0.38 467/468 235 0.64 0.44 0.42 0.22 0.46 469/470 236 0.630.39 0.35 0.34 0.37 0.27 471/472 237 0.63 0.43 0.38 0.40 0.31 0.32473/474 238 0.62 0.16 0.06 0.48 0.21 475/476 239 0.62 0.39 0.32 0.320.38 0.31 477/478 240 0.61 0.25 0.37 0.31 0.39 0.31 479/480 241 0.590.35 0.22 0.40 0.30 0.25 481/482 242 0.57 0.39 0.43 0.24 0.41 483/484243 0.56 0.02 0.03 0.34 0.10 485/486 244 0.54 0.27 0.26 0.29 0.13 0.10487/488 245 0.53 0.02 0.05 0.43 0.15 489/490 246 0.51 0.22 0.27 0.260.14 0.25 491/492 247 0.50 0.27 0.25 0.24 0.13 0.08 493/494 248 0.500.15 0.18 0.16 0.12 495/496 249 0.72 0.89 0.84 0.78 0.78 0.87 497/498250 0.80 0.84 0.82 0.79 0.81 0.75 499/500 251 0.56 0.71 0.69 0.58 0.660.60 501/502 252 0.60 0.77 0.72 0.61 0.64 0.74 503/504 253 0.52 0.800.77 0.76 0.74 0.74 505/506 254 0.58 0.76 0.77 0.60 0.77 0.66 507/508255 0.72 0.78 0.72 0.78 0.78 0.74 509/510 256 0.71 0.66 0.69 0.67 0.740.57 511/512 257 0.51 0.60 0.67 0.58 0.62 0.74 513/514 258 0.90 0.760.75 0.78 0.83 0.75 515/516 259 0.81 0.74 0.72 0.65 0.60 0.64 517/518260 0.67 0.81 0.71 0.76 0.83 0.73 519/520 261 0.65 0.87 0.87 0.86 0.860.89 521/522 262 0.74 0.77 0.62 0.62 0.55 0.72 523/524 263 0.92 0.900.87 0.81 0.87 0.72 525/526 264 0.67 0.72 0.64 0.59 0.66 0.71 527/528265 0.75 0.81 0.81 0.69 0.79 0.74 529/530 266 0.86 0.91 0.84 0.77 0.890.88 531/532 267 0.64 0.92 0.93 0.82 0.89 533/534 268 0.61 0.79 0.770.68 0.57 0.71 535/536 269 0.68 0.80 0.73 0.68 0.70 0.81 537/538 2700.64 0.83 0.75 0.62 0.67 0.77 539/540 271 0.88 0.89 0.82 0.76 0.59 0.84541/542 272 0.86 0.89 0.89 0.53 0.86 543/544 273 0.56 0.88 0.79 0.770.69 545/546 274 0.92 0.93 0.93 0.93 0.94 0.87 547/548 275 0.51 0.790.84 0.78 0.72 0.76 549/550 276 0.52 0.85 0.85 0.85 0.87 0.83 551/552277 0.60 0.90 0.90 0.91 0.91 0.87 553/554 278 0.71 0.60 0.79 0.57 0.89555/556 279 0.81 0.94 0.95 0.67 0.95 557/558 280 0.52 0.86 0.87 0.780.80 559/560 281 0.74 0.94 0.93 0.93 0.93 0.90 561/562 282 0.54 0.950.93 0.92 0.91 0.95 563/564 283 0.75 0.91 0.88 0.89 0.84 565/566 2840.80 0.94 0.95 0.95 0.94 0.92 567/568 285 0.83 0.94 0.92 0.81 0.85569/570 286 0.14 0.08 0.14 0.07 0.42 571/572 287 0.48 0.32 0.39 0.410.39 0.27 573/574 288 0.41 0.41 0.48 0.37 0.42 0.34 575/576 289 0.490.03 0.03 0.10 0.04 577/578 290 0.45 0.18 0.22 0.23 0.38 0.12 579/580291 0.42 0.17 0.28 0.43 0.20 0.19 581/582 292 0.41 0.36 0.33 0.31 0.260.34 583/584 293 0.32 0.12 0.20 0.29 0.31 0.25 585/586 294 0.45 0.110.15 0.18 0.14 0.16 587/588 295 0.45 0.24 0.24 0.24 0.27 0.18 589/590296 NA NA NA NA NA NA 591/592 297 0.91 0.14 0.11 0.91 0.87 0.21 593/594298 0.84 0.10 0.07 0.86 0.80 0.16 595/596 299 0.88 0.07 0.06 0.88 0.840.12 597/598 300 0.76 0.22 0.32 0.66 0.66 0.23 599/600 301 0.79 0.100.14 0.63 0.60 0.11 601/602 302 0.91 0.21 0.12 0.91 0.73 0.20 603/604303 0.89 0.18 0.19 0.58 0.75 0.17 605/606 304 0.87 0.15 0.13 0.82 0.680.18 607/608 305 0.90 0.29 0.25 0.63 0.71 0.28 609/610 306 0.81 0.200.21 0.74 0.65 0.24 611/612 307 0.82 0.22 0.22 0.82 0.80 0.45 613/614308 0.86 0.11 0.28 0.72 0.72 0.53 615/616 309 0.85 0.18 0.28 0.69 0.740.44 617/618 310 0.74 0.13 0.25 0.59 0.66 0.17 619/620 311 0.82 0.190.34 0.72 0.70 0.48 621/622 312 0.87 0.52 0.24 0.75 0.74 0.58 623/624313 0.77 0.34 0.31 0.79 0.65 0.27 625/626 314 0.08 0.84 0.84 0.27 0.100.60 627/628 315 0.04 0.82 0.82 0.05 0.31 0.86 629/630 316 0.04 0.860.84 0.52 0.32 0.85 631/632 317 0.08 0.80 0.77 0.09 0.21 0.67 633/634318 0.04 0.72 0.78 0.32 0.24 0.63 635/636 319 0.10 0.79 0.82 0.06 0.380.81 637/638 320 0.06 0.70 0.80 0.06 0.39 0.79 639/640 321 0.08 0.800.80 0.36 0.28 0.82 641/642 322 0.08 0.76 0.73 0.08 0.20 0.64 643/644323 0.17 0.87 0.85 0.51 0.25 0.89 645/646 324 0.10 0.79 0.79 0.37 0.290.82 647/648 325 0.07 0.75 0.75 0.28 0.21 0.74 649/650 326 0.15 0.820.81 0.41 0.32 0.82 651/652 327 0.07 0.77 0.74 0.08 0.41 0.79 653/654328 0.27 0.90 0.86 0.41 0.35 0.87 655/656 329 0.14 0.85 0.87 0.44 0.470.83 657/658 330 0.07 0.69 0.59 0.04 0.11 0.54 659/660 331 0.09 0.850.75 0.21 0.49 0.75 661/662 332 0.13 0.86 0.81 0.36 0.45 0.84 663/664333 0.04 0.69 0.61 0.09 0.18 0.75 665/666 334 0.12 0.69 0.62 0.18 0.060.53 667/668 335 0.07 0.84 0.73 0.49 0.37 0.85 669/670 336 0.07 0.710.58 0.18 0.11 0.58 671/672 337 0.18 0.77 0.69 0.19 0.27 0.59 673/674338 0.19 0.79 0.76 0.31 0.26 0.77 675/676 339 0.14 0.76 0.70 0.35 0.260.68 677/678 340 0.07 0.77 0.50 0.35 0.09 0.47 679/680 341 0.04 0.630.71 0.24 0.36 0.65 681/682 342 0.12 0.71 0.61 0.11 0.35 0.68 683/684

TABLE 4A Natural Killer Cells-Markers Eosinophil Neutrophil Non- Marker-Basophil Granu- Granu- Classical classical ID TargetID SYMBOL AccessionGranulocytes locytes locytes Monocytes Monocytes NK_nm33 cg24430034 — —0.97 0.97 0.97 0.97 0.95 NK_nm34 cg27274718 ANKRD28 NM_015199 0.92 0.890.91 0.91 0.87 NK_nm35 cg07802362 DNM3 NM_015569 0.90 0.91 0.92 0.920.90 NK_nm36 cg13292607 CTBP2 NM_001083914 0.95 0.91 0.92 0.93 0.92NK_nm37 cg04064701 RHOBTB1 NM_014836 0.91 0.90 0.93 0.93 0.91 NK_nm9cg03368758 LDB2 NM_001290 0.90 0.85 0.88 0.88 0.86 NK_nm39 cg17893934LARP4B NM_015155 0.97 0.96 0.96 0.96 0.96 NK_nm40 cg16360310 CXXC5NM_016463 0.87 0.82 0.85 0.87 0.84 NK_nm41 cg23549472 RNF165 NM_1524700.85 0.86 0.87 0.88 0.88 NK_nm42 cg13620110 EIF3G NM_003755 0.94 0.910.92 0.92 0.93 NK_nm43 cg23060465 EIF2C2 NM_012154 0.97 0.97 0.97 0.970.96 NK_nm44 cg21275838 MYO1E NM_004998 0.88 0.90 0.89 0.89 0.89 NK_nm45cg15259233 FAM120B NM_032448 0.88 0.86 0.88 0.89 0.87 NK_nm46 cg11790417— — 0.88 0.90 0.88 0.89 0.89 NK_nm47 cg06068163 EIF3B NM_001037283 0.890.87 0.90 0.90 0.87 NK_nm48 cg14259466 ADAM8 NM_001109 0.89 0.71 0.960.96 0.93 NK_nm49 cg10592926 ZDHHC14 NM_153746 0.90 0.94 0.95 0.95 0.92NK_nm50 cg05253716 SLC15A4 NM_145648 0.91 0.91 0.92 0.93 0.89 NK_nm51cg17162797 RASA3 NM_007368 0.92 0.91 0.92 0.94 0.92 NK_nm52 cg00462849 —— 0.94 0.94 0.95 0.94 0.92 NK_nm53 cg10055950 C1GALT1 NM_020156 0.910.92 0.92 0.91 0.89 NK_nm54 cg19915997 COLQ NM_080538 0.86 0.87 0.880.88 0.87 NK_nm55 cg06706159 MAST3 NM_015016 0.97 0.97 0.98 0.97 0.94NK_nm56 cg23015664 MAD1L1 NM_003550 0.92 0.94 0.96 0.94 0.94 NK_nm57cg21828319 RFC2 NM_181471 0.69 0.92 0.92 0.91 0.90 NK_nm58 cg05421487AKAP10 NM_007202 0.75 0.85 0.90 0.90 0.89 NK_nm59 cg24467387 SBNO2NM_014963 0.84 0.91 0.93 0.92 0.88 NKT_nm21 cg05585475 — — 0.89 0.860.89 0.90 0.90 NKT_nm22 cg20063728 PDGFA NM_002607 0.91 0.89 0.89 0.910.90 NKT_nm23 cg00879541 C14orf166 NM_016039 0.91 0.90 0.89 0.90 0.84NKT_nm24 cg26215982 — — 0.92 0.91 0.90 0.90 0.91 NKT_nm25 cg08455089TBC1D22B NM_017772 0.85 0.84 0.90 0.88 0.84 NKT_nm26 cg09046550 — — 0.870.89 0.87 0.89 0.88 NKT_nm27 cg27316453 LDHAL6A NM_001144071 0.89 0.900.90 0.88 0.86 NKT_nm28 cg03069731 ST7 NM_018412 0.90 0.86 0.86 0.870.87 NKT_nm29 cg23642827 — — 0.89 0.92 0.90 0.91 0.90 NKT_nm30cg12219570 ZAK NM_016653 0.88 0.87 0.91 0.93 0.91 NKT_nm31 cg16548262 —— 0.89 0.79 0.80 0.84 0.84 NKT_nm32 cg05844859 NCRNA00119 NR_002811 0.870.90 0.88 0.87 0.87 NKT_nm33 cg15740507 TBC1D23 NM_018309 0.88 0.79 0.860.82 0.76 NKT_nm34 cg07406728 — — 0.84 0.85 0.89 0.87 0.83 NKT_nm35cg13994599 SAMD4A NM_001161577 0.82 0.80 0.81 0.81 0.82 NKT_nm36cg03345391 GCK NM_000162 0.84 0.86 0.87 0.82 0.83 NKT_nm37 cg07891862PTK2 NM_153831 0.91 0.91 0.90 0.91 0.87 NKT_nm38 cg25503323 AOAHNM_001637 0.87 0.88 0.84 0.88 0.89 NKT_nm39 cg24037746 C3orf30 NM_1525390.90 0.90 0.90 0.88 0.87 NKT_nm40 cg13382516 SGMS1 NM_147156 0.88 0.860.89 0.89 0.89 NKT_nm41 cg25918166 — — 0.85 0.84 0.85 0.84 0.83 NKT_nm42cg08250738 — — 0.90 0.92 0.92 0.93 0.93 NKT_nm43 cg19083007 RCAN2NM_005822 0.86 0.85 0.86 0.87 0.85 NKT_nm44 cg06228763 ELFN1NM_001128636 0.80 0.76 0.77 0.80 0.78 NKT_nm45 cg19243780 UBE2E2NM_152653 0.82 0.82 0.85 0.89 0.84 NKT_nm46 cg11571124 CLIP1 NM_0029560.89 0.88 0.90 0.89 0.88 NKT_nm47 cg17569413 — — 0.89 0.88 0.89 0.880.89 NKT_nm48 cg14089425 KCNQ1 NM_000218 0.86 0.87 0.89 0.90 0.86NKT_nm49 cg26894807 GPR89A NM_001097613 0.85 0.89 0.89 0.89 0.90NKT_nm50 cg02791542 OSBPL10 NM_017784 0.86 0.86 0.85 0.86 0.84 NKT_nm51cg24585690 IL9 NM_000590 0.86 0.85 0.87 0.87 0.87 NKT_nm52 cg18904552TNKS2 NM_025235 0.87 0.82 0.89 0.90 0.89 NKT_nm53 cg18077068 — — 0.880.87 0.89 0.85 0.86 NKT_nm54 cg03905757 KCNQ1 NM_000218 0.83 0.86 0.860.85 0.84 NKT_nm55 cg12630243 — — 0.91 0.86 0.88 0.91 0.91 NKT_nm56cg12399350 — — 0.83 0.80 0.81 0.86 0.86 NKT_nm57 cg00829600 — — 0.860.83 0.79 0.87 0.88 NKT_nm58 cg24722886 PLEKHA7 NM_175058 0.86 0.81 0.840.83 0.85 NKT_nm59 cg16565562 — — 0.87 0.83 0.84 0.87 0.87 NKT_nm60cg13362028 — — 0.79 0.78 0.76 0.76 0.77 CD4+ CD4+ CD8+ CD4+ Th ThCytotoxic Marker- NK Th CD4+ CD4+ Central Effect. T- NK T- ID classicalB-Cells naive Th1 Th2 Mem. Mem. Cells Cells Discovery Fragment NK_nm330.09 0.97 0.97 0.97 0.97 0.96 0.95 0.93 0.80 CGCTCCCCAAGTGCTGACCACGCGCGCCCCCACG GCTCCCCGACAGCTCC (SEQ ID NO: 696) NK_nm34 0.08 0.900.92 0.90 0.91 0.91 0.92 0.89 0.87 AGTAGGTAAAAACACTG ATGCACTCTGCTTACCATGTAAGCCTCTTAACG (SEQ ID NO: 697) NK_nm35 0.12 0.90 0.91 0.86 0.87 0.900.90 0.83 0.83 CGGCTCCAAATCAAAAG CTGTGGAAGGAGGTAAT TAGCAGGGACTCTAGA (SEQID NO: 698) NK_nm36 0.16 0.93 0.94 0.89 0.89 0.91 0.91 0.87 0.85TTTTGTTGGTTCCTCACG TGGGCAGAAGAGTGAA TGCTCAGTCCCCATCG (SEQ ID NO: 699)NK_nm37 0.16 0.92 0.91 0.91 0.92 0.91 0.91 0.89 0.84 AGCTGATACTGCGTGAGTGTGGTGTTGCACGCCC TGGCACAGATCAAGCG (SEQ ID NO: 700) NK_nm9 0.16 0.880.89 0.93 0.91 0.93 0.93 0.91 0.90 CCCTTCACAACCTGATT GCTAAGCTTGTTAGCATAGAGGTGGTCTAACCG (SEQ ID NO: 701) NK_nm39 0.22 0.97 0.97 0.95 0.96 0.960.96 0.93 0.87 AAAACCGTACGTCTGGG AGGGGTCGCAGAGCGCT GTGTTAACCACAAACG (SEQID NO: 702) NK_nm40 0.15 0.86 0.85 0.86 0.87 0.86 0.86 0.87 0.84CCATTACCACTGGCTTT GTTACAATCTATTACAA CAATAGCAGTTGGCCG (SEQ ID NO: 703)NK_nm41 0.18 0.92 0.84 0.86 0.85 0.87 0.86 0.83 0.84 CGGAAGGGCAACAGAACAAAAGCAGCGTACAAT GAGCAGATGGCCCGGG C (SEQ ID NO: 704) NK_nm42 0.27 0.940.94 0.91 0.90 0.95 0.94 0.93 0.87 GGGGATAATTACGAGGT GCCGGGAGGTGCCCACCCACCAGCCTGGCGTCG (SEQ ID NO: 705) NK_nm43 0.33 0.97 0.97 0.97 0.97 0.970.97 0.94 0.93 CAGAGGGCTCTGAGCGG GCTGTGTGCCGGGCGAG AACACTGCCTGGGCCG (SEQID NO: 706) NK_nm44 0.27 0.86 0.88 0.90 0.90 0.90 0.89 0.90 0.87CGCAGCTTATTTGTCAC TGAGAAAGTTCAAGTTA GTGCTCTAATTCCACC (SEQ ID NO: 707)NK_nm45 0.30 0.89 0.89 0.87 0.86 0.87 0.89 0.90 0.85 CGGGGCAGCTGCCTGCACTGAGCTCTGAGGCCTT TGAAGTGGACCAGAGA (SEQ ID NO: 708) NK_nm46 0.31 0.880.88 0.85 0.87 0.89 0.87 0.89 0.85 TTAAGGGCCAACCCTGA CCACAGCTGAGCCGTGTGAAGAGGCTGACAGCG (SEQ ID NO: 709) NK_nm47 0.33 0.89 0.90 0.87 0.86 0.870.89 0.89 0.88 CGGCTACAAGCTTGACA AGCAGCACACATTCCGG GTCAACCTCTTTACGG (SEQID NO: 710) NK_nm48 0.17 0.93 0.87 0.96 0.96 0.96 0.96 0.96 0.92CGGCGTCTCCAGGCCTG CGGCCAAGCGTGCTTGC CCTTGGTGACCACATT (SEQ ID NO: 711)NK_nm49 0.22 0.93 0.86 0.91 0.92 0.94 0.93 0.91 0.92 GGCGCTCTGCCTGCAGCTATCTCCGTGTCAATGG CATCCTTTGATAGTCG (SEQ ID NO: 712) NK_nm50 0.22 0.910.92 0.91 0.91 0.91 0.92 0.91 0.79 CGCCAGAGTAATGGGTA AGCACTTAGTTCTCATCTTGGGCTGTTTGAAAG (SEQ ID NO: 713) NK_nm51 0.31 0.91 0.92 0.91 0.93 0.920.92 0.93 0.91 CGCTAAACGGTGCCACA GTTTTACTCTCTTGGAA CTGTCCCACATGGGTT (SEQID NO: 714) NK_nm52 0.35 0.94 0.95 0.93 0.92 0.94 0.94 0.95 0.92CGAGGCATCGGCCCGTT TTGTGTCTGGTAAGGGC CAGAGTCCTGGTTCAT (SEQ ID NO: 715)NK_nm53 0.13 0.90 0.92 0.92 0.92 0.93 0.89 0.91 0.81 CGCTCACTGCTTACTTAAATGGACAGTTTTAAGT TTCAGTTTTAAGCTCA (SEQ ID NO: 716) NK_nm54 0.07 0.870.86 0.81 0.82 0.85 0.83 0.82 0.73 CGTGCAGGCATTCTCAC TCACACTGGGCAGCCCGCTGTCGGGTCTCTCTA (SEQ ID NO: 717) NK_nm55 0.19 0.98 0.98 0.98 0.98 0.980.98 0.88 0.70 CGAGCTCGGCCTCTGGC CCACGAGTGCGCCGCCC CGCCTCCCCATCCAGC (SEQID NO: 718) NK_nm56 0.04 0.95 0.93 0.95 0.95 0.94 0.96 0.92 0.80CGCGGACCCCGCTTCTG TCACCCCTAACCTCACT GTTGGGTCCGGGACCT (SEQ ID NO: 719)NK_nm57 0.08 0.74 0.67 0.91 0.92 0.92 0.92 0.90 0.84 CGGGGCACAGACGTCCCAGAAGCAAACATGCAA GTCACGGGAGTTTATTT (SEQ ID NO: 720) NK_nm58 0.21 0.900.76 0.86 0.88 0.89 0.90 0.85 0.83 TCTATATCTGATCCATC AGCAAATCTGTTAGGTCTACCTCACACATATCG (SEQ ID NO: 721) NK_nm59 0.23 0.91 0.83 0.88 0.90 0.930.90 0.88 0.82 GTGGGTCTCACTCAGCT GGGCGCTGGGGCCCTGG TGGAGAATGGCTGTCG (SEQID NO: 722) NKT_nm21 0.83 0.81 0.90 0.81 0.83 0.86 0.86 0.67 0.27CGGTAGACAAATGATAG ACATTTGTTGAATCAAG CTGTGAGTTGGAGATC (SEQ ID NO: 723)NKT_nm22 0.85 0.89 0.90 0.69 0.85 0.82 0.79 0.63 0.13 GTCTTTGCCTGACACCTTCTGTGAGGTTTGCGGG CTTCATTTTAAATCCG (SEQ ID NO: 724) NKT_nm23 0.87 0.840.87 0.72 0.80 0.81 0.77 0.70 0.17 GGGGTTATATATTTTTG ACCAAATTCACCATTACTCATTTGGCATTTTCG (SEQ ID NO: 725) NKT_nm24 0.83 0.81 0.89 0.59 0.70 0.740.67 0.59 0.15 GCGTACACACCCTGATA AGGTGTCAAGAACCTCC GTTTGAGTACCCCTCG (SEQID NO: 726) NKT_nm25 0.86 0.81 0.84 0.51 0.62 0.61 0.48 0.60 0.15CCTGCTGTAGATGTGTC ACAGCTAAATTCTTGAA TGGATTTTTATCATCG (SEQ ID NO: 727)NKT_nm26 0.83 0.87 0.88 0.51 0.70 0.63 0.60 0.69 0.22 GAACCAAGCACTGCTTCCTGGGAGAGTGATGTCA GCATGACTCAAAGGCG (SEQ ID NO: 728) NKT_nm27 0.80 0.820.91 0.55 0.65 0.68 0.60 0.69 0.23 CGCAAACCCACCCTCTA TCCGGGTGAGCACCATCTAGTCAGCTGCCAGCA (SEQ ID NO: 729) NKT_nm28 0.84 0.82 0.87 0.56 0.70 0.670.61 0.68 0.24 CGTGGGATCTCTGTTCA TTTTGGTATATTACTTTG CTTTCTGGGCTGAGC (SEQID NO: 730) NKT_nm29 0.82 0.80 0.91 0.60 0.79 0.77 0.74 0.59 0.26CGCATACTTTCAGGGAG AGGCACTATTCTTGGCT TTAAGTTCATGAGTAA (SEQ ID NO: 731)NKT_nm30 0.83 0.82 0.88 0.57 0.61 0.67 0.60 0.68 0.25 CGGGGGGAGAATTAAGCCAAAGAAGTATATTTA TGAATCAGCAAATGTGG (SEQ ID NO: 732) NKT_nm31 0.79 0.820.90 0.61 0.79 0.71 0.71 0.68 0.24 CGGCTTGAACCCTCAGC TTCTACAGTTGTGTCACCCATGTGTCTGTTTCT (SEQ ID NO: 733) NKT_nm32 0.82 0.80 0.86 0.55 0.54 0.660.59 0.68 0.24 GGCCGAGGTGAAACCAT TGGTTTTTAACCTTGACT ACTGATTAAAATCCG (SEQID NO: 734) NKT_nm33 0.77 0.80 0.88 0.59 0.74 0.68 0.61 0.66 0.24ATCAGCACCAAAGCTTT GTCTGAACTTATTTTGCT ACTATTGTTAGGACG (SEQ ID NO: 735)NKT_nm34 0.83 0.86 0.85 0.57 0.67 0.68 0.64 0.68 0.27 CGACTGTGGGGAATGAATAAGATTACAATAAAAC CTGAGGAATTTAATGC (SEQ ID NO: 736) NKT_nm35 0.81 0.800.87 0.54 0.57 0.66 0.62 0.67 0.26 CGAGTGAGTCCAAACTC CTTAGAAAGTTGGTTGCTAAGGACTTGGAAAAG (SEQ ID NO: 737) NKT_nm36 0.82 0.80 0.85 0.57 0.58 0.700.61 0.69 0.28 CCCTTCCCCAAGTTCCA TACAGACCCCTGGATTG TATGAAATGCAAATCG (SEQID NO: 738) NKT_nm37 0.84 0.81 0.88 0.58 0.67 0.72 0.62 0.66 0.14CGGAGAGCAAACAGGG CTAACACAGAAAGCCCT TGTAAAAAACAGAACG A (SEQ ID NO: 739)NKT_nm38 0.83 0.87 0.88 0.50 0.61 0.67 0.60 0.61 0.15 CGAGGAAGGTATGGTAGAAATGCATCCATTACC AAGAAGAAAAGTAATC T (SEQ ID NO: 740) NKT_nm39 0.73 0.830.89 0.60 0.76 0.75 0.71 0.66 0.20 CACATCACTATATGGAA CACGACTATACTTTCAAAAGATGACCAATCTCG (SEQ ID NO: 741) NKT_nm40 0.79 0.75 0.88 0.67 0.74 0.720.69 0.61 0.20 CGTGCCCAGCTTTTCTA TGGGAAAAATTGTTCTT CAGACAGAGCATGAAT (SEQID NO: 742) NKT_nm41 0.80 0.78 0.84 0.48 0.60 0.68 0.59 0.58 0.17CGTCATTATCTGGCAAT AGTTGTTGGATGTGTTT GCTGCCATGCCACGAG (SEQ ID NO: 743)NKT_nm42 0.86 0.78 0.89 0.62 0.70 0.71 0.68 0.63 0.26 CGTAGGTTTCCAAGAAAGATAGGGTGACAAAATT GCCTGTCACTCCGATT (SEQ ID NO: 744) NKT_nm43 0.84 0.770.87 0.49 0.59 0.64 0.60 0.65 0.21 CGGATTTCTATTCAGCC CATGCCCGGGATGCATTAGGATGCCCAGAACAT (SEQ ID NO: 745) NKT_nm44 0.75 0.74 0.81 0.49 0.51 0.510.45 0.52 0.14 GGGAGTGGCCCAGCCCG GTTTGCTCAGTGACCAG GATGTTTCCACAGTCG (SEQID NO: 746) NKT_nm45 0.83 0.87 0.84 0.46 0.50 0.63 0.54 0.69 0.21GTGGTCTGGTTACATCA GCAAACATGTTCTACAA TCAAGGTAAAAACTCG (SEQ ID NO: 747)NKT_nm46 0.72 0.83 0.87 0.51 0.62 0.60 0.56 0.66 0.23 CGAGTACTAAAAGGTCAAATGTGTCAAGTCTAGA ACTAGTACTCTTTTTT (SEQ ID NO: 748) NKT_nm47 0.90 0.830.91 0.53 0.70 0.63 0.59 0.70 0.26 CGCACCATCACACCGTC AGCAACTTGTGGGACCAACTCCCTGCACATCTG (SEQ ID NO: 749) NKT_nm48 0.80 0.76 0.85 0.57 0.70 0.750.70 0.70 0.25 AGTACATCTGTTGACAA CATGGTTTACTGAATAT GTTGAGCCCATTTTCG (SEQID NO: 750) NKT_nm49 0.85 0.80 0.87 0.57 0.47 0.64 0.63 0.61 0.23TCTATCTTCATTTAACTT CCAGTCCTTTGCCCTAC AGATAATTCGTAGCG (SEQ ID NO: 751)NKT_nm50 0.77 0.82 0.87 0.49 0.53 0.61 0.56 0.61 0.21 CGGCCAAAAGAAAGACATAGAATAGAATGGTGG TTGCTGAGGGTTGGAGA (SEQ ID NO: 752) NKT_nm51 0.85 0.780.88 0.62 0.59 0.68 0.67 0.67 0.24 CGGACTGGAGCTCGCTT GCAGACACCTTCAAATCGAGTGGTATTTAAAGC (SEQ ID NO: 753) NKT_nm52 0.88 0.89 0.88 0.50 0.62 0.580.53 0.74 0.27 ACAAACAAAAAGCTATC TGAAAATGCTGCCATGC TAACATATGAACCACG (SEQID NO: 754) NKT_nm53 0.84 0.77 0.87 0.51 0.56 0.63 0.52 0.69 0.26CGAATGGAAATTCAAAG GGAGAACATCTAATGTT CAAGTTGATGTCTATA (SEQ ID NO: 755)NKT_nm54 0.77 0.79 0.84 0.58 0.66 0.73 0.68 0.62 0.26 CGTCCCCTCTAATACTATAGCTGAGAGCTTTTAA TATGAATGGGTGTTAA (SEQ ID NO: 756) NKT_nm55 0.84 0.770.89 0.51 0.57 0.66 0.61 0.69 0.28 CGACTGGTGTTGATTCT CAGTCAATTTAAAGGATGAAAAGGGCTGTAAAA (SEQ ID NO: 757) NKT_nm56 0.73 0.79 0.82 0.54 0.65 0.620.58 0.64 0.25 CCCAGTTCTTCAGAGTT GTCAGGGTCACTGCTCT GGGACCCACGGACTCG (SEQID NO: 758) NKT_nm57 0.79 0.84 0.84 0.49 0.55 0.60 0.55 0.61 0.26CGAAGGAGGGAGTGCA TGAATTCATGTAAGGAT GGAGATCCACATCCCAG (SEQ ID NO: 759)NKT_nm58 0.75 0.81 0.82 0.55 0.57 0.66 0.61 0.59 0.26 CGAGTGTGGAGCTATGATTGGAACCTAGTTCAGG CTCCAAAGCCACACTC (SEQ ID NO: 760) NKT_nm59 0.81 0.760.85 0.48 0.52 0.64 0.59 0.67 0.28 CGGATTTTTGAGACAGT TTGGGAATAGTTTATCCTGTTATTATCTTCAGG (SEQ ID NO: 761) NKT_nm60 0.74 0.73 0.73 0.47 0.51 0.550.44 0.61 0.24 CGTTAGGATTGCTAAAG AGCATTTTCTAAATATT TGAGTGTAAACCACTG (SEQID NO: 762)

TABLE 4B B-Cell Markers Eosinophil Neutrophil Non- Marker- BasophilGranu- Granu- Classical classical ID TargetID SYMBOL AccessionGranulocytes locytes locytes Monocytes Monocytes B_nm45 cg22907103CYBASC3 NM_153611 0.88 0.87 0.86 0.84 0.83 B_nm46 cg15532942 NFATC1NM_006162 0.87 0.91 0.88 0.91 0.89 B_nm47 cg27106643 NFATC1 NM_0061620.89 0.92 0.93 0.9O 0.87 B_nm48 cg07841371 TTLL10 NM_001130045 0.92 0.940.94 0.95 0.92 B_nm49 cg13738327 LRP5 NM_002335 0.98 0.98 0.98 0.98 0.97B_nm50 cg26552743 — — 0.87 0.84 0.86 0.89 0.85 B_nm51 cg05205074 — —0.92 0.92 0.93 0.92 0.88 B_nm52 cg07721872 LOC100129637 NR_024488 0.940.95 0.93 0.96 0.95 B_nm53 cg11661493 UBE2O NM_022066 0.90 0.88 0.890.90 0.87 B_nm54 cg02212339 TRPV1 NM_080704 0.98 0.97 0.97 0.97 0.96B_nm55 cg27565966 CD19 NM_001770 0.91 0.89 0.91 0.91 0.89 B_nm56cg25469923 — — 0.85 0.86 0.87 0.86 0.83 B_nm57 cg22498365 TBCD NM_0059930.86 0.91 0.92 0.90 0.86 B_nm58 cg17232476 SORL1 NM_003105 0.89 0.900.89 0.86 0.83 B_nm59 cg18664915 C7orf50 NM_001134395 0.88 0.90 0.880.89 0.87 B_nm60 cg20602300 C15orf57 NM_052849 0.91 0.90 0.92 0.91 0.90B_nm61 cg18250453 TERF1 NM_003218 0.89 0.85 0.90 0.91 0.90 B_nm62cg06889975 — — 0.90 0.84 0.85 0.87 0.89 B_nm63 cg11699517 BAHCC1NM_001080519 0.99 0.97 0.97 0.97 0.97 B_nm64 cg15035590 LR1G1 NM_0155410.91 0.91 0.90 0.92 0.89 B_nm65 cg15242630 MICAL3 NM_001122731 0.88 0.880.87 0.87 0.85 B_nm66 cg13823257 — — 0.88 0.88 0.89 0.88 0.86 B_nm67cg13915752 CDK19 NM_015076 0.88 0.85 0.90 0.90 0.90 B_nm68 cg04838847GOLSYN NM_001099743 0.98 0.98 0.98 0.97 0.98 B_nm69 cg22281206 INPP5JNM_001002837 0.88 0.89 0.90 0.88 0.85 B_nm70 cg19260718 — — 0.87 0.900.89 0.90 0.86 B_nm71 cg19766988 EIF3G NM_003755 0.89 0.90 0.89 0.900.85 B_nm72 cg20452738 ITPKB NM_002221 0.90 0.89 0.91 0.88 0.90 B_nm73cg26692003 IQSEC1 NM_001134382 0.95 0.96 0.97 0.95 0.91 B_nm74cg00762029 IRF2 NM_002199 0.92 0.91 0.92 0.92 0.90 B_nm75 cg17622855ZDHHC14 NM_153746 0.87 0.88 0.89 0.89 0.89 B_nm76 cg04947949 WDFY4NM_020945 0.88 0.91 0.92 0.91 0.89 B_nm77 cg25131632 — — 0.96 0.97 0.970.97 0.96 B_nm78 cg14482811 LCN8 NM_178469 0.93 0.92 0.96 0.95 0.95B_nm79 cg12177944 PLXND1 NM_015103 0.96 0.96 0.94 0.86 0.68 B_nm80cg21248060 C7orf50 NM_001134395 0.96 0.96 0.97 0.97 0.95 B_nm81cg04828493 CARS2 NM_024537 0.95 0.96 0.95 0.86 0.73 B_nm82 cg01024458RERE NM_012102 0.91 0.92 0.93 0.92 0.93 B_nm83 cg25683989 HVCN1NM_001040107 0.92 0.77 0.92 0.92 0.91 B_nm84 cg22212560 FRMD8 NM_0319040.89 0.86 0.90 0.72 0.62 B_nm85 cg15348679 — — 0.77 0.83 0.88 0.87 0.86B_nm86 cg16210395 CGNL1 NM_032866 0.92 0.92 0.93 0.94 0.93 B_nm87cg08162476 IQSEC1 NM_001134382 0.91 0.92 0.91 0.78 0.74 B_nm15cg07597976 CD19 NM_001770 0.86 0.82 0.82 0.82 0.78 B_nm89 cg07768103RNF44 NM_014901 0.98 0.98 0.98 0.98 0.98 B_nm90 cg13356455 ATP10ANM_024490 0.91 0.89 0.90 0.90 0.90 B_nm91 cg17995557 LHPP NM_022126 0.870.90 0.87 0.89 0.87 B_nm92 cg17679619 — — 0.90 0.85 0.89 0.89 0.88B_nm93 cg27304328 CD84 NM_003874 0.89 0.61 0.84 0.84 0.83 B_nm94cg26438284 CD81 NM_004356 0.89 0.84 0.87 0.89 0.88 CD4+ CD4+ CD8+ CD4+Th Th Cytotoxic Marker- NK Th CD4+ CD4+ Central Effect. T- NK T- IDclassical B-Cells naive Th1 Th2 Mem. Mem. Cells Cells Discovery FragmentB_nm45 0.86 0.04 0.87 0.85 0.86 0.88 0.87 0.87 0.86 AGTCATTGTGACTGAAGATCAGGCCCACCCAGGCAT TGAGGCCTCGGGCG (SEQ ID NO: 763) B_nm46 0.89 0.07 0.870.86 0.85 0.83 0.84 0.88 0.85 CGGCCAGGCCCTCATCCA CCAGAGTAGACCCCAGCACGAGCAGGCGTCGC (SEQ ID NO: 764) B_nm47 0.90 0.11 0.90 0.90 0.89 0.890.90 0.92 0.91 GCTTTCCACGGCTGTGCGC CTCGGGGCTGGAGCGGCC CCAAGTGAAGACG (SEQID NO: 765) B_nm48 0.95 0.10 0.94 0.94 0.93 0.94 0.94 0.93 0.92CGCGGCCCAGGGTTCCGC CTGGCTGGCACCACCCCTG GAAGGGCAGCCCC (SEQ ID NO: 766)B_nm49 0.97 0.03 0.97 0.93 0.96 0.97 0.96 0.95 0.88 CAACGTGAAGAAAACGTGAAATTCTGTCGCTTGTTGC AGCTGACAGCACG (SEQ ID NO: 767) B_nm50 0.89 0.04 0.860.86 0.89 0.87 0.86 0.89 0.87 AAACAGGATCTCTGCAGA TGGAGCTCAGTGTTATGTGTTTTGGATGCTCG (SEQ ID NO: 768) B_nm51 0.91 0.04 0.92 0.86 0.84 0.87 0.870.92 0.88 CGCCCTGGCCTGAAGGGA AGAGTCTACAAGGTTTAT AACCCAGAACCGCA (SEQ IDNO: 769) B_nm52 0.93 0.03 0.93 0.94 0.94 0.91 0.93 0.94 0.93CGTCCGCCTCGTCCACTCC TGGCATTTGGGATAAACA TCCTGTCTCAGAC (SEQ ID NO: 770)B_nm53 0.91 0.04 0.89 0.89 0.90 0.91 0.89 0.89 0.89 CCCTGAAATCGACCCTAACAATAATAGAGGTTTGGA TTTGCATGAACACG (SEQ ID NO: 771) B_nm54 0.97 0.05 0.970.95 0.95 0.97 0.96 0.96 0.95 CGCCATCGAGAGACGCAA CATGGCCCTGGTGACCCTCCTGGTGGAGAACG (SEQ ID NO: 772) B_nm55 0.84 0.06 0.90 0.91 0.90 0.89 0.910.92 0.90 TTGTGAGTCTGGAGGGTTC CTGGAGAATGGGGCCTGA GGCGTGACCACCG (SEQ IDNO: 773) B_nm56 0.82 0.06 0.89 0.85 0.87 0.84 0.85 0.87 0.84CAGGCTACTATTCCTGATG GAGACCCCCATTTCCGTGG CGGCCCCTGACG (SEQ ID NO: 774)B_nm57 0.91 0.07 0.88 0.89 0.91 0.89 0.91 0.89 0.91 TCCTGAAAGTCCCTGGCACAGGACACCACTACGGGGC TCAGCTGGGTGCG (SEQ ID NO: 775) B_nm58 0.89 0.07 0.890.87 0.88 0.89 0.88 0.88 0.88 CGCAACCAGTATCGCTGC AGCAACGGGAACTGTATCAACAGCATTTGGTG (SEQ ID NO: 776) B_nm59 0.88 0.07 0.90 0.86 0.88 0.880.87 0.87 0.84 CGGGCCAGCCAGGCCATG GCATCTGCCTGCTGGGGG CTGTTTTACTGCTG (SEQID NO: 777) B_nm60 0.91 0.07 0.90 0.89 0.91 0.91 0.92 0.91 0.92TCCTTCAGTGGATTTCTCC CTGCTGCTGTCACTGAGCT CCACGCTGCTCG (SEQ ID NO: 778)B_nm61 0.82 0.08 0.89 0.88 0.87 0.89 0.89 0.90 0.88 TTTTTACAAATTGAAAGTTTACCGCAGCCCAGCTTGA GCCAAGTCTAACG (SEQ ID NO: 779) B_nm62 0.90 0.08 0.890.90 0.90 0.91 0.90 0.90 0.89 CTTTATCCAGCAAGAAGC CAGCTGTGTGGCAAGCAATGGAGGTAAGAACG (SEQ ID NO: 780) B_nm63 0.99 0.08 0.98 0.98 0.98 0.990.99 0.99 0.98 CCCCGTGGGACGTGGGGC AGGCAGCGAGCTTGAGTG TTTGCGCTTCCTCG (SEQID NO: 781) B_nm64 0.88 0.09 0.92 0.92 0.88 0.92 0.91 0.91 0.89CGGAAAGCCCCATTCACA GGATTTGCATTGATTTGCC CTGATCTAGTTTG (SEQ ID NO: 782)B_nm65 0.88 0.09 0.88 0.86 0.87 0.86 0.88 0.88 0.86 CGGGGCAGTTTTGTGGCCTTTTGCTATTGAATCTGCCA GATGTGTCCAAG (SEQ ID NO: 783) B_nm66 0.89 0.09 0.880.85 0.87 0.88 0.88 0.89 0.84 AGAGCAAGTCAGGCACAC CATACTCTACCTGGAACAGCTGCTAAACTCCG (SEQ ID NO: 784) B_nm67 0.91 0.10 0.89 0.90 0.90 0.900.90 0.92 0.89 CCCTGACAAAACAAACTC TGTAAGCTGTGTCAGCCAT GCAAGGCACCACG (SEQID NO: 785) B_nm68 0.98 0.10 0.98 0.98 0.98 0.97 0.98 0.98 0.98CGCCTTCCGTATCAAAACC TAAATAGAAGTTGTTGTTA CCGTGTGCCAAT (SEQ ID NO: 786)B_nm69 0.89 0.10 0.89 0.88 0.87 0.87 0.87 0.89 0.85 CCCACTCTGTGACGCTCAGAAGATAGCATCCCCTCCTA AGGAACTTGCCG (SEQ ID NO: 787) B_nm70 0.89 0.11 0.870.88 0.88 0.89 0.87 0.90 0.85 CGTCATTGCCAACTCCAAT GCCTCAATGCACATGGCGGGGCCCAGCCACA (SEQ ID NO: 788) B_nm71 0.89 0.11 0.89 0.87 0.86 0.88 0.860.90 0.90 CTCCCTGAGGACCAGTTTT TTCCCCTGGGGAGTCATCA TGAATCACTTCG (SEQ IDNO: 789) B_nm72 0.90 0.11 0.91 0.88 0.88 0.90 0.90 0.90 0.89CGGCTGCCCAACCCTGACT CCAGGCTGGACACTGGAG ATGATGCAGACCA (SEQ ID NO: 790)B_nm73 0.96 0.12 0.97 0.96 0.96 0.96 0.97 0.96 0.96 ACTCAGTGACTGACGTTTACGGTCACACGAAGGAATC ACTACACCAAGCG (SEQ ID NO: 791) B_nm74 0.93 0.13 0.920.91 0.91 0.92 0.92 0.92 0.91 CGCACGGGCTCTGCCGTTC AGAACACAGCCACATCCCGTGATCTCATTTG (SEQ ID NO: 792) B_nm75 0.87 0.13 0.88 0.85 0.86 0.89 0.880.89 0.88 CTGAGTTTTCATCAAACAC CTGCTGAGCAGCTGGCAC GTGCCAGGACACG (SEQ IDNO: 793) B_nm76 0.88 0.13 0.90 0.89 0.90 0.90 0.89 0.88 0.86CTAGAGACAAGCGATGAG CTGCACTGAGGATCAAGG ATCAGGCATTAGCG (SEQ ID NO: 794)B_nm77 0.96 0.03 0.97 0.90 0.91 0.92 0.91 0.92 0.78 CATCTGGGTGGCTGGAAACCCAAGAACGGTGCCTAG CTCGGCTCTGTCCG (SEQ ID NO: 795) B_nm78 0.70 0.04 0.900.96 0.94 0.97 0.96 0.97 0.95 GGGCTCGTTCTGGCCTGCG CTGCGAGGGCTGTGGGCACTGATGGGCAACG (SEQ ID NO: 796) B_nm79 0.97 0.05 0.97 0.93 0.92 0.95 0.940.95 0.93 CGAGGTCGGTCTCCCACG ACTGCCCACCATCTGGCCG GCCACCCTGAAAG (SEQ IDNO: 797) B_nm80 0.95 0.10 0.97 0.96 0.97 0.97 0.97 0.97 0.96CGTGCCTGCCCCGCCGTGC ACACACCTCAGCCCCCGG GAGACGTGCCTGC (SEQ ID NO: 798)B_nm81 0.85 0.05 0.96 0.92 0.95 0.95 0.93 0.93 0.83 CGCCCCCACTCAGTCACACGACACTGCTCTCCTGGCCC ACTGCGGCATCC (SEQ ID NO: 799) B_nm82 0.91 0.03 0.920.76 0.80 0.82 0.82 0.91 0.87 CGCTAACATTATGCTCTGT GGCAGGTTGCCCTGTCTGCTGTGCTCACCTT (SEQ ID NO: 800) B_nm83 0.89 0.06 0.91 0.89 0.92 0.90 0.910.90 0.89 CGCTGGTTGACTGGCAGA GCAACTTCTGGACCCAGC AGAGTTCAGCTTTG (SEQ IDNO: 801) B_nm84 0.93 0.03 0.90 0.91 0.94 0.93 0.93 0.93 0.92CGTGCTCCAAGAAGTACA AAGAAAAAGTCAAAGCTA CAGCCGCTGACGGC (SEQ ID NO: 802)B_nm85 0.95 0.03 0.82 0.86 0.83 0.85 0.79 0.96 0.94 CGATATAAAATGAACGCGCGTTCAAGATTTCCTTCAA CTCATTGTTAGCG (SEQ ID NO: 803) B_nm86 0.90 0.06 0.930.79 0.83 0.85 0.80 0.85 0.76 CGGTTTACCACACCACCCT TGACTGGGAAATGGGGCTAAGATTTTAATAA (SEQ ID NO: 804) B_nm87 0.88 0.05 0.92 0.87 0.89 0.89 0.880.93 0.86 GGCCAGGGGAGCAGTGAG TCACTCAGGGCGGGATGG GTGAGGGGCGTCCG (SEQ IDNO: 805) B_nm15 0.77 0.02 0.86 0.84 0.85 0.88 0.87 0.88 0.84CGGTCTCTACTCCAAGGG GCTCACATTCTTGTGCAGA AAACAGAAATGAA (SEQ ID NO: 806)B_nm89 0.96 0.15 0.98 0.98 0.98 0.98 0.98 0.80 0.98 CGGAGCAGCTGCCGCGCCTCGAAGTCACTGAAGCAG ACCACACACCTGTG (SEQ ID NO: 807) B_nm90 0.88 0.06 0.900.84 0.81 0.84 0.84 0.90 0.81 ACCCACAGAGAAGCTGCC ATCTAAATAGGGCTGATTTCGAGTTTTGGACG (SEQ ID NO: 808) B_nm91 0.62 0.05 0.88 0.88 0.88 0.87 0.890.88 0.87 AGCTCCTAGGTTTGAAAA GTTCTATGTGCGCTTGACC GGGGGGCCTTACG (SEQ IDNO: 809) B_nm92 0.88 0.06 0.89 0.86 0.82 0.83 0.84 0.89 0.82CGTTAGCAAACACATAGT AGCAGAAACACCTGTCAG AGGACAGTGTCTCA (SEQ ID NO: 810)B_nm93 0.88 0.04 0.89 0.86 0.88 0.87 0.89 0.90 0.86 CGGGATGGAGTTCCCATACCGTAGTTCAGAGGCATA GGGACTTCTGCATT (SEQ ID NO: 811) B_nm94 0.86 0.06 0.890.85 0.86 0.88 0.88 0.84 0.79 GACCCCAGGCTGCCATCTT GGCGCTAACTTCTTCCGAGGCAGAGCCAACG (SEQ ID NO: 812)

TABLE 4C CD8 positive T-Cell Markers Non- CD4+ Marker- Target BasophilEosinophil Neutrophil Classical classical NK NK B- Th ID ID SYMBOLAccession Granulocytes Granulocytes Granulocytes Monocytes Monocytesclassical bright Cells MDSC naive CD8_nm12 cg00219921 CD8A NM_0011458730.91 0.90 0.92 0.90 0.89 0.90 0.90 0.92 0.85 0.84 CD8_nm13 cg25939861CD8A NM_001145873 0.87 0.87 0.89 0.56 0.61 0.84 0.86 0.84 0.81 0.80CD8_nm14 cg18857618 CD8B NM_172213 0.89 0.88 0.86 0.90 0.87 0.88 0.890.84 0.85 0.86 CD8_nm15 cg03318654 CD8A NM_001145873 0.71 0.73 0.72 0.730.71 0.74 0.74 0.72 0.70 0.72 CD8_nm16 cg25535316 PHRF1 NM_020901 0.860.84 0.84 0.83 0.82 0.86 0.88 0.76 0.83 0.73 CD8_nm17 cg07016730 SBF1NM_002972 0.88 0.84 0.87 0.77 0.79 0.88 0.87 0.70 0.82 0.75 CD8_nm18cg21648425 CD8A NM_001145873 0.74 0.74 0.75 0.55 0.51 0.67 0.72 0.710.58 0.69 TEMRA_nm1 cg04467549 — — 0.92 0.94 0.94 0.65 0.67 0.84 0.930.93 0.89 0.93 TEMRA_nm2 cg20063728 PDGFA NM_002607 0.89 0.89 0.89 0.850.86 0.87 0.90 0.89 0.86 0.92 TEMRA_nm3 cg06567722 PCID2 NM_0011272030.98 0.98 0.98 0.84 0.85 0.96 0.98 0.98 0.97 0.96 TEMRA_nm4 cg25002426KIF3C NM_002254 0.92 0.92 0.89 0.87 0.87 0.91 0.90 0.83 0.87 0.93TEMRA_nm5 cg21241195 C6orf10 NM_006781 0.92 0.90 0.91 0.88 0.86 0.900.92 0.73 0.86 0.80 TEMRA_nm7 cg02051545 — — 0.90 0.91 0.92 0.86 0.850.89 0.92 0.90 0.89 0.91 TEMRA_nm8 cg20960322 — — 0.74 0.86 0.84 0.610.74 0.78 0.80 0.89 0.82 0.70 TEMRA_nm9 cg06147361 SOX5 NM_152989 0.870.87 0.88 0.84 0.85 0.89 0.92 0.63 0.87 0.92 TEMRA_nm10 cg05173889 TDRD9NM_153046 0.91 0.88 0.90 0.86 0.82 0.88 0.93 0.81 0.88 0.88 TEMRA_nm11cg12080492 MYBPH NM_004997 0.91 0.90 0.94 0.87 0.88 0.93 0.95 0.91 0.910.94 TEMRA_nm12 cg00922200 SEMA3A NM_006080 0.84 0.84 0.88 0.87 0.870.83 0.84 0.74 0.86 0.90 TEMRA_nm13 cg19592003 DEFB114 NM_001037499 0.740.87 0.84 0.83 0.82 0.76 0.79 0.90 0.87 0.71 TEMRA_nm14 cg14317884 EHD1NM_006795 0.92 0.82 0.85 0.82 0.79 0.91 0.91 0.89 0.84 0.93 TEMRA_nm15cg00879541 C14orf166 NM_016039 0.89 0.90 0.89 0.87 0.86 0.88 0.84 0.840.87 0.90 TEMRA_nm16 cg24142603 MSC NM_005098 0.90 0.95 0.95 0.91 0.880.93 0.95 0.93 0.90 0.95 TEMRA_nm17 cg05585475 — — 0.89 0.86 0.89 0.830.82 0.89 0.90 0.81 0.88 0.90 TEMRA_nm18 cg18080819 SHANK2 NM_0123090.91 0.88 0.90 0.87 0.86 0.90 0.89 0.82 0.87 0.89 TEMRA_nm19 cg13486641NINL NM_025176 0.92 0.93 0.96 0.94 0.94 0.93 0.95 0.87 0.93 0.96TEMRA_nm20 cg13382516 SGMS1 NM_147156 0.87 0.86 0.89 0.79 0.78 0.86 0.890.75 0.84 0.89 TEMRA_nm21 cg26215982 — — 0.87 0.91 0.90 0.83 0.82 0.900.91 0.81 0.87 0.94 TEMRA_nm22 cg03221073 HMCN1 NM_031935 0.90 0.88 0.890.87 0.85 0.88 0.90 0.71 0.83 0.92 TEMRA_nm23 cg02261543 CTR9 NM_0146330.93 0.93 0.94 0.88 0.90 0.91 0.91 0.87 0.91 0.93 TEMRA_nm24 cg03938110NCRNA00110 NR_027021 0.88 0.89 0.87 0.87 0.84 0.87 0.86 0.75 0.85 0.90TEMRA_nm25 cg15449516 — — 0.84 0.86 0.88 0.77 0.79 0.88 0.85 0.64 0.860.91 TEMRA_nm26 cg14365420 — — 0.88 0.92 0.91 0.90 0.88 0.89 0.90 0.800.88 0.90 TEMRA_nm27 cg03668556 — — 0.90 0.91 0.92 0.87 0.89 0.87 0.880.85 0.89 0.90 TEMRA_nm28 cg00472528 — — 0.90 0.89 0.94 0.87 0.81 0.900.93 0.81 0.86 0.94 TEMRA_nm29 cg05633605 ANKRD55 NM_024669 0.82 0.790.81 0.81 0.79 0.80 0.82 0.67 0.79 0.89 TEMRA_nm30 cg27064867 C6orf10NM_006781 0.90 0.91 0.91 0.89 0.86 0.90 0.89 0.82 0.88 0.92 TEMRA_nm31cg18449136 — — 0.88 0.90 0.89 0.84 0.83 0.87 0.86 0.83 0.86 0.89TEMRA_nm32 cg13361307 AFF3 NM_001025108 0.81 0.80 0.79 0.78 0.78 0.810.82 0.82 0.80 0.86 TEMRA_nm33 cg25663823 LRRK1 NM_024652 0.95 0.95 0.950.90 0.90 0.94 0.96 0.95 0.93 0.94 TEMRA_nm34 cg24722886 PLEKHA7NM_175058 0.81 0.81 0.84 0.75 0.72 0.84 0.85 0.81 0.81 0.86 TEMRA_nm35cg01252713 — — 0.88 0.90 0.87 0.87 0.87 0.88 0.88 0.77 0.85 0.90TEMRA_nm36 cg09851620 — — 0.90 0.91 0.92 0.88 0.87 0.89 0.91 0.84 0.890.92 TEMRA_nm37 cg26484813 AHNAK NM_024060 0.86 0.89 0.91 0.86 0.85 0.890.86 0.88 0.84 0.92 TEMRA_nm38 cg25370412 — — 0.85 0.86 0.84 0.85 0.820.83 0.84 0.78 0.85 0.87 TEMRA_nm39 cg12522833 GALR1 NM_001480 0.87 0.920.92 0.92 0.88 0.87 0.90 0.89 0.89 0.90 TEMRA_nm40 cg26512948 — — 0.890.91 0.92 0.89 0.83 0.87 0.89 0.75 0.86 0.90 TEMRA_nm41 cg06627009 FSTL4NM_015082 0.85 0.89 0.92 0.89 0.86 0.91 0.93 0.77 0.87 0.92 TEMRA_nm42cg01186212 ANK3 NM_020987 0.86 0.85 0.82 0.81 0.83 0.82 0.83 0.91 0.820.89 TEMRA_nm43 cg20940398 SYNPO NM_001166208 0.89 0.87 0.88 0.80 0.780.83 0.88 0.81 0.81 0.89 TEMRA_nm44 cg04230397 MUC21 NM_001010909 0.850.84 0.86 0.82 0.81 0.84 0.85 0.72 0.83 0.87 TEMRA_nm45 cg15617591 — —0.84 0.91 0.89 0.86 0.84 0.83 0.83 0.79 0.86 0.91 TEMRA_nm46 cg22112587— — 0.85 0.87 0.90 0.83 0.82 0.90 0.89 0.80 0.86 0.90 TEMRA_nm47cg15302350 LRP5 NM_002335 0.88 0.88 0.89 0.85 0.86 0.89 0.89 0.68 0.840.90 TEMRA_nm48 cg19675599 — — 0.89 0.90 0.86 0.86 0.88 0.90 0.90 0.790.89 0.90 TEMRA_nm49 cg25314245 APP NM_201413 0.88 0.88 0.93 0.88 0.860.90 0.91 0.88 0.90 0.92 TEMRA_nm50 cg17037931 — — 0.83 0.84 0.84 0.850.83 0.85 0.83 0.71 0.81 0.86 TEMRA_nm51 cg11375831 SERPINI2 NM_0062170.90 0.88 0.88 0.87 0.86 0.88 0.88 0.77 0.87 0.88 TEMRA_nm52 cg18766691LPCAT1 NM_024830 0.90 0.91 0.92 0.85 0.86 0.89 0.90 0.64 0.87 0.92TEMRA_nm53 cg10104542 — — 0.84 0.82 0.90 0.83 0.80 0.84 0.84 0.68 0.810.90 TEMRA_nm54 cg01071903 — — 0.88 0.89 0.90 0.85 0.85 0.84 0.88 0.790.87 0.87 TEMRA_nm55 cg12695059 — — 0.93 0.91 0.91 0.85 0.86 0.91 0.920.92 0.89 0.86 TEMRA_nm56 cg11268546 — — 0.89 0.88 0.88 0.86 0.85 0.880.87 0.75 0.85 0.88 TEMRA_nm57 cg19277516 — — 0.90 0.89 0.87 0.89 0.890.88 0.85 0.82 0.85 0.90 TEMRA_nm58 cg25180759 MED13L NM_015335 0.830.91 0.92 0.83 0.83 0.89 0.90 0.84 0.89 0.93 TEMRA_nm59 cg16966340 — —0.88 0.85 0.89 0.86 0.87 0.87 0.81 0.79 0.87 0.91 TEMRA_nm60 cg23645373— — 0.83 0.89 0.89 0.73 0.74 0.84 0.85 0.83 0.83 0.86 TEMRA_nm61cg23642827 — — 0.91 0.92 0.90 0.82 0.83 0.86 0.90 0.80 0.88 0.89TEMRA_nm62 cg27398401 PPAP2B NM_003713.4 0.88 0.90 0.90 0.86 0.84 0.900.90 0.89 0.88 0.90 TEMRA_nm63 cg26372842 OR8S1 NM_001005203 0.88 0.880.90 0.86 0.87 0.85 0.89 0.79 0.86 0.86 TEMRA_nm64 cg02936931 — — 0.850.84 0.80 0.78 0.80 0.87 0.87 0.69 0.84 0.92 TEMRA_nm65 cg10381153CACHD1 NM_020925 0.90 0.90 0.92 0.88 0.91 0.89 0.92 0.79 0.90 0.92TEMRA_nm66 cg06951647 COL4A2 NM_001846 0.88 0.87 0.86 0.89 0.85 0.880.87 0.82 0.86 0.90 TEMRA_nm67 cg13177421 EPS8 NM_004447 0.85 0.80 0.840.87 0.79 0.81 0.87 0.79 0.83 0.87 CD4+ CD4+ CD8+ CD8+ CD8+ Th Th CD4+Cytotoxic CD8+ Th Th CD8+ NK Marker- CD4+ CD4+ CD4+ Central Effect. NK TCD4+ T- naive CD8+ Central Effect. NK T T- ID act. Th1 Th2 Mem. Mem.cells TFH Cells T8n_1 act. Mem. Mem. TEMRA cells Cells DiscoveryFragment CD8_nm12 0.80 0.80 0.80 0.85 0.85 0.76 0.81 0.08 0.10 0.18 0.290.13 0.07 0.23 0.18 TAAAATCTACAGTAC ACCACAAGGGTCAC AATACTGTTGTGCGCACATCG (SEQ ID NO: 813) CD8_nm13 0.79 0.79 0.79 0.84 0.82 0.69 0.82 0.070.07 0.15 0.11 0.07 0.05 0.10 0.12 CGGAAATCAGCTTGG GGGCCTTCTAGCCCTGCAGCTCAGAAAAG TGTCAG (SEQ ID NO: 814) CD8_nm14 0.76 0.78 0.77 0.82 0.790.74 0.77 0.20 0.22 0.30 0.47 0.39 0.14 0.35 0.39 CGAGGTGGATATTAGCAACTCCTTTAGCAG GGCTCAATGGCGTCT TAGAA (SEQ ID NO: 815) CD8_nm15 0.690.70 0.69 0.71 0.72 0.75 0.71 0.15 0.17 0.22 0.20 0.21 0.17 0.25 0.24TCCAACCAATTGTGC TCTCCCAATTCCAAC AACCAAATGAAGCTT CAACG (SEQ ID NO: 816)CD8_nm16 0.59 0.67 0.65 0.64 0.68 0.59 0.61 0.21 0.13 0.45 0.45 0.440.29 0.47 0.50 ATTTTTTACTTTCTAT GTGAAATTCATCATC AAATGAGGATTTGCA CTCG(SEQ ID NO: 817) CD8_nm17 0.56 0.58 0.53 0.61 0.59 0.58 0.53 0.19 0.210.26 0.39 0.26 0.24 0.29 0.30 GCCCACCGGGGTTGC CCTGGTGTTGCCCCCATCTGTAGAGAAGTT AGGCG (SEQ ID NO: 818) CD8_nm18 0.57 0.70 0.71 0.70 0.750.56 0.60 0.22 0.25 0.31 0.27 0.28 0.24 0.27 0.27 CGCTGTTTTGCTCAGGCTGGCCTTGGGACT CCTGAGCTCCAGTGA TCCTC (SEQ ID NO: 819) TEMRA_nm1 0.900.83 0.87 0.90 0.89 0.79 0.91 0.58 0.86 0.29 0.28 0.19 0.12 0.19 0.33TCTGTCAGAGGGCTG TTGTGGGATTATAAG AGCCCACTTGTGAAA TTGCG (SEQ ID NO: 820)TEMRA_nm2 0.80 0.69 0.85 0.82 0.79 0.65 0.83 0.63 0.85 0.38 0.35 0.280.11 0.15 0.13 GTCTTTGCCTGACAC CTTCTGTGAGGTTTG CGGGCTTCATTTTAA ATCCG(SEQ ID NO: 821) TEMRA_nm3 0.95 0.95 0.97 0.97 0.97 0.77 0.94 0.89 0.970.93 0.76 0.59 0.22 0.42 0.60 CGAGGCGCTGGCGA AGCACGAGGCCTTCTTCATTCGCTGCGGAA TCTTCC (SEQ ID NO: 822) TEMRA_nm4 0.86 0.59 0.75 0.780.76 0.53 0.87 0.65 0.92 0.56 0.46 0.40 0.12 0.27 0.36 CGAAAGCAAGCGAGTGAATTAGGATTTCA AAGTGCCCTAATAGT GTGAGT (SEQ ID NO: 823) TEMRA_nm5 0.920.92 0.92 0.74 0.55 0.79 0.85 0.92 0.92 0.91 0.87 0.89 0.14 0.87 0.85CGGCACAGATAAAA ATACAGAGACAATG GTTCCGACCCAGAGA TGAGGCT (SEQ ID NO: 824)TEMRA_nm7 0.81 0.72 0.75 0.76 0.73 0.65 0.83 0.71 0.91 0.46 0.55 0.380.14 0.27 0.27 GTCCGCAGTAATAAC AACCAAAGACACAT ATTCTCAGGCAATGA TAACCG(SEQ ID NO: 825) TEMRA_nm8 0.87 0.85 0.89 0.88 0.87 0.67 0.88 0.72 0.890.86 0.83 0.66 0.11 0.74 0.57 CATGAGAAAACTTCT TTAAGACCACCTGTAGAATTCTGCAATCAC ATACG (SEQ ID NO: 826) TEMRA_nm9 0.75 0.72 0.76 0.750.74 0.66 0.78 0.65 0.89 0.44 0.40 0.40 0.12 0.25 0.23 CGGAAGAATGAAAAGCTAATATTATTGTG TGGCATGATGACTGT CTCTTC (SEQ ID NO: 827) TEMRA_nm10 0.700.58 0.62 0.71 0.65 0.68 0.72 0.72 0.89 0.49 0.59 0.50 0.11 0.47 0.38CGCCCCACCCCAGAA CCAGCTAGCACCCAA GGGCTAGGCAGCCTG CTACT (SEQ ID NO: 828)TEMRA_nm11 0.79 0.64 0.71 0.79 0.74 0.62 0.78 0.76 0.92 0.60 0.69 0.550.16 0.45 0.42 TGCTGTGGGCCTCAG TTTTCCACCTGTTAC AGAGAACCCCTCGCC CTTCG(SEQ ID NO: 829) TEMRA_nm12 0.74 0.65 0.67 0.76 0.68 0.61 0.72 0.72 0.860.50 0.47 0.51 0.11 0.41 0.35 CGGGAATCTGTCTGT GTTACAAAGCAACTAGACTCACCCTATTGG CCTAA (SEQ ID NO: 830) TEMRA_nm13 0.73 0.86 0.83 0.730.57 0.66 0.80 0.82 0.86 0.73 0.72 0.61 0.12 0.79 0.76 CGGTCGTTGTAAAAGAGACTGTCTTGAGAG TGAAAAGCAAATAG ACATAT (SEQ ID NO: 831) TEMRA_nm14 0.640.63 0.64 0.73 0.72 0.60 0.64 0.68 0.89 0.49 0.49 0.38 0.11 0.25 0.27CCTTCTCTTCCCCCC AGGCTATGACTTTGC AGCCGTCCTGGAGTG GTTCG (SEQ ID NO: 832)TEMRA_nm15 0.79 0.72 0.80 0.81 0.77 0.58 0.82 0.70 0.89 0.49 0.42 0.360.16 0.34 0.17 GGGGTTATATATTTT TGACCAAATTCACCA TTACTCATTTGGCAT TTTCG(SEQ ID NO: 833) TEMRA_nm16 0.83 0.87 0.83 0.86 0.78 0.59 0.86 0.69 0.910.36 0.41 0.43 0.20 0.30 0.40 CGCGCAGGGTGGGC GGCTTACCATAGCAAGTGATCCTGCGATAG GGAACG (SEQ ID NO: 834) TEMRA_nm17 0.86 0.81 0.83 0.860.86 0.70 0.87 0.67 0.85 0.39 0.41 0.35 0.19 0.27 0.27 CGGTAGACAAATGATAGACATTTGTTGAAT CAAGCTGTGAGTTGG AGATC (SEQ ID NO: 835) TEMRA_nm18 0.680.60 0.64 0.70 0.66 0.64 0.64 0.74 0.88 0.47 0.66 0.56 0.13 0.51 0.52CGCCACCCCACCTTC ATCCACGGACTCCAG GTACTGTAGGGCTGG GAAAG (SEQ ID NO: 836)TEMRA_nm19 0.88 0.78 0.79 0.85 0.84 0.74 0.87 0.84 0.95 0.56 0.75 0.580.23 0.56 0.49 CAGTGACGTGGTGGG GAGCGTGTGCTTGTG TAGGGACAGCTTTCC AGGCG(SEQ ID NO: 837) TEMRA_nm20 0.68 0.67 0.74 0.72 0.69 0.58 0.71 0.61 0.860.39 0.34 0.29 0.13 0.22 0.20 CGTGCCCAGCTTTTC TATGGGAAAAATTGTTCTTCAGACAGAGCA TGAAT (SEQ ID NO: 838) TEMRA_nm21 0.77 0.59 0.70 0.740.67 0.57 0.82 0.59 0.93 0.32 0.36 0.19 0.16 0.19 0.15 GCGTACACACCCTGATAAGGTGTCAAGAAC CTCCGTTTGAGTACC CCTCG (SEQ ID NO: 839) TEMRA_nm22 0.740.66 0.76 0.73 0.71 0.63 0.79 0.66 0.89 0.58 0.59 0.45 0.15 0.34 0.30ACTTAGAGCCCACCA TGAAGCATCTTTTCT GTTGCTTCACTGACT CACCG (SEQ ID NO: 840)TEMRA_nm23 0.89 0.89 0.82 0.87 0.89 0.81 0.89 0.82 0.92 0.71 0.73 0.800.24 0.63 0.60 GGCCTTCTCTTTCTG GATGGCTGGTCACTG TCTGAGTCCTGATCT GACCG(SEQ ID NO: 841) TEMRA_nm24 0.69 0.58 0.62 0.69 0.65 0.64 0.67 0.69 0.860.39 0.47 0.40 0.13 0.38 0.34 CGGTATTTCAGTTAC ACTCTGTTGATTCAAAAGAAGGTTGTTTGT CCAAG (SEQ ID NO: 842) TEMRA_nm25 0.81 0.67 0.71 0.720.68 0.58 0.85 0.67 0.89 0.62 0.50 0.35 0.15 0.18 0.22 TTGCTCCAGCACTACAGAGCAGATTTGGA GCAGTCAGGTGGGG AAGCTCG (SEQ ID NO: 843) TEMRA_nm26 0.700.61 0.64 0.71 0.68 0.66 0.75 0.73 0.89 0.51 0.63 0.52 0.16 0.48 0.44CGGTCCTCACCTCAC TAGATCACCATGACT CACTGGGTAGATGGG CTATT (SEQ ID NO: 844)TEMRA_nm27 0.89 0.84 0.88 0.89 0.83 0.78 0.88 0.81 0.88 0.80 0.81 0.740.22 0.54 0.60 CGCTATTGCTAAGTA AAACCCATGTGTTTT CAGTCATGGTTAGCA GCAGG(SEQ ID NO: 845) TEMRA_nm28 0.68 0.64 0.69 0.76 0.70 0.61 0.68 0.73 0.890.42 0.55 0.38 0.16 0.32 0.32 CGAGGACGAATCTTG AGGCCTCCACTGGTCTACACGGACAGAAG CACGCC (SEQ ID NO: 846) TEMRA_nm29 0.70 0.60 0.70 0.740.71 0.59 0.72 0.71 0.85 0.39 0.57 0.47 0.11 0.29 0.32 CGTGGGAAAGTAATACAGGGAGGGAACA GCAGCCCATAAAAA GAACGTTA (SEQ ID NO: 847) TEMRA_nm30 0.680.82 0.82 0.76 0.73 0.67 0.72 0.80 0.92 0.57 0.57 0.48 0.18 0.56 0.49CTCATCTTAAGGATG CTTATTATCATAATG CTTTTTATAATTCCTA ATCG (SEQ ID NO: 848)TEMRA_nm31 0.73 0.59 0.70 0.72 0.67 0.71 0.74 0.74 0.88 0.45 0.55 0.480.15 0.35 0.38 CTCTTAACCTGGTGG TCTTTCACTAGCTTT ACAAAGGTGATACA GTTTCG(SEQ ID NO: 849) TEMRA_nm32 0.78 0.59 0.68 0.72 0.66 0.61 0.79 0.65 0.840.58 0.53 0.51 0.12 0.39 0.33 CGAGGCTCTGCACAG GTAAACTCAAGGGTTACCCTGTGCTTTGAA ACCTT (SEQ ID NO: 850) TEMRA_nm33 0.66 0.57 0.62 0.700.63 0.55 0.65 0.76 0.93 0.49 0.49 0.40 0.18 0.35 0.38 TCAGCCCCGGAGGGCAGGCGCCAGTCCATC AGCTTGTATGTCTGT CCTCG (SEQ ID NO: 851) TEMRA_nm34 0.650.55 0.57 0.66 0.61 0.65 0.71 0.59 0.82 0.34 0.35 0.40 0.10 0.25 0.26CGAGTGTGGAGCTAT GATTGGAACCTAGTT CAGGCTCCAAAGCCA CACTC (SEQ ID NO: 852)TEMRA_nm35 0.65 0.53 0.59 0.66 0.61 0.57 0.61 0.69 0.89 0.43 0.58 0.490.12 0.44 0.39 CGACCATTCTCACAA GACATTGAACAGAG AATAAGAGGAGAGA AAAAGGC(SEQ ID NO: 853) TEMRA_nm36 0.68 0.62 0.67 0.72 0.66 0.67 0.74 0.74 0.920.50 0.66 0.57 0.17 0.54 0.46 AAGTTCCCATTAGAT GACTCACTTCAGGAGGGCAGGAACCATTCT GTTCG (SEQ ID NO: 854) TEMRA_nm37 0.86 0.70 0.75 0.790.71 0.67 0.87 0.75 0.90 0.63 0.73 0.53 0.19 0.40 0.28 CGGCTCTGCCAGGACCCACCAGCCAATTCC AAGTCGAGCAAAAG AATCCA (SEQ ID NO: 855) TEMRA_nm38 0.680.59 0.64 0.71 0.69 0.67 0.68 0.74 0.83 0.54 0.55 0.56 0.13 0.58 0.49ACTGTTGATCCTGGG AGTCTCTGGCCTTGT ATTTATGACTTATCA ATTCG (SEQ ID NO: 856)TEMRA_nm39 0.85 0.80 0.85 0.87 0.84 0.78 0.85 0.87 0.86 0.80 0.83 0.810.23 0.79 0.75 ATTCTGTCTAGTCTTT GGTCCCATAGAAATT ATTATCTACATCAAC CTCG(SEQ ID NO: 857) TEMRA_nm40 0.78 0.63 0.67 0.67 0.69 0.60 0.81 0.69 0.910.50 0.41 0.46 0.16 0.30 0.33 ACACTTCTGGCAAAT AGTTCATCTAATTAGAACCATGGGAAACC CCTCCG (SEQ ID NO: 858) TEMRA_nm41 0.76 0.69 0.79 0.810.77 0.76 0.76 0.77 0.89 0.50 0.64 0.64 0.19 0.57 0.56 CGGGGATTCCAACCCCAGGGCACCTCTCTG GCATTCCCATTAAGG AAGCC (SEQ ID NO: 859) TEMRA_nm42 0.850.71 0.71 0.75 0.62 0.77 0.81 0.79 0.86 0.67 0.44 0.57 0.16 0.49 0.51ATTTGTAACATCACA AGAGTTAGAAGACC CCATATTGCTTGAGC TTTTCG (SEQ ID NO: 860)TEMRA_nm43 0.74 0.65 0.72 0.73 0.71 0.55 0.76 0.70 0.83 0.46 0.52 0.430.14 0.33 0.35 CGAGGCTTGTGCTCT TGGCCACCACTGTCT TCTGGAATTATAGGA GTAAA(SEQ ID NO: 861) TEMRA_nm44 0.70 0.57 0.61 0.67 0.65 0.60 0.73 0.66 0.860.42 0.52 0.43 0.13 0.26 0.33 CGAGTAAAATGATG ATCCTCACTCTATGGAAGAGAAGCAGAGC TGGCCCC (SEQ ID NO: 862) TEMRA_nm45 0.64 0.56 0.60 0.690.62 0.60 0.64 0.72 0.87 0.48 0.50 0.41 0.13 0.40 0.35 CGCCTGGAATTTCTTGAAACACCCTTATAC ATGCATAAAACTGTA GGTGG (SEQ ID NO: 863) TEMRA_nm46 0.750.65 0.73 0.79 0.72 0.67 0.77 0.64 0.89 0.39 0.46 0.42 0.17 0.31 0.31CGGTCTTGGGTGGCC CATAGGAGATTAAG AATTTCCTATTATCC AAGCTG (SEQ ID NO: 864)TEMRA_nm47 0.72 0.62 0.66 0.67 0.64 0.56 0.75 0.65 0.90 0.51 0.52 0.450.15 0.46 0.38 CGGCCAGGCTGCAAT GCACATGGCCGCCCT CATTGGCAGGGTCAC ATGAG(SEQ ID NO: 865) TEMRA_nm48 0.63 0.52 0.59 0.65 0.63 0.67 0.65 0.71 0.920.41 0.56 0.49 0.15 0.45 0.40 CGCCACAAATGAGTA AAGCAGGTCTAGCAGGCTTGTCTGTTGAG TTACTG (SEQ ID NO: 866) TEMRA_nm49 0.87 0.80 0.87 0.880.83 0.75 0.89 0.80 0.90 0.59 0.72 0.61 0.24 0.51 0.55 CGAGACACCTGGGGATGAGAATGAACAT GCCCATTTCCAGAAA GCCAAAG (SEQ ID NO: 867) TEMRA_nm50 0.620.54 0.57 0.66 0.62 0.67 0.64 0.71 0.83 0.43 0.55 0.45 0.11 0.47 0.42CCCCTTTTTCCCAGG GACCCACAGAACTGT GAGCAAGAAATAAA TGTTCG (SEQ ID NO: 868)TEMRA_nm51 0.68 0.60 0.64 0.70 0.65 0.65 0.69 0.74 0.89 0.53 0.68 0.490.16 0.50 0.48 CGGTCTCTGCCATTG GTAGGAAAAGTAAT GGACTATTTCTGGAT AAATCA(SEQ ID NO: 869) TEMRA_nm52 0.77 0.67 0.84 0.70 0.67 0.67 0.83 0.62 0.860.45 0.39 0.43 0.19 0.34 0.34 CGGAATAAAACCACT GAAACACAATCAGGGCTACGTGCATTACC TGTGGC (SEQ ID NO: 870) TEMRA_nm53 0.67 0.60 0.73 0.750.73 0.70 0.70 0.71 0.88 0.38 0.52 0.56 0.14 0.50 0.45 CGGATGCCTATCTGTTCCTGACCCCCAAGG TCCCTCAGGATCTGC TGGGA (SEQ ID NO: 871) TEMRA_nm54 0.730.64 0.70 0.73 0.69 0.67 0.73 0.74 0.87 0.57 0.65 0.54 0.17 0.59 0.52CGCAAATCCAAACCA TATCAGGGTTTCACA GCTAGAGAGAAGGA GTCAAT (SEQ ID NO: 872)TEMRA_nm55 0.78 0.79 0.83 0.85 0.84 0.72 0.79 0.65 0.88 0.39 0.54 0.440.22 0.30 0.43 GGTGATTACAGCAGA TGACCCCATCTGCCT GGTGCCTGACTTTAT TTTCG(SEQ ID NO: 873) TEMRA_nm56 0.64 0.57 0.63 0.67 0.63 0.59 0.65 0.71 0.870.46 0.59 0.43 0.14 0.42 0.42 GGGGTTGACCATGGC TGGTAACAGGGGACTCTGGTTGGCCAGTGG CATCG (SEQ ID NO: 874) TEMRA_nm57 0.71 0.55 0.66 0.760.66 0.66 0.72 0.76 0.89 0.69 0.72 0.53 0.17 0.44 0.43 CGAGTTTAACCCCACTTGGAGCCAGAAAG ATGGGCCAAATCAAC ACCAAG (SEQ ID NO: 875) TEMRA_nm58 0.840.79 0.82 0.84 0.79 0.63 0.85 0.74 0.89 0.54 0.49 0.44 0.22 0.31 0.34CACAGACTAATGATA ATCTTTGGGAAATTT GGGTCTACCATAAAT ACTCG (SEQ ID NO: 876)TEMRA_nm59 0.71 0.63 0.69 0.74 0.71 0.64 0.72 0.70 0.86 0.54 0.69 0.550.17 0.41 0.51 AGGTTAAAACCAAG GGCTCAGACTACAGG TGTGTGTAGCATGTG TACACG(SEQ ID NO: 877) TEMRA_nm60 0.72 0.63 0.63 0.72 0.65 0.67 0.70 0.69 0.830.50 0.63 0.47 0.14 0.40 0.41 TTCACTGCAGATGAA ATGGGCTTCTCATGCTACCTCAGTTACCAG AATCG (SEQ ID NO: 878) TEMRA_nm61 0.78 0.60 0.79 0.770.74 0.61 0.82 0.59 0.87 0.34 0.37 0.37 0.19 0.24 0.26 CGCATACTTTCAGGGAGAGGCACTATTCTT GGCTTTAAGTTCATG AGTAA (SEQ ID NO: 879) TEMRA_nm62 0.670.57 0.59 0.67 0.64 0.62 0.66 0.72 0.88 0.44 0.65 0.47 0.16 0.38 0.40CGACAATTTCAATCC AGAGTGTTAAGTGCT GTTACAGAGGAGCTG GGGAG (SEQ ID NO: 880)TEMRA_nm63 0.78 0.58 0.66 0.71 0.71 0.64 0.73 0.75 0.87 0.60 0.67 0.590.17 0.45 0.45 CGTAGTCTGACACAG GAGTCCACTTAGCCA TTGATCTGTGTGGCT CAATT(SEQ ID NO: 881) TEMRA_nm64 0.65 0.54 0.62 0.69 0.61 0.54 0.64 0.61 0.910.35 0.35 0.36 0.13 0.20 0.21 GACTGAAACTTGCAC CAGTTCTGAATGCCTCTAACCTTGGTTGTA TAACG (SEQ ID NO: 882) TEMRA_nm65 0.77 0.63 0.71 0.740.69 0.67 0.78 0.75 0.93 0.49 0.60 0.50 0.20 0.48 0.40 CGAGGCTGAATGAAATCCAATTGGAACTC ACTTGAACACTGTTT TGATGT (SEQ ID NO: 883) TEMRA_nm66 0.660.57 0.66 0.72 0.66 0.63 0.66 0.76 0.87 0.47 0.51 0.49 0.16 0.44 0.40GTGTCCCAGGAAAG GCCCACTAGTGGGTC CCGGTGTGGGACCCA CCCCCG (SEQ ID NO: 884)TEMRA_nm67 0.65 0.57 0.60 0.71 0.60 0.56 0.65 0.67 0.83 0.45 0.45 0.400.13 0.36 0.37 ACAGTGAGCTATGCC CTGAATGACAGACAC CATATTCACAGGCAA AATCG(SEQ ID NO: 885)

TABLE 4D Follicular helper T cells - marker Non- Marker- Target BasophilEosinophil Neutrophil Classical classical ID ID SYMBOL AccessionGranulocytes Granulocytes Granulocytes Monocytes Monocytes TFH_nm1cg13077150 PRKCZ NM_002744 0.91 0.90 0.91 0.89 0.89 TFH_nm2 cg11227141PRKCZ NM_002744 0.86 0.82 0.83 0.86 0.85 TFH_nm3 cg27064482 MKL2NM_014048 0.85 0.87 0.89 0.89 0.88 TFH_nm4 cg21377860 GIMAP8 NM_1755710.92 0.91 0.91 0.92 0.91 TFH_nm5 cg15722603 LIF NM_002309 0.88 0.89 0.900.89 0.90 TFH_nm6 cg00151768 NFATC1 NM_006162 0.90 0.91 0.91 0.93 0.87TFH_nm7 cg15260951 NFATC1 NM_006162 0.94 0.95 0.95 0.95 0.95 TFH_nm8cg16421411 C2orf48 NM_182626 0.97 0.96 0.97 0.96 0.97 TFH_nm9 cg26393261ATXN1 NM_000332 0.97 0.95 0.96 0.97 0.97 TFH_nm10 cg10842070 DNAJC5NM_025219 0.97 0.98 0.97 0.97 0.97 TFH_nm11 cg09232021 MAF NM_1755710.92 0.91 0.91 0.93 0.92 TFH_nm12 cg13144059 SPATS2L NM_015535 0.96 0.970.98 0.98 0.98 TFH_nm13 cg26175815 TMCC1 NM_001017395 0.90 0.90 0.920.90 0.88 TFH_nm14 cg07172701 SER1NC5 NM_178276 0.91 0.78 0.84 0.84 0.87TFH_nm15 cg21911000 CD28 NM_006139 0.88 0.86 0.89 0.91 0.89 TFH_nm16cg15213399 LPP NM_005578 0.92 0.92 0.91 0.90 0.87 TFH_nm17 cg03596635ABTB1 NM_172028 0.95 0.94 0.95 0.95 0.95 TFH_nm18 cg10451262 ZHX1NM_007222 0.91 0.91 0.92 0.90 0.91 TFH_nm19 cg01349034 — — 0.90 0.890.88 0.88 0.86 TFH_nm20 cg15873449 PTPN2 NM_080423 0.85 0.86 0.87 0.880.85 TFH_nm21 cg16152136 — — 0.85 0.89 0.90 0.88 0.89 TFH_nm22cg20968717 LIPC NM_000236 0.90 0.92 0.92 0.94 0.92 TFH_nm23 cg25087423CXCR5 NM_001716 0.90 0.92 0.92 0.91 0.90 TFH_nm24 cg08012294 CTSBNM_147780 0.88 0.92 0.92 0.86 0.76 TFH_nm25 cg17410313 NUB1 NM_0161180.92 0.91 0.92 0.91 0.89 TFH_nm26 cg04337734 SLC25A12 NM_003705 0.890.91 0.87 0.88 0.88 TFH_nm27 cg15039797 HIPK2 NM_022740 0.97 0.97 0.980.97 0.98 TFH_nm28 cg27586885 — — 0.96 0.95 0.96 0.96 0.95 TFH_nm29cg20702205 RNF216 NM_207111 0.91 0.86 0.91 0.89 0.87 TFH_nm30 cg06846719FAM6A NM_021238 0.87 0.88 0.90 0.89 0.87 TFH_nm31 cg23892568 CLEC7ANM_022570 0.87 0.88 0.88 0.81 0.82 TFH_nm32 cg24033742 — — 0.90 0.900.90 0.90 0.90 TFH_nm33 cg03280299 ST7 NM_018412 0.82 0.88 0.89 0.840.86 TFH_nm34 cg16375820 IL6ST NM_175767 0.89 0.86 0.88 0.89 0.87TFH_nm35 cg11307417 ZNF589 NM_016089 0.88 0.90 0.90 0.87 0.87 TFH_nm36cg13774342 DLEU1 — 0.90 0.92 0.90 0.88 0.91 TFH_nm37 cg21653149 ANKFY1NM_016376 0.91 0.91 0.91 0.91 0.92 TFH_nm38 cg14624950 SMURF2 NM_0227390.87 0.89 0.90 0.90 0.89 TFH_nm39 cg13142152 FAM65B — 0.67 0.78 0.860.87 0.85 TFH_nm40 cg15873112 ATXN7L1 NM_020725 0.78 0.80 0.84 0.87 0.85TFH_nm41 cg23342358 PCBP3 — 0.84 0.80 0.76 0.84 0.83 TFH_nm42 cg22535163— — 0.91 0.90 0.90 0.91 0.90 TFH_nm43 cg13637151 PRRC2B NM_013318 0.920.92 0.93 0.91 0.91 TFH_nm44 cg26446535 ARHGAP35 NM_004491 0.90 0.880.90 0.92 0.93 TFH_nm45 cg06346099 SOD2 NM_000636 0.47 0.63 0.79 0.840.77 TFH_nm46 cg13049261 SETD3 NM_032233 0.93 0.92 0.93 0.93 0.92TFH_nm47 cg06019273 ARID1B NM_017519 0.85 0.88 0.91 0.88 0.88 TFH_nm48cg00780520 PVT1 NR_003367 0.80 0.78 0.80 0.81 0.85 TFH_nm49 cg07167688 —— 0.95 0.96 0.95 0.96 0.94 TFH_nm50 cg27168844 IL17A NM_002190 0.69 0.890.92 0.92 0.89 TFH_nm51 cg18883472 CNIH4 NM_014184 0.91 0.92 0.91 0.920.91 TFH_nm52 cg11887733 — — 0.85 0.90 0.90 0.92 0.89 TFH_nm53cg02003272 — — 0.96 0.96 0.96 0.97 0.96 TFH_nm54 cg20298778 PHACTR2NR_027113 0.90 0.92 0.94 0.92 0.89 TFH_nm55 cg19030737 ITPKB NM_0022210.74 0.67 0.83 0.81 0.84 TFH_nm56 cg19324997 HDAC4 NM_006037 0.98 0.970.98 0.98 0.97 CD4+ CD4+ CD4+ Th Th CD4+ Marker- NK NK B- Th CD4+ CD4+CD4+ Central Effect. NK T ID classical bright Cells MDSC naive act. Th1Th2 Mem. Mem. cells TFH_nm1 0.88 0.87 0.86 0.85 0.92 0.33 0.63 0.51 0.550.54 0.78 TFH_nm2 0.87 0.88 0.83 0.81 0.89 0.28 0.60 0.42 0.58 0.57 0.78TFH_nm3 0.84 0.68 0.80 0.77 0.89 0.17 0.66 0.59 0.62 0.63 0.56 TFH_nm40.92 0.89 0.92 0.90 0.79 0.38 0.73 0.51 0.72 0.71 0.83 TFH_nm5 0.80 0.800.88 0.84 0.89 0.24 0.35 0.42 0.47 0.44 0.58 TFH_nm6 0.91 0.82 0.81 0.880.92 0.37 0.71 0.65 0.80 0.74 0.74 TFH_nm7 0.92 0.88 0.82 0.92 0.90 0.140.29 0.26 0.38 0.29 0.55 TFH_nm8 0.96 0.95 0.96 0.93 0.97 0.44 0.68 0.590.69 0.69 0.80 TFH_nm9 0.96 0.94 0.97 0.96 0.96 0.33 0.87 0.79 0.87 0.850.87 TFH_nm10 0.95 0.90 0.50 0.94 0.97 0.29 0.87 0.80 0.86 0.87 0.89TFH_nm11 0.91 0.90 0.91 0.90 0.91 0.25 0.56 0.62 0.53 0.47 0.65 TFH_nm120.97 0.95 0.90 0.96 0.97 0.42 0.88 0.80 0.91 0.85 0.88 TFH_nm13 0.880.81 0.78 0.88 0.87 0.25 0.54 0.49 0.60 0.56 0.75 TFH_nm14 0.90 0.920.88 0.84 0.93 0.25 0.63 0.45 0.57 0.62 0.75 TFH_nm15 0.89 0.88 0.910.87 0.85 0.15 0.38 0.32 0.41 0.25 0.62 TFH_nm16 0.89 0.76 0.90 0.840.91 0.36 0.88 0.77 0.85 0.86 0.67 TFH_nm17 0.94 0.93 0.92 0.91 0.540.29 0.62 0.58 0.57 0.58 0.72 TFH_nm18 0.91 0.91 0.87 0.89 0.90 0.220.49 0.37 0.55 0.45 0.65 TFH_nm19 0.87 0.87 0.93 0.88 0.91 0.36 0.730.74 0.76 0.70 0.78 TFH_nm20 0.86 0.76 0.57 0.85 0.82 0.18 0.56 0.540.52 0.52 0.73 TFH_nm21 0.88 0.88 0.86 0.87 0.83 0.20 0.40 0.50 0.450.42 0.60 TFH_nm22 0.91 0.87 0.72 0.89 0.85 0.36 0.63 0.54 0.64 0.620.76 TFH_nm23 0.86 0.81 0.08 0.85 0.83 0.19 0.59 0.52 0.58 0.58 0.68TFH_nm24 0.91 0.89 0.89 0.80 0.81 0.23 0.46 0.49 0.50 0.45 0.68 TFH_nm250.92 0.89 0.81 0.89 0.92 0.31 0.66 0.65 0.66 0.65 0.77 TFH_nm26 0.860.78 0.86 0.86 0.84 0.28 0.74 0.62 0.65 0.61 0.63 TFH_nm27 0.25 0.620.98 0.91 0.10 0.21 0.52 0.58 0.44 0.45 0.51 TFH_nm28 0.94 0.92 0.940.89 0.95 0.32 0.81 0.55 0.72 0.69 0.71 TFH_nm29 0.91 0.90 0.79 0.890.89 0.29 0.80 0.58 0.70 0.78 0.86 TFH_nm30 0.87 0.76 0.75 0.83 0.870.24 0.58 0.44 0.59 0.59 0.63 TFH_nm31 0.86 0.79 0.67 0.81 0.86 0.170.38 0.35 0.43 0.29 0.63 TFH_nm32 0.90 0.91 0.92 0.89 0.91 0.41 0.720.67 0.74 0.77 0.84 TFH_nm33 0.87 0.78 0.84 0.85 0.86 0.33 0.62 0.520.60 0.61 0.66 TFH_nm34 0.88 0.77 0.88 0.80 0.18 0.25 0.69 0.47 0.560.66 0.65 TFH_nm35 0.89 0.87 0.86 0.85 0.36 0.24 0.57 0.41 0.43 0.540.64 TFH_nm36 0.89 0.82 0.81 0.88 0.89 0.21 0.45 0.35 0.40 0.39 0.55TFH_nm37 0.88 0.76 0.90 0.86 0.85 0.38 0.70 0.70 0.70 0.70 0.60 TFH_nm380.87 0.82 0.87 0.85 0.90 0.31 0.61 0.44 0.60 0.52 0.77 TFH_nm39 0.850.82 0.83 0.81 0.69 0.19 0.42 0.31 0.40 0.33 0.67 TFH_nm40 0.86 0.860.50 0.81 0.67 0.19 0.48 0.35 0.39 0.41 0.54 TFH_nm41 0.86 0.85 0.870.83 0.78 0.34 0.71 0.60 0.70 0.72 0.74 TFH_nm42 0.89 0.85 0.91 0.890.73 0.31 0.65 0.60 0.68 0.53 0.68 TFH_nm43 0.90 0.87 0.92 0.88 0.830.35 0.76 0.65 0.69 0.73 0.71 TFH_nm44 0.91 0.87 0.90 0.89 0.92 0.380.65 0.74 0.69 0.63 0.72 TFH_nm45 0.78 0.78 0.85 0.77 0.86 0.24 0.450.45 0.48 0.44 0.64 TFH_nm46 0.90 0.89 0.90 0.87 0.76 0.23 0.48 0.410.47 0.42 0.65 TFH_nm47 0.84 0.82 0.62 0.87 0.90 0.32 0.54 0.46 0.600.60 0.66 TFH_nm48 0.82 0.80 0.65 0.77 0.87 0.20 0.42 0.27 0.44 0.370.61 TFH_nm49 0.95 0.95 0.94 0.93 0.96 0.31 0.53 0.47 0.57 0.50 0.69TFH_nm50 0.87 0.80 0.70 0.86 0.88 0.24 0.72 0.61 0.62 0.60 0.63 TFH_nm510.89 0.87 0.93 0.89 0.76 0.41 0.76 0.47 0.64 0.71 0.83 TFH_nm52 0.880.83 0.89 0.83 0.58 0.23 0.40 0.39 0.40 0.44 0.66 TFH_nm53 0.96 0.940.89 0.92 0.96 0.35 0.58 0.50 0.55 0.57 0.66 TFH_nm54 0.86 0.79 0.730.89 0.92 0.39 0.79 0.62 0.79 0.71 0.68 TFH_nm55 0.79 0.82 0.82 1.800.41 0.28 0.68 0.48 0.52 0.59 0.63 TFH_nm56 0.79 0.94 0.98 0.93 0.730.41 #DIV/ #DIV/ 0.70 0.68 0.72 0! 0! CD8+ CD8+ CD8+ Cytotoxic CD8+ ThTh CD8+ NK Marker- CD4+ T- naive CD8+ Central Effect. NK T T- DiscoveryID TFH Cells T8n_1 act. Mem. Mem. TEMRA cells Cells Fragment TFH_nm10.23 0.86 0.86 0.68 0.77 0.82 0.86 0.87 0.86 CGTGCTGTGCCC TCGATGCTCCAGCACCTATGGCCC TGCTGACCCTGG AG (SEQ ID NO: 886) TFH_nm2 0.18 0.81 0.850.67 0.73 0.74 0.72 0.75 0.67 CGAGGCACGGCC ACTTCTCCAAAG GGCCAAGCTTCCCTCGTCAGGCGG CT (SEQ ID NO: 887) TFH_nm3 0.08 0.88 0.82 0.70 0.66 0.760.81 0.78 0.82 AGAGAGCTGACA AGGGCATGCACG ATTAATTGCACA CTCGCACACCCA CG(SEQ ID NO: 888) TFH_nm4 0.28 0.88 0.88 0.81 0.90 0.88 0.92 0.91 0.93CGTAAAGTCTGC TCCAAAGATGGC CTCCAGTTTCGC CACAGCTGTTTT GT (SEQ ID NO: 889)TFH_nm5 0.13 0.78 0.89 0.64 0.71 0.62 0.73 0.65 0.60 CGGGACCAGAAGATCCTCAACCC CAGTGCCCTCAG CCTCCACAGCAA GCT (SEQ ID NO: 890) TFH_nm6 0.230.92 0.85 0.86 0.86 0.90 0.88 0.90 0.90 CGGCTCTTCAGG TACAGAGATCTGAACTTGGAAAGA CCTGCCTTTCTA AA (SEQ ID NO: 891) TFH_nm7 0.10 0.87 0.910.63 0.66 0.73 0.93 0.81 0.85 CGGCTCGCTCAG CCATCAGGTGCC CCACGACACACAGGTGGTTTGGGG GT (SEQ ID NO: 892) TFH_nm8 0.32 0.97 0.95 0.87 0.93 0.950.95 0.94 0.97 CGCCCGTCGTTC ATGTCGATTCTC TCAGTCAATCAA AACGCTGCCACA GC(SEQ ID NO: 893) TFH_nm9 0.16 0.96 0.94 0.93 0.93 0.94 0.96 0.96 0.96ATGCAGCGATGT GGCCGGGAGTTA GCATGAAGCGTG GTTATTCTATCA CG (SEQ ID NO: 894)TFH_nm10 0.16 0.97 0.95 0.85 0.90 0.93 0.96 0.94 0.97 CGCTGTCCGCCCTTCGCCACCCAC CGCGCCTGCTGC TCAGGAATGTTC CA (SEQ ID NO: 895) TFH_nm11 0.100.90 0.91 0.85 0.88 0.62 0.91 0.79 0.73 TGTTTCTCTTTAC CGTTCAATGCATATGTGCGCAAGC CACCTCTGATGC G (SEQ ID NO: 896) TFH_nm12 0.24 0.98 0.960.94 0.95 0.97 0.98 0.96 0.97 GGCAGAGTCATC TGCGTGGCGCAC ACTGTTGTATATGCTGCACGTACA CG (SEQ ID NO: 897) TFH_nm13 0.12 0.84 0.84 0.78 0.72 0.810.84 0.87 0.84 GCTTTCTCATTTT TCCGTTCCTCCA CCCACTGGCTGG TTATGGGGGTTC G(SEQ ID NO: 898) TFH_nm14 0.12 0.88 0.90 0.79 0.82 0.87 0.88 0.77 0.88CGTACTTGCAAA GTAATACAGAAA CGTGACTTTCGG CAGCTACCCAAG AT (SEQ ID NO: 899)TFH_nm15 0.09 0.82 0.87 0.61 0.77 0.60 0.87 0.79 0.78 CGGTTAATTATGGAAAAACAGCTT GTTAAGCAAATG CTAATGTAAGAA GA (SEQ ID NO: 900) TFH_nm16 0.150.93 0.90 0.90 0.74 0.84 0.87 0.80 0.94 GTTTTAATAAAG CACTATCAAAAAGACGGCACAGA GTTTCGGTTGCC ACG (SEQ ID NO: 901) TFH_nm17 0.15 0.61 0.500.77 0.84 0.84 0.87 0.88 0.87 AGAGGAATCGTG GTGCTTTGCAAA TGTGTATCAAGGCCTTTGAATGCA CG (SEQ ID NO: 902) TFH_nm18 0.12 0.82 0.90 0.68 0.77 0.770.69 0.72 0.75 AAGAAATCCACT AATGAGTGTTCA CTAGCACAGGCA CATTTATGTTTTC G(SEQ ID NO: 903) TFH_nm19 0.16 0.88 0.91 0.82 0.84 0.82 0.84 0.84 0.81ACTGCACATATC TTTTTGAAAGAC AGCTTTTTAAGG TATGACTCACTA CG (SEQ ID NO: 904)TFH_nm20 0.11 0.89 0.86 0.71 0.78 0.76 0.84 0.86 0.81 CGCCAAGTATTCAGCATCTCTTTG GAATTCATTTGT CAGCCTCTCTGG TT (SEQ ID NO: 905) TFH_nm21 0.100.83 0.85 0.70 0.80 0.68 0.80 0.69 0.68 CGTCAAGCTGGC AGAATTTTAGAGGCATCTCATTTA AATTAGATCTGG CC (SEQ ID NO: 906) TFH_nm22 0.16 0.86 0.890.73 0.83 0.80 0.89 0.90 0.89 CGGGTGACTCAT AGAGAGTGATTA GAAGTAAAAAGGTTCTGGAAATT CCC (SEQ ID NO: 907) TFH_nm23 0.10 0.84 0.82 0.54 0.81 0.770.83 0.85 0.81 TGATGAGTTGTG AGGCAGGTCGCG GCCCTACTGCCT CAGGAGACGATG CG(SEQ ID NO: 908) TFH_nm24 0.15 0.90 0.89 0.85 0.91 0.88 0.89 0.90 0.88CGCCTAACCAGT TGGAAACAGGGC TGTCCTGAGCCA ACACCCAGGAGA GC (SEQ ID NO: 909)TFH_nm25 0.19 0.89 0.89 0.84 0.89 0.87 0.87 0.89 0.84 CGGTAGAGTCTAATTTGCAAGATG TAAATGCAGAAA ATAGACATTTCA GC (SEQ ID NO: 910) TFH_nm26 0.150.87 0.84 0.84 0.79 0.77 0.82 0.81 0.81 CGACGGACACTA AAACTGGGTCAGAAAACTTGGGTT CTAAACTCCTGT GC (SEQ ID NO: 911) TFH_nm27 0.09 0.60 0.600.87 0.87 0.83 0.96 0.87 0.85 CGGTACCATGAT ACGTGCCGCAGA ATGTTCCTGCTGCGACCGTAAAGA AC (SEQ ID NO: 912) TFH_nm28 0.20 0.91 0.93 0.74 0.81 0.800.84 0.77 0.83 CGCCCGCGCCTT TCCCAGGCTCAA GGCCTCCCTGCC CACCAGGCAGGT GG(SEQ ID NO: 913) TFH_nm29 0.21 0.90 0.88 0.85 0.90 0.89 0.90 0.89 0.90CACTAGTAACTC TCCGGTGTCTAG AGTTAGTACTGA TGGACTCCCTGC CG (SEQ ID NO: 914)TFH_nm30 0.12 0.80 0.84 0.69 0.59 0.77 0.69 0.82 0.76 CGCTGAGATTGTTTGAGTTGTTTTT CTTAATTAGTAT TTCATAGCTAAG T (SEQ ID NO: 915) TFH_nm31 0.110.85 0.87 0.79 0.80 0.69 0.83 0.81 0.80 CGGTTAAATTAA TTAATGTCAGACTTAGTTGTGAGA GTAATGAAGGCA GC (SEQ ID NO: 916) TFH_nm32 0.22 0.90 0.890.79 0.87 0.90 0.89 0.88 0.90 CGCTGGGAGAAC TTGAGCGGGGAG CCCAGCACCACACACCCACTTGCC TC (SEQ ID NO: 917) TFH_nm33 0.16 0.85 0.80 0.82 0.69 0.770.85 0.81 0.83 CTGCTCTAGGAA TATATTTACATA CATGTATTTCTC CTATTTCTTCATC G(SEQ ID NO: 918) TFH_nm34 0.14 0.72 0.59 0.81 0.76 0.84 0.84 0.86 0.90CGGGGAATCCCT CCCTGCCACTGT AGAGGATTTATG GGTTGCCCTTAA GT (SEQ ID NO: 919)TFH_nm35 0.16 0.73 0.69 0.77 0.82 0.83 0.89 0.86 0.87 GAGTGTATCCTCTGATGTACACTA AGAGCGGACTTG AGGCTAAAGTTT CG (SEQ ID NO: 920) TFH_nm36 0.130.81 0.89 0.61 0.69 0.66 0.60 0.62 0.63 TGGGAGACTTGT AATTGTGTACCTGTTTGCATTGTTT AGCCTATGCATC G (SEQ ID NO: 921) TFH_nm37 0.19 0.86 0.850.78 0.72 0.77 0.84 0.80 0.79 CGGTGCTTGAGG AAGATGCATCTG CTCTTGACACTGACATACTCGAAG GA (SEQ ID NO: 922) TFH_nm38 0.18 0.85 0.86 0.76 0.77 0.780.76 0.73 0.76 CGGCATCCGAAT ATTCTAGCCCTG GCAGACCTCTTA GCTGCTTTGTTG AT(SEQ ID NO: 923) TFH_nm39 0.13 0.84 0.81 0.65 0.81 0.76 0.74 0.74 0.79TCCCAATCAGTG AGACCTCAAATA ATGAACTTGGCT CTCATTTATACA CG (SEQ ID NO: 924)TFH_nm40 0.12 0.79 0.87 0.73 0.79 0.69 0.73 0.71 0.65 ATTCAAAGACGCTTGCTCTGAAAG CCCGAAATTCAG TCTTTCTGAAGA CG (SEQ ID NO: 925) TFH_nm41 0.190.83 0.83 0.78 0.77 0.80 0.83 0.81 0.80 TACCAGAGTGCC TGTGCTGTTGTATCCTGACACACC AGGTACTGCATA CG (SEQ ID NO: 926) TFH_nm42 0.23 0.85 0.820.84 0.84 0.83 0.90 0.86 0.81 CGCACAAAAATG TAGAAAGAATAT TGGAGACGGAAAATTGTGAATGT ACC (SEQ ID NO: 927) TFH_nm43 0.25 0.90 0.86 0.83 0.85 0.860.89 0.87 0.90 GGAAATCGAATC GTGGATTCACCA GGCCGGTGCTGG CACACTCACCCT CG(SEQ ID NO: 928) TFH_nm44 0.25 0.89 0.86 0.81 0.82 0.80 0.84 0.85 0.85GTTGTCAGAATT TCCTTCCCTTTAA AGGCTGAATAGG CCAGGCGTGATC G (SEQ ID NO: 929)TFH_nm45 0.12 0.80 0.84 0.77 0.80 0.74 0.76 0.71 0.69 CCACTACAAAAACAGTCATAAAGA GCTTAACATACT CAGCATAACGAT CG (SEQ ID NO: 930) TFH_nm46 0.180.78 0.89 0.61 0.66 0.62 0.62 0.62 0.62 CGATGGGTAGGT GGAATAACAGCCCCCTCCCAAAGC TTAGCAACAACA GC (SEQ ID NO: 931) TFH_nm47 0.18 0.81 0.830.74 0.71 0.77 0.78 0.78 0.79 AGAATGGAAAAT GTAAATTAAGCC TTTGTTTTCCATCATCATTCTCATC G (SEQ ID NO: 932) TFH_nm48 0.11 0.73 0.83 0.56 0.67 0.690.67 0.73 0.76 CGCCACCTCCAT GCTGTGTTTCTG TGGCTGGAGCTT TTCTGCACTGGA AA(SEQ ID NO: 933) TFH_nm49 0.26 0.88 0.95 0.71 0.80 0.83 0.56 0.88 0.79TGCCTGAGGCCG CCCGCTGTTCAG CGGAAGAGCCA ACATCTGTGCTA TCG (SEQ ID NO: 934)TFH_nm50 0.19 0.84 0.87 0.76 0.81 0.62 0.78 0.66 0.63 CGGTCCAGAAATACTATCTGGTCC AAATCAGCAAGA GCATCGCACGTT AG (SEQ ID NO: 935) TFH_nm51 0.260.85 0.85 0.85 0.89 0.87 0.89 0.89 0.89 AATTACCCTCAT GATGAACATTTCCCTACTCTGAGT AAAGATGCTATC CG (SEQ ID NO: 936) TFH_nm52 0.17 0.76 0.880.58 0.69 0.66 0.76 0.80 0.75 TAAATAAAGATC ATCTGGTCCAAG GATGGCAAATATGTGGCACAAGTA CG (SEQ ID NO: 937) TFH_nm53 0.27 0.90 0.96 0.65 0.62 0.800.86 0.84 0.89 AAGGCGCAGCCA AGGACTATTACA CCTCTGGCTGCT CGGACGCATCTT CG(SEQ ID NO: 938) TFH_nm54 0.23 0.86 0.91 0.67 0.74 0.74 0.90 0.76 0.78CGGGTGGCTGAA TGGAAAAACAA ATGGGGCTTCAC CTGTGACTCAGA CCA (SEQ ID NO: 939)TFH_nm55 0.16 0.69 0.60 0.69 0.63 0.82 0.85 0.79 0.86 CGGCTCAGGAGACTGAAACATCCA AAGCCTGAATTG GTCCTTATATCA TG (SEQ ID NO: 940) TFH_nm56 0.290.91 0.84 0.87 0.81 0.85 0.97 0.89 0.92 CGCCCCGCACGT ACTGTGTGCCTCGTTCTTTATCTGT GTTCGTTTATTC A (SEQ ID NO: 941)

TABLE 4E CD4 positive T cell Marker Non- Marker- Basophil EosinophilNeutrophil Classical classical ID TargetID SYMBOL Accession GranulocytesGranulocytes Granulocytes Monocytes Monocytes nCD4_nm1 cg24885723 CA6NM_001215 0.91 0.93 0.90 0.92 0.91 nCD4_nm2 cg26280976 — — 0.92 0.920.94 0.93 0.92 nCD4_nm3 cg00912164 — — 0.89 0.90 0.90 0.89 0.91 nCD4_nm4cg04116354 MAN1C1 NM_020379 0.89 0.87 0.88 0.88 0.88 nCD4_nm5 cg13484324— — 0.92 0.92 0.87 0.91 0.92 nCD4_nm6 cg10555744 MAN1C1 NM_020379 0.880.90 0.93 0.91 0.92 nCD4_nm7 cg08639389 STIM2 NM_001169117 0.91 0.920.92 0.93 0.92 nCD_meth1 cg25737313 — — 0.04 0.03 0.03 0.03 0.03nCD_meth1 cg13921921 ARHGEF2 NM_004723 0.21 0.25 0.05 0.03 0.05nCD_meth1 cg03290131 DUSP5 NM_004419 0.10 0.15 0.08 0.02 0.03 nCD_meth1cg04742550 ITGAX NM_000887 0.00 0.01 0.01 0.01 0.01 nCD_meth1 cg21268578GGA1 NM_001001560 0.03 0.03 0.04 0.03 0.02 CD4mem_nm1 cg11106864RAP1GDS1 NM_001100427 0.80 0.92 0.88 0.89 0.89 CD4mem_nm2 cg08877853GPR63 NM_001143957 0.85 0.85 0.89 0.88 0.90 CD4mem_nm3 cg14108380SDCCAG3 NM_001039708 0.95 0.95 0.94 0.96 0.96 CD4mem_nm4 cg10328548SS18L1 NM_198935 0.92 0.92 0.91 0.93 0.92 CD4mem_nm5 cg03188793 TALDO1NM_006755 0.82 0.71 0.84 0.87 0.86 CD4mem_nm6 cg09187865 — — 0.91 0.910.82 0.80 0.80 CD4mem_nm7 cg04936610 FAM38A NM_001142864 0.78 0.82 0.830.84 0.86 CD4mem_nm8 cg21685655 PON2 NM_000305 0.84 0.86 0.87 0.85 0.85CD4mem_nm9 cg21132587 ALLC NM_018436 0.96 0.96 0.97 0.97 0.96CD4mem_nm10 cg04026937 HLA- NM_002124 0.78 0.76 0.74 0.76 0.72 DRB1CD4mem_nm11 cg18591489 — — 0.91 0.91 0.91 0.90 0.89 CD4mem_nm12cg26296371 FARS2 NM_006567 0.75 0.82 0.76 0.80 0.75 CD4mem_nm13cg26899005 HCFC1 NM_005334 0.89 0.89 0.91 0.90 0.93 CD4mem_nm14cg08299859 — — 0.93 0.94 0.93 0.94 0.93 CD4mem_nm15 cg05450979 NUBP1NM_002484 0.73 0.70 0.78 0.77 0.68 CD4mem_nm16 cg15700429 HLA- NR_0012980.79 0.88 0.89 0.88 0.85 DRB6 CD4mem_nm17 cg25232888 OSBPL5 NM_0011440630.79 0.74 0.90 0.92 0.92 CD4mem_nm18 cg05606115 — — 0.86 0.89 0.91 0.920.92 CD4mem_nm19 cg15654485 HLA- NR_001298 0.87 0.86 0.89 0.90 0.90 DRB6CD4mem_nm20 cg20601736 ERICH1 NM_207332 0.88 0.88 0.88 0.90 0.87CD4mem_nm21 cg01419713 PLAT NM_000930 0.87 0.91 0.91 0.90 0.89CD4mem_nm22 cg13213216 KIAA1210 NM_020721 0.95 0.95 0.97 0.97 0.96CD4mem_nm23 cg23812489 FLG2 NM_001014342 0.92 0.91 0.92 0.90 0.91CD4mem_nm24 cg08916385 GNRHR NM_000406 0.91 0.88 0.90 0.89 0.87CD4mem_nm25 cg13011976 PAGE2B NM_001015038 0.87 0.89 0.87 0.89 0.88CD4mem_nm26 cg09354553 — — 0.94 0.95 0.93 0.94 0.92 CD4mem_nm27cg00944599 TRRAP NM_003496 0.86 0.83 0.88 0.87 0.82 CD4mem_nm28cg07904290 — — 0.96 0.98 0.97 0.97 0.97 CD4mem_nm29 cg22626897 SMYD3NM_001167740 0.91 0.91 0.91 0.90 0.91 CD4mem_nm30 cg18887230 SMURF1NM_020429 0.89 0.89 0.89 0.89 0.87 CD4mem_nm31 cg16490805 — — 0.79 0.630.71 0.73 0.71 CD4mem_nm32 cg18203203 — — 0.71 0.73 0.74 0.70 0.71CD4mem_nm33 cg22951524 AHRR NM_020731 0.82 0.83 0.84 0.84 0.84CD4mem_nm34 cg07712165 TBCD NM_005993 0.90 0.90 0.91 0.91 0.91CD4mem_nm35 cg01201914 — — 0.82 0.82 0.83 0.82 0.82 CD4mem_nm36cg07951602 — — 0.82 0.85 0.82 0.84 0.83 CD4mem_nm37 cg21498326 — — 0.860.89 0.87 0.89 0.83 CD4mem_nm38 cg11791078 RANBP3L NM_145000 0.82 0.700.74 0.75 0.76 CD4mem_nm39 cg15613905 MCC NM_002387 0.76 0.80 0.81 0.820.82 CD4mem_nm40 cg09307431 — — 0.87 0.86 0.86 0.86 0.87 CD4mem_nm41cg21911000 CD28 NM_006139 0.88 0.86 0.89 0.91 0.89 CD4mem_nm42cg20770572 HLA- NM_002123 0.87 0.87 0.88 0.87 0.86 DQB1 CD4mem_nm43cg22787186 — — 0.62 0.65 0.84 0.80 0.81 CD4+ CD4+ CD4+ Th Th CD8+Marker- Th CD4+ CD4+ Central Effect. Cytotoxic NK T- ID naive Th1 Th2Mem. Mem. T-Cells Cells Discovery Fragment nCD4_nm1 0.18 0.85 0.89 0.820.90 0.54 0.92 CGGATAGATTAGTTC TGGAATAATGCCTGA GACACAGCACCCAG AACCTC(SEQ ID NO: 942) nCD4_nm2 0.21 0.87 0.83 0.77 0.88 0.68 0.92TGTTGTGGGAAGCTT TCCCGTGCGCTGTAG GATGTTTAGCAGCAC CCTCG (SEQ ID NO: 943)nCD4_nm3 0.19 0.81 0.72 0.75 0.87 0.52 0.91 GTACTCTTACACTCACGGGGGTGCCGGGC CCCTGGAACCTGCAA CTCACG (SEQ ID NO: 944) nCD4_nm4 0.160.74 0.57 0.59 0.75 0.57 0.89 CGGAATTTTTTAGTG CAAAATATTTACTAGTGTGAGGCAGAACAT TATTA (SEQ ID NO: 945) nCD4_nm5 0.22 0.88 0.78 0.66 0.740.66 0.92 CGAGTCTATGTAATT AAGAGACTGAGAAT TACACTAGGGACCTC CTATAG (SEQ IDNO: 946) nCD4_nm6 0.20 0.81 0.68 0.65 0.81 0.54 0.93 GTAGCTAAGTAAGGGGCATTCATTTCTCC CTTTCTTGTTAAGGA ACTACG (SEQ ID NO: 947) nCD4_nm7 0.190.69 0.62 0.59 0.69 0.55 0.87 CATACTTCAAACATA ACGTGTCTTAAAACAACTTTTGATCTCTGT CACCG (SEQ ID NO: 948) nCD_meth1 0.61 0.14 0.14 0.240.15 0.35 0.07 CGCCCCCGCGGGGCC CAGCCAGATGTCAGC TGCAGTTATTAGCCT GGGCG(SEQ ID NO: 949) nCD_meth1 0.69 0.16 0.35 0.34 0.29 0.43 0.05CGTGTCTTGATTCCA CCTTTAGAGGCTGCC CAGGGTTTCACACCC GACCC (SEQ ID NO: 950)nCD_meth1 0.63 0.07 0.19 0.25 0.16 0.42 0.05 CGAGCCTGTGGCTTTCAAGCTGTGGACATC TGGCCTAGCTAGATT TCTAC (SEQ ID NO: 951) nCD_meth1 0.690.14 0.16 0.27 0.17 0.11 0.01 CGCAACTGATCCGAG GACAGGCTCGGCCTCCCACACGCCCCCACC CCCCA (SEQ ID NO: 952) nCD_meth1 0.74 0.24 0.23 0.320.25 0.17 0.04 GTCTCCTTCATTCATT GGCCTCTGCTGGGGC CTCCTATGGGTGTCT TACG(SEQ ID NO: 953) CD4mem_nm1 0.92 0.90 0.91 0.47 0.02 0.89 0.85CCATACCACTTGTGC ATGCATGTGATGTTC TAATACCAATTGAAG AACCG (SEQ ID NO: 954)CD4mem_nm2 0.93 0.87 0.87 0.44 0.03 0.91 0.83 GGCAGTGTTGACTGCGTTCCATACCGGGAC ATCCAACACAACATT TGTCG (SEQ ID NO: 955) CD4mem_nm3 0.920.11 0.08 0.26 0.13 0.67 0.59 CGGATGCCCTCGTGG GCCAGCTATCCCCAGGCACAGCGAGACAG CGACGT (SEQ ID NO: 956) CD4mem_nm4 0.94 0.90 0.90 0.480.11 0.93 0.93 CCACCGTGCCCAGCT CTTTTCTTTCTCTAAG AATCCTCTGGCATTC TGCG(SEQ ID NO: 957) CD4mem_nm5 0.73 0.91 0.91 0.46 0.03 0.91 0.88CTCACTCCCATGCTG TTACAGGTCACCTCT TGCAGGGGCATATTT GATCG (SEQ ID NO: 958)CD4mem_nm6 0.87 0.93 0.92 0.50 0.12 0.94 0.90 AAATATTACCTATTAGATTGGTAACAATGA AAAAGACTTGGCAG CCGCCG (SEQ ID NO: 959) CD4mem_nm7 0.880.85 0.85 0.44 0.06 0.86 0.80 CGCCAACAGAGGAT GGCCAGCCCCACCCCAGAGGACAGCGCAC CCACGGC (SEQ ID NO: 960) CD4mem_nm8 0.83 0.75 0.73 0.460.04 0.86 0.87 CGTTATCAGTAGTTC TAAACAGCCATAGTA GTCACAGTGCCAGAA GTGAG(SEQ ID NO: 961) CD4mem_nm9 0.97 0.97 0.98 0.55 0.31 0.97 0.98GCCGGGCGAGCTGA GATCAGACAACAGG CGCTGGACGCATCCT AACTACG (SEQ ID NO: 962)CD4mem_nm10 0.88 0.75 0.75 0.46 0.06 0.84 0.76 GGAAGTCAGAAAGCTGCTCACTCCATTCC ACTGTGAGAGGGCTT GTCACG (SEQ ID NO: 963) CD4mem_nm11 0.690.18 0.09 0.27 0.15 0.70 0.57 TGTGAGTTAGTTCTA CAGCACAATGCTTGGCTGCTGTTTCAGCAA TTGCG (SEQ ID NO: 964) CD4mem_nm12 0.79 0.55 0.53 0.450.04 0.70 0.72 CGACTTCCCAGCCAA GGGAAACTGTCACCG AGGGTGGGACTAAA TCTGAC(SEQ ID NO: 965) CD4mem_nm13 0.73 0.56 0.57 0.20 0.17 0.76 0.71CGCGCGCCTATTGAT TTGTTTCTGAGGAGA GTACACCGTTCACTA TTGTA (SEQ ID NO: 966)CD4mem_nm14 0.93 0.94 0.94 0.59 0.14 0.93 0.93 TCTGCGTATTCCTTTCTGTTCTTTAAAAATG TTAAACCATGGGGTG CTCG (SEQ ID NO: 967) CD4mem_nm15 0.830.82 0.81 0.48 0.03 0.82 0.69 CGCCCCACACTGGGG TCACCCACCTATGAGCGGATCCAGGGGCA CTCTGC (SEQ ID NO: 968) CD4mem_nm16 0.74 0.76 0.80 0.390.13 0.72 0.72 TTCCTCAGCTCCTGT TCTTGGCCTGAAACC CCACAGCCTTGATGG CAGCG(SEQ ID NO: 969) CD4mem_nm17 0.97 0.94 0.94 0.52 0.19 0.95 0.86CGTACAGAGCCTTAA ACCACATCGTGGCGG TGCCGTCTGAGCTGT AGCGG (SEQ ID NO: 970)CD4mem_nm18 0.90 0.88 0.85 0.49 0.16 0.86 0.80 CTTTTCCTTGCTAAATCAATTCCCTAAGAC ATCAGGACTGTGAGA CATCG (SEQ ID NO: 971) CD4mem_nm19 0.890.87 0.88 0.44 0.18 0.87 0.90 CTCATATAACCCCAA GAGGTAAATTAGTATAATTTAACCTACATT ATACG (SEQ ID NO: 972) CD4mem_nm20 0.87 0.83 0.82 0.430.17 0.87 0.83 CAGAAACCTCACACT CAATTAGCGAGACTG CAAACACTCTGTATT AACCG(SEQ ID NO: 973) CD4mem_nm21 0.81 0.14 0.16 0.22 0.19 0.72 0.68CGCCTCCCACCCCTG GCAGGCTGCCATCTT TGCCAAGCACAGGA GGTCGC (SEQ ID NO: 974)CD4mem_nm22 0.96 0.96 0.96 0.59 0.26 0.96 0.95 ATCATTGTTCTCTCCGTGCAGCTAGGTATG CCGCAAGGTCTCGGG TTCCG (SEQ ID NO: 975) CD4mem_nm23 0.920.91 0.91 0.51 0.19 0.92 0.90 CATTTTCCCAAGGGT CCAGGCCCTAAACATGCCAGACTACCAGTG GATCG (SEQ ID NO: 976) CD4mem_nm24 0.92 0.53 0.51 0.180.27 0.88 0.83 CGCATTTGAGGAGCT CTAAGTTGTTGAATC TAAGTTGTTGGATGA GTCAA(SEQ ID NO: 977) CD4mem_nm25 0.83 0.37 0.30 0.25 0.19 0.77 0.69CGTTGTCAGGAGCGC TGGTGGTTTAGGTTC TCCACAGACGCAGG AAAACA (SEQ ID NO: 978)CD4mem_nm26 0.91 0.90 0.93 0.61 0.20 0.93 0.70 CGCCAACACAGACGAACCCCAACACGTGG CAAACCCCAACACA GGCGAAC (SEQ ID NO: 979) CD4mem_nm27 0.720.15 0.20 0.24 0.16 0.81 0.66 TCCTCAACATGGTAT GGGGTTCGCTATCACCAGCGTGAAGATGG AAAACG (SEQ ID NO: 980) CD4mem_nm28 0.97 0.97 0.96 0.200.46 0.95 0.93 CGATGACTAATTTGG TTAGCGGCAACAACA GGCTTCTTGCGGCGA GGCCT(SEQ ID NO: 981) CD4mem_nm29 0.88 0.89 0.87 0.54 0.23 0.90 0.89CGGCGTGTGTCTTTG TTGAATGCCTTATTG AGGTCACACACTCTA TGCTT (SEQ ID NO: 982)CD4mem_nm30 0.71 0.24 0.15 0.26 0.21 0.71 0.68 CGGCCATCCTGCTTTAGGGATGAATTGAA ACTGGAAAGAGAGT AGTACCA (SEQ ID NO: 983) CD4mem_nm31 0.730.70 0.69 0.28 0.05 0.86 0.83 TGAGAAGGGGCACC CAATGTGCTTCCTCTTGGGGTGCAGCGGTG TGGCCG (SEQ ID NO: 984) CD4mem_nm32 0.76 0.52 0.56 0.210.04 0.77 0.67 CGCACACACATACTT GCATGTGGATGCAAA CACAATTGGTGCATG GGTTT(SEQ ID NO: 985) CD4mem_nm33 0.83 0.74 0.75 0.43 0.16 0.80 0.71CGCATCTGAGCGTAG ACACACAGATCTGAG CTTGGATGGTGGTCA CTGCG (SEQ ID NO: 986)CD4mem_nm34 0.91 0.91 0.91 0.22 0.44 0.91 0.90 CAGAAGGTCACACAGACGGTTGCGCTGCT CTCTCACCACTGCAA GCTCCG (SEQ ID NO: 987) CD4mem_nm35 0.870.46 0.87 0.42 0.16 0.84 0.82 CGCCTAGGCTCAAGC AATCTGGCTCTGGATGTCTTTAACTTGTGA TTGAA (SEQ ID NO: 988) CD4mem_nm36 0.88 0.78 0.79 0.200.17 0.80 0.70 CGCCTCTCAAGAGCA CGATGTAAGGGCTCC AAGATGAGTTTGGGC TTCCC(SEQ ID NO: 989) CD4mem_nm37 0.88 0.14 0.18 0.35 0.24 0.74 0.59CGGTTAAACATTGGT ATAGAAACCAGATCT ACTTTTAATTGAAAT CAGAC (SEQ ID NO: 990)CD4mem_nm38 0.61 0.66 0.60 0.07 0.09 0.65 0.71 CGGAAAAGGAGCTTGTCTTGAGAAACAAC AAAGAATTGAGCTAT AGTTTC (SEQ ID NO: 991) CD4mem_nm39 0.840.44 0.44 0.10 0.33 0.74 0.61 TGCAGTTAGGACTCC ATAGCAGGCCTGCAGTGGCCCTGGTGATAA CCTCG (SEQ ID NO: 992) CD4mem_nm40 0.81 0.19 0.24 0.330.26 0.66 0.53 AGGAAGCCTTTAAAG GACTGGACCCGGAA AGCACCTACTAAAGT GTATCG(SEQ ID NO: 993) CD4mem_nm41 0.85 0.38 0.32 0.41 0.25 0.82 0.78CGGTTAATTATGGAA AAACAGCTTGTTAAG CAAATGCTAATGTAA GAAGA (SEQ ID NO: 994)CD4mem_nm42 0.88 0.83 0.83 0.27 0.42 0.83 0.79 CGGTGACAGATTTCTATCCAGGCCAGATCA AAGTCCGGTGGTTTC GGAAT (SEQ ID NO: 995) CD4mem_nm43 0.840.85 0.83 0.27 0.25 0.80 0.82 CGGTACCTCTACTGC TGAGTCCAAAGTCACCGCGGCATACCCAGC TCGGC (SEQ ID NO: 996)

TABLE 4F Monocytes-Markers Basophil Eosinophil Non- Marker- TargetGranu- Granu- Neutrophil Classical classical ID ID SYMBOL Accessionlocytes locytes Granulocytes Monocytes Monocytes MOC_nm21 cg23244761PARK2 NM_004562 0.96 0.96 0.97 0.03 0.06 MOC_nm22 cg13430807 MTMR11NM_181873 0.84 0.84 0.86 0.03 0.07 MOC_nm23 cg05923857 TCF7L2NM_001146284 0.79 0.82 0.81 0.02 0.08 MOC_nm24 cg01041239 LDLRAD4NM_181482 0.76 0.85 0.77 0.03 0.08 (C18orf1) MOC_nm25 cg21459713 ERICH1NM_207332 0.90 0.92 0.94 0.08 0.14 MOC_nm26 cg12655112 EHD4 NM_1392650.96 0.82 0.68 0.01 0.04 MOC_nm27 cg10480329 CENPA NM_001809 0.91 0.860.84 0.07 0.09 MOC_nm28 cg14428166 MYOF NM_133337 0.94 0.92 0.85 0.110.11 MOC_nm29 cg25898577 PPM1F NM_014634 0.89 0.85 0.73 0.06 0.07MOC_nm30 cg16636767 FAR1 NM_0322P8 0.91 0.92 0.91 0.10 0.15 MOC_nm31cg02244028 SCN11A NM_014139 0.89 0.90 0.86 0.13 0.12 MOC_nm32 cg07213487TRRAP NM_003496 0.90 0.91 0.91 0.10 0.13 MOC_nm33 cg03963853 MGRN1NM_015246 0.98 0.97 0.97 0.26 0.27 MOC_nm34 cg22056336 RBM47 NM_0190270.90 0.89 0.87 0.18 0.16 MOC_nm35 cg18066690 KIAA0146 NM_001080394 0.920.91 0.91 0.06 0.10 MOC_nm36 cg00101629 KAZN NM_201628 0.90 0.89 0.840.11 0.14 (KIAA1- 26) MOC_nm37 cg20918393 RIN2 — 0.97 0.97 0.90 0.210.12 MOC_nm38 cg10732094 ERCC1 — 0.86 0.81 0.76 0.13 0.09 ncMOC_nm1cg04143805 ANKRD11 NM_013275 0.88 0.88 0.89 0.82 0.32 ncMOC_nm3cg07004744 ERICH1 NM_207332 0.95 0.94 0.93 0.93 0.39 ncMOC_nm6cg07369606 SECTM1 NM_003004 0.89 0.89 0.93 0.91 0.48 ncMOC_nm8cg02029908 DUSP1 NM_004417 0.93 0.94 0.94 0.92 0.23 ncMOC_nm9 cg16908740— — 0.91 0.86 0.90 0.85 0.18 ncMOC_nm10 cg08969823 — — 0.96 0.94 0.940.96 0.30 ncMOC_nm11 cg14684854 — — 0.91 0.90 0.91 0.91 0.26 ncMOC_nm12cg24534048 — — 0.98 0.97 0.96 0.82 0.18 ncMOC_nm13 cg19683800 CYB561NM_001017917 0.90 0.76 0.85 0.87 0.24 ncMOC_nm15 cg08376310 KCNQ1NM_000218 0.88 0.79 0.91 0.81 0.19 ncMOC_nm19 cg07457429 — — 0.91 0.910.92 0.87 0.29 ncMOC_nm20 cg10492417 FANCA NM_000135 0.86 0.89 0.90 0.830.25 ncMOC_nm21 cg01742428 FAM26F NM_001010919 0.91 0.92 0.92 0.91 0.36ncMOC_nm22 cg19586199 PRKACA NM_207518 0.91 0.93 0.97 0.96 0.45ncMOC_nm24 cg10143416 — — 0.93 0.95 0.94 0.95 0.46 ncMOC_nm25 cg03263792TSPAN16 NM_012466 0.87 0.77 0.79 0.85 0.37 ncMOC_nm26 cg09779405 — —0.86 0.83 0.81 0.73 0.25 ncMOC_nm27 cg16288101 — — 0.90 0.85 0.85 0.740.26 ncMOC_nm28 cg20380448 NAAA NM_001042402 0.80 0.81 0.77 0.83 0.35ncMOC_nm29 cg05390144 ELF5 NM_001422 0.87 0.88 0.88 0.87 0.42 ncMOC_nm30cg13187188 GPR152 NM_206997 0.88 0.88 0.88 0.88 0.44 ncMOC_nm31cg04322596 TCF7L2 NM_001146284 0.93 0.90 0.90 0.92 0.49 ncMOC_nm32cg07744832 UHRF1BP1L NM_001006947 0.87 0.88 0.89 0.89 0.48 ncMOC_nm33cg13318914 DDAH2 NM_013974 0.87 0.80 0.84 0.80 0.39 ncMOC_nm34cg14439774 SMG6 NM_017575 0.87 0.83 0.86 0.87 0.46 ncMOC_nm35 cg15896579— — 0.80 0.72 0.75 0.76 0.36 ncMOC_nm36 cg09736194 LOC285740 NR_0271130.88 0.75 0.85 0.87 0.49 ncMOC_nm37 cg18898336 RGS12 NM_198229 0.89 0.880.89 0.85 0.46 ncMOC_nm38 cg09262230 TMEM181 NM_020823 0.94 0.95 0.960.95 0.57 ncMOC_nm39 cg10794991 — — 0.97 0.95 0.97 0.84 0.46 ncMOC_nm40cg02667577 WIPI2 NM_016003 0.85 0.84 0.88 0.85 0.28 ncMOC_nm42cg06070445 BCL6 NM_001706 0.88 0.69 0.69 0.70 0.18 ncMOC_nm44 cg24143729RASA3 NM_007368 0.86 0.85 0.84 0.67 0.25 ncMOC_nm46 cg11129609 WDR46NM_005452 0.79 0.60 0.52 0.58 0.13 ncMOC_nm48 cg02317313 LOC338799NR_002809 0.80 0.57 0.77 0.61 0.21 ncMOC_nm50 cg04690793 SNRPC NR_0294720.89 0.40 0.77 0.75 0.11 CD4+ CD4+ CD8+ CD4+ Th Th Cytotoxic Marker- NKTh CD4+ CD4+ Central Effect. T- NK T- ID classical B-Cells naive Th1 Th2Mem. Mem. Cells Cells Discovery Fragment MOC_nm21 0.97 0.98 0.98 0.980.99 0.99 0.98 0.97 0.98 TGGGATGGAACGGCTGC GACAGATCTCCATTAAAGCCAGCGCGTCGTTCG (SEQ ID NO: 997) MOC_nm22 0.89 0.82 0.86 0.87 0.90 0.890.89 0.90 0.86 TTCTTGGACCCCTCTTCT TTGTCCCTTCTTCCTCTT TATCACCCAGAGCG (SEQID NO: 998) MOC_nm23 0.92 0.92 0.80 0.83 0.84 0.80 0.84 0.90 0.90CGGCCATCAACCAGATC CTTGGGCGGAGGGTAGG TGACGCCCTTCTCAGG (SEQ ID NO: 999)MOC_nm24 0.93 0.83 0.75 0.94 0.95 0.89 0.95 0.75 0.89 CGCCGCTCATGGGCCTGGTGTGCATGCAGCTGCG CAGAGGGCCTCTGCCT (SEQ ID NO: 1000) MOC_nm25 0.91 0.930.92 0.84 0.90 0.89 0.91 0.92 0.89 TTGTGAGGAGGATGGTG TGGACACCAGCGAGGAAGACCCGACACTGGCCG (SEQ ID NO: 1001) MOC_nm26 0.97 0.88 0.95 0.90 0.800.87 0.80 0.97 0.96 AGAGAAACTCCACGCCC ACTAACAGTCATTCTCTA TTTCGTTTGCATGCG(SEQ ID NO: 1002) MOC_nm27 0.94 0.91 0.93 0.93 0.94 0.93 0.93 0.93 0.92CGATCTTAAGAGAAAGG GCAGGAGTGTTTCCTTG ACCCCACATTCTCACT (SEQ ID NO: 1003)MOC_nm28 0.95 0.95 0.95 0.93 0.95 0.95 0.95 0.96 0.95 CGCCCCCGGGGTAGCGGCTCTCGTTCTGATAGACT TCATCAGTGAACTCC (SEQ ID NO: 1004) MOC_nm29 0.84 0.910.89 0.88 0.88 0.87 0.88 0.92 0.89 CGCTGATCCAGTCACCG GGGAGGGGCTGACTGGCAGCCACACAGAGGTTT (SEQ ID NO: 1005) MOC_nm30 0.92 0.88 0.90 0.92 0.920.92 0.92 0.90 0.90 CGGTTCCCAATTTGAAG AGTGGAGACAGAAGTCA AGAAAATAAGCTTTTC(SEQ ID NO: 1006) MOC_nm31 0.88 0.91 0.91 0.89 0.88 0.89 0.90 0.91 0.88CGGCTCAGCCTTATTGTC TTGCTTAATGTCTGGGTC TCAGTTTTAGAGAC (SEQ ID NO: 1007)MOC_nm32 0.90 0.60 0.92 0.90 0.89 0.90 0.90 0.92 0.92 TGTGAAGCAGCTAGAGGCGCGCTGGAAACCTGAT GCATGCTGCTGCCTCG (SEQ ID NO: 1008) MOC_nm33 0.97 0.980.98 0.99 0.98 0.98 0.98 0.97 0.98 TGGCCACGGGTCATTCG TGGTTCCCCTGGAGCCTTGCGGTGTATAGAGCG (SEQ ID NO: 1009) MOC_nm34 0.85 0.75 0.88 0.81 0.83 0.840.83 0.87 0.82 CGTGAACTTCCTAGAGG CCAAAGTAAAAATAAAA ACAGGGTCGCTAACAT (SEQID NO: 1010) MOC_nm35 0.91 0.91 0.93 0.91 0.92 0.94 0.91 0.92 0.91CGGAAGGTGAGTGGGCA ATGAAATGTCCAATTTT AAAAGAAATTCCACGT (SEQ ID NO: 1011)MOC_nm36 0.88 0.75 0.92 0.83 0.86 0.85 0.85 0.86 0.69 CGCAAGAATGCACTTAGTTAATCCAACAAGTATTT ATTCAGTGCCTGAGT (SEQ ID NO: 1012) MOC_nm37 0.98 0.980.98 0.98 0.98 0.98 0.98 0.98 0.98 TTTCAACAACACCACTG AAAGAATGTAAACGGAGCTGGTCGCGTTGGTCG (SEQ ID NO: 1013) MOC_nm38 0.87 0.71 0.87 0.88 0.880.89 0.90 0.90 0.87 GAGGAAGTCCTTTCTGG AGTCTGACCCTCAGTCT GCCTGCTTCAAATGCG(SEQ ID NO: 1014) ncMOC_nm1 0.91 0.88 0.90 0.88 0.88 0.89 0.88 0.89 0.87CGAAATCAGCGGAGGCC CCTGCTGAGTGAGTGGA CACACCCAGGCGCACG (SEQ ID NO: 1015)ncMOC_nm3 0.96 0.95 0.94 0.96 0.96 0.95 0.97 0.96 0.95 AACATGAGCAGCATGGACAACGCGGTACAACGGG GCGAGAGCGCCAACCG (SEQ ID NO: 1016) ncMOC_nm6 0.95 0.950.89 0.88 0.89 0.90 0.90 0.93 0.88 CGCAGGCTTGGAGCCAT GCCAGTGACACGCCTAGGAAAGTTCACGCACCG (SEQ ID NO: 1017) ncMOC_nm8 0.93 0.93 0.93 0.92 0.910.89 0.89 0.94 0.88 CCCACTATATATTGGTCC CGAATGTGCTGAGTTCA GCAAATGTCTTGACG(SEQ ID NO: 1018) ncMOC_nm9 0.93 0.92 0.91 0.88 0.90 0.90 0.90 0.91 0.89CGGAAGAACACTTGTAT ATGCTGACATCAGCAAG CAAAATGCATACAGTT (SEQ ID NO: 1019)ncMOC_nm10 0.95 0.97 0.96 0.96 0.95 0.97 0.96 0.96 0.95GGCTTCCGGTGACCAGG ATAGGAAGTGTTGCAGG CCCTGCCCCGAGGGCG (SEQ ID NO: 1020)ncMOC_nm11 0.88 0.88 0.91 0.84 0.84 0.86 0.85 0.89 0.84CGCCGAGCTCAGCAGAA ACCCGCCCAGAAGGTCA AGGACCAGCAAAAGGG (SEQ ID NO: 1021)ncMOC_nm12 0.98 0.97 0.98 0.97 0.97 0.97 0.98 0.98 0.98GAGGCCTGGCACGGCGG CACCGGAAGCGGGTACT GGTGCCCTAAGGAGCG (SEQ ID NO: 1022)ncMOC_nm13 0.93 0.92 0.86 0.91 0.92 0.94 0.93 0.94 0.91TGCGGGCCTCTCCTGCCC TTTGTACTCCACGAGGT GTGAGGAAGTTGCCG (SEQ ID NO: 1023)ncMOC_nm15 0.98 0.94 0.84 0.98 0.97 0.98 0.98 0.98 0.97CGCGCTCACAGCCTCCG TTCCCAGACACGCCCGG GCCTGAGCCCCCAGGC (SEQ ID NO: 1024)ncMOC_nm19 0.92 0.92 0.92 0.92 0.91 0.91 0.90 0.93 0.90CGGTCATAGTCCTCTGG AGTTGACATCAGTGGGA CCTCGGTGAAACTGCA (SEQ ID NO: 1025)ncMOC_nm20 0.88 0.90 0.89 0.75 0.73 0.78 0.77 0.87 0.86CGCTGTCCGGAACTGGG GTGCTCCACCCACACTG TCTGGAACTGGCACAG (SEQ ID NO: 1026)ncMOC_nm21 0.92 0.93 0.92 0.92 0.91 0.93 0.93 0.92 0.94CGCCCATCATAGAAGTA CCAGAACTTGAGCTGGA CTTTGCTGATTTAGCT (SEQ ID NO: 1027)ncMOC_nm22 0.98 0.98 0.91 0.97 0.95 0.97 0.98 0.97 0.97CGCGGTTGCGCTAAGGG GAGAGCTGCCTTGATAA GACCTCTTGGGCACCC (SEQ ID NO: 1028)ncMOC_nm24 0.95 0.93 0.93 0.91 0.92 0.92 0.92 0.91 0.85TGGGGAAGTCGCTGCTG AGAACTCCGATGCCAAG CGCTGACCCAGCCTCG (SEQ ID NO: 1029)ncMOC_nm25 0.86 0.85 0.88 0.82 0.84 0.86 0.86 0.87 0.76TGAATGGATCCAGAGGC TCTGTGATGCAGAAATC TAGCTACAAGCCACCG (SEQ ID NO: 1030)ncMOC_nm26 0.85 0.91 0.89 0.89 0.91 0.93 0.91 0.91 0.86CGTAATGATCTTGAGGA AGAAAGAAAATGCAAA GGGAAGTATGAAATAGC (SEQ ID NO: 1031)ncMOC_nm27 0.88 0.86 0.89 0.89 0.89 0.89 0.90 0.90 0.89CGGTCTAATTAAAATAG GGAACAAGAACCAAAA AATCCCCTAGTTCCAGG (SEQ ID NO: 1032)ncMOC_nm28 0.83 0.83 0.84 0.80 0.81 0.82 0.83 0.84 0.79CGGTGGAGTTCGGAGCA ATTTTTTGCAGGCAGGA AGTGGATCTTACAAAG (SEQ ID NO: 1033)ncMOC_nm29 0.88 0.85 0.87 0.75 0.81 0.81 0.81 0.83 0.72CGGGCCAAATCATCACT GGGCAGAACTAGGCCAT AGGGTGCAAAATATAG (SEQ ID NO: 1034)ncMOC_nm30 0.95 0.92 0.85 0.85 0.86 0.89 0.87 0.87 0.73CGCCCCATAGGAAGTAG TAGAAGCGGCAGGCAGC TGTCCCCAGCGGCCAG (SEQ ID NO: 1035)ncMOC_nm31 0.92 0.91 0.92 0.91 0.92 0.93 0.93 0.91 0.87GGCCATAGTCACACCAA CAGTCAAACAGGAATCG TCCCAGAGTGATGTCG (SEQ ID NO: 1036)ncMOC_nm32 0.86 0.89 0.87 0.87 0.87 0.86 0.89 0.87 0.80CGGCCTCCTTAGAATGTT TTAAGAATCGGCCATTA ACTCCTGTGCTTGCT (SEQ ID NO: 1037)ncMOC_nm33 0.89 0.90 0.86 0.86 0.86 0.86 0.87 0.91 0.85CTCAGCTGTGGGGGCGT GTGCTGAGCACCAAGCA GAGGGAGCTGAGCCCG (SEQ ID NO: 1038)ncMOC_nm34 0.81 0.89 0.87 0.87 0.89 0.87 0.87 0.89 0.85GCCAAATGACTGTGTTG GCCTATGGGTGACCTGG CCCCTGGCTAGAATCG (SEQ ID NO: 1039)ncMOC_nm35 0.76 0.81 0.80 0.79 0.80 0.78 0.81 0.82 0.73CTGGATGGCAGACAGTG CGTGCAAGCATCACAGC CCACTGGAAGAGGCCG (SEQ ID NO: 1040)ncMOC_nm36 0.91 0.90 0.90 0.90 0.89 0.89 0.91 0.90 0.86TTCTTCAAAACCCTAGTC AGATATTGTTACTTCACT GAAAACTCTCACCG (SEQ ID NO: 1041)ncMOC_nm37 0.88 0.88 0.88 0.81 0.84 0.84 0.83 0.83 0.76TGGCTGATGTCTGCTGA ACACCCGATCATTCACT CAACAGACAGCTCTCG (SEQ ID NO: 1042)ncMOC_nm38 0.95 0.89 0.93 0.95 0.95 0.96 0.96 0.96 0.95AGGTCAGCAGACGGTCA CCGGGGAAAGCATCCAG GCATCTTGTCGCCTCG (SEQ ID NO: 1043)ncMOC_nm39 0.96 0.95 0.97 0.97 0.97 0.97 0.96 0.98 0.97CGAGGAGTTGCACTCTA GCTGCCGTGCCAGCAGT CTCGTCTGCTGTGACG (SEQ ID NO: 1044)ncMOC_nm40 0.58 0.66 0.89 0.84 0.84 0.82 0.84 0.74 0.78CGGACTGACTGAACTTG ACCTGTGACCTCTGACC CGGGGAGCAGAGAACA (SEQ ID NO: 1045)ncMOC_nm42 0.86 0.89 0.86 0.86 0.83 0.86 0.87 0.89 0.88CGTGCTGTAGAACATGC AAGACAGCACCCTGATG TGGGTGAATCTCATTT (SEQ ID NO: 1046)ncMOC_nm44 0.86 0.63 0.85 0.83 0.84 0.85 0.84 0.81 0.83GGTCGTGACCCTGCCTC CACCCTGTGTAAAGTCA CAGCTGCAGGATCTCG (SEQ ID NO: 1047)ncMOC_nm46 0.67 0.82 0.80 0.78 0.77 0.79 0.77 0.83 0.77CTGACAAGGGCAGAGGC ACAAGCAGGAGGGTGCA GCCTGTGGAAGGCCCG (SEQ ID NO: 1048)ncMOC_nm48 0.89 0.86 0.78 0.87 0.86 0.87 0.86 0.83 0.87GGGGATGCCGGCGACTC AGTAGTAAGGCAAGTCC TGCCACCTCCTGGCCG (SEQ ID NO: 1049)ncMOC_nm50 0.85 0.87 0.90 0.91 0.93 0.93 0.92 0.91 0.91CGGGGCACAGTTAACTT ACCCCTTAGGACCAGGA AGTAATCTTTGTGGTA (SEQ ID NO: 1050)

TABLE 4G Granolucytes and Subtypes Marker Marker- Target BasophilEosinophil Neutrophil ID ID SYMBOL Accession Granulocytes GranulocytesGranulocytes GRC_nm38 cg15010903 TIMP2 NM_003255 0.22 0.09 0.10 GRC_nm39cg11014468 DCP1A NM_018403 3.06 3.09 0.09 GRC_nm40 cg07468327 — — 0.090.07 0.12 GRC_nm41 cg21285555 PCMTD1 NM_052937 0.18 0.08 0.05 GRC_nm42cg08110693 PXT1 NM_152990 0.06 0.01 0.20 GRC_nm43 cg13595556 — — 0.110.06 0.04 GRC_nm44 cg03423077 LOC339524 NR_026986 0.01 0.07 0.15GRC_nm45 cg00121045 UNKL NM_023076 0.14 0.13 0.11 GRC_nm46 cg07305933PVT1 NR_003367 0.05 0.05 0.04 GRC_nm47 cg23661721 — — 0.09 0.08 0.06GRC_nm48 cg06168950 — — 0.10 0.11 0.12 GRC_nm49 cg08435683 SLC23A2NM_005116 0.02 0.11 0.49 GRC_nm50 cg00335124 PDE4D NM_001165899 0.120.05 0.05 GRC_nm51 cg06526020 NUDT3 NM_006703 0.31 0.06 0.05 GRC_nm52cg03820688 MTIF2 NM_002453 0.08 0.27 0.16 GRC_nm53 cg15034267 GTPBP1NM_004286 0.14 0.11 0.33 GRC_nm54 cg01400750 ANAPC10 NM_014885 0.37 0.060.03 GRC_nm55 cg24419094 RRM2 NM_001034 0.16 0.09 0.25 GRC_nm56cg11313468 HNRNPUL1 NM_007040 0.31 0.11 0.06 GRC_nm57 cg00705730 NCK2NM_003581 0.67 0.07 0.04 GRC_nm58 cg15609237 TTN NM_133378 0.43 0.090.16 GRC_nm59 cg19513582 UBE2H NM_003344 0.65 0.08 0.13 GRC_nm60cg10687936 ZNF148 NM_021964 0.05 0.12 0.58 GRC_nm61 cg18168663 REC8NM_001048205 0.06 0.10 0.26 GRC_nm62 cg26814100 MAP7 NM_003980 0.13 0.120.28 GRC_nm63 cg10692528 NCAPD2 NM_014865 0.08 0.16 0.61 GRC_nm64cg05120113 GLB1 NM_001135602 0.12 0.17 0.45 GRC_nm65 cg01799818 VPS53NM_018289 0.31 0.12 0.42 GRC_nm66 cg02722672 GRK4 NM_001004057 0.55 0.060.25 GRC_nm67 cg06997767 TRPS1 NM_014112 0.03 0.11 0.21 GRC_nm68cg05575639 CHD7 NM_017780 0.38 0.09 0.17 GRC_nm69 cg18502618 COL18A1NM_130444 0.62 0.11 0.21 GRC_nm70 cg05684528 — — 0.07 0.08 0.16 GRC_nm71cg11958668 RNF103 NM_005667 0.27 0.14 0.65 GRC_nm72 cg14543285 RCOR1NM_015156 0.63 0.11 0.10 GRC_nm73 cg20836212 VKORC1L1 NM_173517 0.060.18 0.64 GRC_nm74 cg25643253 VKORC1L1 NM_173517 0.07 0.18 0.65 GRC_nm75cg19282952 — — 0.10 0.17 0.54 GRC_nm76 cg24559796 — — 0.06 0.16 0.55GRC_nm77 cg08864944 PBX1 NM_002585 0.05 0.06 0.05 GRC_nm78 cg13416889ZNF609 NM_015042 0.17 0.20 0.67 GRC_nm79 cg21762728 C6orf70 NM_0183410.44 0.13 0.14 GRC_nm80 cg11596902 — — 0.16 0.05 0.05 GRC_nm81cg11231701 CDK5RAP1 NM_016082 0.60 0.04 0.09 GRC_nm82 cg26647135 PILRBNM_175047 0.65 0.15 0.18 GRC_nm83 cg07268332 AMPD3 NM_001025389 0.570.08 0.14 GRC_nm84 cg19935471 MATN2 NM_030583 0.76 0.10 0.10 GRC_nm85cg08505883 — — 0.09 0.11 0.39 bGRC_nm1 cg02329886 HDC NM_002112 0.060.84 0.90 bGRC_nm2 cg26676468 MCC NM_002387 0.02 0.90 0.96 bGRC_nm3cg01782059 ERI3 NM_024066 0.03 0.75 0.97 bGRC_nm4 cg12646067 TTLL8NM_001080447 0.03 0.87 0.96 bGRC_nm5 cg05012676 ZFPM1 NM_153813 0.040.88 0.96 bGRC_nm6 cg17306637 TFB1M; NM_016020 0.05 0.87 0.89 CLDN20bGRC_nm7 cg22197708 MS4A2 NM_001142303 0.05 0.81 0.91 bGRC_nm8cg03520003 DENND3 NM_014957 0.09 0.81 0.90 bGRC_nm9 cg16643422 DLC1NM_182643 0.06 0.59 0.86 bGRC_nm10 cg18281744 MAS1L NM_052967 0.08 0.820.89 bGRC_nm11 cg07862744 MAD1L1 NM_003550 0.16 0.92 0.93 bGRC_nm12cg03555710 PFKFB3 NM_001145443 0.08 0.81 0.96 bGRC_nm13 cg24057792 — —0.05 0.69 0.93 bGRC_nm14 cg26673070 — — 0.05 0.84 0.92 bGRC_nm15cg24130568 TBCD NM_005993 0.04 0.88 0.92 bGRC_nm16 cg04498104 PFKFB4NM_004567 0.06 0.80 0.91 bGRC_nm17 cg12037509 DPYSL2 NM_001386 0.07 0.840.92 bGRC_nm18 cg11294011 — — 0.08 0.92 0.94 bGRC_nm19 cg02752529 FBXL14NM_152441 0.04 0.71 0.89 bGRC_nm20 cg02426739 SFSWAP NM_004592; 0.050.75 0.91 NM_001261411 bGRC_nm21 cg12087639 ADK NM_001123 0.09 0.89 0.95bGRC_nm22 cg10319857 NFAT5 NM_138714 0.04 0.60 0.91 bGRC_nm23 cg21715896— — 0.06 0.78 0.88 bGRC_nm24 cg14200678 MEGF9 NM_001080497 0.08 0.820.91 bGRC_nm25 cg20964248 SIK2 NM_015191 0.04 0.80 0.90 bGRC_nm26cg03380342 — — 0.07 0.85 0.91 bGRC_nm27 cg07818422 WDFY2 NM_052950 0.050.64 0.92 bGRC_nm28 cg23639055 — — 0.07 0.84 0.90 bGRC_nm29 cg00086283 —— 0.11 0.88 0.94 bGRC_nm30 cg12018521 TES NM_015641 0.06 0.84 0.90bGRC_nm31 cg12486498 C1orf198 NM_001136494 0.12 0.88 0.94 bGRC_nm32cg19699264 SDPR NM_004657 0.07 0.88 0.92 bGRC_nm33 cg05865769 MAP2K4NM_003010 0.08 0.75 0.91 bGRC_nm34 cg11809342 TANC1 NM_033394 0.08 0.760.91 bGRC_nm35 cg02800334 ANXA13 NM_001003954 0.05 0.80 0.88 bGRC_nm36cg09151061 ZNF366 NM_152625 0.09 0.90 0.92 bGRC_nm37 cg14633252 SHBNM_003028 0.05 0.78 0.89 bGRC_nm38 cg09473249 ABCC1 NM_019862 0.07 0.730.88 bGRC_nm39 cg19975917 LPP NM_005578 0.07 0.63 0.90 bGRC_nm40cg02387491 LIN7A; NM_004664 0.08 0.63 0.92 MIR617 bGRC_nm41 cg24143196TECR NM_138501 0.08 0.66 0.91 bGRC_nm42 cg22609618 CDC14A NM_003672 0.070.88 0.87 bGRC_nm43 cg24791846 — — 0.09 0.85 0.91 bGRC_nm44 cg10330847 —— 0.06 0.65 0.90 bGRC_nm45 cg04988216 ROR1 NM_005012 0.13 0.90 0.91bGRC_nm46 cg26009797 — — 0.06 0.78 0.86 bGRC_nm47 cg24736010 — — 0.080.82 0.91 bGRC_nm48 cg04657468 ARID5B NM_032199 0.09 0.70 0.88 bGRC_nm49cg04023434 RGL1 NM_015149 0.10 0.69 0.92 bGRC_nm50 cg15192986 CPB2NM_016413 0.09 0.82 0.88 eGRC_nm2 cg15090899 RPS6KA2 NM_001006932 0.970.16 0.83 eGRC_nm3 cg20761853 TIMP2 NM_003255 0.74 0.13 0.61 eGRC_nm4cg11900509 ANXA11 NM_145868 0.92 0.13 0.62 eGRC_nm5 cg03269757 ATL2NM_022374 0.52 0.14 0.78 eGRC_nm6 cg09411597 C10orf18 NM_017782 0.820.13 0.61 eGRC_nm7 cg13872812 BBX NM_020235 0.81 0.22 0.95 eGRC_nm8cg21237481 — — 0.80 0.17 0.76 eGRC_nm9 cg23060513 FARSA NM_004461 0.850.18 0.54 eGRC_nm10 cg08742095 CALU NM_001219 0.81 0.15 0.57 eGRC_nm11cg22011526 C6orf89 NM_152734 0.88 0.16 0.59 eGRC_nm12 cg24520381 PPP1R1BNM_181505 0.85 0.16 0.73 eGRC_nm13 cg10454864 — — 0.54 0.21 0.93eGRC_nm14 cg10387956 HEXA NM_000520 0.62 0.14 0.81 eGRC_nm15 cg18898103ETS1 NM_001143820 0.86 0.16 0.53 eGRC_nm16 cg00006459 — — 0.78 0.19 0.87eGRC_nm17 cg20240243 MEF2A NM_001130927 0.68 0.18 0.91 eGRC_nm18cg23990557 IGF1R NM_000875 0.86 0.17 0.59 eGRC_nm19 cg19788934 C12orf43NM_022895 0.79 0.18 0.70 eGRC_nm20 cg11668148 HEXA NM_000520 0.87 0.190.87 eGRC_nm21 cg16386158 IL1RL1 NM_016232 0.56 0.18 0.83 eGRC_nm22cg26234644 TMEM220 NM_001004313 0.69 0.18 0.70 eGRC_nm23 cg25381747 — —0.71 0.18 0.85 eGRC_nm24 cg22221575 PCYT1A NM_005017 0.57 0.16 0.82eGRC_nm25 cg11310939 MARCH3 NM_178450 0.60 0.21 0.89 eGRC_nm26cg09596645 — — 0.82 0.20 0.85 eGRC_nm27 cg00391067 LOC100271715NM_001145451 0.70 0.17 0.72 eGRC_nm28 cg01835368 C7orf36 NM_020192 0.740.15 0.58 eGRC_nm29 cg16797699 — — 0.74 0.16 0.66 eGRC_nm30 cg13953978USP20 NM_001110303 0.61 0.20 0.83 eGRC_nm31 cg17572056 OSTalphaNM_152672 0.98 0.11 0.27 eGRC_nm32 cg04836151 — — 0.98 0.15 0.49eGRC_nm33 cg02803925 PCYT1A NM_005017 0.97 0.21 0.95 eGRC_nm34cg00421164 RREB1 NM_001003700 0.87 0.12 0.39 eGRC_nm35 cg03695871DKFZp761E198 NM_138368 0.89 0.17 0.51 eGRC_nm36 cg26921611 EIF4EBP1NM_004095 0.77 0.10 0.47 eGRC_nm37 cg15171342 TMED3 NM_007364 0.82 0.210.77 eGRC_nm38 cg05736642 HTT NM_002111 0.89 0.22 0.82 eGRC_nm39cg23039807 — — 0.86 0.14 0.45 eGRC_nm40 cg04128967 — — 0.41 0.12 0.83eGRC_nm41 cg11183227 MAN2A2 NM_006122 0.98 0.27 0.75 eGRC_nm42cg23037469 DCAF5 NM_003861 0.89 0.16 0.44 eGRC_nm43 cg25578728 CHD7NM_017780 0.85 0.20 0.78 eGRC_nm44 cg12910830 MAT2B NM_182796 0.73 0.210.87 eGRC_nm45 cg08077807 PRKCH NM_006255 0.74 0.20 0.92 eGRC_nm46cg14209186 TMEM156 NM_024943 0.75 0.21 0.76 eGRC_nm47 cg05078091 APLP2NR_024516 0.58 0.23 0.92 eGRC_nm48 cg19764973 STX3 NM_004177 0.87 0.240.87 eGRC_nm49 cg25203627 TSNAX- NR_028394 0.89 0.25 0.80 DISC1eGRC_nm50 cg22106847 DMXL1 NM_005509 0.89 0.26 0.82 eGRC_nm51 cg17960717— — 0.90 0.28 0.87 nGRC_nm1 cg03146219 NADSYN1 NM_018161 0.98 0.88 0.07nGRC_nm3 cg13785123 ENO1 NM_001428 0.95 0.78 0.04 nGRC_nm4 cg23819411MCF2L2 NM_015078 0.95 0.69 0.03 GRC_18nm cg25600606 HIPK3 NM_0010482000.91 0.77 0.04 nGRC_nm7 cg25074794 MARCH 8 NM_001002265 0.90 0.56 0.04nGRC_nm8 cg13618969 FAM125B NM_033446 0.88 0.76 0.03 nGRC_nm9 cg26056277— — 0.93 0.68 0.05 nGRC_nm10 cg11153071 RPTOR NM_001163034 0.97 0.850.06 nGRC_nm11 cg01498832 RPTOR NM_001163034 0.86 0.76 0.12 nGRC_nm12cg21090866 VPS53 NM_018289 0.91 0.87 0.07 nGRC_nm13 cg05971678 CHST15NM_015892 0.93 0.66 0.04 nGRC_nm15 cg09694051 MED21 NM_004264 0.87 0.750.01 nGRC_nm16 cg24131359 CPM NM_001874 0.96 0.91 0.13 nGRC_nm17cg13984928 ITGAE NM_002208 0.97 0.75 0.04 nGRC_nm20 cg13468144 ANKFY1NM_016376 0.90 0.72 0.04 nGRC_nm22 cg01699630 ARG1 NM_000045 0.91 0.740.05 nGRC_nm24 cg10934870 PCYOX1 NM_016297 0.90 0.85 0.05 nGRC_nm25cg26396370 KLF11 NM_003597 0.83 0.75 0.05 nGRC_nm26 cg25693317 SH3PXD2BNM_001017995 0.90 0.75 0.08 nGRC_nm28 cg12031275 — — 0.95 0.77 0.11nGRC_nm29 cg23128584 DIP2C NM_014974 0.85 0.51 0.05 nGRC_nm30 cg02279108— — 0.87 0.74 0.06 nGRC_nm31 cg25757820 — — 0.92 0.76 0.08 nGRC_nm32cg06465076 CAST NM_001750 0.76 0.59 0.07 nGRC_nm33 cg27510066 CSGALNACT1NR_024040 0.87 0.67 0.06 nGRC_nm34 cg06784232 CSGALNACT1 NR_024040 0.830.79 0.24 nGRC_nm35 cg01040749 INPP5A NM_005539 0.85 0.51 0.08 nGRC_nm36cg07102397 FOXN3 NM_005197 0.88 0.72 0.10 nGRC_nm37 cg13633625 — — 0.820.67 0.05 nGRC_nm38 cg23338668 — — 0.87 0.83 0.07 nGRC_nm39 cg22400420RGL1 NM_015149 0.87 0.78 0.07 nGRC_nm40 cg24737761 — — 0.86 0.54 0.06nGRC_nm41 cg23911433 — — 0.87 0.81 0.05 nGRC_nm42 cg09010699 — — 0.870.79 0.07 nGRC_nm43 cg06633438 MLLT1 NM_005934 0.92 0.79 0.09 nGRC_nm44eg16000989 DCAF4L1 NM_001029955 0.94 0.73 0.11 nGRC_nm45 cg03610527HDLBP NM_203346 0.84 0.57 0.10 nGRC_nm46 cg17419815 C12orf71NM_001080406 0.89 0.67 0.07 nGRC_nm47 cg06059360 NKTR NM_005385 0.750.71 0.09 nGRC_nm48 cg07052231 PEX5 NM_001131023 0.86 0.73 0.09nGRC_nm49 cg02368812 NQO2 NM_000904 0.96 0.79 0.19 nGRC_nm50 cg05418105— — 0.88 0.66 0.08 CD4+ CD4+ Non- CD4+ Th Th Marker- Classical classicalNK Th CD4+ CD4+ Central Effect. ID Monocytes Monocytes classical B-Cellsnaive Th1 Th2 Mem. Mem. GRC_nm38 0.85 0.87 0.89 0.87 0.90 0.86 0.87 0.880.87 GRC_nm39 3.93 0.91 0.91 0.91 0.90 0.91 0.92 0.92 0.91 GRC_nm40 0.760.82 0.87 0.87 0.92 0.87 0.89 0.88 0.87 GRC_nm41 0.78 0.80 0.78 0.870.89 0.86 0.87 0.88 0.87 GRC_nm42 0.72 0.77 0.88 0.87 0.89 0.86 0.870.89 0.89 GRC_nm43 0.68 0.77 0.87 0.91 0.91 0.86 0.89 0.89 0.88 GRC_nm440.67 0.74 0.90 0.91 0.92 0.90 0.91 0.91 0.90 GRC_nm45 0.67 0.74 0.810.85 0.93 0.75 0.83 0.87 0.84 GRC_nm46 0.56 0.63 0.77 0.74 0.86 0.670.68 0.76 0.73 GRC_nm47 0.53 0.65 0.90 0.89 0.87 0.89 0.89 0.90 0.89GRC_nm48 0.61 0.64 0.83 0.87 0.90 0.85 0.85 0.85 0.84 GRC_nm49 0.95 0.940.95 0.96 0.94 0.96 0.96 0.96 0.97 GRC_nm50 0.76 0.84 0.34 0.91 0.670.69 0.66 0.70 0.71 GRC_nm51 0.80 0.83 0.90 0.90 0.89 0.91 0.89 0.900.89 GRC_nm52 0.80 0.82 0.90 0.89 0.88 0.87 0.84 0.86 0.87 GRC_nm53 0.840.84 0.85 0.87 0.87 0.84 0.84 0.84 0.87 GRC_nm54 0.78 0.81 0.87 0.860.55 0.83 0.85 0.79 0.87 GRC_nm55 0.79 0.80 0.87 0.87 0.84 0.84 0.810.88 0.79 GRC_nm56 0.74 0.84 0.89 0.87 0.89 0.85 0.85 0.86 0.86 GRC_nm570.87 0.89 0.89 0.89 0.91 0.90 0.85 0.90 0.89 GRC_nm58 0.79 0.87 0.950.66 0.97 0.96 0.96 0.97 0.94 GRC_nm59 0.90 0.89 0.81 0.94 0.87 0.850.82 0.87 0.87 GRC_nm60 0.84 0.86 0.90 0.92 0.92 0.88 0.85 0.90 0.89GRC_nm61 0.73 0.74 0.71 0.84 0.77 0.56 0.60 0.66 0.63 GRC_nm62 0.73 0.820.92 0.92 0.90 0.91 0.92 0.92 0.92 GRC_nm63 0.86 0.89 0.87 0.90 0.920.86 0.81 0.85 0.87 GRC_nm64 0.81 0.83 0.89 0.89 0.93 0.86 0.79 0.870.81 GRC_nm65 0.86 0.85 0.89 0.90 0.90 0.87 0.86 0.89 0.89 GRC_nm66 0.820.90 0.93 0.95 0.95 0.95 0.95 0.95 0.95 GRC_nm67 0.64 0.73 0.43 0.760.93 0.56 0.88 0.75 0.66 GRC_nm68 0.78 0.78 0.86 0.52 0.73 0.90 0.880.85 0.88 GRC_nm69 0.88 0.85 0.90 0.97 0.97 0.97 0.96 0.98 0.97 GRC_nm700.63 0.71 0.77 0.77 0.86 0.55 0.61 0.70 0.60 GRC_nm71 0.89 0.91 0.810.92 0.89 0.88 0.86 0.88 0.86 GRC_nm72 0.82 0.83 0.86 0.87 0.86 0.860.84 0.86 0.87 GRC_nm73 0.82 0.86 0.89 0.90 0.91 0.90 0.89 0.90 0.90GRC_nm74 0.82 0.82 0.86 0.86 0.87 0.85 0.85 0.87 0.86 GRC_nm75 0.82 0.800.88 0.69 0.88 0.90 0.91 0.92 0.92 GRC_nm76 0.76 0.81 0.87 0.86 0.890.84 0.85 0.86 0.86 GRC_nm77 0.63 0.51 0.14 0.76 0.85 0.75 0.76 0.740.74 GRC_nm78 0.86 0.88 0.84 0.90 0.89 0.90 0.89 0.88 0.87 GRC_nm79 0.730.80 0.93 0.92 0.90 0.92 0.93 0.91 0.94 GRC_nm80 0.59 0.61 0.88 0.910.90 0.51 0.59 0.62 0.56 GRC_nm81 0.74 0.78 0.78 0.78 0.80 0.71 0.760.75 0.77 GRC_nm82 0.84 0.85 0.88 0.88 0.89 0.89 0.89 0.90 0.90 GRC_nm830.74 0.78 0.86 0.50 0.81 0.82 0.80 0.82 0.82 GRC_nm84 0.85 0.79 0.840.80 0.84 0.86 0.85 0.83 0.87 GRC_nm85 0.67 0.74 0.87 0.90 0.90 0.850.87 0.88 0.85 bGRC_nm1 0.91 0.89 0.90 0.91 0.91 0.91 0.91 0.90 0.91bGRC_nm2 0.96 0.95 0.95 0.96 0.95 0.97 0.96 0.96 0.96 bGRC_nm3 0.96 0.960.97 0.96 0.96 0.96 0.97 0.97 0.97 bGRC_nm4 0.95 0.95 0.95 0.96 0.950.96 0.95 0.96 0.94 bGRC_nm5 0.96 0.95 0.95 0.96 0.96 0.96 0.96 0.950.96 bGRC_nm6 0.88 0.90 0.90 0.92 0.89 0.89 0.89 0.89 0.91 bGRC_nm7 0.900.89 0.88 0.89 0.90 0.86 0.87 0.88 0.87 bGRC_nm8 0.92 0.91 0.90 0.910.91 0.91 0.92 0.90 0.91 bGRC_nm9 0.86 0.86 0.87 0.85 0.89 0.76 0.780.81 0.80 bGRC_nm10 0.90 0.90 0.57 0.86 0.91 0.85 0.85 0.87 0.86bGRC_nm11 0.91 0.92 0.93 0.93 0.92 0.92 0.93 0.92 0.93 bGRC_nm12 0.970.97 0.97 0.98 0.97 0.96 0.96 0.96 0.96 bGRC_nm13 0.94 0.91 0.93 0.930.93 0.94 0.93 0.93 0.91 bGRC_nm14 0.92 0.92 0.92 0.91 0.92 0.92 0.910.91 0.91 bGRC_nm15 0.85 0.78 0.94 0.76 0.92 0.93 0.95 0.95 0.94bGRC_nm16 0.90 0.91 0.84 0.93 0.94 0.94 0.92 0.93 0.93 bGRC_nm17 0.930.91 0.93 0.92 0.92 0.92 0.93 0.92 0.93 bGRC_nm18 0.93 0.93 0.91 0.930.93 0.94 0.93 0.94 0.93 bGRC_nm19 0.90 0.90 0.89 0.89 0.91 0.89 0.880.91 0.87 bGRC_nm20 0.92 0.91 0.61 0.84 0.95 0.96 0.95 0.97 0.95bGRC_nm21 0.92 0.92 0.91 0.93 0.92 0.92 0.92 0.93 0.93 bGRC_nm22 0.910.88 0.90 0.89 0.90 0.90 0.89 0.90 0.90 bGRC_nm23 0.90 0.87 0.90 0.910.91 0.89 0.88 0.90 0.91 bGRC_nm24 0.89 0.89 0.90 0.90 0.90 0.91 0.910.94 0.91 bGRC_nm25 0.85 0.85 0.89 0.88 0.89 0.87 0.89 0.89 0.87bGRC_nm26 0.91 0.90 0.90 0.89 0.90 0.91 0.89 0.91 0.90 bGRC_nm27 0.920.91 0.90 0.91 0.91 0.86 0.87 0.88 0.89 bGRC_nm28 0.90 0.90 0.89 0.880.89 0.91 0.89 0.90 0.89 bGRC_nm29 0.95 0.94 0.94 0.93 0.94 0.94 0.940.94 0.94 bGRC_nm30 0.90 0.88 0.65 0.90 0.92 0.91 0.91 0.92 0.91bGRC_nm31 0.93 0.93 0.95 0.95 0.95 0.94 0.93 0.94 0.96 bGRC_nm32 0.900.91 0.92 0.90 0.91 0.86 0.88 0.90 0.86 bGRC_nm33 0.92 0.89 0.90 0.900.90 0.89 0.90 0.92 0.93 bGRC_nm34 0.92 0.91 0.89 0.91 0.92 0.88 0.880.90 0.90 bGRC_nm35 0.88 0.86 0.87 0.88 0.90 0.85 0.84 0.88 0.85bGRC_nm36 0.92 0.91 0.90 0.89 0.93 0.90 0.91 0.90 0.91 bGRC_nm37 0.810.80 0.90 0.90 0.92 0.88 0.88 0.90 0.88 bGRC_nm38 0.90 0.89 0.90 0.900.90 0.89 0.90 0.88 0.91 bGRC_nm39 0.91 0.90 0.89 0.91 0.91 0.90 0.860.90 0.90 bGRC_nm40 0.91 0.91 0.90 0.92 0.91 0.89 0.91 0.90 0.91bGRC_nm41 0.93 0.93 0.78 0.92 0.92 0.89 0.87 0.91 0.91 bGRC_nm42 0.910.88 0.88 0.79 0.89 0.86 0.85 0.87 0.87 bGRC_nm43 0.89 0.89 0.92 0.900.90 0.88 0.91 0.91 0.90 bGRC_nm44 0.91 0.89 0.73 0.89 0.89 0.90 0.890.89 0.89 bGRC_nm45 0.94 0.94 0.92 0.92 0.93 0.91 0.93 0.93 0.94bGRC_nm46 0.89 0.87 0.87 0.88 0.88 0.85 0.74 0.85 0.84 bGRC_nm47 0.910.91 0.89 0.90 0.91 0.82 0.83 0.86 0.85 bGRC_nm48 0.91 0.87 0.89 0.890.91 0.89 0.92 0.91 0.91 bGRC_nm49 0.90 0.93 0.90 0.89 0.91 0.91 0.910.91 0.92 bGRC_nm50 0.89 0.87 0.90 0.87 0.87 0.87 0.88 0.88 0.88eGRC_nm2 0.95 0.96 0.78 0.97 0.97 0.97 0.96 0.97 0.97 eGRC_nm3 0.93 0.940.91 0.93 0.92 0.91 0.90 0.92 0.90 eGRC_nm4 0.98 0.98 0.97 0.84 0.610.94 0.92 0.88 0.96 eGRC_nm5 0.88 0.87 0.93 0.92 0.92 0.92 0.92 0.910.92 eGRC_nm6 0.87 0.86 0.88 0.74 0.91 0.90 0.88 0.89 0.90 eGRC_nm7 0.950.95 0.96 0.96 0.97 0.95 0.94 0.95 0.94 eGRC_nm8 0.87 0.87 0.93 0.920.93 0.92 0.91 0.93 0.93 eGRC_nm9 0.83 0.89 0.93 0.97 0.94 0.95 0.940.95 0.94 eGRC_nm10 0.89 0.92 0.88 0.91 0.91 0.87 0.85 0.87 0.87eGRC_nm11 0.85 0.86 0.90 0.89 0.91 0.89 0.90 0.91 0.89 eGRC_nm12 0.860.89 0.90 0.87 0.89 0.84 0.88 0.89 0.87 eGRC_nm13 0.94 0.93 0.92 0.940.94 0.94 0.93 0.92 0.93 eGRC_nm14 0.84 0.84 0.85 0.89 0.89 0.85 0.860.87 0.86 eGRC_nm15 0.87 0.84 0.89 0.88 0.89 0.87 0.89 0.88 0.89eGRC_nm16 0.90 0.89 0.89 0.90 0.93 0.87 0.86 0.89 0.89 eGRC_nm17 0.870.85 0.87 0.85 0.90 0.90 0.88 0.88 0.88 eGRC_nm18 0.86 0.90 0.88 0.890.89 0.85 0.86 0.87 0.87 eGRC_nm19 0.86 0.84 0.86 0.86 0.89 0.86 0.860.87 0.87 eGRC_nm20 0.89 0.86 0.87 0.89 0.87 0.85 0.83 0.87 0.85eGRC_nm21 0.91 0.92 0.74 0.89 0.91 0.87 0.85 0.89 0.88 eGRC_nm22 0.750.73 0.91 0.85 0.91 0.91 0.92 0.92 0.93 eGRC_nm23 0.86 0.83 0.86 0.870.87 0.85 0.85 0.86 0.86 eGRC_nm24 0.82 0.81 0.85 0.79 0.84 0.82 0.810.81 0.81 eGRC_nm25 0.91 0.88 0.89 0.90 0.90 0.80 0.79 0.88 0.85eGRC_nm26 0.83 0.84 0.86 0.84 0.86 0.78 0.81 0.82 0.78 eGRC_nm27 0.760.77 0.88 0.83 0.91 0.74 0.79 0.82 0.81 eGRC_nm28 0.71 0.73 0.80 0.860.88 0.78 0.75 0.77 0.77 eGRC_nm29 0.74 0.76 0.74 0.75 0.82 0.68 0.710.80 0.78 eGRC_nm30 0.86 0.85 0.83 0.87 0.64 0.72 0.70 0.73 0.78eGRC_nm31 0.95 0.98 0.98 0.98 0.96 0.98 0.98 0.98 0.98 eGRC_nm32 0.840.86 0.98 0.98 0.98 0.99 0.99 0.99 0.99 eGRC_nm33 0.99 0.99 0.98 0.980.99 0.96 0.99 0.98 0.98 eGRC_nm34 0.86 0.87 0.91 0.90 0.91 0.92 0.920.91 0.91 eGRC_nm35 0.84 0.91 0.93 0.94 0.92 0.93 0.93 0.92 0.94eGRC_nm36 0.71 0.79 0.88 0.91 0.90 0.87 0.85 0.87 0.86 eGRC_nm37 0.930.92 0.92 0.93 0.93 0.92 0.93 0.93 0.93 eGRC_nm38 0.92 0.92 0.92 0.920.92 0.93 0.93 0.93 0.93 eGRC_nm39 0.73 0.79 0.90 0.90 0.91 0.89 0.910.90 0.91 eGRC_nm40 0.79 0.82 0.90 0.83 0.90 0.84 0.89 0.84 0.86eGRC_nm41 0.98 0.98 0.98 0.98 0.98 0.98 0.98 0.98 0.98 eGRC_nm42 0.860.87 0.89 0.90 0.90 0.87 0.88 0.90 0.89 eGRC_nm43 0.91 0.89 0.92 0.880.91 0.91 0.89 0.90 0.91 eGRC_nm44 0.91 0.90 0.91 0.92 0.91 0.91 0.920.92 0.89 eGRC_nm45 0.92 0.93 0.82 0.93 0.92 0.89 0.87 0.92 0.90eGRC_nm46 0.88 0.87 0.92 0.92 0.93 0.90 0.92 0.92 0.91 eGRC_nm47 0.930.93 0.92 0.93 0.91 0.93 0.91 0.93 0.94 eGRC_nm48 0.91 0.90 0.91 0.900.90 0.89 0.90 0.89 0.90 eGRC_nm49 0.89 0.91 0.92 0.88 0.91 0.91 0.900.91 0.92 eGRC_nm50 0.90 0.91 0.90 0.91 0.91 0.90 0.90 0.91 0.91eGRC_nm51 0.92 0.89 0.93 0.91 0.92 0.91 0.93 0.92 0.92 nGRC_nm1 0.970.98 0.97 0.97 0.96 0.98 0.98 0.97 0.97 nGRC_nm3 0.88 0.92 0.96 0.970.95 0.97 0.96 0.96 0.95 nGRC_nm4 0.78 0.86 0.96 0.94 0.96 0.92 0.960.96 0.92 GRC_18nm 0.87 0.87 0.92 0.92 0.91 0.91 0.93 0.94 0.92 nGRC_nm70.83 0.90 0.95 0.95 0.94 0.93 0.93 0.96 0.94 nGRC_nm8 0.89 0.91 0.900.89 0.91 0.89 0.90 0.90 0.89 nGRC_nm9 0.80 0.84 0.96 0.95 0.95 0.930.94 0.95 0.93 nGRC_nm10 0.60 0.77 0.97 0.97 0.96 0.98 0.97 0.97 0.97nGRC_nm11 0.61 0.70 0.86 0.89 0.89 0.63 0.83 0.73 0.70 nGRC_nm12 0.920.93 0.88 0.91 0.93 0.95 0.93 0.91 0.89 nGRC_nm13 0.61 0.73 0.97 0.960.96 0.97 0.97 0.97 0.97 nGRC_nm15 0.80 0.84 0.88 0.83 0.89 0.85 0.860.85 0.86 nGRC_nm16 0.94 0.98 0.96 0.96 0.97 0.97 0.97 0.97 0.97nGRC_nm17 0.58 0.61 0.85 0.97 0.96 0.95 0.96 0.96 0.95 nGRC_nm20 0.900.91 0.91 0.92 0.88 0.75 0.79 0.84 0.87 nGRC_nm22 0.90 0.88 0.87 0.880.90 0.85 0.88 0.89 0.84 nGRC_nm24 0.85 0.90 0.89 0.87 0.85 0.83 0.820.85 0.87 nGRC_nm25 0.81 0.83 0.91 0.86 0.87 0.89 0.89 0.88 0.92nGRC_nm26 0.84 0.89 0.91 0.92 0.92 0.91 0.90 0.90 0.91 nGRC_nm28 0.760.81 0.95 0.96 0.93 0.96 0.95 0.96 0.95 nGRC_nm29 0.66 0.81 0.91 0.940.91 0.91 0.91 0.89 0.92 nGRC_nm30 0.89 0.90 0.88 0.92 0.92 0.81 0.830.86 0.86 nGRC_nm31 0.74 0.76 0.90 0.92 0.92 0.91 0.91 0.92 0.91nGRC_nm32 0.76 0.83 0.91 0.92 0.92 0.92 0.90 0.92 0.93 nGRC_nm33 0.790.83 0.89 0.87 0.91 0.83 0.88 0.86 0.87 nGRC_nm34 0.83 0.86 0.84 0.850.86 0.84 0.85 0.86 0.84 nGRC_nm35 0.82 0.86 0.91 0.90 0.89 0.89 0.900.91 0.92 nGRC_nm36 0.86 0.86 0.92 0.84 0.90 0.91 0.91 0.92 0.91nGRC_nm37 0.64 0.67 0.92 0.87 0.90 0.91 0.91 0.91 0.92 nGRC_nm38 0.870.86 0.88 0.88 0.89 0.83 0.81 0.86 0.84 nGRC_nm39 0.84 0.88 0.84 0.870.88 0.87 0.87 0.88 0.87 nGRC_nm40 0.81 0.83 0.85 0.89 0.90 0.88 0.890.89 0.88 nGRC_nm41 0.78 0.87 0.85 0.87 0.85 0.80 0.82 0.84 0.83nGRC_nm42 0.67 0.69 0.89 0.89 0.90 0.90 0.89 0.90 0.88 nGRC_nm43 0.730.80 0.90 0.94 0.69 0.92 0.92 0.87 0.91 nGRC_nm44 0.67 0.76 0.94 0.940.95 0.90 0.92 0.92 0.94 nGRC_nm45 0.70 0.72 0.93 0.95 0.94 0.93 0.920.94 0.93 nGRC_nm46 0.61 0.65 0.91 0.90 0.90 0.88 0.88 0.88 0.87nGRC_nm47 0.74 0.78 0.87 0.85 0.90 0.90 0.89 0.87 0.89 nGRC_nm48 0.700.81 0.87 0.88 0.88 0.87 0.89 0.87 0.88 nGRC_nm49 0.80 0.83 0.97 0.980.98 0.97 0.97 0.98 0.97 nGRC_nm50 0.58 0.62 0.91 0.84 0.89 0.90 0.920.90 0.89 CD8+ Cytotoxic Marker- T- NK T- ID Cells Cells DiscoveryFragment GRC_nm38 0.89 0.86 CGGCCTGGGCGTGGTC TTGCAAAATGCTTCCAAAGCCACCTTAGCCTG TT (SEQ ID NO: 1051) GRC_nm39 0.92 0.92CCACAGACCCTTTCTC CTTCACTGATTACAGA ATCATACCAAGCACA GCG (SEQ ID NO: 1052)GRC_nm40 0.89 0.85 TGGGCCTGGTGCTTGG GTTTGCTAACTTCTGG TTCTTCATGTGTATCA CG(SEQ ID NO: 1053) GRC_nm41 0.89 0.84 CGACATGGGCAATGT GGGGAAAGAGACCATTGTGTAAATGATCTAC AATG (SEQ ID NO: 1054) GRC_nm42 0.91 0.85CGAAGGCCAGAGCCT GTTTGTAAACCATTAA CAGGAATAACAAGAG ATAA (SEQ ID NO: 1055)GRC_nm43 0.91 0.84 GACCGAGGCCGACAA TTCAGTCGCCACACAA GAGGTCAGAAATATA CTCG(SEQ ID NO: 1056) GRC_nm44 0.89 0.88 TGGGGATAAACGGTG TAACACTGGGGCAGGTCAGTTTCCTTGTTGG TACG (SEQ ID NO: 1057) GRC_nm45 0.85 0.73TTTGAGGAAAATACCT TGAAACCGTCGGTAG GACTAGATAGGTGAC AACG (SEQ ID NO: 1058)GRC_nm46 0.78 0.70 CGTCTTGGTGATAACA GGCACTTGAGAAATA AGTTTTTAAAGAGTTG ATT(SEQ ID NO: 1059) GRC_nm47 0.88 0.90 AACACAGTGTGGGCT GATGCAATCAGTGTTTGCTGCCCTTGGGCGCT TCG (SEQ ID NO: 1060) GRC_nm48 0.87 0.82CGGGCAGATTTTTTCA GAGCAATTGAATGTAT TCAAAGATGTCTTAAT TA (SEQ ID NO: 1061)GRC_nm49 0.96 0.95 GAAGCTGGGGCAGGT AACACGCAGAGCCGC CACGTGGAACGGTCT GTCCG(SEQ ID NO: 1062) GRC_nm50 0.65 0.61 GGAGGCACTTGTAGCT GAGTGAGGGCATTTCCTTTGTGCAGTGGTATG CG (SEQ ID NO: 1063) GRC_nm51 0.90 0.88TTCTTGTTATCTCATTT AGGACTCATAACTCA GTTGTGTAAGCTTTAT CG (SEQ ID NO: 1064)GRC_nm52 0.88 0.87 ACTATCACTAGACATA TCCTCTCTTTAGAGAA ATCACACAAAATTCTA CG(SEQ ID NO: 1065) GRC_nm53 0.89 0.81 AAGGATTTGCTCTCCA GATGCAGCTGTGCCTTCCTTTGAAATATCTTT CG (SEQ ID NO: 1066) GRC_nm54 0.74 0.87TCTTGAGAAATGTACT TTAGACTAGCTTGAGT TGACACATTACAAAGT CG (SEQ ID NO: 1067)GRC_nm55 0.83 0.85 CGGTATCAGCAATTGA AGCATTACAGTAAAA GACCTCCGATTACCAA CTG(SEQ ID NO: 1068) GRC_nm56 0.88 0.79 CGGCCCCTTCTGACCC CATAGCTGGCACGGGCTCCTGACCACAGGTA TGC (SEQ ID NO: 1069) GRC_nm57 0.89 0.90TGCCCCGGTGGTGCAG TCAGTGGAAGCAGCT GTAATCTATGGGGTCA TCG (SEQ ID NO: 1070)GRC_nm58 0.98 0.96 CGGTGTCACAAGAAA ACCTTGCAGACTCGCC CTCGTAGACGGTCATG GAC(SEQ ID NO: 1071) GRC_nm59 0.79 0.77 CGTGGTACATGAGAA CCTTACTATAAAGTGGCTCTTTAGGACCGTTC TGA (SEQ ID NO: 1072) GRC_nm60 0.92 0.91CATGAACTCTCTGCGT TCCAAACTATAGATTG TGATTAATTATTTTGT CG (SEQ ID NO: 1073)GRC_nm61 0.73 0.38 GCACCCCAGTTATCTA GCCCTCATCAATTTGT GCAAGAAGGCCGGGC TCG(SEQ ID NO: 1074) GRC_nm62 0.92 0.92 CGCAAGTGATTTATAG GCATTGTCTTTGCAGCCACTCTATGAGGCAG ACA (SEQ ID NO: 1075) GRC_nm63 0.89 0.88CCACTCTGACCTTAGA CAAGTTACTTAATTGT CTCAGTGCCTTGGTTT CG (SEQ ID NO: 1076)GRC_nm64 0.90 0.87 ATTTCATCAACTGTCC CACTAACATCCTGTAT ATACCAAGCTTCTTAT CG(SEQ ID NO: 1077) GRC_nm65 0.91 0.87 CGCTTTGGAAGAAGG ATTAGGTAATTGTAGTACAATCTTCCACCCAG TTC (SEQ ID NO: 1078) GRC_nm66 0.96 0.93CGGACCTCAAGTCCCT GTGCTAGCCACGGTA GTTCTTCACACCCCGT CAC (SEQ ID NO: 1079)GRC_nm67 0.82 0.61 ATGGCGGATATGTATG CAACGCGTGTGGCCTC TACCAGAAGCTTCACT CG(SEQ ID NO: 1080) GRC_nm68 0.89 0.91 AGGTAGCCATGCTGCT AAGGTCACAGTCACTAAGATATTTTTTGTCA TCG (SEQ ID NO: 1081) GRC_nm69 0.97 0.97GGTTACGGGGCAGTG GCCATGAGCCTCTGTC GGACTGACGCAAGGA GCCG (SEQ ID NO: 1082)GRC_nm70 0.70 0.34 AAAAAATAGACAACC TCCCAGTTGCCACAGA CATGTACTGTAAGCAG ACG(SEQ ID NO: 1083) GRC_nm71 0.91 0.87 CGGGAAATACACATT ATGCTAATGTTGATGACAGAATTTATTTGGTT GCC (SEQ ID NO: 1084) GRC_nm72 0.88 0.80CGGTGCCATCTTGTGA AAAGGGCTCTGCAGC TTTTAATGTGTACAGT TTC (SEQ ID NO: 1085)GRC_nm73 0.91 0.88 GGCCTACATTCTGTAC TTTGTGCTGAAGGAGT TCTGCATCATCTGCAT CG(SEQ ID NO: 1086) GRC_nm74 0.88 0.86 CGTGACGATGCAGAT GATGCAGAACTCCTTCAGCACAAAGTACAGA ATGT (SEQ ID NO: 1087) GRC_nm75 0.92 0.89CGCCAGCCTGCATTTT AGATGGACCATAACT CAAGATAGGCGTTGA AGCA (SEQ ID NO: 1088)GRC_nm76 0.86 0.79 CGAGGGCACTGGACA TGCTGGATTTGGGGAG ACTGTTATGCGATCTC AAA(SEQ ID NO: 1089) GRC_nm77 0.77 0.58 CAGAGGAAGCCACAT AACCTCAAAAGGTCAAGACACCTAGACATG GTCCG (SEQ ID NO: 1090) GRC_nm78 0.89 0.86CAACCTGTCCACTCGG TTTTCTGTTTCTTTGAG ATTATTTTCTACTAAC G (SEQ ID NO: 1091)GRC_nm79 0.93 0.93 CGGTGTGATGTGATGA AATCAGGATTTTGTGT AAGCTAGCTCTCAAG AAA(SEQ ID NO: 1092) GRC_nm80 0.80 0.47 ATCCTGCTTCCATGGA GTAAAATTCCAGACTGGGACAAGCGTTCTTTC CG (SEQ ID NO: 1093) GRC_nm81 0.82 0.68CGTGTCTCTTTAAAGC TGCTATGTGAACAGCT TTTACAGTCATTAAAT TT (SEQ ID NO: 1094)GRC_nm82 0.90 0.87 TGTATGTCCAGCTGGA CTTGGCAGAAGTACA CAGACTGGTCCTCCTT CCG(SEQ ID NO: 1095) GRC_nm83 0.85 0.80 GACACATGATCCTCGG GCTGCTGCTGGGCTTTAGCTACCCAGAGATT ACG (SEQ ID NO: 1096) GRC_nm84 0.87 0.86ATTTCCTATGGCCAGT GTTCTACAGAAGTAA GACTGTGCAAACTTTA TCG (SEQ ID NO: 1097)GRC_nm85 0.90 0.88 GGCTTCTGACTGGAGG ACAATGACCCAGCTG ATCCTTCTGACGTCTT ACG(SEQ ID NO: 1098) bGRC_nm1 0.91 0.89 AAGAAAGAACCCTTT AAATAAAGGGCCCACACTGGCTGCCAGGGA GTGCG (SEQ ID NO: 1099) bGRC_nm2 0.94 0.95CGGGGGGCCACCGAA TACTCCCCGAGCGCAT ACTATTTACAGAAGA GTCA (SEQ ID NO: 1100)bGRC_nm3 0.97 0.97 GACGTGCAGATAACG TTGAGCTGCCCTGTCC CCGAGCCATAAGCAG AGCG(SEQ ID NO: 1101) bGRC_nm4 0.95 0.96 CGGTCACTTCCAGGTT TTGACGATCATGAATAACGTTTCTGTCGACAT CT (SEQ ID NO: 1102) bGRC_nm5 0.96 0.96CGCCTATCGGCCCATC TCCCTGCTGTCCATCA GGCCGGGCCCCCGCCT CA (SEQ ID NO: 1103)bGRC_nm6 0.91 0.90 CGTCCTAGACACCCTG GCCTGGAAACTAGGA CATCTGCCTCGGGCCT GTT(SEQ ID NO: 1104) bGRC_nm7 0.88 0.85 CGCTGCAGCAGATGG TCTTGGAAATACAACAGGCTGCATTCTAACTG CTG (SEQ ID NO: 1105) bGRC_nm8 0.92 0.92ATAACTTGGAGGCAG CGTAGATGGCGCCTG GTGACTGCAGTGTGCC CACG (SEQ ID NO: 1106)bGRC_nm9 0.84 0.71 CGTCAGGGCTGTGGTG ATGAAGTCCAGATGTT ATAACTTAACAGTGTT TT(SEQ ID NO: 1107) bGRC_nm10 0.88 0.82 GGCCTGCTGTCCCACT GCCATGCTCATCTGCATATGTATGGTTTCATT CG (SEQ ID NO: 1108) bGRC_nm11 0.93 0.93CGCTAATGCCAAGAT AAGCTAATGCTGTGCT TCACCTGGACACAGG GAAA (SEQ ID NO: 1109)bGRC_nm12 0.97 0.96 TCACCTGCGGAGGAC CCCGTGCTGGGGAGG TGGTGGCTGGTAGTGAGACG (SEQ ID NO: 1110) bGRC_nm13 0.94 0.94 CGAAGGCTTTGTAATTCACAGTGATAAGTGC AGTTAATATGTTATCT GAT (SEQ ID NO: 1111) bGRC_nm14 0.920.93 ACTGCCCATTTTTTAA AACTTCAAATCCAAA AGATGTGATAAATAG TACG (SEQ ID NO:1112) bGRC_nm15 0.92 0.93 CTCTCGGGAAGACAG GGCTGCTGTGTATCCTGATTGTGGTGGTGGAT ACG (SEQ ID NO: 1113) bGRC_nm16 0.95 0.91GAGGGGACAGTCCTG GGTCCCCGCCAATCCG GCCCTTGAGGTTGAGC TCG (SEQ ID NO: 1114)bGRC_nm17 0.90 0.93 ATAGGTGAATTCTATA GCCAGGTGGCCTCCA GAAGCTTACGAAATGATCG (SEQ ID NO: 1115) bGRC_nm18 0.93 0.93 CGCCCTGCGTTGCGTTCTCCACACAGCAGCC ACGGTGACTTTGTTAA AAT (SEQ ID NO: 1116) bGRC_nm19 0.900.88 CGGAATATTCAAAAC CAGATGGACAGTTAG GTCGATAGATAAGAC AGATA (SEQ ID NO:1117) bGRC_nm20 0.94 0.94 AGTGCGCTGCTGCGG GAGGAAGCCAGTGTCTTCCTGGAGACGGCTT CACG (SEQ ID NO: 1118) bGRC_nm21 0.93 0.90CGCTTTGAGATTGAAG AGAACATACACTGGA CCATATAGGGGTCTTC TAC (SEQ ID NO: 1119)bGRC_nm22 0.91 0.87 CGGCTTCCTTTGATGG GAGACAGGAGGAGTA GAAATAAGCTGAGCTACAC (SEQ ID NO: 1120) bGRC_nm23 0.90 0.91 ACTGAGCAGCAAGTATTCCTTGTGTACCAGT CTCTGTTCCAGAAACA ACG (SEQ ID NO: 1121) bGRC_nm24 0.930.91 CGGAGAAATGCAAAT CTGATAATAAGCACAT ATATAGATGGCATTTA AAT (SEQ ID NO:1122) bGRC_nm25 0.86 0.89 GCTTTATCTAACAATT TATTTAACAAACAGTTAACTAGCACTGTGTGC CG (SEQ ID NO: 1123) bGRC_nm26 0.92 0.90CGGAACCCTGACTTTG GAGGCTTCAGACATCC TGAAATATAATTCAGA TA (SEQ ID NO: 1124)bGRC_nm27 0.91 0.89 CCTGGTCACAACATTC AGAGGACACACAGGT AGGATTAACAGTAAAATCG (SEQ ID NO: 1125) bGRC_nm28 0.92 0.87 GCCAGGATCACAAAGTTTCTGCCTTATCATTT ATGGTTATTGTTACCT CG (SEQ ID NO: 1126) bGRC_nm29 0.940.95 AATAAGAAGAGTCCG TACCTCTTTCCCCTCA CTCTGCACCCAGAATA CCG (SEQ ID NO:1127) bGRC_nm30 0.91 0.89 TTCAGCAGATGAGATC TCAGCAATCCCCACTAGGCTGGCTTCTAATAA CG (SEQ ID NO: 1128) bGRC_nm31 0.96 0.95TGGCTTCTGCCAGAGA AGCCCCGGACAGCTG CGAGCGCTGGCTGAG AACG (SEQ ID NO: 1129)bGRC_nm32 0.90 0.82 GGCAGGTCTTCTGACT TGGTCTCATTTTCTGC ATGGCTTTCTCCCTCTCG (SEQ ID NO: 1130) bGRC_nm33 0.90 0.91 CGTGGCTTTTGATTATCTGCAAAGATTAATG AGCCCTAATGAACGG GTCA (SEQ ID NO: 1131) bGRC_nm34 0.920.90 GTCCCACTGGGGCAC ACAGCAGAGCAATGA AATTCCTGCATATTAA GACG (SEQ ID NO:1132) bGRC_nm35 0.83 0.84 CGGTAGACTGATGAA ATAAGGTTTGGTTCATATCCATAACAGTTGAC TAC (SEQ ID NO: 1133) bGRC_nm36 0.89 0.87CGGTAGGTGTGCACA AGCCAGAGCAGAGTC CCATTCCTTGCATCCG CCAC (SEQ ID NO: 1134)bGRC_nm37 0.84 0.83 CCTGGCACCTGCTTCA CAGCCTTCCCGCTTGC CTGCTTTGTGGTGAGTCG (SEQ ID NO: 1135) bGRC_nm38 0.91 0.89 CGGTCTGATCTGAACTCGGCTTCAGTTGGTCT GGAATGCACCGGCTG CAT (SEQ ID NO: 1136) bGRC_nm39 0.910.91 CGCTGAATCATGGAGT TTATCTTAAGGATGGA TCTGAATGAGATCTGA TA (SEQ ID NO:1137) bGRC_nm40 0.91 0.87 AAATTCTGAATTTTCG CTACACTGTCCACAGTACCAAATGGCAATAA CCG (SEQ ID NO: 1138) bGRC_nm41 0.93 0.91CGGTGGCTGTTTCCAT AGTAGCCTCATATCAC TGCCAAATCTCATCTG AT (SEQ ID NO: 1139)bGRC_nm42 0.86 0.88 CTATCTGTGACAGATA ACCTATATCACAGATA GATCTATCTGTGACCTCG (SEQ ID NO: 1140) bGRC_nm43 0.89 0.88 CGCAATAAGCACAGAGCTGGACTTGAACCCA AGTTTTGCCACACAGG CCT (SEQ ID NO: 1141) bGRC_nm44 0.900.90 GGCTCTGTGGGTTTGG CTCTTAGAGTCAAGAT GGTCACCGCCTCCAAG CG (SEQ ID NO:1142) bGRC_nm45 0.94 0.93 CACTAATTACCACTCA GTTCTTGGGCTGTAGCAAAGATAATTTCAATT CG (SEQ ID NO: 1143) bGRC_nm46 0.89 0.86CGCAGTTATCTGTGGC TGATCATGGCTTGTCA TACTGCTACTCCTAGA TG (SEQ ID NO: 1144)bGRC_nm47 0.89 0.85 CGCTGGTGTGGGACC AGTCTCCTAGACCCAA GTGCTAGGAGTAGAATGCT (SEQ ID NO: 1145) bGRC_nm48 0.89 0.86 GCATCCTAACAAATGAACAATCTTTAGCTAA AGACACTGACCAGAT TACG (SEQ ID NO: 1146) bGRC_nm49 0.910.89 CGTATGAGGTTATGTA GCATGTGAGGATAGG CATAGCTTTGTTACGT GTC (SEQ ID NO:1147) bGRC_nm50 0.90 0.91 CGCTGATAAATCTCTT GAGTTTTTCAAGAAGGTGACAGTGTATACCAT GA (SEQ ID NO: 1148) eGRC_nm2 0.97 0.98 CGCGGTGACACCTACAGCCACGCAAGCACC TGCGTAAACACGTGCT ACAG (SEQ ID NO: 1149) eGRC_nm3 0.920.86 CGGCAACCCCAAAGC ACCTGTTAAGACTCCT GACCCCCAAGTGGCA TGCA (SEQ ID NO:1150) eGRC_nm4 0.72 0.98 CCATGGAGGAGCGTG ACGGAGAGATCTGCGTGTGACGCTGTGTGCT CTCG (SEQ ID NO: 1151) eGRC_nm5 0.92 0.93CCCTATAATATCTTTA CTGTAAGGCAGCTACT TCTCCCTAAATAATTT CG (SEQ ID NO: 1152)eGRC_nm6 0.88 0.90 TAAAAAATTTCTTGCC ACATACGAGTTTAAAC CAAGATAATCACGGC ACG(SEQ ID NO: 1153) eGRC_nm7 0.96 0.95 CGCTATAGCAGTTTTT AAAAGCTTCTTCGATTGTTGACCGGTCCGTTA AG (SEQ ID NO: 1154) eGRC_nm8 0.93 0.93 CGGAAGCCAAGCTCTGTCCCAAGCACTGTGC TGATGATATCTCATTT CAT (SEQ ID NO: 1155) eGRC_nm9 0.950.96 CGCCGCTGCACCTCAT CCTCCATGCTGTCCAC CTGCCAGGATAAGGA GTG (SEQ ID NO:1156) eGRC_nm10 0.88 0.87 CGTGGAAGAGGGACA GAATTTTAGAGAGAGAAACTCATTTGAGAA ATGGG (SEQ ID NO: 1157) eGRC_nm11 0.91 0.89CGTCGTTATTCTTAGG AGATGCATGTTGAAAT ATTTAGAAATGATTTT AT (SEQ ID NO: 1158)eGRC_nm12 0.88 0.84 ACAGGGACCTAATTA ACTGACAGTTGGTCTG ATTGCCAAGCTGAGGGGCG (SEQ ID NO: 1159) eGRC_nm13 0.93 0.93 CGAAACACAGTCATTCATGTTGGTAATTGTGA CAGAGATTATGTGGCC CA (SEQ ID NO: 1160) eGRC_nm14 0.850.82 AGATGGATAGTGGCTT CCTAATATCCCCTTTT CATCAGTGTTAAAAAT CG (SEQ ID NO:1161) eGRC_nm15 0.89 0.88 TGAGGTTAAGAAATTT GCTCATGGCCATACACGCAGCAAGCAGTTCT ACG (SEQ ID NO: 1162) eGRC_nm16 0.91 0.87CGGTTGCTTAAGCTGA CACTGCAGAGCATTGC AAGAAGTGTTGATTA AAA (SEQ ID NO: 1163)eGRC_nm17 0.90 0.91 ATTTGTATTTTGACAG CCCATGGTAGCATCAG ATAAATTGCCTTTTAACG (SEQ ID NO: 1164) eGRC_nm18 0.88 0.85 CGCACAACTGCTCCATCTTTTAAGATATTGGA AGTGAGAGCACGGGA GGA (SEQ ID NO: 1165) eGRC_nm19 0.880.87 CTCCACAATAAGCTAA AGCCAACTCCTGCAAC AGGCTCCTGTGATCAA CG (SEQ ID NO:1166) eGRC_nm20 0.87 0.81 CGGTGCCTGGGGCTCA GGTCTGTTCAAACTCCTGCTCACAGAAGCCTA CA (SEQ ID NO: 1167) eGRC_nm21 0.88 0.85CGCAATCCTCAGAAG CTGACAGGAGCTTCA GAGAGGAGAATTACC TTACC (SEQ ID NO: 1168)eGRC_nm22 0.93 0.91 ATTTACACATCCATAG GCCTCATTTCTGCTGT TCTAAAGAGTCTTTATCG (SEQ ID NO: 1169) eGRC_nm23 0.86 0.84 AACTCCTAAGGCCAAAGGAATGTGGTATGCT CACTGACTTGGCTTGG ACG (SEQ ID NO: 1170) eGRC_nm24 0.830.79 GGGGTAAATGGATGC AGAGCAGGCTTCTAA GGTGCAGTCCCCCTCC TTCG (SEQ ID NO:1171) eGRC_nm25 0.84 0.77 CCAGGTGCAACATAT GCATGCCAGTTGGTGCATGCAGCTTGTGAGGT CCG (SEQ ID NO: 1172) eGRC_nm26 0.83 0.78CGGGCAGTCTGTGGTT CCTGACCAGACTGCTG GGGGTCAAATCTCTTT CA (SEQ ID NO: 1173)eGRC_nm27 0.82 0.75 GAATTTCCTAATATAT TTCTAACAGATAATGG TCACCACCACTACCCTCG (SEQ ID NO: 1174) eGRC_nm28 0.81 0.67 CGATTGTTAGGAAACCAAATGTTCTGAACATT ATTTTCATTAGAAAAG GG (SEQ ID NO: 1175) eGRC_nm29 0.810.66 AGCGGGAGGCTGGTG GCGTGCATCAGGCCAT GGGGGTGGGGCTTGG ACCG (SEQ ID NO:1176) eGRC_nm30 0.68 0.77 CGACTGCTCAAACTGG GTTTGGAGAACAACCCAGTATGGCTTTTACA GAG (SEQ ID NO: 1177) eGRC_nm31 0.98 0.98CGGGATAAAGCACAG CTCCTCCGCCAGCCCG GCGCGCAGCGGGCCT CACC (SEQ ID NO: 1178)eGRC_nm32 0.99 0.98 CGCACTCCGGTGACTC AGAATTGTCGCCGCTC CGTGCAAGTAAGTGTTTG (SEQ ID NO: 1179) eGRC_nm33 0.99 0.96 GGTGATGAACGAGAA TGAGCGCTATGACGCAGTCCAGCACTGCCGC TACG (SEQ ID NO: 1180) eGRC_nm34 0.91 0.93AGTATCTAGAAAAAC CCAGAGAATGATATTC CACAAAACGGTAAGC ATCG (SEQ ID NO: 1181)eGRC_nm35 0.95 0.92 CGCGGGAGCTGCGGG CTGCGGTGATCCAGCT TCTGGACACCTCCTATCTG (SEQ ID NO: 1182) eGRC_nm36 0.89 0.84 CGCCCTAGGGCCAAGAGTTGGGCCCCGTCTG AGCTTTTTTCAACTCT GTT (SEQ ID NO: 1183) eGRC_nm37 0.930.92 CCCAATAGAGGCTGTC TCAACAGTGGCCAAC AGAACTCTCATGAGTA TCG (SEQ ID NO:1184) eGRC_nm38 0.94 0.95 GTAGACCTTGCTAATA ACTTGCCTATAAGTTCCACAATACTCCCACTA CG (SEQ ID NO: 1185) eGRC_nm39 0.91 0.89CGCAGAGTCTTGACCA CAAGGAAAATCTTGTT TTTGAGCAATAACCCT TC (SEQ ID NO: 1186)eGRC_nm40 0.85 0.80 CGTCAAGCTTTGTTGA GTCAGACAGTGTCTGT CCAAACTACTCAAGTCAG (SEQ ID NO: 1187) eGRC_nm41 0.98 0.98 GGGCGAAGTCGCTGG TGCCAGAGTCAATGACACGGAGAGGAAACG CTTCG (SEQ ID NO: 1188) eGRC_nm42 0.90 0.89TTTACTGATTTAGGAT GTCGACCATCTAGTCT GCCAGAGCTGCAATA ACG (SEQ ID NO: 1189)eGRC_nm43 0.89 0.91 CGGCAAGTCCTATTGA GATTATAACAATGAC ACTGATAAAAAAGAAGATG (SEQ ID NO: 1190) eGRC_nm44 0.92 0.93 AGCACGTTCATGACCCTTGAAAGTCTTCGAAA ACAGATTACTGGGCTT CG (SEQ ID NO: 1191) eGRC_nm45 0.890.87 CGTGCACTCTGAACAA GCATTCATTTGGCTGC ACAGGGCCAGATCAA GGT (SEQ ID NO:1192) eGRC_nm46 0.91 0.88 ACTAGCTTTGCGAAAG CCACAGGGAAGTGATCTTGGTTGTGCAGGTG TCG (SEQ ID NO: 1193) eGRC_nm47 0.93 0.94AAATGAATGTAGATA CCATCTTAGCCAGGTG ATGAAACAAACTGGT ATCG (SEQ ID NO: 1194)eGRC_nm48 0.90 0.88 CGGAAATCAGAGGGA GAAGACGCATATCTTG TTTCAGTGAGGGTGATCCC (SEQ ID NO: 1195) eGRC_nm49 0.91 0.91 CGGTCAGAGGGGACCATCTGTTTATCTTACA GGCTTAATATGATCAC AGG (SEQ ID NO: 1196) eGRC_nm50 0.880.88 TACCAGCCCTTCATTT CTTTGCTTTGACTCTTT AATTTCCAAGATAATC G (SEQ ID NO:1197) eGRC_nm51 0.93 0.92 CGGAAGGCTGGGGAA ACAGGCTCTGCCCTATATCTGAGGGAAGTGT GCAT (SEQ ID NO: 1198) nGRC_nm1 0.97 0.96CGCCAGGTTTCGAGAT GAAATCTCCGCCCTGT AGCTCCGGACGTCCTC CA (SEQ ID NO: 1199)nGRC_nm3 0.97 0.97 CGGCTAAGTCCCCACG TACGCCATTAAACAAC GGTCAAATGGTAACA TGT(SEQ ID NO: 1200) nGRC_nm4 0.96 0.95 CTGCCCTTGGTCAGCA CCGTGTAGGGCATGTGCTCACCCGCTGGAGAT CG (SEQ ID NO: 1201) GRC_18nm 0.93 0.94CGAAACAGATTGCATT TCCTAGAAGGCCCCCA GCGATGTGGATTGAA GCG (SEQ ID NO: 1202)nGRC_nm7 0.94 0.93 CGGCTTGAGCGCCAG CAGCCTGCACAGGTTC CATGAGCTGGAGAGC TGCG(SEQ ID NO: 1203) nGRC_nm8 0.92 0.91 CGGACTACGAGTACC AGCACTCCAATTTGTATGCCATATCAGGTATG TGG (SEQ ID NO: 1204) nGRC_nm9 0.95 0.88AATACCTGGCACGCC AGGGTGATGCAACTG GGAGCTTCTGCACGTT CGCG (SEQ ID NO: 1205)nGRC_nm10 0.98 0.98 CAGCGCCCGTGTGATG ATGATGCTCACGCTCC GGTGTGACACAGACGGCG (SEQ ID NO: 1206) nGRC_nm11 0.75 0.48 CGGGAGGAGCTGGGTGGATACCTTTCTAACT TCCGAGGCTGGCTACT CCT (SEQ ID NO: 1207) nGRC_nm12 0.930.94 CCCTCTGCCCAGCGCG TCTGGGACGTGTGCCC AAGAGCTTATTGAGA ACG (SEQ ID NO:1208) nGRC_nm13 0.96 0.95 TCAGGAAATTGCGAA GAAATTCTGCGGCGGGTGCAGGATGCCCAC CCTCG (SEQ ID NO: 1209) nGRC_nm15 0.92 0.86CGTGGAGATGAACTA GAACAGGTATGAGGT TCTAGCAGAAGAAAC ATTTG (SEQ ID NO: 1210)nGRC_nm16 0.97 0.97 CGATATTAGAAAGGA GCTCAAGGTAGTACA CTTCACGTGCCCCGGTAACG (SEQ ID NO: 1211) nGRC_nm17 0.88 0.92 CGGCACTTTCAACCAAACAGAGACACTCCGG CTCGTACACAACCAGC CGT (SEQ ID NO: 1212) nGRC_nm20 0.910.90 CGCAATCCAGTCACAC TTGTGAAAATGCTGAA GACGGTGGTTACGGA AGC (SEQ ID NO:1213) nGRC_nm22 0.89 0.88 CGCTGAGCCAGAACA ATAGGACTTCTTCTGTAGTTGTGAAACTTGTC AGT (SEQ ID NO: 1214) nGRC_nm24 0.86 0.83GTACCAACTGAATTCA ATTTAAAAACAAAGA TGTCAGACATGCATCT TCG (SEQ ID NO: 1215)nGRC_nm25 0.90 0.89 GTGTATGGATTCGGCA TGGAGCCCTCAGCTGG CGGCTCTGGGTGCTGACG (SEQ ID NO: 1216) nGRC_nm26 0.92 0.86 CGCACTTCTGTGCGCTCACTATGAGAAGCTGT GTTTACTCGCTCCGTG CT (SEQ ID NO: 1217) nGRC_nm28 0.960.94 TCCCAGTCATTCTCGG GGTAAGTTCCGAAGTT GGAGGTGTCGCCTTCG CG (SEQ ID NO:1218) nGRC_nm29 0.95 0.91 CGTCCTCCGTCTGCCG CCCACTAATCGTTCCCCATACAGACTTCCTGG CG (SEQ ID NO: 1219) nGRC_nm30 0.90 0.77AGGTCACAGATGCAG ACGTTTGCTCGAAGTG GCTGCCGAGCTCAGA CCCG (SEQ ID NO: 1220)nGRC_nm31 0.90 0.92 GTGGAGGATCCAATTC TAAGACAGCTCATTCA TTCACATGGCTGTTAGCG (SEQ ID NO: 1221) nGRC_nm32 0.92 0.91 TTCTCAACACCAGTTTTCTGAGCAGGGTGAA TAACTCTGCTCATACC TCG (SEQ ID NO: 1222) nGRC_nm33 0.870.78 TCCTATTACTCCAGAC GAATCTGTTTCATGTG CTGAAGCTCTCCCCTT CG (SEQ ID NO:1223) nGRC_nm34 0.84 0.84 AAAACCAAGTCTAGG ATTTTTCCATGGATGGTTTCTCAGCCGCTCTC ACG (SEQ ID NO: 1224) nGRC_nm35 0.92 0.90GGCTGTGGTTCTCTGC TTGTGCCCACTTTGTG TTTGTAAATAGCGAGT CG (SEQ ID NO: 1225)nGRC_nm36 0.91 0.91 CGGGGGCTAGAGTTC ATAATTTCTGGTAATC GCTCAACCCTGTGATTACG (SEQ ID NO: 1226) nGRC_nm37 0.92 0.91 CGCTTTGCTTAGAGATCAACAGAGTGACATC CTAGGGTCTGAGCCTC AAC (SEQ ID NO: 1227) nGRC_nm38 0.830.83 CAAAAGCCTGTGAGG AGCTCCTGGAAGACA TTAAGTTCTCTACAGC AACG (SEQ ID NO:1228) nGRC_nm39 0.87 0.78 CGCAGGAGTAAAATT GGGTAAAACAAGCACATGGGAACTGAGGCA ATCTC (SEQ ID NO: 1229) nGRC_nm40 0.87 0.83CGGGTGCAACTGGCA CCAAGAACAACACCC ATGCCCAGGTGACAA CTGCG (SEQ ID NO: 1230)nGRC_nm41 0.82 0.69 CGTGTTCATAAATGAG TGCAGTGATATCAATT TAAGAACATCCATCATGT (SEQ ID NO: 1231) nGRC_nm42 0.88 0.88 ATGTTTGTACACAGCTGCCTCCTTGACTGTAG TTGATTGGCCTCTGTG CG (SEQ ID NO: 1232) nGRC_nm43 0.880.95 GAGACGAGCGTCTCA GACTTGAGGAAATAC ACGCGTGGAAGACGT GCGCG (SEQ ID NO:1233) nGRC_nm44 0.94 0.92 GTTCTTCTCCGTGACA GGATGTTCTTTTCCGTGACAGGAAGTTCCGT CCG (SEQ ID NO: 1234) nGRC_nm45 0.94 0.91AAGTGGGATCCGCAA GATGATGGATGAGTTT GAGGTAGACCCCTTTC CCG (SEQ ID NO: 1235)nGRC_nm46 0.91 0.84 TGACGCTGTATTTCCT GAAACTGCTCAGCAA GATTTCCAGCTATCCAGCG (SEQ ID NO: 1236) nGRC_nm47 0.87 0.90 CGGTCAGTTCCTGTGAGGAGGAAACAATGAT ACTGCATTATAGACAT CGT (SEQ ID NO: 1237) nGRC_nm48 0.860.86 CGGGGAGGGACTAGA TCAGAAGAGATCAAG GGCTCTATTCAGGAAC GTTG (SEQ ID NO:1238) nGRC_nm49 0.98 0.97 CGTGGGCATCACGTA AGCAGCACACTAGGAGGCCCAGGCGCAGGC AAAGA (SEQ ID NO: 1239) nGRC_nm50 0.89 0.90CAAATCACTGTAGTTC AGACAAAACCTTCAT ACCATTTTATTATTTA ACG (SEQ ID NO: 1240)

TABLE 4H T-Cell Marker Non- Marker- Target Basophil EosinophilNeutrophil Classical classical ID ID SYMBOL Accession GranulocytesGranulocytes Granulocytes Monocytes Monocytes OTL_nm18 cg03388043 CCDC57NM_198082 0.95 0.96 0.97 0.96 0.96 OTL_nm19 cg19163395 HDAC5NM_001015053 0.97 0.95 0.97 0.92 0.91 OTL_nm5 cg24612198 CD3E NM_0007330.92 0.95 0.93 0.94 0.93 OTL_nm4 cg07545925 CD3G NM_000073 0.90 0.890.90 0.92 0.89 OTL_nm22 cg24441810 TMEM177 NM_001105198 0.86 0.89 0.920.91 0.92 OTL_nm23 cg17311865 — — 0.93 0.93 0.91 0.91 0.89 OTL_nm24cg17615629 HLA-E NM_005516 0.90 0.88 0.93 0.94 0.92 OTL_nm25 cg08659421IL32 NM_001012632 0.89 0.90 0.91 0.90 0.90 OTL_nm26 cg07930673 — — 0.890.88 0.88 0.89 0.90 OTL_nm27 cg10111816 CDR2 NM_001802 0.82 0.75 0.840.85 0.86 OTL_nm28 cg25643644 CD3D NM_000732 0.88 0.89 0.89 0.91 0.88OTL_nm29 cg07630255 MPI NM_002435 0.87 0.89 0.89 0.89 0.87 OTL_nm30cg18222759 — — 0.92 0.90 0.92 0.90 0.94 OTL_nm31 cg02772121 TRIM15NM_033229 0.89 0.85 0.84 0.87 0.85 OTL_nm32 cg03274669 — — 0.87 0.870.86 0.85 0.89 OTL_nm33 cg25276892 TNRC6B NM_001024843 0.76 0.58 0.870.89 0.91 OTL_nm34 cg09232358 — — 0.88 0.89 0.89 0.85 0.86 OTL_nm35cg24215459 TNIP3 NM_001128843 0.82 0.84 0.87 0.88 0.86 OTL_nm36cg26137915 — — 0.88 0.89 0.89 0.88 0.87 OTL_nm37 cg04403423 ATP1A1NM_001160233 0.86 0.89 0.89 0.90 0.89 OTL_nm38 cg20567280 — — 0.81 0.840.85 0.83 0.81 OTL_nm39 cg27111890 UBASH3A NM_001001895 0.65 0.86 0.890.89 0.88 OTL_nm40 cg10505658 CCDC57 NM_198082 0.82 0.73 0.81 0.86 0.82OTL_nm41 cg24961795 PLCG1 NM_002660 0.86 0.86 0.85 0.84 0.82 OTL_nm42cg00027570 CD2 NM_001767 0.79 0.84 0.86 0.88 0.84 OTL_nm43 cg23318020 —— 0.81 0.85 0.85 0.86 0.85 OTL_nm44 cg14841483 ACSL6 NM_001009185 0.800.79 0.77 0.82 0.84 OTL_nm45 cg03002526 HACE1 NM_020771 0.85 0.86 0.890.85 0.85 OTL_nm46 cg17922695 SEPT9 NM_001113492 0.84 0.71 0.73 0.870.68 OTL_nm47 cg03040292 — — 0.63 0.84 0.90 0.89 0.87 OTL_nm48cg11753157 BCL11B NM_022898 0.71 0.76 0.80 0.79 0.75 OTL_nm49 cg07203767— — 0.81 0.84 0.85 0.86 0.83 OTL_nm50 cg15227911 CHD3 NM_001005271 0.700.72 0.82 0.77 0.72 OTL_nm51 cg01830053 — — 0.77 0.61 0.71 0.78 0.79OTL_nm52 cg26271776 — — 0.79 0.83 0.81 0.81 0.77 OTL_nm53 cg16239536HMHA1 NM_012292 0.84 0.82 0.83 0.82 0.81 OTL_nm54 cg08445740 FAM71BNM_130899 0.79 0.84 0.85 0.84 0.81 OTL_nm55 cg27666046 SECTM1 NM_0030040.70 0.73 0.73 0.76 0.72 OTL_nm56 cg26053876 — — 0.81 0.83 0.79 0.770.72 OTL_nm57 cg06110802 RPS3A NM_001006 0.79 0.77 0.85 0.82 0.83OTL_nm58 cg07555731 OR5AU1 NM_001004731 0.72 0.69 0.72 0.69 0.69OTL_nm59 cg13827677 SET NM_003011 0.62 0.56 0.72 0.80 0.74 OTL_nm60cg24033471 CACNA1C NM_001129844 0.66 0.68 0.71 0.71 0.66 CD4+ CD4+ CD4+Th Th CD8+ Marker- NK Th CD4+ CD4+ Central Effect. Cytotoxic NK T-Discovery ID classical B-Cells naive Th1 Th2 Mem. Mem. T-Cells CellsFragment OTL_nm18 0.84 0.97 0.07 0.02 0.02 0.03 0.03 0.03 0.07GGCTTGCGTAGT CAAGGCTGCCCG CGTGCCACGTGT GGTGGACAGCA TCG (SEQ ID NO: 1241)OTL_nm19 0.94 0.86 0.18 0.02 0.02 0.03 0.02 0.18 0.05 CGCGCCTAGCTGGCACTCCATTCA TTGCGGACACAG CCGAGCCCTCCG GG (SEQ ID NO: 1242) OTL_nm5 0.890.94 0.14 0.04 0.04 0.05 0.07 0.09 0.08 AGTCATCTGTTT TGCTTTTTTTCCAGAAGTAGTAA GTCTGCTGGCCT CCG (SEQ ID NO: 1243) OTL_nm4 0.87 0.88 0.080.04 0.04 0.04 0.05 0.04 0.06 CGGAAAAACAA AAGGCATCTGCA CCTGCAGCCCTGCTGAGGCCCCTG CTG (SEQ ID NO: 1244) OTL_nm22 0.90 0.82 0.07 0.05 0.050.04 0.04 0.05 0.10 GCATGGGTTCTG ATGGGGGCCCTG CCATAGGCCGCC TGGTGACCCACGCG (SEQ ID NO: 1245) OTL_nm23 0.89 0.82 0.18 0.00 0.03 0.05 0.02 0.120.25 CGCACATCTCAT GAATGCCATGGT ATTCCTTATTTC GTGTCAGCCCTT CC (SEQ ID NO:1246) OTL_nm24 0.74 0.77 0.08 0.04 0.05 0.02 0.04 0.03 0.08 CGCACCCAGCCGCACCTACTCTTT TGTAAAGCACCT GTGACAATGAA GGA (SEQ ID NO: 1247) OTL_nm250.80 0.83 0.16 0.06 0.05 0.04 0.06 0.06 0.07 CAAGCCCCAGG GCTCCTTGAGGAAACAACAGGGG TGCCAGACGTGG CCCG (SEQ ID NO: 1248) OTL_nm26 0.79 0.89 0.090.09 0.09 0.08 0.10 0.09 0.16 CGGGGGAGGCT GCTGAGTGGTTT TGAAATTATACAGAGCTGGATTTG AAC (SEQ ID NO: 1249) OTL_nm27 0.84 0.83 0.08 0.04 0.050.04 0.07 0.05 0.06 CTTCTGTCGTTT CAATTGGCATCT GGTGAACTATGC CTAACAGCTTAACG (SEQ ID NO: 1250) OTL_nm28 0.57 0.90 0.10 0.06 0.07 0.08 0.09 0.060.08 GGAGTTCATTGC TGGGTGTGACTG GAGAGGTCAGG CAGGAGCTCTCA TCG (SEQ ID NO:1251) OTL_nm29 0.77 0.82 0.08 0.07 0.07 0.06 0.09 0.12 0.16 AGATTTTCCCTAGCCCTGCAGCTG CCCTCCATGGAT GGACTTGTATCT CG (SEQ ID NO: 1252) OTL_nm300.90 0.81 0.19 0.11 0.10 0.11 0.10 0.16 0.17 CTGCTGTTCAGG GAAATGGCTTCCTTTCAGATGTGT TTCTCATAGTCT CG (SEQ ID NO: 1253) OTL_nm31 0.74 0.83 0.100.05 0.06 0.09 0.06 0.10 0.10 GGCGGGACGCT GTTTCGACACTG CAGGTAGGGTGTAAGGATTGCTCA TCG (SEQ ID NO: 1254) OTL_nm32 0.61 0.91 0.09 0.05 0.040.05 0.05 0.12 0.23 TGCCTGAAATGA TACAGTAGTGTA TAAACCAAGTAT CTCTGCTTGCATCG (SEQ ID NO: 1255) OTL_nm33 0.85 0.73 0.03 0.03 0.03 0.04 0.04 0.100.10 CGGTTTGCATCT CCAGCCCCCGCG GCTCACAGGCCG TGTAACTTCACT GC (SEQ ID NO:1256) OTL_nm34 0.85 0.89 0.22 0.10 0.12 0.13 0.13 0.11 0.10 CGGCCATATTCTGGCAGGGTCAG TGGCTCCAACTA ACATTTGTTTGG TAC (SEQ ID NO: 1257) OTL_nm350.55 0.63 0.09 0.04 0.05 0.05 0.06 0.04 0.05 CGAAGAATTGTA TTTGCATGTCTGAAATGAAAGCC CAGAGAATAGG GTGG (SEQ ID NO: 1258) OTL_nm36 0.57 0.86 0.120.11 0.10 0.10 0.13 0.10 0.17 TGGAAACCCCTT CAGCAGCGTATG GTGCTGGGGACCTTCTGGGGAGAT CG (SEQ ID NO: 1259) OTL_nm37 0.81 0.64 0.08 0.13 0.09 0.080.15 0.11 0.22 AAAGCATGCAG CGTGGAGGGCT GGTCCAGGTCAG GTGGCATCAAA GAGCG(SEQ ID NO: 1260) OTL_nm38 0.76 0.79 0.11 0.06 0.08 0.07 0.08 0.08 0.20CGGTACCCCAAA ATTTGGTGCTTT GACATGCTGAAC TAGAGAAGCAG CCG (SEQ ID NO: 1261)OTL_nm39 0.84 0.92 0.14 0.13 0.13 0.12 0.14 0.12 0.16 CGCATTCTTGCTCCCGAATACTAG CCAAGTCCCTAC AGAGGCTGATCC CG (SEQ ID NO: 1262) OTL_nm400.58 0.83 0.11 0.05 0.05 0.04 0.06 0.08 0.11 GCAGCCTCTGGG TGGGTGGCGGAGGCTGAGGCGA TGCTGTCCACCA CACG (SEQ ID NO: 1263) OTL_nm41 0.83 0.77 0.160.09 0.08 0.10 0.11 0.11 0.15 CGAGTCTGAACC ATCTCAACTCAG AAAACACCAGAAGAAAAAGTGT GGAG (SEQ ID NO: 1264) OTL_nm42 0.81 0.82 0.17 0.10 0.110.10 0.14 0.14 0.15 CGGTGTTTCTGC ACTGTTGATCCT GCTCTCGTCTCT GGCTACCCCCACTG (SEQ ID NO: 1265) OTL_nm43 0.51 0.83 0.11 0.08 0.04 0.07 0.09 0.090.19 CGCTGAAACTTA GCAGGCACTCA GTAAATATTTTG CTAAGCAGTTAA AAC (SEQ ID NO:1266) OTL_nm44 0.78 0.84 0.11 0.07 0.08 0.07 0.11 0.13 0.20 CGCCTGCAGAAAGTGATCTTTCC GAGACAGGACG ATGTGCTCATCT CCTT (SEQ ID NO: 1267) OTL_nm450.78 0.81 0.18 0.16 0.12 0.13 0.10 0.16 0.19 AGTCAAAGTCA AATCATGGGTAGATTCCGTCACTA ACAAAGTGAGC CACG (SEQ ID NO: 1268) OTL_nm46 0.68 0.68 0.080.03 0.04 0.03 0.06 0.04 0.13 CGTCCTGAGTTC CCAGACGTCATA GGTGCTTGCTCAACGAGTGTTTGA AT (SEQ ID NO: 1269) OTL_nm47 0.59 0.63 0.09 0.07 0.05 0.050.06 0.12 0.20 CTACCAAAGCAC TGGAGCTCATAA CAAGCTGCCTGT CCTTGGCCACCT CG(SEQ ID NO: 1270) OTL_nm48 0.87 0.70 0.08 0.08 0.05 0.05 0.07 0.09 0.23CCACTGGAGATA TACTCTACCCTG GGGAGTTAAGA TAATTGTGAGCA CCG (SEQ ID NO: 1271)OTL_nm49 0.66 0.84 0.15 0.12 0.13 0.12 0.15 0.13 0.14 CGGGCTGGGGAGGTGTAAAGAC AAATCCCGGTGA CCCTGGCCCTAA AAAG (SEQ ID NO: 1272) OTL_nm500.78 0.82 0.06 0.05 0.05 0.05 0.06 0.12 0.21 CGCGCGTGCTTT TGAGAAGGCATATGCTGGGTGTG TCTGTCTGTGCC TAT (SEQ ID NO: 1273) OTL_nm51 0.73 0.72 0.040.02 0.02 0.03 0.04 0.10 0.24 ACGCTAGTGCAG CACTTTTGAAAG TAAAAAGCACTTTGCAATAATTAA CG (SEQ ID NO: 1274) OTL_nm52 0.79 0.71 0.22 0.11 0.11 0.110.11 0.19 0.14 CGTCGTCCTGGC TAGGATCTAGCA TCTCAGTGCAAA ATGGGCTATGTA AG(SEQ ID NO: 1275) OTL_nm53 0.58 0.74 0.14 0.09 0.11 0.12 0.15 0.15 0.23AGCCCGGGGTG CAGGACTCAGA CAGAAACCTCA GGGAGGCGGGG CTGACG (SEQ ID NO: 1276)OTL_nm54 0.56 0.64 0.11 0.12 0.13 0.14 0.16 0.15 0.15 CGGTGATTCAAGACCTCCAAGAAT TCCTGTGGTTCC CAGTAAATCCCC AC (SEQ ID NO: 1277) OTL_nm550.57 0.60 0.14 0.03 0.03 0.03 0.04 0.07 0.11 CGAGGACGCCTT AGGGACGTTTTGGGGCTTAAAGCC ACTAAAGACGTT TC (SEQ ID NO: 1278) OTL_nm56 0.68 0.75 0.190.08 0.17 0.11 0.14 0.14 0.13 CGCCCACACAGT TTGGAGTTAAAC AGATCTCAACAAATGAACACAGTT AT (SEQ ID NO: 1279) OTL_nm57 0.83 0.66 0.18 0.21 0.20 0.220.21 0.15 0.23 CTGGTTCATCTC AGGTGTTGTTGC TTTGTGAACATT CACTAAGCTCTA CG(SEQ ID NO: 1280) OTL_nm58 0.61 0.55 0.16 0.09 0.08 0.12 0.12 0.15 0.12TCTTCTTAGTGA GCATGCTCATAG CTAACCTTCTTT GAACTTCCTCAA CG (SEQ ID NO: 1281)OTL_nm59 0.61 0.72 0.12 0.16 0.15 0.13 0.18 0.13 0.21 CTATCGCTTGGGGCTGTTGTGAGG CCTCGGTGAGAT AACCGTGCCATG CG (SEQ ID NO: 1282) OTL_nm600.52 0.56 0.15 0.10 0.13 0.13 0.17 0.12 0.13 TCTCTCCTTTGC TATGGGAGGGCTTGAATCTGTGGC AGCCTTCAAAAC CG (SEQ ID NO: 1283)

TABLE 41 MDSC (myeloid-derived suppressor cells) Marker EosinophilNeutrophil Non- Marker- Target Basophil Granulo- Granulo- Classicalclassical ID ID SYMBOL Accession Granulocytes cytes cytes MonocytesMonocytes MDSC_nm1 cg10317717 UPP1 NM_001287426 0.97 0.95 0.95 0.95 0.93MDSC_nm2 cg09365002 DAXX NM_001141969 0.96 0.96 0.92 0.88 0.90 MDSC_nm3cg22496559 M4SF19 NM_001204897 0.94 0.95 0.95 0.92 0.80 MDSC_nm4cg24956391 SRC NM_005417 0.79 0.82 0.87 0.77 0.54 MDSC_nm5 cg22788953TYH3 NM_025250 0.91 0.84 0.89 0.83 0.84 MDSC_nm6 cg06489615 CLCN7NM_001114331 0.91 0.88 0.87 0.85 0.77 MDSC_nm7 cg18995788 — — 0.93 0.900.92 0.65 0.63 MDSC_nm8 cg13152501 SMURF1 NM_001199847 0.91 0.91 0.910.81 0.81 MDSC_nm9 cg18129996 — — 0.88 0.89 0.90 0.90 0.90 MDSC_nm10cg20700740 — — 0.97 0.81 0.02 0.51 0.59 MDSC_nm11 cg02341139 ZC3H8NM_032494 0.90 0.91 0.92 0.87 0.88 MDSC_nm12 cg19984911 SYNPONM_001109974 0.84 0.90 0.82 0.72 0.76 MDSC_nm13 cg22137471 ATP6V1E2NM_080653 0.90 0.87 0.90 0.87 0.84 MDSC_nm14 cg08822891 SNX29 NM_0321670.84 0.77 0.51 0.72 0.76 MDSC_nm15 cg00476608 ATN1 NM_001007026 0.890.85 0.38 0.55 0.56 MDSC_nm16 cg20278790 CTSZ NM_001336 0.89 0.89 0.900.72 0.56 MDSC_nm17 cg08697732 — — 0.91 0.91 0.92 0.79 0.62 MDSC_nm18cg00864293 CMIP NM_030629 0.87 0.82 0.82 0.87 0.87 MDSC_nm19 cg14444376GPNMB NM_001005340 0.87 0.90 0.91 0.73 0.59 MDSC_nm20 cg00945409 — —0.88 0.88 0.88 0.88 0.87 MDSC_nm21 cg03366992 PDXK NM_003681 0.86 0.810.65 0.76 0.75 MDSC_nm22 cg04173586 DOT1L NM_032482 0.72 0.08 0.21 0.730.38 MDSC_nm23 cg00426089 — — 0.85 0.89 0.87 0.87 0.82 MDSC_nm24cg10864200 CGF3 NM_006315 0.34 0.47 0.60 0.58 0.65 MDSC_nm25 cg04252044— — 0.85 0.83 0.82 0.63 0.40 MDSC_nm26 cg01905967 — — 0.84 0.85 0.850.83 0.82 MDSC_nm27 cg03500164 — — 0.90 0.89 0.86 0.66 0.71 MDSC_nm28cg01734240 NANOG NM_024865 0.90 0.90 0.88 0.57 0.58 MDSC_nm29 cg09127592TRIM35 NM_171982 0.77 0.76 0.70 0.81 0.79 MDSC_nm30 cg09088625 CCR1NM_001295 0.82 0.87 0.89 0.87 0.83 MDSC_NM_31 cg17699214 APBB2NM_001166050 0.88 0.89 0.86 0.82 0.76 MDSC_nm32 cg07937803 MFSD12NM_001042680 0.71 0.51 0.90 0.90 0.85 MDSC_nm33 cg27282397 HS1BP3NM_022460 0.81 0.85 0.85 0.68 0.46 MDSC_nm34 cg01359676 RXRBNM_001270401 0.84 0.87 0.86 0.88 0.87 MDSC_nm35 cg05476182 PHF15NM_015288 0.75 0.78 0.76 0.66 0.63 MDSC_nm36 cg14812474 SORCS2 NM_0207770.80 0.83 0.85 0.82 0.74 MDSC_nm37 cg08210681 — — 0.89 0.89 0.91 0.660.45 MDSC_nm38 cg17074014 ITGAE NM_002208 0.96 0.67 0.03 0.42 0.49MDSC_nm39 cg15320001 MRAS NM_001085049 0.84 0.85 0.81 0.56 0.48MDSC_nm40 cg19399285 — — 0.85 0.86 0.86 0.83 0.86 MDSC_nm41 cg21164050 —— 0.81 0.85 0.85 0.77 0.78 MDSC_nm42 cg21204530 RGIC1 NM_001031711 0.790.84 0.82 0.86 0.88 MDSC_nm43 cg07260017 CSF1R NM_001288705 0.80 0.870.86 0.83 0.62 MDSC_nm44 cg06193597 AC104809.3 — 0.87 0.82 0.81 0.870.86 MDSC_nm45 cg26174398 — — 0.73 0.67 0.79 0.72 0.51 MDSC_nm46cg24587185 SH3RF3 NM_001099289 0.83 0.84 0.85 0.81 0.72 MDSC_nm47cg05827190 MFSD7 NM_032219 0.89 0.79 0.63 0.60 0.39 MDSC_nm48 cg03176993— — 0.80 0.79 0.73 0.58 0.42 MDSC_nm49 cg03372334 MBNL2 NM_144778 0.720.68 0.69 0.70 0.69 MDSC_nm50 cg21877464 SPARC NM_003118 0.80 0.73 0.320.48 0.44 MDSC_nm51 cg09854726 FKBP2 NM_001135208 0.90 0.72 0.82 0.710.36 MDSC_nm52 cg16490209 BCAT1 NM_001178091 0.86 0.80 0.73 0.61 0.51MDSC_nm53 cg18114313 — — 0.80 0.75 0.64 0.52 0.44 MDSC_nm54 cg22307974 —— 0.64 0.43 0.50 0.49 0.41 MDSC_nm55 cg19132462 AMPD3 NM_000480 0.630.06 0.07 0.44 0.37 MDSC_nm56 cg12229979 MYO9B NM_001130065 0.68 0.390.76 0.63 0.53 MDSC_nm57 cg06093152 — — 0.82 0.53 0.47 0.48 0.33 CD4+CD4+ NK CD4+ Th Th CD4+ Marker- NK bright NK B- Th CD4+ CD4+ CentralEffect NK T CD4+ ID classical NKB_1 NKB_2 bright Cells MDSC naive act.CD4+ Th1 Th2 Mem. Mem. cells TFH MDSC_nm1 0.95 0.96 0.93 0.94 0.97 0.150.95 0.92 0.93 0.95 0.96 0.95 0.83 0.90 MDSC_nm2 0.96 0.96 0.95 0.950.96 0.21 0.96 0.95 0.96 0.97 0.97 0.96 0.92 0.94 MDSC_nm3 0.76 0.910.86 0.88 0.82 0.28 0.93 0.91 0.93 0.94 0.93 0.94 0.79 0.91 MDSC_nm40.93 0.91 0.78 0.85 0.56 0.10 0.94 0.75 0.82 0.82 0.85 0.84 0.80 0.62MDSC_nm5 0.95 0.89 0.88 0.89 0.94 0.29 0.94 0.90 0.92 0.92 0.94 0.950.88 0.90 MDSC_nm6 0.92 0.91 0.93 0.92 0.93 0.35 0.93 0.92 0.92 0.920.92 0.92 0.91 0.91 MDSC_nm7 0.95 0.95 0.97 0.96 0.98 0.21 0.98 0.870.90 0.92 0.95 0.95 0.88 0.91 MDSC_nm8 0.91 0.92 0.89 0.91 0.92 0.360.91 0.90 0.91 0.90 0.91 0.91 0.90 0.88 MDSC_nm9 0.89 0.89 0.89 0.890.91 0.37 0.92 0.90 0.89 0.89 0.91 0.90 0.90 0.90 MDSC_nm10 0.98 0.980.95 0.96 0.98 0.17 0.84 0.97 0.98 0.98 0.97 0.98 0.94 0.97 MDSC_nm110.90 0.90 0.84 0.87 0.90 0.28 0.92 0.88 0.86 0.88 0.90 0.88 0.84 0.89MDSC_nm12 0.89 0.92 0.89 0.90 0.91 0.29 0.92 0.89 0.90 0.89 0.91 0.900.89 0.91 MDSC_nm13 0.87 0.89 0.89 0.89 0.87 0.19 0.88 0.89 0.88 0.880.88 0.88 0.89 0.89 MDSC_nm14 0.90 0.89 0.90 0.90 0.91 0.27 0.91 0.900.86 0.89 0.87 0.88 0.78 0.88 MDSC_nm15 0.92 0.90 0.92 0.91 0.88 0.250.91 0.86 0.89 0.89 0.90 0.90 0.88 0.89 MDSC_nm16 0.89 0.86 0.83 0.840.47 0.33 0.90 0.86 0.87 0.89 0.89 0.89 0.84 0.87 MDSC_nm17 0.88 0.890.88 0.89 0.83 0.23 0.91 0.82 0.85 0.87 0.85 0.87 0.87 0.86 MDSC_nm180.89 0.90 0.88 0.89 0.91 0.28 0.92 0.73 0.73 0.77 0.78 0.77 0.76 0.68MDSC_nm19 0.87 0.83 0.81 0.82 0.84 0.22 0.93 0.81 0.87 0.88 0.88 0.860.78 0.84 MDSC_nm20 0.87 0.89 0.81 0.85 0.86 0.18 0.88 0.80 0.81 0.840.84 0.85 0.78 0.83 MDSC_nm21 0.86 0.83 0.87 0.85 0.89 0.25 0.88 0.810.84 0.83 0.83 0.84 0.84 0.80 MDSC_nm22 0.90 0.96 0.95 0.95 0.78 0.210.98 0.92 0.96 0.96 0.96 0.96 0.92 0.93 MDSC_nm23 0.85 0.79 0.75 0.770.62 0.33 0.89 0.81 0.84 0.85 0.86 0.87 0.76 0.81 MDSC_nm24 0.88 0.880.86 0.87 0.87 0.33 0.92 0.89 0.93 0.93 0.93 0.94 0.87 0.87 MDSC_nm250.87 0.90 0.89 0.90 0.88 0.17 0.89 0.80 0.85 0.87 0.85 0.81 0.82 0.71MDSC_nm26 0.87 0.88 0.87 0.87 0.85 0.33 0.91 0.86 0.87 0.89 0.84 0.810.76 0.89 MDSC_nm27 0.84 0.74 0.80 0.77 0.87 0.23 0.91 0.75 0.86 0.890.91 0.91 0.75 0.79 MDSC_nm28 0.87 0.81 0.74 0.78 0.87 0.26 0.90 0.790.83 0.84 0.84 0.82 0.79 0.79 MDSC_nm29 0.83 0.86 0.79 0.82 0.92 0.280.91 0.82 0.88 0.88 0.88 0.86 0.80 0.82 MDSC_nm30 0.81 0.64 0.74 0.690.85 0.28 0.88 0.83 0.86 0.85 0.86 0.86 0.77 0.83 MDSC_NM_31 0.89 0.880.87 0.88 0.90 0.16 0.91 0.70 0.76 0.77 0.74 0.76 0.76 0.74 MDSC_nm320.90 0.88 0.89 0.88 0.84 0.21 0.91 0.76 0.76 0.79 0.83 0.81 0.80 0.85MDSC_nm33 0.84 0.81 0.88 0.84 0.81 0.25 0.85 0.81 0.82 0.83 0.82 0.830.84 0.82 MDSC_nm34 0.85 0.83 0.84 0.83 0.82 0.25 0.86 0.70 0.75 0.740.75 0.75 0.73 0.61 MDSC_nm35 0.84 0.85 0.82 0.84 0.85 0.26 0.88 0.800.81 0.82 0.81 0.81 0.76 0.77 MDSC_nm36 0.83 0.75 0.71 0.73 0.83 0.240.87 0.75 0.79 0.79 0.78 0.79 0.68 0.77 MDSC_nm37 0.85 0.82 0.82 0.820.83 0.13 0.88 0.73 0.82 0.83 0.85 0.83 0.80 0.75 MDSC_nm38 0.84 0.890.89 0.89 0.98 0.19 0.93 0.68 0.93 0.92 0.92 0.91 0.86 0.81 MDSC_nm390.81 0.81 0.81 0.81 0.81 0.28 0.87 0.84 0.80 0.82 0.83 0.83 0.78 0.83MDSC_nm40 0.86 0.88 0.85 0.86 0.83 0.28 0.88 0.66 0.76 0.69 0.77 0.730.76 0.69 MDSC_nm41 0.83 0.84 0.85 0.85 0.82 0.25 0.91 0.73 0.69 0.800.82 0.74 0.73 0.75 MDSC_nm42 0.78 0.85 0.85 0.85 0.85 0.21 0.85 0.670.63 0.68 0.71 0.69 0.70 0.61 MDSC_nm43 0.77 0.83 0.84 0.83 0.82 0.220.88 0.63 0.67 0.66 0.67 0.68 0.61 0.68 MDSC_nm44 0.84 0.90 0.92 0.910.55 0.16 0.78 0.42 0.62 0.65 0.45 0.13 0.79 0.55 MDSC_nm45 0.79 0.830.84 0.84 0.70 0.14 0.84 0.61 0.65 0.57 0.64 0.61 0.71 0.59 MDSC_nm460.70 0.75 0.73 0.74 0.83 0.19 0.84 0.57 0.54 0.64 0.66 0.63 0.52 0.54MDSC_nm47 0.88 0.91 0.87 0.89 0.83 0.25 0.90 0.71 0.77 0.77 0.79 0.790.78 0.74 MDSC_nm48 0.83 0.84 0.79 0.81 0.81 0.18 0.88 0.78 0.75 0.820.81 0.81 0.78 0.70 MDSC_nm49 0.83 0.79 0.80 0.79 0.76 0.19 0.70 0.880.80 0.80 0.74 0.87 0.68 0.72 MDSC_nm50 0.83 0.84 0.83 0.83 0.84 0.200.86 0.74 0.75 0.78 0.79 0.80 0.75 0.78 MDSC_nm51 0.88 0.88 0.82 0.850.55 0.19 0.91 0.68 0.71 0.75 0.78 0.79 0.68 0.70 MDSC_nm52 0.77 0.860.80 0.83 0.87 0.21 0.87 0.74 0.61 0.80 0.77 0.72 0.68 0.77 MDSC_nm530.83 0.83 0.84 0.84 0.35 0.21 0.88 0.70 0.64 0.77 0.72 0.70 0.71 0.73MDSC_nm54 0.74 0.69 0.69 0.69 0.69 0.17 0.81 0.71 0.76 0.81 0.77 0.810.65 0.73 MDSC_nm55 0.84 0.87 0.81 0.84 0.51 0.15 0.73 0.82 0.76 0.810.77 0.76 0.68 0.82 MDSC_nm56 0.63 0.76 0.66 0.71 0.71 0.15 0.88 0.740.77 0.73 0.72 0.72 0.74 0.66 MDSC_nm57 0.78 0.85 0.83 0.84 0.75 0.140.90 0.59 0.59 0.69 0.68 0.63 0.61 0.45 CD8+ CD8+ CD8+ Cytotoxic CD8+ ThTh CD8+ NK Marker- T- naive CD8+ Central Effect. TE NK T T- Discovery IDCells T8n_1 act. Mem. Mem. MRA cells Cells Fragment MDSC_nm1 0.96 0.940.95 0.94 0.95 0.94 0.88 0.89 CGCCTGGAGC GCCTCCCACTG CAGACGTCTGTCCGCCTCCAGC CGCTCTC (SEQ ID NO: 1284) MDSC_nm2 0.97 0.96 0.95 0.96 0.960.96 0.95 0.96 CGCCGGGCCA ACACAGGATCT GATAGTGCAG GGTCAACGCCT ACGTGGGA(SEQ ID NO: 1285) MDSC_nm3 0.87 0.93 0.92 0.82 0.88 0.60 0.59 0.72CGCGCCCCCAC GCCCCTGCCCA CAGGCCTGCAT TGAAGGCGCTT CCGCTC (SEQ ID NO: 1286)MDSC_nm4 0.93 0.91 0.83 0.88 0.87 0.91 0.81 0.87 AAGGATGGCA TCCATCCGTAAAGGGCTTCCTC GGTCCAGCGCC AGGAACG (SEQ ID NO: 1287) MDSC_nm5 0.95 0.940.91 0.88 0.93 0.95 0.93 0.93 CGCGGCCGAG CTGTCTGTCCA AGCCTGGGCCCCAGCACCCAG CGCAAGCT (SEQ ID NO: 1288) MDSC_nm6 0.93 0.90 0.92 0.90 0.910.90 0.91 0.91 GAGTGTTGGCT CACGTGTTCCT GAGCCTGTCTG TTTTTAGTTAG TGTCCG(SEQ ID NO: 1289) MDSC_nm7 0.95 0.96 0.83 0.92 0.88 0.87 0.85 0.90CGGGCAGATA CGAGCAGATT GACTCGCCAG GACTGTCATTG GGCCACCGC (SEQ ID NO: 1290)MDSC_nm8 0.92 0.91 0.90 0.91 0.91 0.90 0.91 0.91 CTGACCTCATC CCGGAGGCCGCTTCAGTTCTC GAATGGATGTC TCTTCCG (SEQ ID NO: 1291) MDSC_nm9 0.91 0.880.90 0.87 0.88 0.87 0.89 0.90 CGCCACAGGA ATGGCTCTTAT GATCCTTTTGGATGGCTAGATT TCTGAAA (SEQ ID NO: 1292) MDSC_nm10 0.96 0.93 0.97 0.98 0.970.98 0.97 0.98 CCTCCTGTGAG CAACCTTTCGG CGTCTGCAGAG CTCGTGGCGTA AGAGCG(SEQ ID NO: 1293) MDSC_nm11 0.91 0.89 0.88 0.89 0.83 0.83 0.82 0.85CGACAGCAAT CCCGTGAGAA ACTGTGGGAC AGAACCACCC AGCTAAGCAG (SEQ ID NO: 1294)MDSC_nm12 0.92 0.90 0.89 0.89 0.85 0.89 0.88 0.89 CGGCAAAGGC AGCCAATTGCTTGGCTGACGA AGCCAGGAAA ATCCCACAT (SEQ ID NO: 1295) MDSC_nm13 0.89 0.880.89 0.86 0.86 0.86 0.88 0.88 AAAGAATGAG GTCACTGTCAC CAATGAAGTCACCACTGCATG ATTCATCG (SEQ ID NO: 1296) MDSC_nm14 0.91 0.91 0.91 0.900.88 0.87 0.87 0.88 TGTGGATTCCT CCAAACTGTGA TTGCTACATCT TAATTTTCAGCAGGACG (SEQ ID NO: 1297) MDSC_nm15 0.90 0.90 0.88 0.89 0.89 0.90 0.900.90 AGATACTGGG GGACGTGCTTC GGTTGTCCTGG TCGATATCCCT AGGGTCG (SEQ ID NO:1298) MDSC_nm16 0.89 0.90 0.85 0.87 0.84 0.86 0.86 0.88 TGGCAAGTCGCTCATGGAAACC ATTAGTGTCCA TCAGTCATCAG AAGGCG (SEQ ID NO: 1299) MDSC_nm170.86 0.91 0.80 0.82 0.80 0.78 0.75 0.76 CCATAGCACCC CCATAATAAAGCAGCCCGTG AGGGCAGCCT GGCTGTTCG (SEQ ID NO: 1300) MDSC_nm18 0.87 0.910.80 0.89 0.86 0.87 0.83 0.84 CGGAGCAGGC CACAGTCAGG GTGGAAGAAAACGAGGGAAG ACTGAGAAAC (SEQ ID NO: 1301) MDSC_nm19 0.89 0.86 0.81 0.780.81 0.83 0.77 0.85 CGGCACTGCCT GATCTGGTCTC TCAAGTTCAAC CTCTTACAACTCATGTG (SEQ ID NO: 1302) MDSC_nm20 0.86 0.86 0.79 0.80 0.78 0.64 0.790.80 GCCTTGTCCTG GGGCTGAGCA GTGGTGCAACC CAGCCCTGAG GAATTCCG (SEQ ID NO:1303) MDSC_nm21 0.87 0.87 0.84 0.86 0.79 0.84 0.85 0.85 CCACCTGAGGTGAGCAATCAG AGGACACCCCT CGAGTCACTGG GAGTTCG (SEQ ID NO: 1304) MDSC_nm220.97 0.95 0.92 0.88 0.94 0.97 0.90 0.96 CGGCACAGTCC CGCCCACCACTAGAAAGCCCG CTCCCGCCAGC TCTCGCC (SEQ ID NO: 1305) MDSC_nm23 0.89 0.840.83 0.80 0.78 0.83 0.74 0.85 AGCTTTGTATA GATGCATGCAC TTGGAAACCAGCAAAGCTAA AAATACCG (SEQ ID NO: 1306) MDSC_nm24 0.93 0.90 0.92 0.86 0.910.89 0.93 0.93 CGCAGGAGCG CACACACGTTC CCACACGCCAC TCAATTCCAGA ACAACGG(SEQ ID NO: 1307) MDSC_nm25 0.91 0.87 0.85 0.90 0.82 0.85 0.85 0.86GTATGTGTGAG TCAATCTAATG TGCCCTCCCTC AGCATAATCCT GTCACG (SEQ ID NO: 1308)MDSC_nm26 0.86 0.87 0.86 0.87 0.71 0.45 0.53 0.66 TGGAAATCTCTTTCGTCAAGGC CTCTAGTGACC GCTGGGGATTC TTCTCG (SEQ ID NO: 1309) MDSC_nm270.90 0.80 0.78 0.76 0.78 0.78 0.74 0.86 TCATACATTTC AACTTGCTGCTGTTCTGAGTAG CGTGATGAAAT CTTGCG (SEQ ID NO: 1310) MDSC_nm28 0.86 0.870.80 0.77 0.84 0.76 0.81 0.82 CGGAGTAGTCT TGAAAGACAT GACAAATCACCAGACCTGGG AAGAAGCTA (SEQ ID NO: 1311) MDSC_nm29 0.66 0.44 0.80 0.830.89 0.86 0.85 0.90 GGCGGCGGGG CACAGCGTGG GGGTGTGCAGT GACTGAGAGATGGTTCACG (SEQ ID NO: 1312) MDSC_nm30 0.85 0.86 0.84 0.81 0.49 0.84 0.680.64 GAATGATCTCT GCACTGTAGG ACATCCTTGGC CCTGCCTACCA AATGACG (SEQ ID NO:1313) MDSC_NM_31 0.83 0.88 0.74 0.78 0.75 0.78 0.80 0.78 CGGCTGTTCCAGACCCTAATGA GTTCAGTTGTC CTACAAAGCA GGAAGAG (SEQ ID NO: 1314) MDSC_nm320.84 0.90 0.70 0.84 0.72 0.68 0.71 0.69 CGGGGTGTCAC TCCTACAAGACAAGAAAAGCC CAGGATTGCTG GCCAATG (SEQ ID NO: 1315) MDSC_nm33 0.85 0.830.81 0.79 0.78 0.77 0.80 0.82 ATACACAGTTC CCTGCACACAC TCGGCTAACTGTGACCAGGGT GAGAGCG (SEQ ID NO: 1316) MDSC_nm34 0.86 0.85 0.78 0.78 0.790.82 0.81 0.80 ATGACCCTGTG ACTAACATCTG TCAGGCAGCTG ACAAACAGCT ATTCACG(SEQ ID NO: 1317) MDSC_nm35 0.87 0.87 0.85 0.79 0.79 0.83 0.81 0.81CTGTTAGGCAG AGCAGCCTAAT GGGAGCAGTG TGACTCATGGA CCTCACG (SEQ ID NO: 1318)MDSC_nm36 0.83 0.82 0.79 0.79 0.76 0.81 0.77 0.76 TCATCCAAGCTTGTGTGAGTCA CAATGAGCAG AAAGCATTCTT CCACCCG (SEQ ID NO: 1319) MDSC_nm370.84 0.87 0.72 0.75 0.69 0.76 0.64 0.77 CGGCCCCAGC ACTGCAAAGCTGTCATCGCTCC TCTCCAGGGAG CCATCCT (SEQ ID NO: 1320) MDSC_nm38 0.80 0.840.56 0.80 0.83 0.96 0.85 0.89 CGGCCCATGTG TCGCACTCGCC TCGGCTCCCACACAGCCGCCTC TGCTCC (SEQ ID NO: 1321) MDSC_nm39 0.80 0.78 0.83 0.79 0.760.80 0.81 0.81 CTACTTTCAAT CTCTATGGATT TCCCTATTCAG GACATTTTCTA TAAACG(SEQ ID NO: 1322) MDSC_nm40 0.79 0.87 0.61 0.66 0.67 0.77 0.73 0.74TATGCTTACTC CCTCTCCCTCT TGTCTGTGTCC CTGTGTGGCCT GAAGCG (SEQ ID NO: 1323)MDSC_nm41 0.82 0.87 0.72 0.78 0.62 0.52 0.56 0.53 CGGAGAGCCA ACACCACCAGTCAGTCACCCAA GCTGGAAATTT AAGCATC (SEQ ID NO: 1324) MDSC_nm42 0.76 0.850.73 0.71 0.70 0.78 0.67 0.71 CGTCTGCAAGA ACAGGGGAGA ACTAAGGTCCCAAGCAGCAAA AGTTAAAA (SEQ ID NO: 1325) MDSC_nm43 0.79 0.86 0.62 0.69 0.670.67 0.70 0.68 CGGCATCTTCA TTTGAGTGGGT GCGGGAAGGA CCTCATTTTGG AACCACA(SEQ ID NO: 1326) MDSC_nm44 0.52 0.91 0.38 0.88 0.82 0.67 0.83 0.74CGCGTGCCTCT GTGCAGTCAGT GAGAAGGGCT CCCGTTCAGAA TGGGCAG (SEQ ID NO: 1327)MDSC_nm45 0.76 0.84 0.65 0.72 0.62 0.60 0.65 0.63 CGTGAGCCAG AGAGAGCTGGCTTTCAGTGTT GTCACCATGGT TACTGCTA (SEQ ID NO: 1328) MDSC_nm46 0.77 0.820.57 0.66 0.55 0.56 0.56 0.63 CGACTGCTCCT CTGGCAAGCA GGACCCATTTCTAAAGCATGA GTCACTAC (SEQ ID NO: 1329) MDSC_nm47 0.83 0.89 0.75 0.77 0.750.79 0.79 0.78 CGCTTCAGACG CATCTCTTCTC AGTGAGTCAG CTGTGGGCCCC ACTCAGG(SEQ ID NO: 1330) MDSC_nm48 0.85 0.87 0.85 0.82 0.80 0.77 0.72 0.72CGGAAAACTT GCTAATGCTGG CTGATTCTCAT TGCTGGGTTTA CTAGTTC (SEQ ID NO: 1331)MDSC_nm49 0.56 0.85 0.88 0.81 0.85 0.86 0.85 0.70 CGCTTTATGGA GCAGCAAAGAAAGTAGTTTCT TGAGATGGGTT CTACTCT (SEQ ID NO: 1332) MDSC_nm50 0.82 0.870.69 0.78 0.76 0.76 0.76 0.76 TAAAATTATTT TTTTCCCTAAA CCCAATCTCTCCTCTTCCTCCT CTGTCG (SEQ ID NO: 1333) MDSC_nm51 0.82 0.89 0.70 0.73 0.690.62 0.74 0.68 CGCTGTCAGGA ATTGTCTCCTG GTTCAACCCAC TCCTGCCTTAG GCCCAC(SEQ ID NO: 1334) MDSC_nm52 0.79 0.89 0.72 0.67 0.61 0.59 0.60 0.57CGATGGTGAG CAAAAGGTGTT GACAGGCCTG GCATGGTGACT CACCCCTG (SEQ ID NO: 1335)MDSC_nm53 0.80 0.87 0.70 0.79 0.69 0.63 0.69 0.64 TCCAAGTCACACAGCCCTTAAA TGAGCCACCA GGTTACCTTTG CATCACG (SEQ ID NO: 1336) MDSC_nm540.81 0.77 0.73 0.70 0.73 0.73 0.72 0.74 CGGAGGCCCA GAGAAGGGAAGTGACATGCTC AAGGTAACAC TGCTAACCA (SEQ ID NO: 1337) MDSC_nm55 0.86 0.870.84 0.85 0.78 0.77 0.75 0.71 CGTGAGGTTGT GTCTTACTGAG CTCACATCATAATTCCTGTGTG CACAGA (SEQ ID NO: 1338) MDSC_nm56 0.79 0.84 0.75 0.72 0.700.61 0.63 0.63 CGAGGACAGT TCCTCCAGAAA TCCAGGTCAGT CACAAGACAA AGAAAAGA(SEQ ID NO: 1339) MDSC_nm57 0.76 0.88 0.65 0.69 0.52 0.68 0.57 0.47CGGCCTCTGAG AGCTGACACG GAACTTGCATC ATTTCTGATGC TTGGCTC (SEQ ID NO: 1340)

TABLE 4J Total Lymphocytes Marker Non- Marker- Basophil EosinophilNeutrophil Classical classical ID TargetID SYMBOL Accession GranulocytesGranulocytes Granulocytes Monocytes Monocytes LYMP_nm1 cg14437551 LTANM_000595 0.94 0.96 0.95 0.95 0.96 LYMP_nm2 cg02668248 KLF2 NM_0162700.89 0.90 0.93 0.90 0.80 LYMP_nm3 cg00446123 LIME1 NM_017806 0.78 0.680.89 0.78 0.72 LYMP_nm4 cg21959598 VOPP1 NM_030796 0.84 0.81 0.89 0.870.84 LYMP_nm5 cg17161520 TBC1D10C NM_198517 0.83 0.82 0.81 0.79 0.73LYMP_nm6 cg03961551 RUNX3 NM_001031680 0.61 0.77 0.85 0.85 0.79 LYMP_nm7cg04450994 SLC22A23 NM_021945 0.53 0.78 0.79 0.77 0.81 LYMP_nm8cg18920397 LY9 NM_001033667 0.81 0.83 0.83 0.68 0.63 LYMP_nm9 cg18825221RAD51L1 NM_133509 0.64 0.66 0.73 0.71 0.65 LYMP_nm10 cg11327657 C21orf70NM_058190 0.02 0.02 0.01 0.02 0.04 LYMP_nm11 cg11597902 — — 0.03 0.020.10 0.03 0.06 LYMP_nm12 cg21159128 SSBP3 NM_001009955 0.03 0.01 0.000.02 0.05 LYMP_nm13 cg05327789 SLCO4A1 NM_016354 0.03 0.01 0.01 0.010.07 LYMP_nm14 cg26709988 CRISPLD2 NM_031476 0.19 0.03 0.03 0.04 0.09LYMP_nm15 cg05260077 — — 0.05 0.03 0.03 0.02 0.06 LYMP_nm16 cg10690440 —— 0.13 0.24 0.06 0.02 0.06 LYMP_nm17 cg20429104 ZNF516 NM_014643 0.280.05 0.02 0.04 0.08 LYMP_nm18 cg02862467 UBR4 NM_020765 0.07 0.03 0.030.04 0.09 LYMP_nm19 cg00500359 OSBPL5 NM_020896 0.04 0.02 0.01 0.16 0.26LYMP_nm20 cg11186858 — — 0.11 0.05 0.28 0.05 0.10 LYMP_nm21 cg15085899NCOR2 NM_006312 0.03 0.06 0.01 0.01 0.01 LYMP_nm22 cg08400494 CARS2NM_024537 0.04 0.02 0.04 0.15 0.11 LYMP_nm23 cg19851816 TUBGCP6NM_020461 0.02 0.02 0.00 0.01 0.03 LYMP_nm24 cg23568192 — — 0.05 0.040.02 0.05 0.10 LYMP_nm25 cg00168694 ETS2 NM_005239 0.06 0.07 0.04 0.040.08 LYMP_nm26 cg06298740 — — 0.07 0.10 0.04 0.04 0.09 LYMP_nm27cg20078972 BRD4 NM_058243 0.05 0.04 0.03 0.04 0.06 LYMP_nm28 cg26942829GFOD1 NM_018988 0.06 0.07 0.05 0.05 0.11 LYMP_nm29 cg03408945 C16orf68NM_024109 0.26 0.01 0.01 0.01 0.06 LYMP_nm30 cg06373940 ERCC3 NM_0001220.06 0.05 0.06 0.06 0.14 LYMP_nm31 cg25576997 C14orf34 NR_026796 0.050.04 0.04 0.04 0.08 LYMP_nm32 cg11703212 TFDP1 NR_026580 0.07 0.05 0.060.09 0.13 LYMP_nm33 cg06474225 HTRA1 NM_002775 0.03 0.21 0.06 0.02 0.04LYMP_nm34 cg04739200 MYB NM_005375 0.10 0.04 0.03 0.05 0.08 LYMP_nm35cg07283015 HRH4 NM_021624 0.08 0.06 0.04 0.07 0.15 LYMP_nm36 cg10456459ETNK1 NM_018638 0.11 0.15 0.06 0.05 0.11 LYMP_nm37 cg20312012 FER1L5NM_001113382 0.08 0.08 0.06 0.05 0.08 LYMP_nm38 cg04478251 ABR NM_0219620.44 0.11 0.14 0.07 0.10 LYMP_nm39 cg06030535 — — 0.05 0.05 0.05 0.050.06 LYMP_nm40 cg07714276 RREB1 NM_001003700 0.14 0.06 0.06 0.05 0.08LYMP_nm41 cg17344091 TRIM27 NM_006510 0.26 0.05 0.02 0.02 0.05 LYMP_nm42cg02353916 LOC285550 NM_001145191 0.04 0.02 0.07 0.03 0.07 LYMP_nm43cg23506143 — — 0.12 0.08 0.06 0.04 0.05 LYMP_nm44 cg13086983 ECE1NM_001113348 0.06 0.07 0.04 0.05 0.09 LYMP_nm45 cg12249234 KSR1NM_014238 0.08 0.05 0.04 0.04 0.08 LYMP_nm46 cg13381110 PHLPP1 NM_1944490.12 0.08 0.06 0.06 0.14 LYMP_nm47 cg01990910 SNX29 NM_001080530 0.010.03 0.02 0.01 0.03 LYMP_nm48 cg25103337 H6PD NM_004285 0.04 0.04 0.020.02 0.05 CD4+ CD4+ CD4+ Th Th CD8+ Marker- NK Th CD4+ CD4+ CentralEffect. Cytotoxic NK T- ID classical B-Cells naive Th1 Th2 Mem. Mem.T-Cells Cells Discovery Fragment LYMP_nm1 0.13 0.04 0.11 0.02 0.02 0.020.03 0.04 0.03 AGAGGAAGCGGC AGTGGCAGCGTGG CAGGCAGCGGGCG GGTTCTAGGTCG(SEQ ID NO: 1341) LYMP_nm2 0.04 0.06 0.10 0.02 0.03 0.02 0.06 0.03 0.05CGTGCCTTCTCGC GCTCCGATCACCT GGCGCTGCACATG AAACGGCACAT (SEQ ID NO: 1342)LYMP_nm3 0.03 0.05 0.05 0.03 0.03 0.03 0.03 0.02 0.02 TCAGAACAGTGCGGGCTAGAGGCGCA CACGTTTCATCTA GGCTTCGGGCG (SEQ ID NO: 1343) LYMP_nm4 0.080.12 0.17 0.10 0.11 0.13 0.12 0.17 0.08 ATAAAAGCAACCC AGGGAGCTATTTGGTGGCTTCTGGCT TCTGACTGCCG (SEQ ID NO: 1344) LYMP_nm5 0.08 0.05 0.09 0.110.08 0.10 0.15 0.05 0.09 GGTGCTCACTGGC TCCAGACGTGGAT CTGCAGCTGGGAATCAAGTGATCG (SEQ ID NO: 1345) LYMP_nm6 0.08 0.13 0.08 0.06 0.06 0.070.08 0.07 0.07 TTTCCCAGTCAGC AGGATGGGCACTG CAGATGTGTGTCT GCATGCCAGCG(SEQ ID NO: 1346) LYMP_nm7 0.04 0.17 0.03 0.01 0.03 0.03 0.03 0.04 0.02CGGGCTCTCACAC GTGGGCCACCATC CGCCTGCCCCAGT CACCCCGGGGC (SEQ ID NO: 1347)LYMP_nm8 0.08 0.14 0.09 0.05 0.05 0.05 0.07 0.05 0.06 CGCAGGCAGGTAGAGGTCCCAAGTCT ATTCAGGGCCTCA TTTGTGACTGA (SEQ ID NO: 1348) LYMP_nm9 0.110.04 0.04 0.02 0.03 0.02 0.03 0.04 0.07 AGAAAGCACCACA GGTAATAAAAACACCTAAAAAGGTCA GCAGAAACTCG (SEQ ID NO: 1349) LYMP_nm10 0.94 0.97 0.950.97 0.96 0.98 0.96 0.96 0.97 CGCAACCCCCAGT GACACAACCCCCA GTGACGCAACCCCGCCACCCAATG (SEQ ID NO: 1350) LYMP_nm11 0.95 0.95 0.94 0.96 0.96 0.950.95 0.97 0.96 CGAGGAGCGGGCG TGCTGCGCTGCTT CTCTTTGAGTCATC TGGGTCCTCG(SEQ ID NO: 1351) LYMP_nm12 0.95 0.86 0.95 0.93 0.92 0.94 0.93 0.96 0.93CGACAATGTAAGC CTCGCCCCCTGCC TGTTGCTCTCGTCC CCACGGCCTG (SEQ ID NO: 1352)LYMP_nm13 0.82 0.95 0.95 0.94 0.95 0.93 0.95 0.96 0.87 CGGCCACGGCGGGCACTCAGCATTTC CTGATGACAGAAC AGTGCCGTTGG (SEQ ID NO: 1353) LYMP_nm14 0.960.96 0.95 0.96 0.96 0.97 0.95 0.97 0.97 CGCAAAAGCCTTG CAACACACAACAGCACAGACAAACCC CGCAGACACGG (SEQ ID NO: 1354) LYMP_nm15 0.90 0.91 0.900.91 0.90 0.89 0.89 0.92 0.90 ATTTCGAAATAAA GGAGCTTGCATGA ATGACGATTTCCAAACTTCTCTCG (SEQ ID NO: 1355) LYMP_nm16 0.95 0.97 0.96 0.96 0.97 0.980.96 0.97 0.95 CCTGCGCTCTGAC ACCAGCCGTGTAA GGGCACAGACTCG GCTGCTGTTCG(SEQ ID NO: 1356) LYMP_nm17 0.96 0.97 0.96 0.96 0.96 0.97 0.96 0.96 0.93CGTTCAGATCTGT TGCGACTCTTCAG ATCACTTCCCGTTT TGCAATCACG (SEQ ID NO: 1357)LYMP_nm18 0.90 0.86 0.90 0.92 0.91 0.92 0.93 0.93 0.92 CACATCCTGCCCCCTGAGCAGTGGAG AGCCACACGTGTG GAAATCTTGCG (SEQ ID NO: 1358) LYMP_nm19 0.920.97 0.96 0.96 0.96 0.97 0.96 0.97 0.96 CGCCCACTTTGCC GGTGGGACAGAGTGGCTGACGGCGTG TGGCACAGGCG (SEQ ID NO: 1359) LYMP_nm20 0.95 0.95 0.960.97 0.98 0.97 0.96 0.98 0.97 CGCACTAACGTGA ATGCCGCATGTAC AGATGACCACAGTGCTCGGAGGGT (SEQ ID NO: 1360) LYMP_nm21 0.72 0.43 0.89 0.97 0.97 0.980.96 0.97 0.97 GAGTGGCAGAGGC GAGAACGGATCGC TGGAGGCCCGACG TCTCGTTCACG(SEQ ID NO: 1361) LYMP_nm22 0.95 0.83 0.93 0.95 0.95 0.94 0.94 0.96 0.94ATATTTAAGGCAT CGCCCCTCAGGGA GCCGAGCACTGAT TTCCACAGCCG (SEQ ID NO: 1362)LYMP_nm23 0.85 0.62 0.83 0.89 0.92 0.90 0.92 0.92 0.93 CGTGCGTGCTCCATCTCCCGCAGCCG AGCCGCCCATTGC TCATCTTTTGC (SEQ ID NO: 1363) LYMP_nm24 0.890.87 0.90 0.89 0.88 0.90 0.90 0.94 0.91 AGCGGGTAAGTAA TGCATTCAAGGTTGCACAACTAGTAA ATGCTTCATCG (SEQ ID NO: 1364) LYMP_nm25 0.84 0.93 0.920.90 0.91 0.91 0.92 0.93 0.87 CGTGGGATCCCAT GCCACCTTCCTGC CAAATGACCATGTGTAAATTGCTT (SEQ ID NO: 1365) LYMP_nm26 0.90 0.91 0.91 0.91 0.91 0.910.92 0.92 0.92 CGAACCAGGAACT CTCTTATTCCATGG ACTGTGGTCTGGG TCAGTAGGCT(SEQ ID NO: 1366) LYMP_nm27 0.87 0.88 0.88 0.89 0.89 0.89 0.90 0.90 0.87CGGCTTCTTTAATT GTGCAATCTGTGT CAGTGGGGAAGCA CAAATAGGAT (SEQ ID NO: 1367)LYMP_nm28 0.90 0.91 0.91 0.90 0.90 0.91 0.90 0.92 0.90 CGGAGATTGCCCAACCAAAGAGCAGA AGTTCACAGAATA TCTCTTCTTGG (SEQ ID NO: 1368) LYMP_nm29 0.820.88 0.85 0.94 0.93 0.92 0.93 0.92 0.96 CGGGCTCCACCAC GAAGCGCAGCTTGCCATCTGCGAGCT GCTCCAGCGCG (SEQ ID NO: 1369) LYMP_nm30 0.90 0.84 0.900.92 0.92 0.94 0.91 0.93 0.92 GTATTTGTTACAG CAGTACCCTATTC CCCGTACCAAAAATCTGTGTTACG (SEQ ID NO: 1370) LYMP_nm31 0.91 0.86 0.91 0.85 0.85 0.880.86 0.90 0.90 AATGATGAAATCC AGCCATTCTGACA CTGTTCCTTATCTA GGATCTCTCG(SEQ ID NO: 1371) LYMP_nm32 0.91 0.89 0.92 0.92 0.91 0.93 0.91 0.92 0.94GAGTCTGGAGAGA GCAATGTCTCCAT GGAGCGGGTGCCT GGCTGTGGTCG (SEQ ID NO: 1372)LYMP_nm33 0.93 0.93 0.92 0.87 0.88 0.90 0.89 0.89 0.84 CGGCGAATCTCATCAAACTTTGAGAA AAAAAAACAGCTC ATCACAGAGAT (SEQ ID NO: 1373) LYMP_nm34 0.880.88 0.88 0.90 0.89 0.89 0.90 0.89 0.88 CGCCAGCAAGGTG CATGATCGTCCACCAGGGCACCATTC TGGATAATGTT (SEQ ID NO: 1374) LYMP_nm35 0.92 0.93 0.910.91 0.89 0.90 0.89 0.92 0.91 CGGATGAGGTCTG CAGTTGCCCCACC TTACTATCTTGAGAGTTCCCAGGG (SEQ ID NO: 1375) LYMP_nm36 0.93 0.92 0.91 0.92 0.92 0.930.94 0.93 0.91 ACGAATTTAAGCT TTATGCCACAATT TCCCAATTCAACA TAAAGCTAACG(SEQ ID NO: 1376) LYMP_nm37 0.86 0.86 0.90 0.90 0.91 0.90 0.91 0.91 0.91GTTTTGTTTCCTCA TACCTTACATTGT GAAATACAAAATT AGCTAATGCG (SEQ ID NO: 1377)LYMP_nm38 0.96 0.95 0.94 0.97 0.96 0.96 0.97 0.97 0.97 CGCGACGCGCTCATCTGCCACCCACA CGAAGACAAAACA CAATGGTTATG (SEQ ID NO: 1378) LYMP_nm39 0.890.88 0.88 0.88 0.86 0.87 0.88 0.89 0.87 CAGAGGCCAGAGA CTTGAATTTACAAGGAGGGTCCTCAA CACAGACATCG (SEQ ID NO: 1379) LYMP_nm40 0.87 0.87 0.900.91 0.91 0.90 0.91 0.92 0.90 ACCCTGGTATTTC ATCACTTTCTTGCC TAACTTAGCAGAAACATGTATCG (SEQ ID NO: 1380) LYMP_nm41 0.89 0.90 0.89 0.91 0.89 0.900.90 0.91 0.91 GTTACACTATAAA TAGATGTTCACTG ACCAAATACTCCT ACTAGTTCTCG(SEQ ID NO: 1381) LYMP_nm42 0.89 0.85 0.85 0.89 0.88 0.86 0.90 0.88 0.85CGGCATTGATGTT GCTTCACGTTGCT GATGCTTAAGCAA TGTATATTGTG (SEQ ID NO: 1382)LYMP_nm43 0.91 0.89 0.85 0.86 0.88 0.90 0.86 0.92 0.90 CGTCGTCTTTAAAATGTGCTATCATTT CCTTGTTATAGTTG TGCAAGATT (SEQ ID NO: 1383) LYMP_nm44 0.880.83 0.88 0.90 0.90 0.90 0.90 0.90 0.89 TGGCTCCAGTTTC CAAGTGACGCAACCAAGTGTCTGGAT TCAGAGAATCG (SEQ ID NO: 1384) LYMP_nm45 0.86 0.86 0.880.87 0.89 0.87 0.89 0.90 0.86 ACAAATGTAAAAG CCTGGCAGCTTCC CCAGGAGAGTGCGGGTATGGGCCG (SEQ ID NO: 1385) LYMP_nm46 0.83 0.89 0.90 0.93 0.93 0.910.92 0.94 0.94 CATAGTGGCGTGT CGTAATAATCTGG CAGCTGGTCCAGC TGGTAGTGCCG(SEQ ID NO: 1386) LYMP_nm47 0.38 0.59 0.88 0.96 0.97 0.96 0.96 0.93 0.94CGCCGGCCAAATG CAACCAGCAGAGA TATGACCCCGACC CGTCTAAAGCC (SEQ ID NO: 1387)LYMP_nm48 0.76 0.73 0.87 0.89 0.90 0.88 0.89 0.89 0.88 TGGGGCCAACAGGCATGATTACCACA CAGGATGTTAGGC AAGGGGTTCCG (SEQ ID NO: 1388)

In table 4, regions that contain CpGs that are specific for the bloodcell types granulocytes, monocytes, CD4+ cells, cytotoxic T-cells,B-cells, Natural Killer-cells, and Natural Killer T-cells are listed, aswell as their SEQ ID NOs for the so-called “discovery fragment”(preferred region) and the discriminative “region of interest” (morepreferred region). The discovery fragments comprise at least one CpGthat is specific for the cell type as indicated, and thus suitable todistinguish this cell type from all other cell types of the haemogram.The discriminative region of interest (ROI) sequences are regions thatare positioned around the discovery region, and which form the basis forthe design of the specific assay for a specific cell type as indicated,and contain additional relevant CpGs, that is, a sequence of CpGs thatcan also be used in order to distinguish between the call types asindicated.

In table 4A to 4J, regions that contain CpGs that are specific for therespective blood cell types as shown in each table header are listed.The sequence provided in the column “discovery fragment” is thepreferred region and comprises at least one CpG that is specific for thecell type of the respective table (identifiable by the shown data). Alsocomprised in the context of the various embodiments and aspects of theinvention is a region 500 base pairs upstream and downstream of(therefore “around”) the sequence of the “discovery fragment” in thehuman genome for each marker. The region 500 base pairs upstream anddownstream of the “discovery fragment” are the discriminative ROI of themarker of the tables 4A to 4J.

The present invention therefore also pertains to a bisulfite conversionof at least one CpG position within any one of the “discovery fragments”or ROI (500 bp up and downstream for each “discovery fragment” in thehuman genome) of any one of the Tables 4 and 4A to 4J as shown above,which is indicative for a respective cell type as listed in the tables4. The T-lymphocytogram in all of the embodiments and aspects of theinvention may therefore contain any of the cell types listed in theabove tables 4 and 4A to 4J, and any combinations of these cell types.

An additional region for neutrophilic granulocytes (nGRC) is derivedfrom the Lipocalin-2, neutrophil gelatinase-associated lipocalin (LCN2)genomic region (Ensembl-ID: ENSG00000148346); herein designated AMP1730.The AMP 1730 genomic sequence and the discriminative ROI 1132 are SEQ IDNOs: 686 and 685 respectively. See also FIG. 2.

Additional regions for eosinophilic granulocytes (eGRC) are derived fromthe proteoglycan 2 (PRG2) genomic region (Ensembl-ID: ENSG00000186652),herein designated as AMP 2034 and 2035, respectively. The AMP 2034 and2035 genomic sequences, and the discriminative RO11403 are SEQ ID NOs:687, 688, and 689, respectively. See also FIG. 3.

Preferably, the cell-specific gene regions as described herein areselected to discriminate one cell type or subpopulation of cells fromall other cell types, such as the leukocytogram, T-lymphocytogram,granulocytogram, monocytogram, B-lymphocytogram and/or NK cytogram asdescribed herein. Thus, highly specific cell-type markers are used as abasis for identification and quantification that are not based onprotein expression levels but on cell type-specific epigeneticinformation. The method provides a clear yes/no information and isindependent of thresholding as the cell-specific CpG-rich genomic regionis bisulfite convertible or not, is detectable by qPCR or not as well asgenomic copies do not vary. The method also detects and identifies aswell as quantifies a potentially unlimited number of subpopulations ofcells, and the detection limit for, for example, regulatory T cells isat 0.3%.

Preferred is a method according to the present invention, wherein thecells that are detected and thus for the epigenetic haemogram areselected from a leukocytogram, and/or a T-lymphocytogram, and/or agranulocytogram, and/or a monocytogram, and/or a B-lymphocytogram,and/or a NK cytogram.

Preferably, said marker regions as analyzed are specific for the cellsof a pre-selected haemogram, and these cells are preferably selectedfrom T-lymphocytes, natural killer cells, B-lymphocytes, monocytes,granulocytes, and combinations thereof, for a leukocytogram, selectedfrom CD3⁺CD4⁺, CD4₊ memory, CD4⁺ effector cells, CD4⁺ naîve, CD3⁺CD8⁺,CD8⁺ positive, CD8⁺ memory, CD8⁺ effector cells, CD8⁺ naîve,CD3⁺CD8⁺CD4⁺, CD3⁺CD8⁺CD4⁺, NKT cells, iTreg, Treg, Tfh, Th1, Th2, TH9,Th17, Th19, Th21, Th22, memory and effector T helper cells, andcombinations thereof, for a T-lymphocytogram, selected from basophilic,eosinophilic, neutrophilic granulocytes, and/or granulocyticmyeloid-derived suppressor cells, and combinations thereof, for agranulocytogram, selected from CD14⁺ monocytes, CD14⁺ monocytes,macrophages, plasmacytoid dendritic cells, myeloid-dendritic cells,intermediate monocytes, classical monocytes, non-classical monocytes,and/or overall dendritic cells, and combinations thereof, for amonocytogram, selected from naîve B cells, pre B cells, memory B cells,transitional B cells and/or immature B cells, and combinations thereof,for a B cell cytogram, and selected from CD56^(dim) and/or CD56^(bright)NK cells for an NK cytogram.

In contrast to the term “cell-specific regions”, the term“cell-unspecific regions” herein shall mean genetic regions in thegenome of cells and/or nucleic acids that are selected to be unspecific,i.e. are specific for more than one, preferably all, cell type and/orsubpopulation of cells. These cell-unspecific regions also include thegenes of certain markers (such as, for example, certain proteinmarkers), such as 5′ untranslated regions, promoter regions, introns,exons, intron/exon borders, 3′ regions, CpG islands, and in particularinclude specific regions as amplified after bisulfite treatment(amplicons) that are “informative” for more than one cell type and/orsubpopulation of cells. Examples for these cell-unspecific regions areknown from the literature, and are selected from, for example regionscomprising a housekeeping gene, such as GAPDH, ACTB (beta-actin), UBC(ubiquitin C), ribosomal proteins (e.g. RPS27A, RPS20, RPL11, RPL38,RPL7, RPS11, RPL26L1), CALR (calreticulin), ACTG1 (gamma actin) RPS20(ribosomal protein S20), HNRPD (ribonucleoprotein D), NACA (nascentpolypeptide-associated complex subunit alpha), NONO (octamer-bindingprotein), PTMAP7 (prothymosin), GFRA4 (GDNF receptor alpha-4), CDC42(GTP-binding protein), EIF3H (translation initiation factor), UBE2D3(ubiquitin-conjugating enzyme), and genes as described in, for example,She et al. (Definition, conservation and epigenetics of housekeeping andtissue-enriched genes. BMC Genomics. 2009 Jun. 17; 10:269.), andPCT/EP2011/051601.

The method according to the present invention generally identifies thequantitative cellular composition of a biological sample. Preferred is amethod according to the present invention, wherein said biologicalsample is a sample of unknown cellular composition. Nevertheless, alsosamples of known cellular composition, or even partially knowncomposition can be quantified.

Biological samples to be analyzed can be stored fresh-frozen,paraffin-embedded or Heparin, Citrate or EDTA-stabilized as cells insamples do not need to be intact. The present method is very robust andallows, in contrast to flow cytometry, a parallel, independentassessment of cell identity and quantity as well as sample composition.A very good correlation to FACS is provided, too.

The biological sample to be analyzed can be any sample comprising one ormore type(s) of cells or that is suspected of comprising one or moretype(s) of cells that are to be quantified. Preferredmaterials/biological samples are selected from a blood sample, inparticular peripheral, capillary or venous blood samples, blood clots,or samples that are considered to contain blood cells as e.g. synovialfluid, lymph fluid, sputum, urine, tumor samples, as well as other fluidand tissue samples, histological preparations, DBS, artificiallygenerated cells and mixtures thereof (e.g. cell culture samples). Yetanother aspect of the present invention then relates to a methodaccording to the present invention, further comprising the step ofconcluding on the immune status of a mammal based on said epigenetichaemogram as produced.

Yet another aspect of the present invention then relates to a methodaccording to the present invention, further comprising the step ofmonitoring said cellular composition in said biological sample asidentified by comparing said composition and/or haemogram as identifiedwith the composition in an earlier biological sample taken from the samemammal, and/or with the composition in a control sample. In this aspect,for example, modifications and changes of the cellular composition in apatient can be monitored during a medical treatment.

Yet another aspect of the present invention then relates to a method fordiagnosing a disease or a predisposition for a disease, comprising amethod according to the present invention as described above, and thestep of concluding on the disease or a predisposition for said diseasebased on the cellular composition in said biological sample asidentified. In this aspect, for example, modifications and changes ofthe cellular composition in a patient can be used for diagnosing adisease or a predisposition for a disease, in particular when the sampleis compared to a sample of a healthy subject or to medical referenceranges. Preferably, said biological sample is a blood sample, inparticular a whole or peripheral blood sample, and said cell-specificregions in the genome of cells in said sample are selected from regionsspecific for blood cell types. The disease to be diagnosed can beselected from the group consisting of immune diseases or conditions,transplant rejections, infection diseases, cancer, neurologicaldiseases, allergy, primary and secondary immune deficiencies andhematologic malignancies such as, for example, lymphatic neoplasms,mature B-cell neoplasms, mature T- and NK-cell neoplasms, Hodgkinlymphomas, lympho-proliferative processes after transplantations, HIVand AIDS, Graft versus Host disease, rheumatoid arthritis, lupuserythematosus, breast cancer, colorectal cancer, esophageal cancer,stomach cancer, leukemia/lymphoma, lung cancer, prostate cancer, uterinecancer, skin cancer, endocrine cancer, kidney cancer, urinary cancer,pancreatic cancer, other gastrointestinal cancers, ovarian cancer,cervical cancer, head and neck cancer, adenomas, birth defects,myopathies, mental retardation, obesity, diabetes, gestational diabetes,multiple sclerosis, and asthma.

In one preferred embodiment of the present invention, the diagnostic useof the epigenetic haemogram is also based on the use of ratios ofdifferent populations and/or/to different subpopulations (subhaemograms)and/or/to of cells belonging to one subhaemogram according to the saidepigenetic haemogram. Such ratios are e.g. but are not limited to,population of regulatory T cells in relation to CD3⁺ T-lymphocytes, orregulatory T cells in relation to population of CD4⁺ T-lymphocytes, orregulatory T cells in relation to population of CD8⁺ T-lymphocytes, orCD3⁺ T-lymphocytes to CD4⁺ T-helper cells, or CD3⁺ T-lymphocytes to CD8⁺cytotoxic T cells, or CD⁺ T-helper cells to CD8⁺ cytotoxic T-cells, orTh1 to Th2, or Th1 to Th17, or Th2 to Th17, or memory or naïve CD4⁺T-helper cells to CD3⁺ T-lymphocytes, or memory CD8⁺ cytotoxic T-cellsto CD3⁺ T-lymphocytes, all as sub-populations of the T-lymphocytogram;or CD3⁺ T-lymphocytes related to neutrophilic granulocytes, ormacrophages to CD4⁺ T-helper cells; CD4⁻ T-lymphocytes related toneutrophilic granulocytes, or CD8⁺ T-lymphocytes related to neutrophilicgranulocytes all as relations between cells of different subhaemograms;or CD3⁺ T-lymphocytes related to granulocytes, or B-lymphocytes to CD3⁺T-lymphocytes, or monocytes to CD3⁺ T-lymphocytes, or monocytes toB-lymphocytes all as ratios out of populations of the leukocytogram; orCD3⁺ T-lymphocytes or monocytes or B-lymphocytes, or granulocytes or NKcells related to overall leukocytes.

But also other ratios of subpopulations assessed according to thepresent invention and according to the epigenetic haemogram can be usedas a diagnostic method. The disease can be selected from the groupconsisting of immune diseases or conditions, transplant rejections,infection diseases, cancer, neurological diseases, allergy, primary andsecondary immune deficiencies and hematologic malignancies such as, forexample, lymphatic neoplasms, mature B-cell neoplasms, mature T- andNK-cell neoplasms, Hodgkin lymphomas, lympho-proliferative processesafter transplantations, HIV and AIDS, Graft versus Host disease,rheumatoid arthritis, lupus erythematosus, breast cancer, colorectalcancer, esophageal cancer, stomach cancer, leukemia/lymphoma, lungcancer, prostate cancer, uterine cancer, skin cancer, endocrine cancer,kidney cancer, urinary cancer, pancreatic cancer, other gastrointestinalcancers, ovarian cancer, cervical cancer, head and neck cancer,adenomas, birth defects, myopathies, mental retardation, obesity,diabetes, gestational diabetes, multiple sclerosis, and asthma. Thediagnostic use encompasses but is not limited to the diagnosis of adisease and/or the follow-up of a disease and/or the predisposition fora disease and/or the monitoring of an effect of a chemical or biologicalsubstance.

The epigenetic haemogram of the invention is in another embodiment usedfor the assessment of the risk to develop a disease in a patient,therefore for diagnostic purposes. In one preferred embodiment of thepresent invention, the use of the epigenetic haemogram for theassessment of the risk to develop a disease is also based on the use ofratios of different populations and/or/to different subpopulations(subhaemograms) and/or/to of cells belonging to one subhaemogramaccording to the said epigenetic haemogram. Such ratios are e.g. but arenot limited to, population of regulatory T cells in relation to CD3⁺T-lymphocytes, or regulatory T cells in relation to population of CD4⁺T-lymphocytes, or regulatory T cells in relation to population of CD8⁺T-lymphocytes, or CD3⁺ T-lymphocytes to CD4⁺ T-helper cells, or CD3⁺T-lymphocytes to CD8⁺ cytotoxic T cells, or CD4⁺ T-helper cells to CD8⁺cytotoxic T-cells, or Th1 to Th2, or Th1 to Th17, or Th2 to Th17, ormemory or naïve CD4⁺ T-helper cells to CD3⁺ T-lymphocytes, or memoryCD8⁺ cytotoxic T-cells to CD3⁺ T-lymphocytes, all as subpopulations ofthe T-lymphocytogram; or CD3⁺ T-lymphocytes related to neutrophilicgranulocytes, or macrophages to CD4⁺ T-helper cells; CD4⁺ T-lymphocytesrelated to neutrophilic granulocytes, or CD8⁺ T-lymphocytes related toneutrophilic granulocytes all as relations between cells of differentsubhaemograms; or CD3⁺ T-lymphocytes related to granulocytes, orB-lymphocytes to CD3⁺ T-lymphocytes, or monocytes to CD3⁺ T-lymphocytes,or monocytes to B-lymphocytes all as ratios out of populations of theleukocytogram; or CD3⁺ T-lymphocytes or monocytes or B-lymphocytes, orgranulocytes or NK cells related to overall leukocytes.

But also other ratios of subpopulations as assessed in accordance withthe present invention and according to the epigenetic haemogram can beused to assess the risk for developing a disease. The disease for theherein described embodiment can be selected from the group consisting ofimmune diseases or conditions, transplant rejections, infectiondiseases, cancer, neurological diseases, allergy, primary and secondaryimmune deficiencies and hematologic malignancies such as, for example,lymphatic neoplasms, mature B-cell neoplasms, mature T- and NK-cellneoplasms, Hodgkin lymphomas, lympho-proliferative processes aftertransplantations, HIV and AIDS, Graft versus Host disease, rheumatoidarthritis, lupus erythematosus, breast cancer, colorectal cancer,esophageal cancer, stomach cancer, leukemia/lymphoma, lung cancer,prostate cancer, uterine cancer, skin cancer, endocrine cancer, kidneycancer, urinary cancer, pancreatic cancer, other gastrointestinalcancers, ovarian cancer, cervical cancer, head and neck cancer,adenomas, birth defects, myopathies, mental retardation, obesity,diabetes, gestational diabetes, multiple sclerosis, and asthma. Thediagnostic use encompasses but is not limited to the diagnosis of adisease and/or the follow-up of a disease and/or the predispositionand/or the assessment of a risk for a disease and/or the monitoring ofan effect of a chemical or biological substance.

As indicated, the above mentioned ratios as assessed in accordance withthe present invention bear the potential to indicate e.g. the risk todevelop a certain disease during the life time of a subject. A clinicalrole in risk assessment was found for the ratio of regulatoryT-lymphocytes to CD3+ T-lymphocytes. Particularly preferred in thecontext of the present invention is that an increase in the ratio ofregulatory T-lymphocytes to CD3+ T-lymphocytes indicates a risk todevelop cancer (cancerous disease) during life time. The cancer isselected from but not limited to the list as provided herein above,wherein a high impact of an increased ratio of regulatory T-lymphocytesto CD3+ T-lymphocytes is expected for the development of lung cancer,which is particularly preferred. Furthermore, ratios bear the potentialto predict the development of Graft versus Host Disease wherein anincreased ratio of regulatory T-lymphocytes to CD4+ T-lymphocytes withinthe first two weeks after stem cell transplantation predicts thedevelopment of a graft versus host disease.

Yet another aspect of the present invention then relates to a method foridentifying the effect of a chemical or biological substance or drug onthe composition of cells, comprising performing the method according tothe present invention as described above, preferably on a blood sampleobtained from a mammal treated with or exposed to said substance, andcomparing the composition of cells in said sample with the compositionof samples before treatment or with the composition of an untreatedsample. The mammal to be treated with said chemical or biologicalsubstance or drug might be healthy or suffers from a disease selectedfrom the group consisting of immune diseases or conditions, transplantrejections, infection diseases, cancer, neurological diseases, allergy,primary and secondary immune deficiencies and hematologic malignanciessuch as, for example, lymphatic neoplasms, mature B-cell neoplasms,mature T- and NK-cell neoplasms, Hodgkin lymphomas, lympho-proliferativeprocesses after transplantations, HIV and AIDS, Graft versus Hostdisease, rheumatoid arthritis, lupus erythematosus, breast cancer,colorectal cancer, esophageal cancer, stomach cancer, leukemia/lymphoma,lung cancer, prostate cancer, uterine cancer, skin cancer, endocrinecancer, kidney cancer, urinary cancer, pancreatic cancer, othergastrointestinal cancers, ovarian cancer, cervical cancer, head and neckcancer, adenomas, birth defects, myopathies, mental retardation,obesity, diabetes, gestational diabetes, multiple sclerosis, and asthma.

Yet another aspect of the present invention then relates to a diagnostickit and its use, comprising materials for performing the methodaccording to the invention as described herein, optionally withinstructions for use. The diagnostic kit particularly containsoligonucleotides (e.g. for producing amplicons) specific for regions ofinterest, bisulfite reagents, and/or components for PCR. The diagnostickit and its use encompasses but is not limited to the diagnosis of adisease and/or the follow-up of a disease and/or the predispositionand/or the assessment of a risk for a disease and/or the monitoring ofan effect of a chemical or biological substance.

As mentioned above, currently, in both, clinical diagnostics andresearch, and drug development, a new method to provide a precise andcomprehensive quantification of leukocytes and their subpopulations isdesired even if biological samples are not intact anymore. The presentinvention, overcomes most problems of current, routinely usedquantitative methods, flow cytometry and immune histochemistry, but moreimportantly, overcomes several biochemical and technical problems ofqPCR in regard to absolute quantification of target cells. The presentinvention thus provides a method to effectively detect and quantify thedifferent cell populations. In particular, the present method for thefirst time allows for an expression-independent method for theassessment of a comprehensive blood cell picture. Moreover, the presentinvention enables flexible time framing which is not dependent on quicksample processing but rather allows long term sample storage andindividual coordination between sample collecting and sample processing.

BRIEF DESCRIPTION OF THE FIGURES

The present invention will now be explained further in the followingexamples and figures, nevertheless, without being limited thereto. Forthe purposes of the present invention, all references as cited hereinare incorporated by reference in their entireties.

FIG. 1 shows a schematic overview over the epigenetic haemogram. Thehaemogram comprises the leukocytogram, which includes B cells,monocytes, granulocytes, CD3⁺ T-lymphocytes, and NK cells. Eachsubpopulation establishes an additional cytogram, respectively i.e. theB-lymphocytogram, monocytogram, granulocytogram, T-lymphocytogram, andNK cytogram. For these five sub-cytograms, the corresponding cell typesare depicted. Each of these five sub-cytograms can be divided intoadditional subpopulations, e.g., the T cell cytogram can be furtherdivided into the CD4⁺ T-helper cytogram and the CD8⁺ cytotoxogram.

FIG. 2 shows a matrix indicating bisulfite-non-convertibility incell-type specific genomic marker region. Different cell types wereanalyzed indicating that CpGs within genomic region AMP1730 arecompletely convertible by bisulfite treatment corresponding to 0%bisulfite-non-convertibility. The total fraction of granulocytescorresponds to neutrophilic granulocytes. Neutrophilic granulocytesaccount for about 90% of granulocytes, eosinophilic for about 7%, andbasophilic for about 3% (see Example 4).

FIG. 3 shows a matrix indicating bisulfite-non-convertibility incell-type specific genomic marker regions. Different cell types wereanalyzed indicating that CpGs within genomic region AMP2034 and 2035are, in contrary to other cell types given, convertible by bisulfite toa high extent and indicative for this specific cell-type (see Example5).

FIG. 4 shows the results of the test-template as amplified according toExample 7. unM (TpG Template): bisulfite-converted test-DNA; Meth (CpGtemplate): non-bisulfite converted test-DNA; NTC: no template control;left panel: Mg2+ concentration 3.2 mM; right panel: Mg2+ concentration3.6 mM.

BRIEF DESCRIPTION OF THE SEQUENCES

SEQ ID No. 1 to 689 show sequences as used in the context of the presentinvention.

EXAMPLES

The present examples have been performed on a sample of known andunknown leukocyte and T-lymphocyte compositions. The person of skillwill understand how to modify the experiments in order to identify andquantify other cell types, in particular blood cells in the context ofan epigenetic haemogram, without undue burden and/or the need to becomeinventive.

Example 1—Assessment of Cell-Specific Assay-Correction Factors Using ASample of Known Composition

The inventors provided a human blood sample of known leukocyte andT-lymphocyte composition. The composition of this blood sample wasanalyzed via flow cytometry. The sample contained 61% granulocytes, 12%monocytes, 3% B-lymphocyte, 4% natural killer cells, and 19%T-lymphocytes (Table 5). The T cell population consisted of 13% of CD4⁺T helper cells, 1.4% regulatory T cells, 5% CD8⁺ cytotoxic cells, and 2%naïve CD8 cells.

In a next step, this sample of known leukocyte and T-lymphocytecomposition was analyzed for the relative amount of bisulfiteconvertible chromatin in cell-type specific gene regions, resulting in aunique, discriminating cell-type specific pattern of bisulfiteconvertible chromatin, e.g. for granulocytes a region in the gene forneutrophil gelatinase-associated lipocalin, for monocytes a region inthe leukocyte immunoglobulin-like receptor gene, for B cells in a regionof the gene for the low-affinity receptor for IgE, for natural killercells a region in the gene for oxysterol-binding protein-like protein 5isoform a, for T-lymphocytesin a region in the CD3D/G gene, for CD4⁺ Thelper cells in a region in the CD4 gene, for regulatory T cells in aregion in the FOXP3 gene, for CD8⁺ cytotoxic T cells in a region in theCD8A/B gene, for naïve CD8⁺ cells a region in the endosialin gene.Analyses were performed by qPCR using a bisulfite-convertednormalization standard indicating the relative amount of numbers of genecopies containing mentioned unique, said cell-type specific pattern ofbisulfite convertibility. These relative numbers of cell-specific genecopies indicate the relative amount of said specific cells.

This relative number of specific cells (said leukocytes andT-lymphocytes) was compared with the result of flow cytometry. Bothresults were set in relation, and a correction factor was determined(Table 1). Flow cytometry revealed 61% and qPCR 91.6% of granulocytes,and therefore the cell-specific granulocyte assay-correction factor was1.502.

Correction factors were determined separately for each set ofassessments as well as are incorporated into data base forassay-specific correction factors. In addition to the individual andseparate determination of correction factors (for each set ofassessments), the average of past correction factors can be used aswell.

TABLE 5 Assessment of cell-specific assay-correction factors. Cellcomposition of human blood sample was assessed by flow cytometry andqPCR for leukocytes as well as T-lymphocytes. qPCR was performed using abisulfite-converted normalizations standard. Correction factors forfollowing qPCRs on samples of unknown composition were determined byratio of qPCR/FC. (C-Factor) correction factor, (FC) Flow cytometry,(GRK01) internal sample number. (qPCR) real time quantitative polymerasechain reaction. FC GRK01 qPCR (%) GRK01 C-Factor Leukocytogramgranulozytes 61.0 91.6 1.502 monozytes 12.0 29.9 2.494 B cells 3.0 1.30.429 natural killer cells 4.0 3.9 0.977 T cells 19.0 29.8 1.568T-Lymphocytogram CD4⁺ T helper cells 13.0 9.7 0.745 regulatory T cells1.4 2.3 1.668 CD8⁺ cytotoxix T cells 5.0 8.0 1.594 naive CD8⁺ cells 2.02.1 1.051

Example 2—Assessment of Absolute Cell Composition in an Unknown BloodSample of Healthy Volunteers Using an Assay-Correction Factor DeterminedUsing a Sample of Known Composition (as Shown in Example 1)

Human blood samples of unknown leukocyte and T-lymphocyte composition ofhealthy volunteers were obtained for assessment of absolute leukocyteand T-lymphocyte composition via qPCR. As for Example 1, DNA of bloodsamples were isolated, bisulfite converted and relative amount ofbisulfite converted DNA assessed via qPCR under the use ofBisulfite-converted normalization standards. Amount of bisulfiteconvertible DNA in cell-specific gene regions was set in relation tobisulfite-convertible DNA of cell-unspecific DNA region (always, cellindependent, constant pattern of bisulfite-convertibility) to obtainrelative amount of assessed cells.

Cell-specific assay-correction factors were determined in a parallelexperimental set for assays of granulocytes, monocytes, B-lymphocytes,natural killer cells, T-lymphocytes, CD4⁺ T helper cells, regulatory Tcells, and CD8⁺ cytotoxic T cells using flow cytometry on a human bloodsample (methodology see example 1, human blood sample differs forExample 2 compared to Example 1). Relative amounts of assessed cells asobtained were corrected using the cell-specific assay correctionfactors. E.g., qPCR for monocytes patient sample S04 gave a relativeamount of monocytes of 7.94%, but the correction revealed an absolutecell amount of 3.69% monocytes.

One would expect the sum of cells belonging to a leukocytogram to be100%, and the sum of cells belonging to a T-lymphocytogram to haveexactly the same amount of cells as determined for T-lymphocytes in theleukocytogram. It is known that even the flow cytometry quantificationis not without limitations, as described above.

TABLE 6 Assessment of absolute cell composition of blood from healthyvolunteers. Cell com- position of human blood samples were assessed byqPCR for leukocytes as well as T-lymphocytes. qPCR was performed using abisulfite-converted normalizations standard. Correction factors forqPCRs were determined in a parallel set of experiments (not described indetail here, example of assessment of C-Factor see Example 1).

(C-Factor) correction factor, (FC) Flow cytometry, (S04)(S08) internalsample numbers. (qPCR) real time quantitative polymerase chain reaction.

Flow cytometry measurement errors are reflected in qPCR corrections. Onthe other hand, the epigenetics based qPCR, as described herein,detected cell types independently of marker expression. Even if acell-specific marker is expressed at a very low amount, or is notpresent at all, epigenetic-qPCR can detect these cells (e.g. as foundfor Th17 cells, see above). In addition, certain cells do expresscell-specific markers, even if these cells did not enter a specificcellular state known to be associated with the marker expression (e.g.as found for regulatory T cells, see description above). Such cells arenot detected by epigenetic-based qPCR. Additionally, for this example,the selection of T-lymphocytes (CD4⁺ T helper cells, CD8⁺ cytotoxiccells) does not represent the complete T-lymphocyte set (see FIG. 1).Cytograms represent the current status of scientific knowledge andcannot exclude the existence of additional cell types or of theincorrect definition of subpopulations thereof.

Example 3—Assessment of Absolute Cell Composition in an Unknown BloodSample of Auto-Immune Diseased Volunteers Using an Assay-CorrectionFactor Determined Using a Sample of Known Composition (as Shown inExample 1)

Human blood samples of unknown leukocyte and T-lymphocyte composition ofauto-immune diseased volunteers were obtained for assessment of absoluteleukocyte and T-lymphocyte composition via qPCR. As for Example 1, DNAof blood samples were isolated, bisulfite converted and relative amountof bisulfite converted DNA assessed via qPCR. Amount of bisulfiteconvertible DNA in cell-specific gene regions was set in relation tobisulfite convertible DNA of cell-unspecific DNA region (always, cellindependent, constant pattern of bisulfite convertibility) to obtainrelative amount of assessed cells.

Cell-specific assay-correction factors were determined in a parallelexperimental set for assays of granulocytes, monocytes, B-lymphocytes,natural killer cells, T-lymphocytes, CD4⁺ T helper cells, regulatory Tcells, and CD8⁺ cytotoxic T cells using flow cytometry on a human bloodsample (methodology see example 1, human blood sample differs forExample 3 compared to Example 1). Obtained relative amounts of assessedcells were corrected using these cell-specific assay correction factors.E.g., qPCR for T-lymphocytes assessed a relative amount of T-lymphocytesof 8.49% for patient M06 and 23.94% for patient M10. Correction revealedan absolute cell amount of 5.4% and 15.3% T cells, respectively.

In comparison to data from healthy patients, see Example 2, forauto-immune diseased patient M06 an obvious decrease in 4 of the 5subtypes of leukocytes within the leukocytogram was observed. Forpatient M10 an obvious decrease in absolute number of only B-lymphocytesand monocytes was observed.

Additionally, also for T-lymphocyte subtypes, differences between bothpatients were observed. qPCR analysis of three subtypes of T-lymphocytesfor patient M06 revealed a strong decrease of CD4+ T helper cells aswell as CD8+ cytotoxic cells whereas the decrease in level of regulatoryT cells was less pronounced. For patient M10 all three cell levelsdecreased simultaneously by about 50-60% compared to the average of thetwo healthy patients in Example 2.

All these differences might be related to e.g. a different medicationand/or disease stage of these both patients and offer a clinical routineinstrument for disease diagnosis, prediction as well as accompanyingmonitoring.

TABLE 8 Assessment of absolute cell composition of blood fromauto-immune disaeased patients. Cell composition of human blood sampleswere assessed by qPCR for leukocytes as well as T- lymphocytes. qPCR wasperformed using a bisulfite-converted normalizations standard. Anobvious decrease of the level of certain cell populations was seen thatis known for auto immune diseases. Cor- rection factors for qPCRs weredetermined in a parallel set of experiments (not described in detailhere, example of assessment of C-Factor see Example 1).

(C-Factor) correction factor, (FC) Flow cytometry, (S04)(S08) internalsample numbers. (qPCR) real time quantitative polymerase chain reaction.

Example 4—Detection of Neutrophilic Granulocytes Based on Amp1730 in theGene for Neutrophil Gelatinase-Associated Lipocalin (LCN2) (See FIG. 2)

FIG. 2 shows a matrix indicating bisulfite-unconvertibility in cell-typespecific genomic marker region. Different cell types were analyzedindicating that CpGs within genomic region AMP1730 are completelyconvertible by bisulfite treatment corresponding to 0%bisulfite-unconvertibility. Within basophil and eosinophil granulocytesspecific CpGs of AMP1730 are not convertible by bisulfite. Therefore,the term “(Total) Granulocytes”” within figure corresponds toneutrophilic granulocytes. Neutrophilic granulocytes account for about90% of granulocytes, eosinophilic for about 7%, and basophilic for about3%.

TABLE 7 Discriminatory quality of AMP1730: qPCR using assay specificprimers for AMP1730 was performed on cells indicated under “sample” toanalyze amount of bisulfite-convertibility of CpGs present in genomicregion given by AMP1730. DNA from purified cell samples was isolated,bisulfite treated and qPCR assay performed under the use of a bisulfite-converted normalization standard. Relative amount of cells was assessedvia comparing copy numbers of busulfite-convertible DNA of AMP1730 withbisulfite-unconvertible DNA of AMP1730, named “TpG/CpG- System” (copynumer convertible/(copy number convertible + copy numbernon-convertible) = % cell type). Cells were purified and sorted via flowcytometry. Within the neutrophiles cell sample, more than 95% of thecells were detected as neutrohiles using AMP1730. (bGRAN) basophiles.(eGRAN) eosinophiles (nGRAN) neutrophiles, (MOC) monocytes, (THC)CD3⁺CD4⁺ T-lymphocyets, (CTL) cytotoxic CD3⁺CD8⁺ T-lymphocytes, (NKC)CD3⁻ natural killer cells, (NKT) CD3⁺ natural killer cells, (BLC)B-lymphocytes. AMP1730 - neutrophilic granulocytes assay PCR-SystemPCR-System specific to “TpG” specific to “CpG” copy numbers copy numbers% nGRC CP acc. To plasmid CP acc. To plasmid “TpG” Sample Value unitsValue units variant bGRAN 35.49 14.27 29.09 875.33 1.60 eGRAN 25.2416.20 30.68 300.00 5.12 nGRAN 30.52 270.67 35.73 11.70 95.86 MOC 35.7212.93 29.85 525.00 2.40 THC 42.70 0.91 30.80 278.00 0.33 CTL 37.72 5.0429.41 706.00 0.71 NKC 36.95 7.03 29.34 740.33 0.94 NKT 38.35 3.85 30.37369.67 1.03 BLC 39.75 2.41 29.91 502.67 0.48

Example 5—Detection of Eosinophilic Granulocytes Based on Amp 2034and/or 2035 (PRG2)

Matrix indicating bisulfite-inconvertibility in cell-type specificgenomic marker regions. Different cell types were analyzed indicatingthat CpGs within genomic region AMP2034 and 2035 are, in contrary toother cell types given, convertible by bisulfite to a high extent andindicative for this specific cell-type (see FIG. 3).

Example 6—Assessment of Cell-Specific Assay-Correction Factor Using aNon-Bisulfite-Converted Nucleic Acid Molecule (Plasmid Standard) asNormalization Standard

The inventors developed non-bisulfite converted, genomic plasmidstandards as a normalization standard. One of these genomic plasmidstandards comprises marker regions being specific for stable regulatoryT cells (TSDR region)(Treg cells) as well as marker regions beingcell-type unspecific (GAPDH, housekeeping gene, detecting all cells,100% of cells). This plasmid standard is used to determine theTreg-specific assay correction factor that allows assessing the absoluteamount of stable Tregs within an unknown blood sample.

In a first step, a human blood sample of unknown composition wasprovided, DNA isolated, and bisulfite treated. Following, the amount ofbisulfite converted TSDR copies and GAPDH copies were assessed (Table 8,section 2). These qPCR analyses were performed using abisulfite-converted normalization standard (Table 8, section 1)indicating the number of bisulfite-converted DNA copies containing theTSDR marker region as well as the GAPDH marker region (Table 8 section2). The relative amount of stable Tregs is calculated as number ofbisulfite converted TSDR copies related to bisulfite converted GAPDHcopies in percent.no. bisulfite-converted TSDR copies/no. bisulfite-converted GAPDHcopies×100=% Treg 67.70/6026.67×100=1,123%

The cell-type specific region for stable regulatory T cells, TSDR, islocated on the X-chromosome. For women an epigenetic silencing of oneallele of the X-chromosome is known. This affect is deduced by using afactor 2 when calculating relative amount of stable Tregs (finalresult=2.25% stable Tregs)(Table 8, section 2).

In a second step, Treg-specific assay-correction factor based on saidgenomic plasmid standard was assessed. Said plasmid standard wasbisulfite converted and number of plasmid copies assessed by qPCR usingprimers specific for bisulfite-converted marker regions for Treg cellsand for GAPDH. These qPCR analyses were also performed using thebisulfite-converted normalization standard (Table 8, section 1). Theefficiency of qPCR for Treg cells and GAPDH should be equal as the novelgenomic, non-bisulfite converted plasmid standard (the substrate)contains an equimolar amount of Treg cell-specific and GAPDH-specificgenomic copies. Therefore, assessed deviation of Treg copy numbers fromGAPDH copy numbers corresponds to differences in assay efficiencies.Treg (TSDR) copy numbers=6760 vs. GAPDH copy numbers=6273.33This deviation defines the cell-type assay-specific correction factor.E.g.:Treg (TSDR) copy numbers/GAPDH copy numbers/100=6760/6273.33=1,077.

For Treg cells an assay correction factor of 1.1 (average, n=3) wasassessed (Table 8, section 3). Correcting the relative amount of Tregcells by factor 1.1 results in an absolute amount of 2.05% Treg cellswithin the unknown blood sample WB01.relative amount of Treg cells/specific assay-correction factor=absoluteamount of Treg 2.25%/1.1=2.05% Treg cells

TABLE 8 Assessment of Treg-specific assay-correction factor using abisulfite-unconverted nucleic acid molecule as a plasmid standard. qPCR1(FOXP3 TSDR) Assay Run-ID: 115_genomSTD_NormalizationFactorTreg 1) qPCRfor bisulfite-converted normalization standard: qPCR for GAPDHbisulfite-converted qPCR for TSDR bisulfite- normalization convertednormalization standard Standards for standard copy Quantification copynumbers numbers Standard- Plasmid normalization CP normalization IDUnits CP Value standard Value standard Standard-1 31250 units  23.1831500.00 23.10 32766.67 Standard-2 6250 units 25.55 6150.00 25.496010.00 Standard-3 1250 units 27.86 1250.00 27.71 1243.33 Standard-4 250 units 30.20 249.00 29.91 260.00 Standard-5  50 units 32.86 53.0032.78 44.13 Standard-6  30 units 34.05 31.80 33.36 32.70 2) qPCR onblood sample of unknown composition for assessment of relative amount ofTreg cells using the bisulfite-converted normalization standard as givenunder 1): qPCR for GAPDH bisulfite converted qPCR for TSDR bisulfite DNASample converted DNA copy ID copy numbers numbers acc. unknown acc. toto relative blood normalization CP normalization amount sample gender CPValue standard (1) Value standard (1) stable Treg WB01 female 32.3867.70 25.49 6026.67 2.25% 3) qPCR on genomic plasmid standard forassessment of Treg-specific correction factor qPCR for GAPDH qPCRbisulfite converted for TSDR bisulfite DNA converted DNA copy Samplecopy numbers numbers acc. % stable ID dilution acc. to to Treg/GAPDHgenomic genom. normalization CP normalization genomic standard standardCP Value standard (1) Value standard (1) plasmid units GP5000 1 25.416760.00 25.44 6273.33 107.76 GP1000 1:5  27.71 1380.00 27.75 1206.67114.36 GP200 1:25 29.93 301.00 29.82 278.00 108.27 Mean: 110.13Normalization Factor: 1.10 4) Correction of relative amount of Tregsusing Treg-specific correction factor to obtain absolute amount of Tregcells Treg relative Normalization Treg absolute amount Factor amount2.25% 1.1 2.05%

Example 7—Development of Cell-Specific QPCR Assay for Detection andDiscrimination of Neutrophil Granulocytes

Detecting Cell-Type Specific, Differential Bisulfite Convertibility:

DNA from the purified neutrophil granulocytes (neutrophils), monocytes,CD4+ cells CD8+ cells, B cells, NK-cells, and NKT cells wasbisulfite-treated and bisulfite converted DNA analyzed at various CpGdinucleotide motifs. The inventors then compared the bisulfiteconvertibility (finding C as for Cytosine that was methylated in theoriginal (genomic) sequence versus T for cytosine that was unmethylatedin the original sequence) of these CpG dinucleotides (see Table 4,position 259).

Surprisingly, it was found that specific areas in the genomic region oflipocalin-2 were differentially methylated in neutrophil granulocytescompared to all other blood cell types tested. These areas were definedas discovery fragments, such as e.g. SEQ ID 517 for neutrophils (Table4, position 259).

Validation of Bisulfite Convertibility:

Then, upon finding of the differential bisulfite convertibility, theinventors analyzed larger genomic regions by means of bisulfitesequencing. This latter procedure served for exploring and extending thediscovered, differentially methylated areas and was conducted, forexample with the differentially bisulfite converted discovery fragment,SEQ ID 517, within the gene lipocalin-2 as disclosed herein (see Table4, SEQ ID 517 discovery fragment and 518 discriminative region ofinterest (ROI)).

Within the discriminative ROI defined as SEQ ID 518 a preferred regionof interest including preferable CpG positions to be analyzed wasidentified (amplicon (AMP) 1730, see FIG. 2 and SEQ ID 685).

Development of Cell-Type Specific qPCR Assay:

In AMP 1730, a detailed analysis was performed in order to develop ahighly specific qPCR assay based on the use of amplification primers andprobes. Amplification primers (forward and reverse) for bisulfiteconverted neutrophils specific AMP 1730 as well as probes were designedand tested (data not shown).

In order to develop a particularly preferred “perfect” primer system forthe assay, primers were developed that do not correspond 100% to theoriginal bisulfite converted sequence but include specific mismatchesthat surprisingly increased the specificity. Mismatches in the primersequence are underlined and bold.

TpG System (Detecting TpG Positions in Bisulfite-Converted DNA):

Forward Primer: q1730 nm2Fw2_M1: ACCAAAAATACAACACTTCAA; Reverse Primer:q1730 nm2R2: GGTAATTGTTAGTAATTTTTGTG; Hydrolysis Probe: q1730 nm2P4:FAM-CACTCTCCCCATCCCTCTATC-BHQ1.CpG System (Detecting CpG Positions in Bisulfite-Converted DNA):

Forward Primer: q1730_m2F1: TACCAAAAATACAACACTCCG Reverse Primer:q1730_m2R2_M1: AGGTAATTGTTAGTAATTTTTACG Hydrolysis Probe: q1730 m2P1:HEX-CTCACTCTCCCCGTCCCTCTATC-BHQ1

The technical specificity of the TpG-specific PCR-system was testedbased on test-templates (see FIG. 4). TpG and the CpG specific PCRsystem were found to be highly specific for the bisulfite converted andthe non-bisulfite converted template, respectively. Additionally, theTpG-specific and CpG-specific PCR system show no cross reactivity withthe CpG and the TpG templates, respectively (FIG. 4 shown forTpG-specific PCR system). In order to further increase specificity ofthe qPCR primer system, Mg2+ concentration was increased from 3.2 mM(usually applied) to 3.5 mM (see FIG. 4).

The biological specificity of the neutrophils-specific qPCR-system wastested using certain sorted cell fractions as well as using whole bloodsamples (see Table 9). The established qPCR assay was found to be highlyspecific for neutrophils.

q1730 (nGRC) Assay Run-ID: UBq1730_b_BSCT-Valid. qPCR forbisulfite-converted normalization standard: qPCR for nGRC qPCR for nGRCnon- bisulfite-converted bisulfite-converted normalization standardnormalization standard (TpG) (CpG) Standards for Quantification CP CPStandard-ID Plasmid Units Value Plasmid units Value Plasmid unitsStandard-1 31250 units  23.5 30433.3 23.,8 30766.,7 Standard-2 6250units 25.8 6340.0 26.,2 6300.,0 Standard-3 1250 units 28.2 1316.7 28.,61240.,0 Standard-4  250 units 30.6 257.7 30.,9 256.,0 Standard-5  50units 32.8 62.2 33.,1 60.,5 Standard-6  30 units NTC NTC ND ND ND NDPCR-System specific to PCR-System specific to “TpG” “CpG” AnalyzedSamples CP CP % nGRC Epoints-ID Cell Type Value Plasmid units ValuePlasmid units “TpG”/“CpG” bGRAN06 Basophils 35.49 14.27 29.09 875.331.60 eGRAN09 Eosinophils 35.24 16.20 30.68 300.00 5.12 nGRAN02Neutrophils 30.52 270.67 35.73 11.70 95.86 MOC28 Monocytes 35.72 12.9329.85 525.00 2.40 THC14 T-Helper Cells 42.70 0.91 30.80 278.00 0.33CTL16 Cyototox. T-Cells 37.72 5.04 29.41 706.00 0.71 NKC_Pool NK Cells36.95 7.03 29.34 740.33 0.94 NKT19 NK T-Cells 38.35 3.85 30.37 369.671.03 BLC06 B-Lymphocytes 39.57 2.41 29.91 502.67 0.48 WBL51 Whole Blood30.61 253.67 31.69 152.67 62.43 WBL55 Whole Blood 29.43 561.00 30.84268.67 67.62 WBL57 Whole Blood 31.59 134.00 32.08 117.67 53.25 WBL58Whole Blood 31.94 107.33 31.68 154.33 41.02

Table 9 summarizes the results of the qPCR-analysis of sorted immunecells and whole blood samples. Shown are the CP-values for plasmidstandards, for immune cell types and whole blood samples, each for thebisulfite converted, neutrophil-specific marker copies (TpG PCR-system)and the non-bisulfite converted, neutrophil-specific marker copies (CpGPCR-system) system. Based on the plasmid standard the corresponding copynumbers (plasmid copies) were calculated from the CP-value as measured.(NTC) no template control; (nGRC) neutrophil granulocytes.

The relative amount of neutrophils in the sample is calculated from thenumber of bisulfite converted, neutrophil-specific marker copies and thesum of bisulfite converted and non-bisulfite convertedneutrophil-specific marker copies in the sample as follows:% neutrophils=no. of bisulfite converted neutrophil copies/no. ofnon-bisulfite converted neutrophil copies×100; %neutrophils=253.67/(253.67+152.67)×100=62.43

The present assay is special in the sense that the amplification of thebisulfite-converted neutrophils-target-DNA using “common” fitted primersand standard PCR-protocols does not provide a sufficient result. Onlyafter using amplification primers that were designed having a mutation(a “mismatch”) at strategic sites as identified herein, together withthe use of a much higher Mg²⁺-concentration in the PCR allows for theefficient amplification of the neutrophils-target region. In a next stepa genomic plasmid standard can be designed and cell-specificassay-correction factor can be assessed (see Example 6).

Example 8—Assessment of Cell-Specific Assay-Correction Factor Using ANon-Bisulfite-Converted Nucleic Acid Molecule (Genomic Plasmid Standard)as Normalization Standard to Quantify Absolute Number of Cells PerMicroliter

The inventors developed non-bisulfite converted, genomic plasmidstandards as a normalization standard. One of these genomic plasmidstandards comprises a marker region being specific for T-lymphocytes aswell as a marker region being cell-type unspecific (GAPDH, housekeepinggene, detecting all cells, 100% of cells). Each single plasmid containsthe same number of copies of these two marker regions (equimolar); twoof these plasmids correspond to the number of DNA copies per one singleimmune cell and are therefore counted as one single cell. A stocksolution containing defined numbers of said genomic plasmid molecules isused to determine the T-lymphocyte-specific assay-correction factor aswell as to assess the absolute number of T-lymphocytes per microliterwithin an unknown blood sample.

In a first step, DNA of four human blood samples of unknown compositionwas isolated. This isolated DNA as well as the genomic plasmids ofgenomic plasmid standard were bisulfite treated. Following, the amountof copies of bisulfite converted T-lymphocyte-specific andGAPDH-specific marker regions were assessed by qPCR (Table 10, sectionB, C). These qPCR analyses were performed using a bisulfite-convertednormalization standard (Table 10, section A) indicating the relativenumber of bisulfite-converted DNA as well as relative number of genomicplasmid copies containing the T-lymphocyte-specific marker region andthe GAPDH marker region (Table 10 section B, C).

The relative amount of T-lymphocytes in percent within unknown bloodsamples is calculated as number of bisulfite convertedT-lymphocyte-specific marker copies related to bisulfite converted GAPDHcopies (Table 10, section B).

${\%\mspace{14mu} T\text{-}{lymphocytes}} = \frac{\;\begin{matrix}{{{no}.\mspace{11mu}{bisulfite}}\text{-}{converted}} \\{T\text{-}{lymphocytes}\text{-}{specific}\mspace{14mu}{marker}\mspace{14mu}{copies} \times 100}\end{matrix}\mspace{11mu}}{{{no}.\mspace{11mu}{bisulfite}}\;\text{-}{converted}\mspace{14mu}{GAPDH}\mspace{14mu}{copies}}$  (e.g.  RD 260314):  1896.7/6570.0 × 100 = 28.87%

In a next step, T-lymphocyte-specific assay-correction factor based onsaid genomic plasmid standard was assessed (Table GR, section C). Asdescribed above, said genomic plasmid standard was bisulfite convertedand number of plasmid copies assessed by qPCR using primers specific forbisulfite-converted marker regions for T-lymphocytes and for GAPDH.These qPCR analyses were also performed using the bisulfite-convertednormalization standard (Table 10, section A). The efficiency of qPCR forT-lymphocytes and GAPDH should be equal as the novel genomic,non-bisulfite converted plasmid standard contains an equimolar amount ofcopies T-lymphocyte-specific and GAPDH-specific marker regions.Therefore, assessed deviation of genomic T-lymphocyte copy numbers fromGAPDH copy numbers corresponds to differences in qPCR assayefficiencies.e.g. Mean T-lymphocyte copy numbers=6058 vs. mean GAPDH copynumbers=5483This deviation defines the cell-type assay-specific correction factor:Mean T-lymphocytes copy numbers/GAPDH copy numbers=6058/5483=1.1.

For T-lymphocytes an assay correction factor of 1.1 (average, n=2) wasassessed (Table 10, section C). Correcting the relative amount ofT-lymphocytes by factor 1.1 results in an absolute amount, e.g., of26.24% T-lymphocytes within the unknown blood sample RD260314 (Table 10,section D).absolute amount of T-lymphocytes=relative amount ofT-lymphocytes/specific assay-correction factore.g.: 28.87%/1.1=26.24% Treg cells

Additionally, the absolute number of T-lymphocytes per microliter withinunknown blood samples was assessed (Table 10, section E). As describedabove, said genomic plasmid standard (stock solution of 6250 copies permicroliter) was bisulfite converted and number of plasmid copiesassessed by qPCR using primers specific for bisulfite-converted markerregion for T-lymphocytes (section C). These qPCR was performed using thebisulfite-converted normalization standard (section A).

The amount of T-lymphocytes per microliter within unknown blood samplesis calculated from relation of known, initial number of genomic plasmidsof stock solution (6250 copies) and qPCR assessed number of copies ofT-lymphocyte-specific marker within unknown blood samples (see sectionB) to qPCR assessed number of copies of genomic plasmid standard (seesection C).

${T\text{-}{lymphocytes}\text{/}{µl}} = \frac{\;\begin{matrix}{{{no}.\mspace{11mu}{plasmid}}\mspace{20mu}{copies}\text{/}{µl} \times {{no}.\mspace{11mu}{bisulfite}}\text{-}{converted}} \\{T\text{-}{lymphocyte}\text{-}{specific}\mspace{14mu}{marker}\mspace{14mu}{copies}}\end{matrix}\mspace{11mu}}{{Mean}\mspace{14mu}{{no}.\mspace{11mu}{of}}\mspace{14mu}{qPCR}\mspace{20mu}{assessed}\mspace{14mu}{plasmid}\mspace{14mu}{copies} \times 2}$(e.g.  RD 260314):  (6250 × 1896.7)/(6058.3 × 2) = 978  T-lymphocytes/µl(See Table 10 below.)

TABLE 10 Assessment of Treg-specific assay-correction factor using abisulfite-unconverted nucleic acid molecule as a plasmid standard.Assessment of absolute cell number in % as well as of cells per μl A)qPCR for bisulfite-converted normalization standard: qPCR for T- qPCRfor GAPDH bisulfite- lymphocyte bisulfite- converted normalizationconverted normalization standard Standards for standard copyQuantification copy numbers numbers Standard- Plasmid CP normalizationnormalization ID Units Value standard CP Value standard Standard-1 31250units  23.99 30500.00 23.30 31533.33 Standard-2 6250 units 26.22 6510.0025.62 6263.33 Standard-3 1250 units 28.65 1223.33 27.93 1260.00Standard-4  250 units 30.90 258.67 30.30 241.33 Standard-5  50 units33.14 50.00 32.86 48.93 B) qPCR on blood sample of unknown compositionfor assessment of relative amount of T- Lymphocytes using thebisulfite-converted normalization standard as given under A): qPCR forGAPDH- specific bisulfite converted qPCR for T-lymphocyte- DNA specificbisulfite converted copy DNA numbers relative Sample ID copy numbersacc. to amount unknown acc. to normalization normalization T- bloodstandard standard lymphocytes sample CP Value (A) CP Value (A) (%)RD260314 28.01 1896.7 25.55 6570.0 28.87 BF260314 27.54 2626.7 24.7211700.0 22.45 MK260314 27.49 2703.3 24.86 10566.7 25.58 LK260314 27.692363.3 24.85 10700.0 22.09 C) qPCR on genomic plasmid standard forassessment of T-Lymphocyte-specific correction factor qPCR for GAPDH-qPCR for T- specific bisulfite converted lymphocyte-specific DNAbisulfite converted copy % T- number DNA numbers lymphocytes/ plasmidcopy numbers acc. to GAPDH Sample ID copies acc. to normalizationnormalization genomic genomic per CP standard standard plasmid standardmicroliter Value (A) CP Value (A) units gnomSTD_02 6250 26.47 5503.325.88 5213.3 106 gnomSTD_02 6250 26.20 6613.3 25.74 5753.3 115 Mean:6058.3 Mean: Mean: 5483 110 Normalization Factor: 1.1 D) Correction ofrelative amount of T-lymphocytes using assay-specific correction factor(C) to obtain absolute amount of T-Lymphocytes (in %) Sample ID T-unknown Relative lymphocytes blood amount T- Normalization absolutesample lymphocytes Factor amount RD260314 28.87 1.1 26.24% BF26031422.45 1.1 20.41% MK260314 25.58 1.1 23.26% LK260314 22.09 1.1 20.08% E)Normalizing relative amount of T-lymphocyte to cell number permicroliter using genomic plasmid standard Sample ID no. plasmid copiesper μl × no. copies T- unknown copy numbers of T- I bcDNA bloodlymphocyte-specific bisulfite Mean qPCR assessed no. of plasmid sampleconverted DNA (see B) copies × 2 RD260314 1896.7  978 T-Lymphocytes/μlBF260314 2626.7 1355 T-Lymphocytes/μl MK260314 2703.3 1394T-Lymphocytes/μl LK260314 2363.3 1219 T-Lymphocytes/μl

The invention claimed is:
 1. A method for producing a neutrophilicgranulocytogram in a mammalian sample, the method comprising:epigenetically detecting neutrophil granulocyte (nGRC) cells in themammalian sample, said epigenetically detecting comprises determiningconversion of at least one CpG position with bisulfite, the at least oneCpG position selected from CpG positions 1 (nucleotide 26), 2(nucleotide 48), 3 (nucleotide 103), 4 (nucleotide 206), 5 (nucleotide251), and 6 (nucleotide 263) in the sequence of SEQ ID NO: 685, orrespective CpG positions in the sequence of SEQ ID NO: 686, wherein theconversion of the at least one CpG position with bisulfite is indicativeof a nGRC cell when compared to a non-nGRC cell; quantifying theepigenetically detected nGRC cells using a normalization standard,wherein said normalization standard comprises a nucleic acid moleculecomprising at least one marker-region specific for the nGRC and at leastone cell-unspecific control-region, wherein said marker-region andcontrol-region are present in the same number of copies on said nucleicacid molecule and/or on a blood cell sample of known composition; andproducing the neutrophilic granulocytogram from the number of epigeneticdetected nGRC cells quantified.
 2. The method according to claim 1,wherein said mammalian sample is selected from a mammalian body fluid,or a subfraction(s) thereof.
 3. The method, according to claim 2,wherein the mammalian sample is selected from peripheral bloodmonocytes, blood clots, dried blood spots, and fresh body fluids.
 4. Themethod according to claim 1, wherein the determining conversion of atleast one CpG position with bisulfite comprises a method selected fromspecific enzymatic digests, dye exclusion technologies, bisulfitesequencing, next generation sequencing, nanopore sequencing, singlemolecule real-time sequencing, analyses of epigenetic modifications inpromoter regions, using primers specific for bisulfite-converted DNA,using blocking oligonucleotides specific for bisulfite-converted DNA,using fluorescence-labeled, quenched oligonucleotide probes, usingprimers for single nucleotide primer extension specific forbisulfate-converted DNA, digital or quantitative PCR analysis, andspecific selective nucleic acid precipitation and/or chromatinprecipitation.
 5. The method according to claim 1, further comprisingdistinguishing said nGRC from all, or at least one, of the cell typesselected from basophils (bGRAN), eosinophils (eGRAN), monocytes (MOC),and B-lymphocytes (BLC).
 6. The method according to claim 1, furthercomprising the step of monitoring said nGRC in said mammalian sample byquantifying the relative amount of said nGRC and by comparing saidrelative amount of nGCR: with a relative amount of nGCR identified in aprior sample taken from a same mammal, and/or with a relative amount ofnGCR identified in a control sample.
 7. The method according to claim 1,wherein said at least one CpG position is selected from CpG positions 4(nucleotide 206) and 5 (nucleotide 251).